in . . O
clinical . . O
trials . . O
, . . O
gilenya . . O
was . . O
discontinued . . O
if . . O
the . . O
elevation . . O
exceeded . . O
5 . . O
times . . O
the . . O
uln . . O
. . . O

the . . O
most . . O
common . . O
laboratory . . O
abnormalities . . O
( . . O
> . . O
= . . O
25% . . O
) . . O
are . . O
increased . . B-AdverseReaction
ast . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
alt . . I-AdverseReaction
, . . O
lymphopenia . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
alkaline . . I-AdverseReaction
phosphatase . . I-AdverseReaction
, . . O
hypocalcemia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
hypophosphatemia . . B-AdverseReaction
, . . O
and . . O
hyperbilirubinemia . . B-AdverseReaction
. . . O

5.9 . . O
blood . . O
pressure . . O
effects . . O

in . . O
ms . . O
controlled . . O
clinical . . O
trials . . O
, . . O
patients . . O
treated . . O
with . . O
gilenya . . O
0.5 . . O
mg . . O
had . . O
an . . O
average . . O
increase . . O
over . . O
placebo . . O
of . . O
approximately . . O
3 . . B-Severity
mmhg . . I-Severity
in . . O
systolic . . O
pressure . . O
, . . O
and . . O
approximately . . O
2 . . B-Severity
mmhg . . I-Severity
in . . O
diastolic . . O
pressure . . O
, . . O
first . . O
detected . . O
after . . O
approximately . . O
1 . . O
month . . O
of . . O
treatment . . O
initiation . . O
, . . O
and . . O
persisting . . O
with . . O
continued . . O
treatment . . O
. . . O

hypertension . . B-AdverseReaction
was . . O
reported . . O
as . . O
an . . O
adverse . . O
reaction . . O
in . . O
8% . . O
of . . O
patients . . O
on . . O
gilenya . . O
0.5 . . O
mg . . O
and . . O
in . . O
4% . . O
of . . O
patients . . O
on . . O
placebo . . O
. . . O

fatal . . B-AdverseReaction
adverse . . O
reactions . . O
occurred . . O
in . . O
6% . . O
of . . O
patients . . O
receiving . . O
cometriq . . O
and . . O
resulted . . O
from . . O
hemorrhage . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
septicemia . . B-AdverseReaction
, . . O
fistulas . . B-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
arrest . . I-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
and . . O
unspecified . . O
death . . B-AdverseReaction
. . . O

fatal . . B-AdverseReaction
adverse . . O
reactions . . O
occurred . . O
in . . O
5% . . O
of . . O
patients . . O
receiving . . O
placebo . . B-Factor
and . . O
resulted . . O
from . . O
septicemia . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
and . . O
general . . B-AdverseReaction
deterioration . . I-AdverseReaction
. . . O

because . . O
of . . O
the . . O
continuing . . O
pharmacodynamic . . O
effects . . O
of . . O
fingolimod . . O
, . . O
initiating . . O
other . . O
drugs . . O
during . . O
this . . O
period . . O
warrants . . O
the . . O
same . . O
considerations . . O
needed . . O
for . . O
concomitant . . O
administration . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
risk . . B-Factor
of . . O
additive . . O
immunosuppressant . . B-AdverseReaction
effects . . I-AdverseReaction
) . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7 . . O
) . . O
] . . O
. . . O

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
leading . . O
to . . O
permanent . . O
discontinuation . . O
in . . O
patients . . O
treated . . O
with . . O
cometriq . . O
were . . O
: . . O
hypocalcemia . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
lipase . . I-AdverseReaction
, . . O
ppes . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
pancreatitis . . B-AdverseReaction
, . . O
tracheal . . B-AdverseReaction
fistula . . I-AdverseReaction
formation . . I-AdverseReaction
and . . O
vomiting . . B-AdverseReaction
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
another . . O
section . . O
of . . O
the . . O
label . . O
: . . O

* . . O
gastrointestinal . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
patients . . O
recently . . O
exposed . . O
to . . O
opioids . . O
are . . O
expected . . O
to . . O
be . . O
more . . O
sensitive . . O
to . . O
the . . O
effects . . O
of . . O
entereg . . O
and . . O
therefore . . O
may . . B-Factor
experience . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
and . . O
vomiting . . B-AdverseReaction
, . . O
and . . O
diarrhea . . B-AdverseReaction
. . . O

( . . O
5.6 . . O
) . . O
* . . O
not . . O
recommended . . O
in . . O
pancreatic . . O
or . . O
gastric . . O
anastomosis . . O
. . . O

there . . O
were . . O
more . . O
reports . . O
of . . O
myocardial . . B-AdverseReaction
infarctions . . I-AdverseReaction
in . . O
patients . . O
treated . . O
with . . O
alvimopan . . O
0.5 . . O
mg . . O
twice . . O
daily . . O
compared . . O
with . . O
placebo . . O
- . . O
treated . . O
patients . . O
in . . O
a . . O
12 . . O
- . . O
month . . O
study . . O
of . . O
patients . . O
treated . . O
with . . O
opioids . . O
for . . O
chronic . . O
non . . O
- . . O
cancer . . O
pain . . O
( . . O
alvimopan . . O
0.5 . . O
mg . . O
, . . O
n . . O
= . . O
538 . . O
; . . O
placebo . . O
, . . O
n . . O
= . . O
267 . . O
) . . O
. . . O

entereg . . O
is . . O
available . . O
only . . O
through . . O
a . . O
program . . O
under . . O
a . . O
rems . . O
that . . O
restricts . . O
use . . O
to . . O
enrolled . . O
hospitals . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

the . . O
most . . O
common . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
grade . . B-Severity
1-4 . . I-Severity
adverse . . O
reactions . . O
were . . O
anemia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
hematuria . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
anorexia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
dysguesia . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
and . . O
alopecia . . B-AdverseReaction
. . . O

entereg . . O
is . . O
available . . O
only . . O
for . . O
short . . O
- . . O
term . . O
( . . O
15 . . O
doses . . O
) . . O
use . . O
in . . O
hospitalized . . O
patients . . O
. . . O

only . . O
hospitals . . O
that . . O
have . . O
enrolled . . O
in . . O
and . . O
met . . O
all . . O
of . . O
the . . O
requirements . . O
for . . O
the . . O
e . . O
. . . O
a . . O
. . . O
s . . O
. . . O
e . . O
. . . O
program . . O
may . . O
use . . O
entereg . . O
. . . O

twenty . . O
- . . O
two . . O
( . . O
6% . . O
) . . O
patients . . O
discontinued . . O
jevtana . . O
treatment . . O
due . . O
to . . O
neutropenia . . B-AdverseReaction
, . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
, . . O
infection . . B-AdverseReaction
, . . O
or . . O
sepsis . . B-AdverseReaction
. . . O

the . . O
incidence . . O
of . . O
grade . . O
> . . O
= . . O
2 . . O
hematuria . . B-AdverseReaction
was . . O
6% . . O
in . . O
jevtana . . O
- . . O
treated . . O
patients . . O
and . . O
2% . . O
in . . O
mitoxantrone . . O
- . . O
treated . . O
patients . . O
. . . O

hepatic . . O
laboratory . . O
abnormalities . . O
: . . O

therefore . . O
, . . O
the . . O
use . . O
of . . O
entereg . . O
is . . O
not . . O
recommended . . O
in . . O
this . . O
population . . O
. . . O

the . . O
incidences . . O
of . . O
grade . . B-Severity
3-4 . . I-Severity
increased . . B-AdverseReaction
ast . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
alt . . I-AdverseReaction
, . . O
and . . O
increased . . B-AdverseReaction
bilirubin . . I-AdverseReaction
were . . O
each . . O
< . . O
= . . O
1% . . O
. . . O

5.6 . . O
risk . . O
of . . O
serious . . O
adverse . . O
reactions . . O
in . . O
patients . . O
with . . O
complete . . O
gastrointestinal . . O
obstruction . . O

no . . O
studies . . O
have . . O
been . . O
conducted . . O
in . . O
patients . . O
with . . O
complete . . O
gastrointestinal . . O
obstruction . . O
or . . O
in . . O
patients . . O
who . . O
have . . O
surgery . . O
for . . O
correction . . O
of . . O
complete . . O
bowel . . O
obstruction . . O
. . . O

3% . . O
. . . O

[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
, . . O
14.2 . . O
. . . O
) . . O
] . . O

adverse . . O
reactions . . O
leading . . O
to . . O
study . . O
discontinuation . . O
: . . O
11.4% . . O
of . . O
the . . O
women . . O
discontinued . . O
from . . O
the . . O
clinical . . O
trials . . O
due . . O
to . . O
an . . O
adverse . . O
reaction . . O
; . . O
the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
were . . O
menstrual . . B-AdverseReaction
disorder . . I-AdverseReaction
( . . O
metrorrhagia . . B-AdverseReaction
, . . O
menorrhagia . . B-AdverseReaction
, . . O
menstruation . . B-AdverseReaction
irregular . . I-AdverseReaction
, . . O
genital . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
vaginal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
dysfunctional . . B-AdverseReaction
uterine . . I-AdverseReaction
bleeding . . I-AdverseReaction
) . . O
( . . O
2.3% . . O
) . . O
; . . O
mood . . B-AdverseReaction
changes . . I-AdverseReaction
( . . O
depression . . B-AdverseReaction
, . . O
mood . . B-AdverseReaction
swings . . I-AdverseReaction
, . . O
mood . . B-AdverseReaction
altered . . I-AdverseReaction
, . . O
depressed . . B-AdverseReaction
mood . . I-AdverseReaction
, . . O
dysthymic . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
crying . . B-AdverseReaction
) . . O
( . . O
1.2% . . O
) . . O
; . . O
acne . . B-AdverseReaction
( . . O
1.1% . . O
) . . O
, . . O
headache . . B-AdverseReaction
( . . O
including . . O
migraines . . B-AdverseReaction
) . . O
( . . O
1.1% . . O
) . . O
, . . O
and . . O
weight . . B-AdverseReaction
increased . . I-AdverseReaction
( . . O
0.7 . . O
% . . O
) . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

5.3 . . O
radiation . . O
risk . . O

vascular . . O
disorders . . O
: . . O
venous . . O
and . . O
arterial . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
including . . O
pulmonary . . B-AdverseReaction
emboli . . I-AdverseReaction
, . . O
deep . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
, . . O
cerebral . . B-AdverseReaction
thrombosis . . I-AdverseReaction
, . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
and . . O
stroke . . B-AdverseReaction
) . . O
, . . O
hypertension . . B-AdverseReaction

gastrointestinal . . O
disorders . . O
: . . O
gastrointestinal . . B-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
for . . O
example . . O
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
) . . O

( . . O
5.1 . . O
) . . O
* . . O
hypersensitivity . . B-AdverseReaction
: . . O
anaphylactoid . . O
/ . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
with . . O
cardiovascular . . O
, . . O
respiratory . . O
or . . O
cutaneous . . B-AdverseReaction
manifestations . . I-AdverseReaction
, . . O
ranging . . O
from . . O
mild . . B-Severity
to . . O
severe . . B-Severity
, . . O
including . . O
death . . B-AdverseReaction
, . . O
have . . O
uncommonly . . O
occurred . . O
. . . O

nsf . . B-AdverseReaction
may . . B-Factor
result . . O
in . . O
fatal . . B-AdverseReaction
or . . O
debilitating . . B-Severity
fibrosis . . B-AdverseReaction
affecting . . O
the . . O
skin . . O
, . . O
muscle . . O
and . . O
internal . . O
organs . . O
. . . O

screen . . O
patients . . O
for . . O
acute . . O
kidney . . O
injury . . O
and . . O
other . . O
conditions . . O
that . . O
may . . O
reduce . . O
renal . . O
function . . O
. . . O

features . . O
of . . O
acute . . O
kidney . . O
injury . . O
consist . . O
of . . O
rapid . . O
( . . O
over . . O
hours . . O
to . . O
days . . O
) . . O
and . . O
usually . . O
reversible . . O
decrease . . O
in . . O
kidney . . O
function . . O
, . . O
commonly . . O
in . . O
the . . O
setting . . O
of . . O
surgery . . O
, . . O
severe . . O
infection . . O
, . . O
injury . . O
or . . O
drug . . O
- . . O
induced . . O
kidney . . O
toxicity . . O
. . . O

* . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
] . . O

* . . O
relapsed . . O
classical . . O
hl . . O
and . . O
relapsed . . O
salcl . . O
: . . O
neutropenia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
and . . O
vomiting . . B-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

for . . O
patients . . O
receiving . . O
hemodialysis . . O
, . . O
physicians . . O
may . . O
consider . . O
the . . O
prompt . . O
initiation . . O
of . . O
hemodialysis . . O
following . . O
the . . O
administration . . O
of . . O
a . . O
gbca . . O
in . . O
order . . O
to . . O
enhance . . O
the . . O
contrast . . O
agent's . . O
elimination . . O
. . . O

the . . O
data . . O
below . . O
reflect . . O
exposure . . O
to . . O
adcetris . . O
as . . O
monotherapy . . O
in . . O
327 . . O
patients . . O
with . . O
classical . . O
hodgkin . . O
lymphoma . . O
( . . O
hl . . O
) . . O
and . . O
systemic . . O
anaplastic . . O
large . . O
cell . . O
lymphoma . . O
( . . O
salcl . . O
) . . O
, . . O
including . . O
160 . . O
patients . . O
in . . O
two . . O
uncontrolled . . O
single . . O
- . . O
arm . . O
trials . . O
( . . O
studies . . O
1 . . O
and . . O
2 . . O
) . . O
and . . O
167 . . O
patients . . O
in . . O
one . . O
placebo . . O
- . . O
controlled . . O
randomized . . O
trial . . O
( . . O
study . . O
3 . . O
) . . O
. . . O

in . . O
studies . . O
1 . . O
and . . O
2 . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
were . . O
neutropenia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
and . . O
vomiting . . B-AdverseReaction
. . . O

anaphylactic . . O
and . . O
anaphylactoid . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
dotarem . . O
, . . O
involving . . O
cardiovascular . . O
, . . O
respiratory . . O
, . . O
and . . O
/ . . O
or . . O
cutaneous . . O
manifestations . . O
. . . O

summary . . O
of . . O
clinical . . O
trial . . O
experience . . O
in . . O
relapsed . . O
classical . . O
hl . . O
( . . O
study . . O
1 . . O
) . . O

median . . O
duration . . O
of . . O
treatment . . O
was . . O
9 . . O
cycles . . O
( . . O
range . . O
, . . O
1-16 . . O
) . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

screen . . O
all . . O
patients . . O
for . . O
renal . . O
impairment . . O
by . . O
obtaining . . O
a . . O
history . . O
and . . O
/ . . O
or . . O
laboratory . . O
tests . . O
. . . O

the . . O
median . . O
number . . O
of . . O
treatment . . O
cycles . . O
in . . O
each . . O
study . . O
arm . . O
was . . O
15 . . O
( . . O
range . . O
, . . O
1-16 . . O
) . . O
and . . O
80 . . O
patients . . O
( . . O
48% . . O
) . . O
in . . O
the . . O
adcetris . . O
- . . O
treatment . . O
arm . . O
received . . O
16 . . O
cycles . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

5.4 . . O
extravasation . . O
and . . O
injection . . O
site . . O
reactions . . O

extravasation . . O
into . . O
tissues . . O
during . . O
dotarem . . O
administration . . O
may . . B-Factor
result . . O
in . . O
tissue . . O
irritation . . O
[ . . O
see . . O
nonclinical . . O
toxicology . . O
( . . O
13.2 . . O
) . . O
] . . O
. . . O

summary . . O
of . . O
clinical . . O
trial . . O
experience . . O
in . . O
relapsed . . O
salcl . . O
( . . O
study . . O
2 . . O
) . . O

in . . O
studies . . O
1 . . O
and . . O
2 . . O
, . . O
54% . . O
of . . O
patients . . O
experienced . . O
any . . O
grade . . O
of . . O
neuropathy . . B-AdverseReaction
. . . O

of . . O
these . . O
patients . . O
, . . O
49% . . O
had . . O
complete . . O
resolution . . O
, . . O
31% . . O
had . . O
partial . . O
improvement . . O
, . . O
and . . O
20% . . O
had . . O
no . . O
improvement . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

grade . . O
3 . . O
events . . O
were . . O
reported . . O
in . . O
3 . . O
of . . O
the . . O
25 . . O
patients . . O
treated . . O
with . . O
adcetris . . O
who . . O
experienced . . O
infusion . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
reactions . . I-AdverseReaction
. . . O

during . . O
its . . O
development . . O
for . . O
the . . O
adjunctive . . O
treatment . . O
of . . O
seizures . . O
associated . . O
with . . O
lgs . . O
, . . O
onfi . . O
was . . O
administered . . O
to . . O
333 . . O
healthy . . O
volunteers . . O
and . . O
300 . . O
patients . . O
with . . O
a . . O
current . . O
or . . O
prior . . O
diagnosis . . O
of . . O
lgs . . O
, . . O
including . . O
197 . . O
patients . . O
treated . . O
for . . O
12 . . O
months . . O
or . . O
more . . O
. . . O

excerpt . . O
: . . O
image . . O
interpretation . . O
errors . . O
( . . O
especially . . O
false . . O
positives . . O
) . . O
have . . O
been . . O
observed . . O
( . . O
5.1 . . O
) . . O
. . . O

neuraceq . . O
, . . O
like . . O
all . . O
radiopharmaceuticals . . O
, . . O
contributes . . O
to . . O
a . . O
patient's . . O
long . . B-AdverseReaction
- . . I-AdverseReaction
term . . I-AdverseReaction
cumulative . . I-AdverseReaction
radiation . . I-AdverseReaction
exposure . . I-AdverseReaction
. . . O

serious . . O
adverse . . O
reactions . . O

the . . O
most . . O
common . . O
serious . . O
adverse . . O
reactions . . O
experienced . . O
by . . O
patients . . O
with . . O
salcl . . O
were . . O
septic . . B-AdverseReaction
shock . . I-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
supraventricular . . B-AdverseReaction
arrhythmia . . I-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
and . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
3% . . O
) . . O
. . . O

errors . . O
may . . O
occur . . O
in . . O
the . . O
neuraceq . . O
estimation . . O
of . . O
brain . . O
neuritic . . O
beta . . O
- . . O
amyloid . . O
plaque . . O
density . . O
during . . O
image . . O
interpretation . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

other . . O
important . . O
serious . . O
adverse . . O
reactions . . O
reported . . O
include . . O
pml . . B-AdverseReaction
, . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
and . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

neuraceq . . O
scan . . O
results . . O
are . . O
indicative . . O
of . . O
the . . O
presence . . O
of . . O
brain . . O
neuritic . . O
beta . . O
- . . O
amyloid . . O
plaques . . O
only . . O
at . . O
the . . O
time . . O
of . . O
image . . O
acquisition . . O
and . . O
a . . O
negative . . O
scan . . O
result . . O
does . . O
not . . O
preclude . . O
the . . O
development . . O
of . . O
brain . . O
neuritic . . O
beta . . O
- . . O
amyloid . . O
plaques . . O
in . . O
the . . O
future . . O
. . . O

discontinuations . . O

adverse . . O
reactions . . O
led . . O
to . . O
treatment . . O
discontinuation . . O
in . . O
21% . . O
of . . O
patients . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

adverse . . O
reactions . . O
that . . O
led . . O
to . . O
treatment . . O
discontinuation . . O
in . . O
2 . . O
or . . O
more . . O
patients . . O
were . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
14% . . O
) . . O
, . . O
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
7% . . O
) . . O
, . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
1% . . O
) . . O
, . . O
paraesthesia . . B-AdverseReaction
( . . O
1% . . O
) . . O
and . . O
vomiting . . B-AdverseReaction
( . . O
1% . . O
) . . O
. . . O

6.2 . . O
post . . O
marketing . . O
experience . . O

physicians . . O
should . . O
exercise . . O
caution . . O
when . . O
administering . . O
ilaris . . O
to . . O
patients . . O
with . . O
infections . . O
, . . O
a . . O
history . . O
of . . O
recurring . . O
infections . . O
or . . O
underlying . . O
conditions . . O
which . . O
may . . O
predispose . . O
them . . O
to . . O
infections . . O
. . . O

hepatobiliary . . O
disorders . . O
: . . O
hepatotoxicity . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
. . . O

( . . O
5.4 . . O
) . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
, . . O
including . . O
fatal . . B-AdverseReaction
outcomes . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.11 . . O
) . . O
] . . O
. . . O

ilaris . . O
should . . O
not . . O
be . . O
administered . . O
to . . O
patients . . O
during . . O
an . . O
active . . O
infection . . O
requiring . . O
medical . . O
intervention . . O
. . . O

approximately . . O
7% . . O
of . . O
patients . . O
in . . O
these . . O
trials . . O
developed . . O
persistently . . O
positive . . O
antibodies . . O
( . . O
positive . . O
test . . O
at . . O
more . . O
than . . O
2 . . O
timepoints . . O
) . . O
and . . O
30% . . O
developed . . O
transiently . . O
positive . . O
antibodies . . O
( . . O
positive . . O
in . . O
1 . . O
or . . O
2 . . O
post . . O
- . . O
baseline . . O
timepoints . . O
) . . O
. . . O

generally . . O
, . . O
the . . O
observed . . O
infections . . B-AdverseReaction
responded . . O
to . . O
standard . . O
therapy . . O
. . . O

two . . O
of . . O
the . . O
patients . . O
( . . O
1% . . O
) . . O
with . . O
persistently . . O
positive . . O
antibodies . . O
experienced . . O
adverse . . O
reactions . . O
consistent . . O
with . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
that . . O
led . . O
to . . O
discontinuation . . O
of . . O
treatment . . O
. . . O

an . . O
increased . . O
incidence . . O
of . . O
serious . . B-Severity
infections . . B-AdverseReaction
has . . O
been . . O
associated . . O
with . . O
administration . . O
of . . O
another . . O
il . . B-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
blocker . . I-DrugClass
in . . O
combination . . O
with . . O
tnf . . O
inhibitors . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
incidence . . O
of . . O
antibodies . . O
to . . O
adcetris . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

excerpt . . O
: . . O
* . . O
do . . O
not . . O
initiate . . O
in . . O
acutely . . O
deteriorating . . O
copd . . O
patients . . O
( . . O
5.2 . . O
) . . O
* . . O
do . . O
not . . O
use . . O
for . . O
relief . . O
of . . O
acute . . O
symptoms . . O
. . . O

concomitant . . O
short . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonists . . O
can . . O
be . . O
used . . O
as . . O
needed . . O
for . . O
acute . . O
relief . . O
( . . O
5.2 . . O
) . . O
* . . O
do . . O
not . . O
exceed . . O
the . . O
recommended . . O
dose . . O
. . . O

patients . . O
testing . . O
positive . . O
in . . O
tuberculosis . . O
screening . . O
should . . O
be . . O
treated . . O
according . . O
to . . O
standard . . O
medical . . O
practice . . O
prior . . O
to . . O
therapy . . O
with . . O
ilaris . . O
. . . O

healthcare . . O
providers . . O
should . . O
follow . . O
current . . O
cdc . . O
guidelines . . O
both . . O
to . . O
evaluate . . O
for . . O
and . . O
to . . O
treat . . O
possible . . O
latent . . O
tuberculosis . . O
infections . . O
before . . O
initiating . . O
therapy . . O
with . . O
ilaris . . O
. . . O

the . . O
impact . . O
of . . O
treatment . . O
with . . O
anti . . O
- . . O
interleukin . . O
- . . O
1 . . O
( . . O
il . . O
- . . O
1 . . O
) . . O
therapy . . O
on . . O
the . . O
development . . O
of . . O
malignancies . . O
is . . O
not . . O
known . . O
. . . O

however . . O
, . . O
treatment . . O
with . . O
immunosuppressants . . O
, . . O
including . . O
ilaris . . O
, . . O
may . . O
result . . O
in . . O
an . . O
increase . . O
in . . O
the . . O
risk . . B-Factor
of . . O
malignancies . . B-AdverseReaction
. . . O

because . . O
il . . O
- . . O
1 . . O
blockade . . O
may . . O
interfere . . O
with . . O
immune . . O
response . . O
to . . O
infections . . O
, . . O
it . . O
is . . O
recommended . . O
that . . O
prior . . O
to . . O
initiation . . O
of . . O
therapy . . O
with . . O
ilaris . . O
, . . O
adult . . O
and . . O
pediatric . . O
patients . . O
receive . . O
all . . O
recommended . . O
vaccinations . . O
, . . O
as . . O
appropriate . . O
, . . O
including . . O
pneumococcal . . O
vaccine . . O
and . . O
inactivated . . O
influenza . . O
vaccine . . O
. . . O

[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

macrophage . . O
activation . . O
syndrome . . O
( . . O
mas . . O
) . . O
is . . O
a . . O
known . . O
, . . O
life . . O
- . . O
threatening . . O
disorder . . O
that . . O
may . . O
develop . . O
in . . O
patients . . O
with . . O
rheumatic . . O
conditions . . O
, . . O
in . . O
particular . . O
sjia . . O
, . . O
and . . O
should . . O
be . . O
aggressively . . O
treated . . O
. . . O

arcapta . . O
neohaler . . O
should . . O
not . . O
be . . O
used . . O
for . . O
the . . O
relief . . O
of . . O
acute . . O
symptoms . . O
, . . O
i . . O
. . . O
e . . O
. . . O
as . . O
rescue . . O
therapy . . O
for . . O
the . . O
treatment . . O
of . . O
acute . . O
episodes . . O
of . . O
bronchospasm . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
biomarin . . O
at . . O
1-866-906-6100 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

increasing . . O
the . . O
daily . . O
dosage . . O
of . . O
arcapta . . O
neohaler . . O
beyond . . O
the . . O
recommended . . O
dose . . O
is . . O
not . . O
appropriate . . O
in . . O
this . . O
situation . . O
. . . O

5.3 . . O
excessive . . O
use . . O
of . . O
arcapta . . O
neohaler . . O
and . . O
use . . O
with . . O
other . . O
long . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonists . . O

clinically . . O
significant . . O
cardiovascular . . O
effects . . O
and . . O
fatalities . . O
have . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
excessive . . O
use . . O
of . . O
inhaled . . O
sympathomimetic . . O
drugs . . O
. . . O

immediate . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
may . . B-Factor
occur . . O
after . . O
administration . . O
of . . O
arcapta . . O
neohaler . . O
. . . O

if . . O
signs . . O
suggesting . . O
allergic . . O
reactions . . O
( . . O
in . . O
particular . . O
, . . O
difficulties . . O
in . . O
breathing . . O
or . . O
swallowing . . O
, . . O
swelling . . O
of . . O
tongue . . O
, . . O
lips . . O
and . . O
face . . O
, . . O
urticaria . . O
, . . O
skin . . O
rash . . O
) . . O
occur . . O
, . . O
arcapta . . O
neohaler . . O
should . . O
be . . O
discontinued . . O
immediately . . O
and . . O
alternative . . O
therapy . . O
instituted . . O
. . . O

if . . O
such . . O
effects . . O
occur . . O
, . . O
arcapta . . O
neohaler . . O
may . . O
need . . O
to . . O
be . . O
discontinued . . O
. . . O

therefore . . O
, . . O
the . . O
possibility . . O
of . . O
an . . O
association . . O
between . . O
neutralizing . . O
antibody . . O
titer . . O
and . . O
treatment . . O
effect . . O
cannot . . O
be . . O
assessed . . O
. . . O

arcapta . . O
neohaler . . O
has . . O
not . . O
been . . O
investigated . . O
in . . O
patients . . O
whose . . O
diabetes . . O
mellitus . . O
is . . O
not . . O
well . . O
controlled . . O
. . . O

6 . . O
adverse . . O
reactions . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

5.1 . . O
agranulocytosis . . O
/ . . O
neutropenia . . O

pool . . O
of . . O
placebo . . O
- . . O
controlled . . O
trials . . O

the . . O
data . . O
in . . O
table . . O
1 . . O
are . . O
derived . . O
from . . O
4 . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

measure . . O
the . . O
absolute . . O
neutrophil . . O
count . . O
( . . O
anc . . O
) . . O
before . . O
starting . . O
ferriprox . . O
therapy . . O
and . . O
monitor . . O
the . . O
anc . . O
weekly . . O
on . . O
therapy . . O
. . . O

the . . O
mean . . O
age . . O
of . . O
participants . . O
was . . O
55 . . O
years . . O
, . . O
1% . . O
of . . O
participants . . O
were . . O
75 . . O
years . . O
or . . O
older . . O
and . . O
53% . . O
of . . O
participants . . O
were . . O
male . . O
. . . O

advise . . O
patients . . O
taking . . O
ferriprox . . O
to . . O
immediately . . O
interrupt . . O
therapy . . O
and . . O
report . . O
to . . O
their . . O
physician . . O
if . . O
they . . O
experience . . O
any . . O
symptoms . . O
indicative . . O
of . . O
infection . . O
. . . O

at . . O
baseline . . O
, . . O
the . . O
population . . O
had . . O
type . . O
2 . . O
diabetes . . O
for . . O
an . . O
average . . O
of . . O
7 . . O
years . . O
and . . O
had . . O
a . . O
mean . . O
hba1c . . O
of . . O
8.1% . . O
. . . O

for . . O
neutropenia . . O
( . . O
anc . . O
< . . O
1.5 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
and . . O
> . . O
0.5 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
) . . O
: . . O

these . . O
adverse . . O
reactions . . O
were . . O
not . . O
present . . O
at . . O
baseline . . O
, . . O
occurred . . O
more . . O
commonly . . O
on . . O
tanzeum . . O
than . . O
on . . O
placebo . . O
, . . O
and . . O
occurred . . O
in . . O
at . . O
least . . O
5% . . O
of . . O
patients . . O
treated . . O
with . . O
tanzeum . . O
. . . O

obtain . . O
a . . O
complete . . O
blood . . O
cell . . O
( . . O
cbc . . O
) . . O
count . . O
, . . O
including . . O
a . . O
white . . O
blood . . O
cell . . O
( . . O
wbc . . O
) . . O
count . . O
corrected . . O
for . . O
the . . O
presence . . O
of . . O
nucleated . . O
red . . O
blood . . O
cells . . O
, . . O
an . . O
absolute . . O
neutrophil . . O
count . . O
( . . O
anc . . O
) . . O
, . . O
and . . O
a . . O
platelet . . O
count . . O
daily . . O
until . . O
recovery . . O
( . . O
anc . . O
> . . O
= . . O
1.5 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
) . . O
. . . O

table . . O
1 . . O
. . . O

in . . O
animal . . B-Animal
studies . . O
, . . O
administration . . O
of . . O
deferiprone . . O
during . . O
the . . O
period . . O
of . . O
organogenesis . . O
resulted . . O
in . . O
embryofetal . . B-AdverseReaction
death . . I-AdverseReaction
and . . O
malformations . . O
at . . O
doses . . O
lower . . O
than . . O
equivalent . . O
human . . O
clinical . . O
doses . . O
. . . O

women . . O
of . . O
reproductive . . O
potential . . O
should . . O
be . . O
advised . . O
to . . O
avoid . . O
pregnancy . . O
when . . O
taking . . O
ferriprox . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
and . . O
nonclinical . . O
toxicology . . O
( . . O
13.1 . . O
) . . O
] . . O
. . . O

injection . . O
site . . O
reactions . . O

injection . . B-AdverseReaction
site . . I-AdverseReaction
pruritus . . I-AdverseReaction
also . . O
contributed . . O
to . . O
the . . O
frequently . . O
reported . . O
reactions . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

tudorza . . O
pressair . . O
was . . O
studied . . O
in . . O
two . . O
3 . . O
- . . O
month . . O
( . . O
trials . . O
b . . O
and . . O
c . . O
) . . O
and . . O
one . . O
6 . . O
- . . O
month . . O
( . . O
trial . . O
d . . O
) . . O
placebo . . O
- . . O
controlled . . O
trials . . O
in . . O
patients . . O
with . . O
copd . . O
. . . O

patients . . O
with . . O
unstable . . O
cardiac . . O
disease . . O
, . . O
narrow . . O
- . . O
angle . . O
glaucoma . . O
, . . O
or . . O
symptomatic . . O
prostatic . . O
hypertrophy . . O
or . . O
bladder . . O
outlet . . O
obstruction . . O
were . . O
excluded . . O
from . . O
these . . O
trials . . O
. . . O

hypoglycemia . . B-AdverseReaction
was . . O
more . . O
frequent . . O
when . . O
tanzeum . . O
was . . O
added . . O
to . . O
sulfonylurea . . O
or . . O
insulin . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

atrial . . O
fibrillation . . O
/ . . O
flutte . . O
r . . O

appendicitis . . O

* . . O
invasive . . B-AdverseReaction
fungal . . I-AdverseReaction
infections . . I-AdverseReaction
- . . O
for . . O
patients . . O
who . . O
develop . . O
a . . O
systemic . . O
illness . . O
on . . O
simponi . . O
aria . . O
, . . O
consider . . O
empiric . . O
antifungal . . O
therapy . . O
for . . O
those . . O
who . . O
reside . . O
in . . O
or . . O
travel . . O
to . . O
regions . . O
where . . O
mycoses . . O
are . . O
endemic . . O
( . . O
5.1 . . O
) . . O
. . . O

consistent . . O
with . . O
the . . O
high . . O
homology . . O
of . . O
albiglutide . . O
with . . O
human . . O
glp . . O
- . . O
1 . . O
, . . O
the . . O
majority . . O
of . . O
patients . . O
( . . O
approximately . . O
79% . . O
) . . O
with . . O
anti . . O
- . . O
albiglutide . . O
antibodies . . O
also . . O
tested . . O
positive . . O
for . . O
anti . . O
- . . O
glp . . O
- . . O
1 . . O
antibodies . . O
; . . O
none . . O
were . . O
neutralizing . . O
. . . O

a . . O
minority . . O
of . . O
patients . . O
( . . O
approximately . . O
17% . . O
) . . O
who . . O
tested . . O
positive . . O
for . . O
anti . . O
- . . O
albiglutide . . O
antibodies . . O
also . . O
transiently . . O
tested . . O
positive . . O
for . . O
antibodies . . O
to . . O
human . . O
albumin . . O
. . . O

the . . O
detection . . O
of . . O
antibody . . O
formation . . O
is . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O
, . . O
a . . O
similar . . O
proportion . . O
of . . O
patients . . O
experienced . . O
at . . O
least . . O
one . . O
event . . O
of . . O
alanine . . O
aminotransferase . . O
( . . O
alt . . O
) . . O
increase . . O
of . . O
3 . . O
- . . O
fold . . O
or . . O
greater . . O
above . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
( . . O
0.9% . . O
and . . O
0.9% . . O
for . . O
all . . O
comparators . . O
versus . . O
tanzeum . . O
) . . O
. . . O

in . . O
one . . O
of . . O
the . . O
3 . . O
cases . . O
an . . O
alternate . . B-Negation
etiology . . I-Negation
was . . O
identified . . O
to . . O
explain . . O
the . . O
rise . . B-AdverseReaction
in . . I-AdverseReaction
liver . . I-AdverseReaction
enzyme . . I-AdverseReaction
( . . O
acute . . O
viral . . O
hepatitis . . O
) . . O
. . . O

in . . O
the . . O
third . . O
case . . O
, . . O
elevation . . B-AdverseReaction
in . . I-AdverseReaction
alt . . I-AdverseReaction
( . . O
10 . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
) . . O
was . . O
accompanied . . O
by . . O
an . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
total . . I-AdverseReaction
bilirubin . . I-AdverseReaction
( . . O
4 . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
) . . O
and . . O
occurred . . O
8 . . O
days . . O
after . . O
the . . O
first . . O
dose . . O
of . . O
tanzeum . . O
. . . O

evaluate . . O
patients . . O
for . . O
tuberculosis . . O
risk . . O
factors . . O
and . . O
test . . O
for . . O
latent . . O
infection . . O
prior . . O
to . . O
initiating . . O
simponi . . O
aria . . O
and . . O
periodically . . O
during . . O
therapy . . O
. . . O

if . . O
patients . . O
develop . . O
a . . O
serious . . O
systemic . . O
illness . . O
and . . O
they . . O
reside . . O
or . . O
travel . . O
in . . O
regions . . O
where . . O
mycoses . . O
are . . O
endemic . . O
, . . O
consider . . O
invasive . . O
fungal . . O
infection . . O
in . . O
the . . O
differential . . O
diagnosis . . O
. . . O

consider . . O
appropriate . . O
empiric . . O
antifungal . . O
therapy . . O
and . . O
take . . O
into . . O
account . . O
both . . O
the . . O
risk . . O
for . . O
severe . . O
fungal . . O
infection . . O
and . . O
the . . O
risks . . O
of . . O
antifungal . . O
therapy . . O
while . . O
a . . O
diagnostic . . O
workup . . O
is . . O
being . . O
performed . . O
. . . O

the . . O
use . . O
of . . O
tnf . . O
- . . O
blockers . . O
, . . O
of . . O
which . . O
simponi . . O
aria . . O
is . . O
a . . O
member . . O
, . . O
has . . O
been . . O
associated . . O
with . . O
reactivation . . B-AdverseReaction
of . . I-AdverseReaction
hepatitis . . I-AdverseReaction
b . . I-AdverseReaction
virus . . I-AdverseReaction
( . . O
hbv . . O
) . . O
in . . O
patients . . O
who . . O
are . . O
chronic . . O
hepatitis . . O
b . . O
carriers . . O
( . . O
i . . O
. . . O
e . . O
. . . O
, . . O
surface . . O
antigen . . O
positive . . O
) . . O
. . . O

all . . O
patients . . O
should . . O
be . . O
tested . . O
for . . O
hbv . . O
infection . . O
before . . O
initiating . . O
tnf . . O
- . . O
blocker . . O
therapy . . O
. . . O

ear . . O
and . . O
labyrinth . . O
disorders . . O
: . . O
deafness . . B-AdverseReaction
, . . O
tinnitus . . B-AdverseReaction
, . . O
vertigo . . B-AdverseReaction
. . . O

adequate . . O
data . . O
are . . O
not . . O
available . . O
on . . O
whether . . O
anti . . O
- . . O
viral . . O
therapy . . O
can . . O
reduce . . O
the . . O
risk . . O
of . . O
hbv . . O
reactivation . . O
in . . O
hbv . . O
carriers . . O
who . . O
are . . O
treated . . O
with . . O
tnf . . O
- . . O
blockers . . O
. . . O

in . . O
patients . . O
who . . O
develop . . O
hbv . . O
reactivation . . O
, . . O
tnf . . O
- . . O
blockers . . O
should . . O
be . . O
stopped . . O
and . . O
antiviral . . O
therapy . . O
with . . O
appropriate . . O
supportive . . O
treatment . . O
should . . O
be . . O
initiated . . O
. . . O

infections . . O
and . . O
infestations . . O
: . . O
herpes . . B-AdverseReaction
zoster . . I-AdverseReaction
. . . O

therefore . . O
, . . O
prescribers . . O
should . . O
exercise . . O
caution . . O
when . . O
considering . . O
resumption . . O
of . . O
tnf . . O
- . . O
blockers . . O
in . . O
this . . O
situation . . O
and . . O
monitor . . O
patients . . O
closely . . O
. . . O

5.2 . . O
malignancies . . O

psychiatric . . O
disorders . . O
: . . O
agitation . . B-AdverseReaction
, . . O
anxiety . . B-AdverseReaction
, . . O
depression . . B-AdverseReaction
, . . O
insomnia . . B-AdverseReaction
, . . O
irritability . . B-AdverseReaction
, . . O
libido . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
nervousness . . B-AdverseReaction
, . . O
panic . . B-AdverseReaction
attack . . I-AdverseReaction
, . . O
personality . . B-AdverseReaction
change . . I-AdverseReaction
. . . O

the . . O
malignancies . . O
occurred . . O
after . . O
a . . O
median . . O
of . . O
30 . . O
months . . O
( . . O
range . . O
1 . . O
to . . O
84 . . O
months . . O
) . . O
after . . O
the . . O
first . . O
dose . . O
of . . O
tnf . . O
- . . O
blocker . . O
therapy . . O
. . . O

most . . O
of . . O
the . . O
patients . . O
were . . O
receiving . . O
concomitant . . O
immunosuppressants . . O
. . . O

reproductive . . O
system . . O
and . . O
breast . . O
changes . . O
: . . O
breast . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
erectile . . B-AdverseReaction
dysfunction . . I-AdverseReaction
, . . O
gynecomastia . . B-AdverseReaction
. . . O

in . . O
the . . O
phase . . O
3 . . O
randomized . . O
controlled . . O
studies . . O
, . . O
the . . O
incidences . . O
of . . O
adjudicated . . O
aptc . . O
events . . O
per . . O
100 . . O
patient . . O
- . . O
years . . O
of . . O
exposure . . O
were . . O
: . . O
placebo . . O
0 . . O
( . . O
95% . . O
ci . . O
0.00-6.16 . . O
) . . O
, . . O
uloric . . O
40 . . O
mg . . O
0 . . O
( . . O
95% . . O
ci . . O
0.00-1.08 . . O
) . . O
, . . O
uloric . . O
80 . . O
mg . . O
1.09 . . O
( . . O
95% . . O
ci . . O
0.44-2.24 . . O
) . . O
, . . O
and . . O
allopurinol . . O
0.60 . . O
( . . O
95% . . O
ci . . O
0.16-1.53 . . O
) . . O
. . . O

this . . O
rare . . B-AdverseReaction
type . . I-AdverseReaction
of . . I-AdverseReaction
t . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
lymphoma . . I-AdverseReaction
has . . O
a . . O
very . . O
aggressive . . O
disease . . O
course . . O
and . . O
is . . O
usually . . O
fatal . . B-AdverseReaction
. . . O

6.2 . . O
postmarketing . . O
experience . . O

a . . O
risk . . O
for . . O
the . . O
development . . O
for . . O
hepatosplenic . . O
t . . O
- . . O
cell . . O
lymphoma . . O
in . . O
patients . . O
treated . . O
with . . O
tnf . . O
- . . O
blockers . . O
cannot . . O
be . . O
excluded . . O
. . . O

in . . O
controlled . . O
trials . . O
of . . O
other . . O
tnf . . O
- . . O
blockers . . O
in . . O
patients . . O
at . . O
higher . . O
risk . . O
for . . O
malignancies . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
patients . . O
with . . O
copd . . O
, . . O
patients . . O
with . . O
wegener's . . O
granulomatosis . . O
treated . . O
with . . O
concomitant . . O
cyclophosphamide . . O
) . . O
a . . O
greater . . O
portion . . O
of . . O
malignancies . . B-AdverseReaction
occurred . . O
in . . O
the . . O
tnf . . O
- . . O
blocker . . O
group . . O
compared . . O
to . . O
the . . O
controlled . . O
group . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
tubulointerstitial . . B-AdverseReaction
nephritis . . I-AdverseReaction
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
generalized . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
stevens . . B-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
skin . . I-AdverseReaction
reactions . . I-AdverseReaction
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

there . . O
is . . O
no . . O
clinical . . O
trial . . O
experience . . O
with . . O
xtandi . . O
in . . O
patients . . O
who . . O
have . . O
had . . O
a . . O
seizure . . O
. . . O

in . . O
several . . O
exploratory . . O
trials . . O
of . . O
other . . O
tnf . . O
- . . O
blockers . . O
in . . O
the . . O
treatment . . O
of . . O
chf . . O
, . . O
there . . O
were . . O
greater . . O
proportions . . O
of . . O
tnf . . O
- . . O
blocker . . O
treated . . O
patients . . O
who . . O
had . . O
chf . . B-AdverseReaction
exacerbations . . I-AdverseReaction
requiring . . O
hospitalization . . O
or . . O
increased . . B-AdverseReaction
mortality . . I-AdverseReaction
. . . O

simponi . . O
aria . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
chf . . O
and . . O
simponi . . O
aria . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
chf . . O
. . . O

5.1 . . O
seizure . . O

5.4 . . O
demyelinating . . O
disorders . . O

cases . . O
of . . O
central . . B-AdverseReaction
demyelination . . I-AdverseReaction
, . . O
ms . . B-AdverseReaction
, . . O
optic . . B-AdverseReaction
neuritis . . I-AdverseReaction
, . . O
and . . O
peripheral . . B-AdverseReaction
demyelinating . . I-AdverseReaction
polyneuropathy . . I-AdverseReaction
have . . O
rarely . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
the . . O
subcutaneous . . O
formulation . . O
of . . O
golimumab . . O
. . . O

prescribers . . O
should . . O
exercise . . O
caution . . O
in . . O
considering . . O
the . . O
use . . O
of . . O
tnf . . O
- . . O
blockers . . O
, . . O
including . . O
simponi . . O
aria . . O
, . . O
in . . O
patients . . O
with . . O
central . . O
or . . O
peripheral . . O
nervous . . O
system . . O
demyelinating . . O
disorders . . O
. . . O

because . . O
of . . O
the . . O
risk . . O
of . . O
seizure . . O
associated . . O
with . . O
xtandi . . O
use . . O
, . . O
patients . . O
should . . O
be . . O
advised . . O
of . . O
the . . O
risk . . O
of . . O
engaging . . O
in . . O
any . . O
activity . . O
where . . O
sudden . . O
loss . . O
of . . O
consciousness . . O
could . . O
cause . . O
serious . . O
harm . . O
to . . O
themselves . . O
or . . O
others . . O
. . . O

concurrent . . O
administration . . O
of . . O
anakinra . . O
( . . O
an . . O
interleukin . . O
- . . O
1 . . O
antagonist . . O
) . . O
and . . O
another . . O
tnf . . O
- . . O
blocker . . O
, . . O
was . . O
associated . . O
with . . O
a . . O
greater . . O
portion . . O
of . . O
serious . . O
infections . . O
and . . O
neutropenia . . O
and . . O
no . . O
additional . . O
benefits . . O
compared . . O
with . . O
the . . O
tnf . . O
- . . O
blocker . . O
alone . . O
. . . O

5.8 . . O
hematologic . . O
cytopenias . . O

( . . O
5.4 . . O
) . . O
* . . O
other . . O
serious . . B-Severity
infections . . B-AdverseReaction
: . . O
increased . . O
risk . . B-Factor
of . . O
bacterial . . O
, . . O
viral . . O
, . . O
fungal . . O
, . . O
and . . O
protozoal . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
including . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
and . . O
tuberculosis . . B-AdverseReaction
. . . O

caution . . O
should . . O
be . . O
exercised . . O
when . . O
using . . O
tnf . . O
- . . O
blockers . . O
, . . O
including . . O
simponi . . O
aria . . O
, . . O
in . . O
patients . . O
who . . O
have . . O
or . . O
have . . O
had . . O
significant . . O
cytopenias . . O
. . . O

in . . O
patients . . O
receiving . . O
anti . . O
- . . O
tnf . . O
therapy . . O
, . . O
limited . . O
data . . O
are . . O
available . . O
on . . O
the . . O
response . . O
to . . O
live . . O
vaccination . . O
, . . O
or . . O
on . . O
the . . O
secondary . . O
transmission . . O
of . . O
infection . . O
by . . O
live . . O
vaccines . . O
. . . O

5.10 . . O
hypersensitivity . . O
reactions . . O

as . . O
the . . O
total . . O
burden . . O
of . . O
immunosuppression . . O
is . . O
a . . O
risk . . O
factor . . O
for . . O
ptld . . O
, . . O
higher . . O
than . . O
the . . O
recommended . . O
doses . . O
or . . O
more . . O
frequent . . O
dosing . . O
of . . O
nulojix . . O
and . . O
higher . . O
than . . O
recommended . . O
doses . . O
of . . O
concomitant . . O
immunosuppressive . . O
agents . . O
are . . O
not . . O
recommended . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
. . . O

ebv . . O
serostatus . . O

ebv . . O
seropositive . . O
patients . . O
are . . O
defined . . O
as . . O
having . . O
evidence . . O
of . . O
acquired . . O
immunity . . O
shown . . O
by . . O
the . . O
presence . . O
of . . O
igg . . O
antibodies . . O
to . . O
viral . . O
capsid . . O
antigen . . O
( . . O
vca . . O
) . . O
and . . O
ebv . . O
nuclear . . O
antigen . . O
( . . O
ebna . . O
) . . O
. . . O

stop . . O
natazia . . O
at . . O
least . . O
4 . . O
weeks . . O
before . . O
and . . O
through . . O
2 . . O
weeks . . O
after . . O
major . . O
surgery . . O
. . . O

transplant . . O
recipients . . O
who . . O
are . . O
ebv . . O
seronegative . . O
, . . O
or . . O
with . . O
unknown . . O
serostatus . . O
, . . O
should . . O
not . . O
receive . . O
nulojix . . O
[ . . O
see . . O
boxed . . O
warning . . O
and . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

cmv . . O
prophylaxis . . O
is . . O
recommended . . O
for . . O
at . . O
least . . O
3 . . O
months . . O
after . . O
transplantation . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

( . . O
5.13 . . O
, . . O
7.1 . . O
) . . O

5.1 . . O
thromboembolic . . O
disorders . . O
and . . O
other . . O
vascular . . O
problems . . O

the . . O
physician . . O
responsible . . O
for . . O
the . . O
maintenance . . O
therapy . . O
should . . O
have . . O
complete . . O
information . . O
requisite . . O
for . . O
the . . O
follow . . O
- . . O
up . . O
of . . O
the . . O
patient . . O
[ . . O
see . . O
boxed . . O
warning . . O
] . . O
. . . O

however . . O
, . . O
pregnancy . . B-Factor
increases . . O
the . . O
risk . . O
of . . O
venous . . B-AdverseReaction
thromboembolism . . I-AdverseReaction
as . . O
much . . O
or . . O
more . . O
than . . O
the . . O
use . . O
of . . O
cocs . . O
. . . O

patients . . O
receiving . . O
immunosuppressants . . O
, . . O
including . . O
nulojix . . O
, . . O
are . . O
at . . O
increased . . O
risk . . O
of . . O
developing . . O
malignancies . . B-AdverseReaction
, . . O
in . . O
addition . . O
to . . O
ptld . . B-AdverseReaction
, . . O
including . . O
the . . O
skin . . O
[ . . O
see . . O
boxed . . O
warning . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

5.4 . . O
progressive . . O
multifocal . . O
leukoencephalopathy . . O

if . . O
feasible . . O
, . . O
stop . . O
natazia . . O
at . . O
least . . O
4 . . O
weeks . . O
before . . O
and . . O
through . . O
2 . . O
weeks . . O
after . . O
major . . O
surgery . . O
or . . O
other . . O
surgeries . . O
known . . O
to . . O
have . . O
an . . O
elevated . . O
risk . . O
of . . O
thromboembolism . . O
. . . O

start . . O
natazia . . O
no . . O
earlier . . O
than . . O
4 . . O
weeks . . O
after . . O
delivery . . O
, . . O
in . . O
women . . O
who . . O
are . . O
not . . O
breastfeeding . . O
. . . O

pml . . O
is . . O
usually . . O
diagnosed . . O
by . . O
brain . . O
imaging . . O
, . . O
cerebrospinal . . O
fluid . . O
( . . O
csf . . O
) . . O
testing . . O
for . . O
jc . . O
viral . . O
dna . . O
by . . O
polymerase . . O
chain . . O
reaction . . O
( . . O
pcr . . O
) . . O
, . . O
and . . O
/ . . O
or . . O
brain . . O
biopsy . . O
. . . O

these . . O
infections . . O
may . . O
lead . . O
to . . O
serious . . B-Severity
, . . O
including . . O
fatal . . B-AdverseReaction
, . . O
outcomes . . O
[ . . O
see . . O
boxed . . O
warning . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

prophylaxis . . O
for . . O
pneumocystis . . O
jiroveci . . O
is . . O
recommended . . O
after . . O
transplantation . . O
. . . O

5.2 . . O
carcinoma . . O
of . . O
the . . O
breasts . . O
and . . O
reproductive . . O
organs . . O

patients . . O
should . . O
be . . O
evaluated . . O
for . . O
tuberculosis . . O
and . . O
tested . . O
for . . O
latent . . O
infection . . O
prior . . O
to . . O
initiating . . O
nulojix . . O
. . . O

polyoma . . O
virus . . O
nephropathy . . O

[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
. . . O
] . . O

physicians . . O
should . . O
also . . O
consider . . O
the . . O
risk . . O
that . . O
reduced . . O
immunosuppression . . O
represents . . O
to . . O
the . . O
functioning . . O
allograft . . O
. . . O

the . . O
fatal . . B-AdverseReaction
case . . O
of . . O
pml . . B-AdverseReaction
was . . O
reported . . O
in . . O
a . . O
patient . . O
receiving . . O
higher . . O
than . . O
recommended . . O
doses . . O
of . . O
nulojix . . O
and . . O
mmf . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

women . . O
with . . O
a . . O
history . . O
of . . O
coc . . B-DrugClass
- . . O
related . . O
cholestasis . . B-AdverseReaction
may . . O
have . . O
the . . O
condition . . O
recur . . O
with . . O
subsequent . . O
coc . . O
use . . O
. . . O

5.8 . . O
immunizations . . O

women . . O
with . . O
uncontrolled . . O
hypertension . . O
or . . O
hypertension . . O
with . . O
vascular . . O
disease . . O
should . . O
not . . O
use . . O
cocs . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
below . . O
and . . O
also . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

cocs . . B-DrugClass
may . . O
decrease . . B-AdverseReaction
glucose . . I-AdverseReaction
tolerance . . I-AdverseReaction
in . . O
a . . O
dose . . O
- . . O
related . . O
fashion . . O
. . . O

the . . O
prolia . . O
postmarketing . . O
active . . O
safety . . O
surveillance . . O
program . . O
is . . O
available . . O
to . . O
collect . . O
information . . O
from . . O
prescribers . . O
on . . O
specific . . O
adverse . . O
events . . O
. . . O

5.7 . . O
headache . . O

if . . O
a . . O
woman . . O
taking . . O
natazia . . O
develops . . O
new . . O
headaches . . O
that . . O
are . . O
recurrent . . O
, . . O
persistent . . O
, . . O
or . . O
severe . . B-Severity
, . . O
evaluate . . O
the . . O
cause . . O
and . . O
discontinue . . O
natazia . . O
if . . O
indicated . . O
. . . O

5.8 . . O
bleeding . . O
irregularities . . O

a . . O
total . . O
of . . O
3876 . . O
women . . O
were . . O
exposed . . O
to . . O
placebo . . O
and . . O
3886 . . O
women . . O
were . . O
exposed . . O
to . . O
prolia . . O
administered . . O
subcutaneously . . O
once . . O
every . . O
6 . . O
months . . O
as . . O
a . . O
single . . O
60 . . O
mg . . O
dose . . O
. . . O

all . . O
women . . O
were . . O
instructed . . O
to . . O
take . . O
at . . O
least . . O
1000 . . O
mg . . O
of . . O
calcium . . O
and . . O
400 . . O
iu . . O
of . . O
vitamin . . O
d . . O
supplementation . . O
per . . O
day . . O
. . . O

the . . O
incidence . . O
of . . O
all . . O
- . . O
cause . . O
mortality . . B-AdverseReaction
was . . O
2.3% . . O
( . . O
n . . O
= . . O
90 . . O
) . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
1.8% . . O
( . . O
n . . O
= . . O
70 . . O
) . . O
in . . O
the . . O
prolia . . O
group . . O
. . . O

based . . O
on . . O
patient . . O
diaries . . O
from . . O
three . . O
clinical . . O
trials . . O
evaluating . . O
the . . O
safety . . O
and . . O
efficacy . . O
of . . O
natazia . . O
for . . O
contraception . . O
, . . O
10-23% . . O
of . . O
women . . O
experienced . . O
intracyclic . . B-AdverseReaction
bleeding . . I-AdverseReaction
per . . O
cycle . . O
. . . O

table . . O
1 . . O
. . . O

the . . O
administration . . O
of . . O
oral . . O
contraceptives . . O
to . . O
induce . . O
withdrawal . . O
bleeding . . O
should . . O
not . . O
be . . O
used . . O
as . . O
a . . O
test . . O
for . . O
pregnancy . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

5.10 . . O
depression . . O

women . . O
with . . O
a . . O
history . . O
of . . O
depression . . O
should . . O
be . . O
carefully . . O
observed . . O
and . . O
natazia . . O
discontinued . . O
if . . O
depression . . O
recurs . . O
to . . O
a . . O
serious . . O
degree . . O
. . . O

these . . O
included . . O
no . . O
subjects . . O
in . . O
the . . O
normal . . O
renal . . O
function . . O
group . . O
, . . O
10% . . O
of . . O
subjects . . O
in . . O
the . . O
creatinine . . O
clearance . . O
50 . . O
to . . O
80 . . O
ml . . O
/ . . O
min . . O
group . . O
, . . O
29% . . O
of . . O
subjects . . O
in . . O
the . . O
creatinine . . O
clearance . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
group . . O
, . . O
and . . O
29% . . O
of . . O
subjects . . O
in . . O
the . . O
hemodialysis . . O
group . . O
. . . O

serious . . O
infections . . O
receptor . . O
activator . . O
of . . O
nuclear . . O
factor . . O
kappa . . O
- . . O
b . . O
ligand . . O
( . . O
rankl . . O
) . . O
is . . O
expressed . . O
on . . O
activated . . O
t . . O
and . . O
b . . O
lymphocytes . . O
and . . O
in . . O
lymph . . O
nodes . . O
. . . O

5.12 . . O
monitoring . . O

skin . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
including . . O
erysipelas . . B-AdverseReaction
and . . O
cellulitis . . B-AdverseReaction
, . . O
leading . . O
to . . O
hospitalization . . O
were . . O
reported . . O
more . . O
frequently . . O
in . . O
patients . . O
treated . . O
with . . O
prolia . . O
( . . O
< . . O
0.1% . . O
placebo . . O
vs . . O
. . . O
0.4% . . O
prolia . . O
) . . O
. . . O

women . . O
with . . O
a . . O
tendency . . O
to . . O
chloasma . . O
should . . O
avoid . . O
exposure . . O
to . . O
the . . O
sun . . O
or . . O
ultraviolet . . O
radiation . . O
while . . O
taking . . O
cocs . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
cubist . . O
pharmaceuticals . . O
at . . O
1-877 . . O
- . . O
cubist . . O
- . . O
6 . . O
( . . O
1-877-282-4786 . . O
) . . O
or . . O
fda . . O
at . . O
( . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
) . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

of . . O
these . . O
reports . . O
, . . O
1 . . O
patient . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
all . . O
8 . . O
patients . . O
in . . O
the . . O
prolia . . O
group . . O
had . . O
serious . . O
events . . O
, . . O
including . . O
one . . O
death . . B-AdverseReaction
in . . O
the . . O
prolia . . O
group . . O
. . . O

the . . O
safety . . O
of . . O
dificid . . O
200 . . O
mg . . O
tablets . . O
taken . . O
twice . . O
a . . O
day . . O
for . . O
10 . . O
days . . O
was . . O
evaluated . . O
in . . O
564 . . O
patients . . O
with . . O
cdad . . O
in . . O
two . . O
active . . O
- . . O
comparator . . O
controlled . . O
trials . . O
with . . O
86.7% . . O
of . . O
patients . . O
receiving . . O
a . . O
full . . O
course . . O
of . . O
treatment . . O
. . . O

the . . O
safety . . O
of . . O
prolia . . O
in . . O
the . . O
treatment . . O
of . . O
men . . O
with . . O
osteoporosis . . O
was . . O
assessed . . O
in . . O
a . . O
1 . . O
- . . O
year . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
study . . O
. . . O

selected . . O
adverse . . O
reactions . . O
with . . O
an . . O
incidence . . O
of . . O
> . . O
= . . O
2% . . O
reported . . O
in . . O
dificid . . O
patients . . O
in . . O
controlled . . O
trials . . O
dificid . . O
( . . O
n . . O
= . . O
564 . . O
) . . O
vancomycin . . O
( . . O
n . . O
= . . O
583 . . O
) . . O
system . . O
organ . . O
class . . O
preferred . . O
term . . O
n . . O
( . . O
% . . O
) . . O
n . . O
( . . O
% . . O
) . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
anemia . . B-AdverseReaction
14 . . O
( . . O
2% . . O
) . . O
12 . . O
( . . O
2% . . O
) . . O
neutropenia . . B-AdverseReaction
14 . . O
( . . O
2% . . O
) . . O
6 . . O
( . . O
1% . . O
) . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
62 . . O
( . . O
11% . . O
) . . O
66 . . O
( . . O
11% . . O
) . . O
vomiting . . B-AdverseReaction
41 . . O
( . . O
7% . . O
) . . O
37 . . O
( . . O
6% . . O
) . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
33 . . O
( . . O
6% . . O
) . . O
23 . . O
( . . O
4% . . O
) . . O
gastrointestinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
20 . . O
( . . O
4% . . O
) . . O
12 . . O
( . . O
2% . . O
) . . O
the . . O
following . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
< . . O
2% . . O
of . . O
patients . . O
taking . . O
dificid . . O
tablets . . O
in . . O
controlled . . O
trials . . O
: . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
hyperglycemia . . B-AdverseReaction
, . . O
metabolic . . B-AdverseReaction
acidosis . . I-AdverseReaction

the . . O
percentage . . O
of . . O
patients . . O
who . . O
withdrew . . O
from . . O
the . . O
study . . O
due . . O
to . . O
adverse . . O
events . . O
was . . O
0% . . O
and . . O
2.5% . . O
for . . O
the . . O
placebo . . O
and . . O
prolia . . O
groups . . O
, . . O
respectively . . O
. . . O

as . . O
such . . O
, . . O
reliability . . O
in . . O
estimating . . O
their . . O
frequency . . O
or . . O
in . . O
establishing . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
is . . O
not . . O
always . . O
possible . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
described . . O
elsewhere . . O
in . . O
labeling . . O
: . . O

the . . O
safety . . O
of . . O
prolia . . O
in . . O
the . . O
treatment . . O
of . . O
bone . . O
loss . . O
in . . O
men . . O
with . . O
nonmetastatic . . O
prostate . . O
cancer . . O
receiving . . O
androgen . . O
deprivation . . O
therapy . . O
( . . O
adt . . O
) . . O
was . . O
assessed . . O
in . . O
a . . O
3 . . O
- . . O
year . . O
, . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
multinational . . O
study . . O
of . . O
1468 . . O
men . . O
aged . . O
48 . . O
to . . O
97 . . O
years . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

approximately . . O
1000 . . O
patients . . O
received . . O
at . . O
least . . O
2 . . O
years . . O
of . . O
treatment . . O
with . . O
gilenya . . O
0.5 . . O
mg . . O
. . . O

in . . O
all . . O
clinical . . O
studies . . O
, . . O
including . . O
uncontrolled . . O
extension . . O
studies . . O
, . . O
the . . O
exposure . . O
to . . O
gilenya . . O
0.5 . . O
mg . . O
was . . O
approximately . . O
4119 . . O
person . . O
- . . O
years . . O
. . . O

a . . O
total . . O
of . . O
120 . . O
women . . O
were . . O
exposed . . O
to . . O
placebo . . O
and . . O
129 . . O
women . . O
were . . O
exposed . . O
to . . O
prolia . . O
administered . . O
once . . O
every . . O
6 . . O
months . . O
as . . O
a . . O
single . . O
60 . . O
mg . . O
subcutaneous . . O
dose . . O
. . . O

table . . O
1 . . O
adverse . . O
reactions . . O
reported . . O
in . . O
studies . . O
1 . . O
and . . O
3 . . O
( . . O
occurring . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
patients . . O
and . . O
reported . . O
for . . O
gilenya . . O
0.5 . . O
mg . . O
at . . O
> . . O
= . . O
1% . . O
higher . . O
rate . . O
than . . O
for . . O
placebo . . O
) . . O
primary . . O
system . . O
organ . . O
class . . O
preferred . . O
term . . O
gilenya . . O
0.5 . . O
mg . . O
n . . O
= . . O
783 . . O
% . . O
placebo . . O
n . . O
= . . O
773 . . O
% . . O
infections . . O
influenza . . B-AdverseReaction
11 . . O
8 . . O
sinusitis . . B-AdverseReaction
11 . . O
8 . . O
bronchitis . . B-AdverseReaction
8 . . O
5 . . O
herpes . . B-AdverseReaction
zoster . . I-AdverseReaction
2 . . O
1 . . O
tinea . . B-AdverseReaction
versicolor . . I-AdverseReaction
2 . . O
< . . O
1 . . O
cardiac . . O
disorders . . O
bradycardia . . B-AdverseReaction
3 . . O
1 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
25 . . O
24 . . O
migraine . . B-AdverseReaction
6 . . O
4 . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
13 . . O
12 . . O
diarrhea . . B-AdverseReaction
13 . . O
10 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
11 . . O
10 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
asthenia . . B-AdverseReaction
2 . . O
1 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
10 . . O
9 . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
10 . . O
7 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
alopecia . . B-AdverseReaction
3 . . O
2 . . O
actinic . . B-AdverseReaction
keratosis . . I-AdverseReaction
2 . . O
1 . . O
investigations . . O
liver . . B-AdverseReaction
transaminase . . I-AdverseReaction
elevations . . I-AdverseReaction
( . . O
alt . . O
/ . . O
ggt . . O
/ . . O
ast . . O
) . . O
15 . . O
4 . . O
blood . . B-AdverseReaction
triglycerides . . I-AdverseReaction
increased . . I-AdverseReaction
3 . . O
1 . . O
respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
12 . . O
11 . . O
dyspnea . . B-AdverseReaction
9 . . O
7 . . O
eye . . O
disorders . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
4 . . O
2 . . O
vascular . . O
disorders . . O
hypertension . . B-AdverseReaction
8 . . O
4 . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
lymphopenia . . B-AdverseReaction
7 . . O
< . . O
1 . . O
leukopenia . . B-AdverseReaction
2 . . O
< . . O
1 . . O
neoplasms . . O
benign . . O
, . . O
malignant . . O
and . . O
unspecified . . O
( . . O
including . . O
cysts . . O
and . . O
polyps . . O
) . . O
skin . . B-AdverseReaction
papilloma . . I-AdverseReaction
3 . . O
2 . . O
basal . . B-AdverseReaction
cell . . I-AdverseReaction
carcinoma . . I-AdverseReaction
2 . . O
1 . . O
adverse . . O
reactions . . O
of . . O
dizziness . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
eczema . . B-AdverseReaction
and . . O
pruritus . . B-AdverseReaction
were . . O
also . . O
reported . . O
in . . O
studies . . O
1 . . O
and . . O
3 . . O
but . . O
did . . O
not . . O
meet . . O
the . . O
reporting . . O
rate . . O
criteria . . O
for . . O
inclusion . . O
in . . O
table . . O
1 . . O
( . . O
difference . . O
was . . O
less . . O
than . . O
1% . . O
) . . O
. . . O

vascular . . B-AdverseReaction
events . . I-AdverseReaction
, . . O
including . . O
ischemic . . O
and . . O
hemorrhagic . . B-AdverseReaction
strokes . . I-AdverseReaction
, . . O
and . . O
peripheral . . B-AdverseReaction
arterial . . I-AdverseReaction
occlusive . . I-AdverseReaction
disease . . I-AdverseReaction
were . . O
reported . . O
in . . O
premarketing . . O
clinical . . O
trials . . O
in . . O
patients . . O
who . . O
received . . O
gilenya . . O
doses . . O
( . . O
1.25-5 . . O
mg . . O
) . . O
higher . . O
than . . O
recommended . . O
for . . O
use . . O
in . . O
ms . . O
. . . O
similar . . O
events . . O
have . . O
been . . O
reported . . O
with . . O
gilenya . . O
0.5 . . O
mg . . O
in . . O
the . . O
postmarketing . . O
setting . . O
although . . O
a . . O
causal . . O
relationship . . O
has . . O
not . . O
been . . O
established . . O
. . . O

the . . O
relationship . . O
to . . O
gilenya . . O
remains . . O
uncertain . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

( . . O
5.5 . . O
) . . O
* . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
: . . O
qt . . O
interval . . O
should . . O
be . . O
monitored . . O
in . . O
patients . . O
taking . . O
concomitant . . O
medications . . O
known . . O
to . . O
increase . . O
the . . O
qt . . O
interval . . O
or . . O
with . . O
certain . . O
heart . . O
conditions . . O
. . . O

additionally . . O
, . . O
the . . O
observed . . O
incidence . . O
of . . O
a . . O
positive . . O
antibody . . O
( . . O
including . . O
neutralizing . . O
antibody . . O
) . . O
test . . O
result . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
, . . O
including . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

5.1 . . O
retinal . . O
abnormalities . . O
and . . O
potential . . O
vision . . O
loss . . O

exclusive . . O
of . . O
an . . O
uncommon . . O
, . . O
mild . . B-Severity
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
no . . O
adverse . . O
reactions . . O
to . . O
11 . . O
c . . O
- . . O
choline . . O
have . . O
been . . O
reported . . O
. . . O

the . . O
safety . . O
data . . O
described . . O
in . . O
this . . O
section . . O
reflect . . O
exposure . . O
to . . O
blincyto . . O
in . . O
clinical . . O
trials . . O
in . . O
which . . O
212 . . O
patients . . O
with . . O
relapsed . . O
or . . O
refractory . . O
all . . O
received . . O
up . . O
to . . O
28 . . O
mcg . . O
/ . . O
day . . O
. . . O

the . . O
median . . O
age . . O
of . . O
the . . O
study . . O
population . . O
was . . O
37 . . O
years . . O
( . . O
range . . O
: . . O
18 . . O
to . . O
79 . . O
years . . O
) . . O
, . . O
63% . . O
were . . O
male . . O
, . . O
79% . . O
were . . O
white . . O
, . . O
3% . . O
were . . O
asian . . O
, . . O
and . . O
3% . . O
were . . O
black . . O
or . . O
african . . O
american . . O
. . . O

patients . . O
should . . O
have . . O
baseline . . O
ophthalmologic . . O
testing . . O
by . . O
an . . O
ophthalmic . . O
professional . . O
and . . O
follow . . O
- . . O
up . . O
testing . . O
every . . O
6 . . O
months . . O
. . . O

the . . O
best . . O
method . . O
of . . O
detection . . O
of . . O
these . . O
abnormalities . . O
and . . O
the . . O
optimal . . O
frequency . . O
of . . O
periodic . . O
ophthalmologic . . O
monitoring . . O
are . . O
unknown . . O
. . . O

patients . . O
who . . O
cannot . . O
be . . O
monitored . . O
should . . O
usually . . O
not . . O
be . . O
treated . . O
with . . O
potiga . . O
. . . O

the . . O
adverse . . O
reactions . . O
reported . . O
most . . O
frequently . . O
as . . O
the . . O
reason . . O
for . . O
discontinuation . . O
of . . O
treatment . . O
included . . O
encephalopathy . . B-AdverseReaction
and . . O
sepsis . . B-AdverseReaction
. . . O

of . . O
these . . O
29 . . O
patients . . O
, . . O
5 . . O
( . . O
17% . . O
) . . O
required . . O
catheterization . . O
, . . O
with . . O
post . . O
- . . O
voiding . . O
residuals . . O
of . . O
up . . O
to . . O
1,500 . . O
ml . . O
. . . O
potiga . . O
was . . O
discontinued . . O
in . . O
3 . . O
of . . O
the . . O
5 . . O
patients . . O
who . . O
required . . O
catheterization . . O
, . . O
and . . O
all . . O
were . . O
able . . O
to . . O
void . . O
spontaneously . . O
; . . O
however . . O
, . . O
1 . . O
of . . O
the . . O
3 . . O
patients . . O
continued . . O
intermittent . . O
self . . O
- . . O
catheterization . . O
. . . O

hydronephrosis . . B-AdverseReaction
occurred . . O
in . . O
2 . . O
patients . . O
, . . O
one . . O
of . . O
whom . . O
had . . O
associated . . O
renal . . B-AdverseReaction
function . . I-AdverseReaction
impairment . . I-AdverseReaction
that . . O
resolved . . O
upon . . O
discontinuation . . O
of . . O
potiga . . O
. . . O

21 . . O
2 . . O
vascular . . O
disorders . . O
hypotension . . B-AdverseReaction
hypertension . . B-AdverseReaction
118 . . O
25 . . O
additional . . O
important . . O
adverse . . O
reactions . . O
that . . O
did . . O
not . . O
meet . . O
the . . O
threshold . . O
criteria . . O
for . . O
inclusion . . O
in . . O
table . . O
2 . . O
were . . O
: . . O

because . . B-Factor
of . . O
the . . O
increased . . O
risk . . O
of . . O
urinary . . O
retention . . O
on . . O
potiga . . O
, . . O
urologic . . O
symptoms . . O
should . . O
be . . O
carefully . . O
monitored . . O
. . . O

potiga . . O
can . . B-Factor
cause . . O
skin . . B-AdverseReaction
discoloration . . I-AdverseReaction
. . . O

as . . O
with . . O
all . . O
therapeutic . . O
proteins . . O
, . . O
there . . O
is . . O
potential . . O
for . . O
immunogenicity . . O
. . . O

the . . O
immunogenicity . . O
of . . O
blincyto . . O
has . . O
been . . O
evaluated . . O
using . . O
either . . O
an . . O
electrochemiluminescence . . O
detection . . O
technology . . O
( . . O
ecl . . O
) . . O
or . . O
an . . O
enzyme . . O
- . . O
linked . . O
immunosorbent . . O
assay . . O
( . . O
elisa . . O
) . . O
screening . . O
immunoassay . . O
for . . O
the . . O
detection . . O
of . . O
binding . . O
anti . . O
- . . O
blinatumomab . . O
antibodies . . O
. . . O

these . . O
effects . . O
were . . O
dose . . O
- . . O
related . . O
and . . O
generally . . O
appeared . . O
within . . O
the . . O
first . . O
8 . . O
weeks . . O
of . . O
treatment . . O
. . . O

anti . . O
- . . O
blinatumomab . . O
antibody . . O
formation . . O
may . . O
affect . . O
pharmacokinetics . . O
of . . O
blincyto . . O
. . . O

the . . O
psychiatric . . B-AdverseReaction
symptoms . . I-AdverseReaction
in . . O
the . . O
vast . . O
majority . . O
of . . O
patients . . O
in . . O
both . . O
controlled . . O
and . . O
open . . O
- . . O
label . . O
trials . . O
resolved . . O
within . . O
7 . . O
days . . O
of . . O
discontinuation . . O
of . . O
potiga . . O
. . . O

additionally . . O
, . . O
the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
( . . O
including . . O
neutralizing . . O
antibody . . O
) . . O
positivity . . O
in . . O
an . . O
assay . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
, . . O
including . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

table . . O
2 . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
blinatumomab . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

potiga . . O
causes . . O
dose . . O
- . . O
related . . O
increases . . O
in . . O
dizziness . . B-AdverseReaction
and . . O
somnolence . . B-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

( . . O
6.1 . . O
) . . O
excerpt . . O
: . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
janssen . . O
therapeutics . . O
, . . O
division . . O
of . . O
janssen . . O
products . . O
, . . O
lp . . O
at . . O
1-800 . . O
- . . O
janssen . . O
( . . O
1-800-526-7736 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

somnolence . . B-AdverseReaction
was . . O
reported . . O
in . . O
22% . . O
of . . O
patients . . O
treated . . O
with . . O
potiga . . O
and . . O
12% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
. . . O

6.1 . . O
clinical . . O
studies . . O
experience . . O

because . . O
clinical . . O
studies . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
the . . O
rates . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

studies . . O
1 . . O
and . . O
2 . . O
were . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
trial . . O
in . . O
newly . . O
diagnosed . . O
patients . . O
with . . O
pulmonary . . O
mdr . . O
- . . O
tb . . O
. . . O

in . . O
both . . O
studies . . O
1 . . O
and . . O
2 . . O
, . . O
aminotransferase . . B-AdverseReaction
elevations . . I-AdverseReaction
of . . O
at . . O
least . . O
3 . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
developed . . O
more . . O
frequently . . O
in . . O
the . . O
sirturo . . O
treatment . . O
group . . O
( . . O
11 . . O
/ . . O
102 . . O
[ . . O
10.8% . . O
] . . O
vs . . O
6 . . O
/ . . O
105 . . O
[ . . O
5.7% . . O
] . . O
) . . O
than . . O
in . . O
the . . O
placebo . . O
treatment . . O
group . . O
. . . O

pooled . . O
analyses . . O
of . . O
199 . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
( . . O
mono . . O
- . . O
and . . O
adjunctive . . O
- . . O
therapy . . O
) . . O
of . . O
11 . . O
different . . O
aeds . . O
showed . . O
that . . O
patients . . O
randomized . . O
to . . O
one . . O
of . . O
the . . O
aeds . . O
had . . O
approximately . . O
twice . . O
the . . O
risk . . B-Factor
( . . O
adjusted . . O
relative . . O
risk . . O
1.8 . . O
, . . O
95% . . O
confidence . . O
interval . . O
[ . . O
ci . . O
] . . O
: . . O
1.2 . . O
, . . O
2.7 . . O
) . . O
of . . O
suicidal . . B-AdverseReaction
thinking . . I-AdverseReaction
or . . O
behavior . . O
compared . . O
with . . O
patients . . O
randomized . . O
to . . O
placebo . . O
. . . O

in . . O
these . . O
trials . . O
, . . O
which . . O
had . . O
a . . O
median . . O
treatment . . O
duration . . O
of . . O
12 . . O
weeks . . O
, . . O
the . . O
estimated . . O
incidence . . O
of . . O
suicidal . . B-AdverseReaction
behavior . . I-AdverseReaction
or . . O
ideation . . O
among . . O
27,863 . . O
aed . . O
- . . O
treated . . O
patients . . O
was . . O
0.43% . . O
compared . . O
with . . O
0.24% . . O
among . . O
16,029 . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
representing . . O
an . . O
increase . . O
of . . O
approximately . . O
1 . . O
case . . O
of . . O
suicidal . . B-AdverseReaction
thinking . . I-AdverseReaction
or . . O
behavior . . O
for . . O
every . . O
530 . . O
patients . . O
treated . . O
. . . O

there . . O
were . . O
4 . . O
suicides . . B-AdverseReaction
in . . O
drug . . O
- . . O
treated . . O
patients . . O
in . . O
the . . O
trials . . O
and . . O
none . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
but . . O
the . . O
number . . B-Factor
is . . I-Factor
too . . I-Factor
small . . I-Factor
to . . O
allow . . O
any . . O
conclusion . . O
about . . O
drug . . O
effect . . O
on . . O
suicide . . B-AdverseReaction
. . . O

increased . . O
mortality . . O

in . . O
the . . O
open . . O
- . . O
label . . O
study . . O
3 . . O
, . . O
6.9% . . O
( . . O
16 . . O
/ . . O
233 . . O
) . . O
subjects . . O
died . . B-AdverseReaction
. . . O

risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behaviors . . O
by . . O
indication . . O
for . . O
antiepileptic . . O
drugs . . O
in . . O
the . . O
pooled . . O
analysis . . O

excerpt . . O
: . . O
* . . O
thrombocytopenia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
( . . O
neutropenia . . B-AdverseReaction
and . . O
lymphopenia . . B-AdverseReaction
) . . O
, . . O
and . . O
anemia . . B-AdverseReaction
: . . O
monitor . . O
blood . . O
counts . . O
and . . O
modify . . O
dosage . . O
for . . O
hematologic . . O
toxicities . . O
. . . O

epilepsy . . O
and . . O
many . . O
other . . O
illnesses . . O
for . . O
which . . O
aeds . . O
are . . O
prescribed . . O
are . . O
themselves . . O
associated . . O
with . . O
morbidity . . O
and . . O
mortality . . O
and . . O
an . . O
increased . . O
risk . . O
of . . O
suicidal . . O
thoughts . . O
and . . O
behavior . . O
. . . O

behaviors . . O
of . . O
concern . . O
should . . O
be . . O
reported . . O
immediately . . O
to . . O
healthcare . . O
providers . . O
. . . O

advise . . O
women . . O
of . . O
potential . . O
harm . . O
to . . O
the . . O
fetus . . O
and . . O
to . . O
avoid . . O
pregnancy . . O
while . . O
receiving . . O
beleodaq . . O
. . . O

as . . O
with . . O
all . . O
aeds . . O
, . . O
when . . O
potiga . . O
is . . O
discontinued . . O
, . . O
it . . O
should . . O
be . . O
withdrawn . . O
gradually . . O
when . . O
possible . . O
to . . O
minimize . . O
the . . O
potential . . O
of . . O
increased . . O
seizure . . O
frequency . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
. . . O

5.2 . . O
infections . . O

( . . O
a . . O
) . . O
premature . . O
discontinuation . . O
of . . O
eliquis . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction

[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.4 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
, . . O
and . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

epidural . . O
or . . O
spinal . . B-AdverseReaction
hematomas . . I-AdverseReaction
may . . B-Factor
occur . . O
in . . O
patients . . O
treated . . O
with . . O
eliquis . . O
who . . O
are . . O
receiving . . O
neuraxial . . O
anesthesia . . O
or . . O
undergoing . . O
spinal . . O
puncture . . O
. . . O

monitor . . O
patients . . O
frequently . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
neurological . . O
impairment . . O
. . . O

women . . O
of . . O
childbearing . . O
potential . . O
should . . O
be . . O
advised . . O
to . . O
avoid . . O
pregnancy . . O
while . . O
receiving . . O
beleodaq . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
described . . O
in . . O
more . . O
detail . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
section . . O
of . . O
the . . O
label . . O
: . . O

consider . . O
these . . O
risks . . O
when . . O
scheduling . . O
patients . . O
for . . O
spinal . . O
procedures . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

the . . O
safety . . O
evaluation . . O
of . . O
zykadia . . O
is . . O
based . . O
on . . O
255 . . O
alk . . O
- . . O
positive . . O
patients . . O
in . . O
study . . O
1 . . O
( . . O
246 . . O
patients . . O
with . . O
nsclc . . O
and . . O
9 . . O
patients . . O
with . . O
other . . O
cancers . . O
who . . O
received . . O
zykadia . . O
at . . O
a . . O
dose . . O
of . . O
750 . . O
mg . . O
daily . . O
) . . O
. . . O

in . . O
the . . O
monotherapy . . O
epilepsy . . O
trials . . O
( . . O
study . . O
1 . . O
and . . O
study . . O
2 . . O
) . . O
, . . O
13% . . O
of . . O
patients . . O
randomized . . O
to . . O
receive . . O
aptiom . . O
at . . O
the . . O
recommended . . O
doses . . O
of . . O
1200 . . O
mg . . O
and . . O
1600 . . O
mg . . O
once . . O
daily . . O
discontinued . . O
from . . O
the . . O
trials . . O
as . . O
a . . O
result . . O
of . . O
an . . O
adverse . . O
event . . O
. . . O

dose . . O
reductions . . O
due . . O
to . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
59% . . O
of . . O
patients . . O
treated . . O
with . . O
zykadia . . O
. . . O

the . . O
adverse . . O
reactions . . O
most . . O
commonly . . O
( . . O
> . . O
= . . O
1% . . O
in . . O
any . . O
aptiom . . O
treatment . . O
group . . O
, . . O
and . . O
greater . . O
than . . O
placebo . . O
) . . O
leading . . O
to . . O
discontinuation . . O
, . . O
in . . O
descending . . O
order . . O
of . . O
frequency . . O
, . . O
were . . O
dizziness . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
ataxia . . B-AdverseReaction
, . . O
diplopia . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
vertigo . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
dysarthria . . B-AdverseReaction
, . . O
and . . O
tremor . . B-AdverseReaction
. . . O

adverse . . O
reactions . . O
during . . O
titration . . O
were . . O
less . . O
frequent . . O
for . . O
patients . . O
who . . O
began . . O
therapy . . O
at . . O
an . . O
initial . . O
dose . . O
of . . O
400 . . O
mg . . O
for . . O
1 . . O
week . . O
and . . O
then . . O
increased . . O
to . . O
800 . . O
mg . . O
compared . . O
to . . O
patients . . O
who . . O
initiated . . O
therapy . . O
at . . O
800 . . O
mg . . O
. . . O

table . . O
3 . . O
: . . O
adverse . . O
reactions . . O
incidence . . O
in . . O
pooled . . O
controlled . . O
clinical . . O
trials . . O
of . . O
adjunctive . . O
therapy . . O
in . . O
adults . . O
( . . O
events . . O
> . . O
= . . O
2% . . O
of . . O
patients . . O
in . . O
the . . O
aptiom . . O
800 . . O
mg . . O
or . . O
1200 . . O
mg . . O
dose . . O
group . . O
and . . O
more . . O
frequent . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O
) . . O
placebo . . O
aptiom . . O
800 . . O
mg . . O
1200 . . O
mg . . O
( . . O
n . . O
= . . O
426 . . O
) . . O
% . . O
( . . O
n . . O
= . . O
415 . . O
) . . O
% . . O
( . . O
n . . O
= . . O
410 . . O
) . . O
% . . O
ear . . O
and . . O
labyrinth . . O
disorders . . O
vertigo . . B-AdverseReaction
< . . O
1 . . O
2 . . O
6 . . O
eye . . O
disorders . . O
diplopia . . B-AdverseReaction
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
visual . . B-AdverseReaction
impairment . . I-AdverseReaction
211 . . O
962 . . O
1151 . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
vomiting . . B-AdverseReaction
diarrhea . . B-AdverseReaction
constipation . . B-AdverseReaction
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
gastritis . . B-AdverseReaction
53311 . . O
< . . O
1 . . O
1064222 . . O
1610222 . . O
< . . O
1 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
asthenia . . B-AdverseReaction
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
42 . . O
< . . O
11 . . O
4222 . . O
7321 . . O
infections . . O
and . . O
infestations . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
1 . . O
2 . . O
2 . . O
injury . . O
, . . O
poisoning . . O
and . . O
procedural . . O
complications . . O
fall . . B-AdverseReaction
1 . . O
3 . . O
1 . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
hyponatremia . . B-AdverseReaction
< . . O
1 . . O
2 . . O
2 . . O
nervous . . O
system . . O
disorders . . O
dizziness . . B-AdverseReaction
somnolence . . B-AdverseReaction
headache . . B-AdverseReaction
ataxia . . B-AdverseReaction
balance . . B-AdverseReaction
disorder . . I-AdverseReaction
tremor . . B-AdverseReaction
dysarthria . . B-AdverseReaction
memory . . B-AdverseReaction
impairment . . I-AdverseReaction
nystagmus . . B-AdverseReaction
9892 . . O
< . . O
110 . . O
< . . O
1 . . O
< . . O
1 . . O
201113432111 . . O
281815634222 . . O
psychiatric . . O
disorders . . O
depression . . B-AdverseReaction
insomnia . . B-AdverseReaction
21 . . O
12 . . O
32 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
1 . . O
2 . . O
1 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
1 . . O
1 . . O
3 . . O
vascular . . O
disorders . . O
hypertension . . B-AdverseReaction
1 . . O
1 . . O
2 . . O
other . . O
adverse . . O
reactions . . O
with . . O
aptiom . . O
use . . O

the . . O
following . . O
serious . . O
adverse . . O
reactionsare . . O
discussed . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

* . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O
[ . . O
see . . O
boxed . . O
warning . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
0.5% . . O
) . . O
are . . O
nausea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
feeling . . B-AdverseReaction
hot . . I-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
and . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
6 . . O
) . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

although . . O
there . . O
were . . O
few . . O
non . . O
- . . O
caucasian . . O
patients . . O
, . . O
no . . O
differences . . O
in . . O
the . . O
incidences . . O
of . . O
adverse . . O
reactions . . O
compared . . O
to . . O
caucasian . . O
patients . . O
were . . O
observed . . O
. . . O

the . . O
adverse . . O
reactions . . O
described . . O
in . . O
this . . O
section . . O
reflect . . O
eovist . . O
exposure . . O
in . . O
1,989 . . O
subjects . . O
with . . O
the . . O
majority . . O
( . . O
1,581 . . O
subjects . . O
) . . O
receiving . . O
the . . O
recommended . . O
dose . . O
. . . O

overall . . O
, . . O
59% . . O
of . . O
the . . O
subjects . . O
were . . O
men . . O
and . . O
the . . O
ethnic . . O
distribution . . O
was . . O
64% . . O
caucasian . . O
, . . O
22% . . O
asian . . O
, . . O
3% . . O
hispanic . . O
, . . O
2% . . O
black . . O
, . . O
and . . O
0.5% . . O
of . . O
subjects . . O
consisted . . O
of . . O
other . . O
ethnic . . O
groups . . O
. . . O

the . . O
average . . O
age . . O
was . . O
57 . . O
years . . O
( . . O
age . . O
range . . O
from . . O
19 . . O
to . . O
84 . . O
years . . O
) . . O
. . . O

overall . . O
, . . O
4% . . O
of . . O
subjects . . O
reported . . O
one . . O
or . . O
more . . O
adverse . . O
reactions . . O
following . . O
eovist . . O
administration . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
novartis . . O
pharmaceuticals . . O
corporation . . O
at . . O
1-888-669-6682 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

of . . O
these . . O
, . . O
806 . . O
received . . O
fanapt . . O
for . . O
at . . O
least . . O
6 . . O
months . . O
, . . O
with . . O
463 . . O
exposed . . O
to . . O
fanapt . . O
for . . O
at . . O
least . . O
12 . . O
months . . O
. . . O

elevation . . B-AdverseReaction
of . . I-AdverseReaction
serum . . I-AdverseReaction
iron . . I-AdverseReaction
values . . O
and . . O
serum . . O
bilirubin . . O
laboratory . . O
values . . O
were . . O
reported . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
patients . . O
after . . O
administration . . O
of . . O
eovist . . O
. . . O

warning . . O
: . . O
distant . . B-AdverseReaction
spread . . I-AdverseReaction
of . . I-AdverseReaction
toxin . . I-AdverseReaction
effect . . I-AdverseReaction

these . . O
symptoms . . O
have . . O
been . . O
reported . . O
hours . . O
to . . O
weeks . . O
after . . O
injection . . O
. . . O

the . . O
risk . . O
of . . O
symptoms . . O
is . . O
probably . . O
greatest . . O
in . . O
children . . O
treated . . O
for . . O
spasticity . . O
but . . O
symptoms . . O
can . . O
also . . O
occur . . O
in . . O
adults . . O
treated . . O
for . . O
spasticity . . O
and . . O
other . . O
conditions . . O
, . . O
particularly . . O
in . . O
those . . O
patients . . O
who . . O
have . . O
underlying . . O
conditions . . O
that . . O
would . . O
predispose . . O
them . . O
to . . O
these . . O
symptoms . . O
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O

warning . . O
: . . O
distant . . B-AdverseReaction
spread . . I-AdverseReaction
of . . I-AdverseReaction
toxin . . I-AdverseReaction
effect . . I-AdverseReaction

dizziness . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
and . . O
weight . . B-AdverseReaction
increased . . I-AdverseReaction
were . . O
at . . O
least . . O
twice . . O
as . . O
common . . O
on . . O
20 . . O
to . . O
24 . . O
mg . . O
/ . . O
day . . O
as . . O
on . . O
10 . . O
to . . O
16 . . O
mg . . O
/ . . O
day . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

excerpt . . O
: . . O
* . . O
mineralocorticoid . . B-AdverseReaction
excess . . I-AdverseReaction
: . . O
use . . O
zytiga . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
cardiovascular . . O
disease . . O
. . . O

the . . O
safety . . O
of . . O
zytiga . . O
in . . O
patients . . O
with . . O
lvef . . O
< . . O
50% . . O
or . . O
nyha . . O
class . . O
iii . . O
or . . O
iv . . O
heart . . O
failure . . O
in . . O
study . . O
1 . . O
or . . O
lvef . . O
< . . O
50% . . O
or . . O
nyha . . O
class . . O
ii . . O
to . . O
iv . . O
heart . . O
failure . . O
in . . O
study . . O
2 . . O
was . . O
not . . O
established . . O
. . . O

in . . O
short . . O
- . . O
term . . O
placebo . . O
- . . O
controlled . . O
trials . . O
( . . O
4 . . O
- . . O
to . . O
6 . . O
- . . O
weeks . . O
) . . O
, . . O
there . . O
were . . O
1.0% . . O
( . . O
13 . . O
/ . . O
1342 . . O
) . . O
iloperidone . . O
- . . O
treated . . O
patients . . O
with . . O
hematocrit . . O
at . . O
least . . O
one . . O
time . . O
below . . O
the . . O
extended . . O
normal . . O
range . . O
during . . O
post . . O
- . . O
randomization . . O
treatment . . O
, . . O
compared . . O
to . . O
0.3% . . O
( . . O
2 . . O
/ . . O
585 . . O
) . . O
on . . O
placebo . . O
. . . O

the . . O
extended . . O
normal . . O
range . . O
for . . O
lowered . . O
hematocrit . . O
was . . O
defined . . O
in . . O
each . . O
of . . O
these . . O
trials . . O
as . . O
the . . O
value . . O
15% . . O
below . . O
the . . O
normal . . O
range . . O
for . . O
the . . O
centralized . . O
laboratory . . O
that . . O
was . . O
used . . O
in . . O
the . . O
trial . . O
. . . O

increased . . O
dosage . . O
of . . O
corticosteroids . . O
may . . O
be . . O
indicated . . O
before . . O
, . . O
during . . O
and . . O
after . . O
stressful . . O
situations . . O
. . . O

reactions . . O
are . . O
further . . O
categorized . . O
by . . O
meddra . . O
system . . O
organ . . O
class . . O
and . . O
listed . . O
in . . O
order . . O
of . . O
decreasing . . O
frequency . . O
according . . O
to . . O
the . . O
following . . O
definitions . . O
: . . O
frequent . . O
adverse . . O
events . . O
are . . O
those . . O
occurring . . O
in . . O
at . . O
least . . O
1 . . O
/ . . O
100 . . O
patients . . O
( . . O
only . . O
those . . O
not . . O
listed . . O
in . . O
table . . O
7 . . O
appear . . O
in . . O
this . . O
listing . . O
) . . O
; . . O
infrequent . . O
adverse . . O
reactions . . O
are . . O
those . . O
occurring . . O
in . . O
1 . . O
/ . . O
100 . . O
to . . O
1 . . O
/ . . O
1000 . . O
patients . . O
; . . O
rare . . O
events . . O
are . . O
those . . O
occurring . . O
in . . O
fewer . . O
than . . O
1 . . O
/ . . O
1000 . . O
patients . . O
. . . O

blood . . O
and . . O
lymphatic . . O
disorders . . O
: . . O
infrequent . . O
- . . O
anemia . . B-AdverseReaction
, . . O
iron . . B-AdverseReaction
deficiency . . I-AdverseReaction
anemia . . I-AdverseReaction
; . . O
rare . . O
- . . O
leukopenia . . B-AdverseReaction

cardiac . . O
disorders . . O
: . . O
frequent . . O
- . . O
palpitations . . B-AdverseReaction
; . . O
rare . . O
- . . O
arrhythmia . . B-AdverseReaction
, . . O
atrioventricular . . B-AdverseReaction
block . . I-AdverseReaction
first . . B-Severity
degree . . I-Severity
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
( . . O
including . . O
congestive . . O
and . . O
acute . . O
) . . O

use . . O
caution . . O
when . . O
treating . . O
patients . . O
whose . . O
underlying . . O
medical . . O
conditions . . O
might . . O
be . . O
compromised . . O
by . . O
increases . . O
in . . O
blood . . O
pressure . . O
, . . O
hypokalemia . . O
or . . O
fluid . . O
retention . . O
, . . O
e . . O
. . . O
g . . O
. . . O
, . . O
those . . O
with . . O
heart . . O
failure . . O
, . . O
recent . . O
myocardial . . O
infarction . . O
or . . O
ventricular . . O
arrhythmia . . O
. . . O

endocrine . . O
disorders . . O
: . . O
infrequent . . O
- . . O
hypothyroidism . . B-AdverseReaction

the . . O
safety . . O
of . . O
zytiga . . O
in . . O
patients . . O
with . . O
left . . O
ventricular . . O
ejection . . O
fraction . . O
< . . O
50% . . O
or . . O
new . . O
york . . O
heart . . O
association . . O
( . . O
nyha . . O
) . . O
class . . O
iii . . O
or . . O
iv . . O
heart . . O
failure . . O
( . . O
in . . O
study . . O
1 . . O
) . . O
or . . O
nyha . . O
class . . O
ii . . O
to . . O
iv . . O
heart . . O
failure . . O
( . . O
in . . O
study . . O
2 . . O
) . . O
was . . O
not . . O
established . . O
because . . O
these . . O
patients . . O
were . . O
excluded . . O
from . . O
these . . O
randomized . . O
clinical . . O
trials . . O
[ . . O
seeclinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

hepatobiliary . . O
disorders . . O
: . . O
infrequent . . O
- . . O
cholelithiasis . . B-AdverseReaction

adrenocortical . . B-AdverseReaction
insufficiency . . I-AdverseReaction
was . . O
reported . . O
in . . O
patients . . O
receiving . . O
zytiga . . O
in . . O
combination . . O
with . . O
prednisone . . O
, . . O
following . . O
interruption . . O
of . . O
daily . . O
steroids . . O
and . . O
/ . . O
or . . O
with . . O
concurrent . . O
infection . . O
or . . O
stress . . O
. . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
frequent . . O
- . . O
myalgia . . B-AdverseReaction
, . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
; . . O
rare . . O
- . . O
torticollis . . B-AdverseReaction

psychiatric . . O
disorders . . O
: . . O
frequent . . O
- . . O
restlessness . . B-AdverseReaction
, . . O
aggression . . B-AdverseReaction
, . . O
delusion . . B-AdverseReaction
; . . O
infrequent . . O
- . . O
hostility . . B-AdverseReaction
, . . O
libido . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
paranoia . . B-AdverseReaction
, . . O
anorgasmia . . B-AdverseReaction
, . . O
confusional . . B-AdverseReaction
state . . I-AdverseReaction
, . . O
mania . . B-AdverseReaction
, . . O
catatonia . . B-AdverseReaction
, . . O
mood . . B-AdverseReaction
swings . . I-AdverseReaction
, . . O
panic . . B-AdverseReaction
attack . . I-AdverseReaction
, . . O
obsessive . . B-AdverseReaction
- . . I-AdverseReaction
compulsive . . I-AdverseReaction
disorder . . I-AdverseReaction
, . . O
bulimia . . B-AdverseReaction
nervosa . . I-AdverseReaction
, . . O
delirium . . B-AdverseReaction
, . . O
polydipsia . . B-AdverseReaction
psychogenic . . I-AdverseReaction
, . . O
impulse . . B-AdverseReaction
- . . I-AdverseReaction
control . . I-AdverseReaction
disorder . . I-AdverseReaction
, . . O
major . . B-AdverseReaction
depression . . I-AdverseReaction

in . . O
the . . O
two . . O
randomized . . O
clinical . . O
trials . . O
, . . O
grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
alt . . O
or . . O
ast . . B-AdverseReaction
increases . . I-AdverseReaction
( . . O
at . . O
least . . O
5 . . O
* . . O
uln . . O
) . . O
were . . O
reported . . O
in . . O
4% . . O
of . . O
patients . . O
who . . O
received . . O
zytiga . . O
, . . O
typically . . O
during . . O
the . . O
first . . O
3 . . O
months . . O
after . . O
starting . . O
treatment . . O
. . . O

patients . . O
whose . . O
baseline . . O
alt . . O
or . . O
ast . . O
were . . O
elevated . . O
were . . O
more . . O
likely . . O
to . . O
experience . . O
liver . . B-AdverseReaction
test . . I-AdverseReaction
elevation . . I-AdverseReaction
than . . O
those . . O
beginning . . O
with . . O
normal . . O
values . . O
. . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
infrequent . . O
- . . O
epistaxis . . B-AdverseReaction
, . . O
asthma . . B-AdverseReaction
, . . O
rhinorrhea . . B-AdverseReaction
, . . O
sinus . . B-AdverseReaction
congestion . . I-AdverseReaction
, . . O
nasal . . B-AdverseReaction
dryness . . I-AdverseReaction
; . . O
rare . . O
- . . O
dry . . B-AdverseReaction
throat . . I-AdverseReaction
, . . O
sleep . . B-AdverseReaction
apnea . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
exertional . . I-AdverseReaction

6.2 . . O
postmarketing . . O
experience . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
fanapt . . O
: . . O
retrograde . . B-AdverseReaction
ejaculation . . I-AdverseReaction
. . . O

re . . O
- . . O
treatment . . O
with . . O
zytiga . . O
at . . O
a . . O
reduced . . O
dose . . O
level . . O
may . . O
take . . O
place . . O
only . . O
after . . O
return . . O
of . . O
liver . . O
function . . O
tests . . O
to . . O
the . . O
patient's . . O
baseline . . O
or . . O
to . . O
ast . . O
and . . O
alt . . O
less . . O
than . . O
or . . O
equal . . O
to . . O
2.5 . . O
* . . O
uln . . O
and . . O
total . . O
bilirubin . . O
less . . O
than . . O
or . . O
equal . . O
to . . O
1.5 . . O
* . . O
uln . . O
[ . . O
seedosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

( . . O
5.1 . . O
) . . O

( . . O
5.3 . . O
) . . O
* . . O
venous . . B-AdverseReaction
thromboembolism . . I-AdverseReaction
: . . O
deep . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
and . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
can . . B-Factor
occur . . O
in . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

skin . . O
reactions . . O
any . . O
gradea . . O
> . . O
baseline . . O
grade . . O
4 . . O

picato . . O
( . . O
r . . O
) . . O
gel . . O
( . . O
n . . O
= . . O
274 . . O
) . . O
vehicle . . O
( . . O
n . . O
= . . O
271 . . O
) . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
( . . O
n . . O
= . . O
274 . . O
) . . O
vehicle . . O
( . . O
n . . O
= . . O
271 . . O
) . . O
erythema . . O
258 . . O
( . . O
94% . . O
) . . O
69 . . O
( . . O
25% . . O
) . . O
66 . . O
( . . O
24% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
flaking . . O
/ . . O
scaling . . O
233 . . O
( . . O
85% . . O
) . . O
67 . . O
( . . O
25% . . O
) . . O
25 . . O
( . . O
9% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
crusting . . O
220 . . O
( . . O
80% . . O
) . . O
46 . . O
( . . O
17% . . O
) . . O
16 . . O
( . . O
6% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
swelling . . O
217 . . O
( . . O
79% . . O
) . . O
11 . . O
( . . O
4% . . O
) . . O
14 . . O
( . . O
5% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
vesiculation . . O
/ . . O
pustulation . . O
154 . . O
( . . O
56% . . O
) . . O
1 . . O
( . . O
0% . . O
) . . O
15 . . O
( . . O
5% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
erosion . . O
/ . . O
ulceration . . O
87 . . O
( . . O
32% . . O
) . . O
3 . . O
( . . O
1% . . O
) . . O
1 . . O
( . . O
0% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
a . . O
mild . . O
( . . O
grade . . O
1 . . O
) . . O
, . . O
moderate . . O
( . . O
grade . . O
2-3 . . O
) . . O
or . . O
severe . . O
( . . O
grade . . O
4 . . O
) . . O
. . . O

discontinue . . O
for . . O
intolerable . . O
grade . . O
2 . . O
, . . O
or . . O
grade . . O
3 . . O
or . . O
4 . . O
rash . . O
not . . O
improving . . O
within . . O
3 . . O
weeks . . O
despite . . O
interruption . . O
of . . O
tafinlar . . O
. . . O

( . . O
5.8 . . O
, . . O
2.3 . . O
) . . O
* . . O
hyperglycemia . . B-AdverseReaction
: . . O
monitor . . O
serum . . O
glucose . . O
levels . . O
in . . O
patients . . O
with . . O
pre . . O
- . . O
existing . . O
diabetes . . O
or . . O
hyperglycemia . . O
. . . O

less . . O
common . . O
adverse . . O
reactions . . O
in . . O
subjects . . O
treated . . O
with . . O
picato . . O
( . . O
r . . O
) . . O
included . . O
: . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
conjunctivitis . . B-AdverseReaction
. . . O

new . . O
primary . . B-AdverseReaction
malignancies . . I-AdverseReaction
, . . I-AdverseReaction
cutaneous . . I-AdverseReaction
and . . O
non . . O
- . . O
cutaneous . . O
, . . O
can . . B-Factor
occur . . O
when . . O
tafinlar . . O
is . . O
administered . . O
as . . O
a . . O
single . . O
agent . . O
or . . O
when . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

if . . O
a . . O
gout . . O
flare . . O
occurs . . O
during . . O
treatment . . O
, . . O
uloric . . O
need . . O
not . . O
be . . O
discontinued . . O
. . . O

do . . O
not . . O
restart . . O
uloric . . O
if . . O
liver . . O
injury . . O
is . . O
confirmed . . O
and . . O
no . . O
alternate . . O
etiology . . O
can . . O
be . . O
found . . O
. . . O

( . . O
5.3 . . O
) . . O

no . . O
dose . . O
modifications . . O
of . . O
tafinlar . . O
or . . O
trametinib . . O
are . . O
required . . O
in . . O
patients . . O
who . . O
develop . . O
new . . O
primary . . O
cutaneous . . O
malignancies . . O
. . . O

5.2 . . O
cardiovascular . . O
events . . O

5.2 . . O
tumor . . O
promotion . . O
in . . O
braf . . O
wild . . O
- . . O
type . . O
melanoma . . O

obtain . . O
a . . O
liver . . O
test . . O
panel . . O
( . . O
serum . . O
alanine . . O
aminotransferase . . O
[ . . O
alt . . O
] . . O
, . . O
aspartate . . O
aminotransferase . . O
[ . . O
ast . . O
] . . O
, . . O
alkaline . . O
phosphatase . . O
, . . O
and . . O
total . . O
bilirubin . . O
) . . O
as . . O
a . . O
baseline . . O
before . . O
initiating . . O
uloric . . O
. . . O

for . . O
patients . . O
with . . O
lesser . . O
elevations . . O
of . . O
serum . . O
alt . . O
or . . O
bilirubin . . O
and . . O
with . . O
an . . O
alternate . . O
probable . . O
cause . . O
, . . O
treatment . . O
with . . O
uloric . . O
can . . O
be . . O
used . . O
with . . O
caution . . O
. . . O

6 . . O
adverse . . O
reactions . . O

excerpt . . O
: . . O
* . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
3% . . O
of . . O
kalbitor . . O
- . . O
treated . . O
patients . . O
and . . O
greater . . O
than . . O
placebo . . O
are . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
and . . O
nasopharyngitis . . B-AdverseReaction
. . . O

( . . O
6 . . O
) . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
dyax . . O
corp . . O
. . . O
at . . O
1-888-452-5248 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
was . . O
fatal . . B-AdverseReaction
in . . O
2% . . O
( . . O
1 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

the . . O
safety . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
kalbitor . . O
in . . O
255 . . O
patients . . O
with . . O
hae . . O
treated . . O
with . . O
either . . O
intravenous . . O
or . . O
subcutaneous . . O
kalbitor . . O
. . . O

withhold . . O
trametinib . . O
and . . O
continue . . O
tafinlar . . O
at . . O
the . . O
same . . O
dose . . O
for . . O
uncomplicated . . O
dvt . . O
or . . O
pe . . O
; . . O
if . . O
improved . . O
within . . O
3 . . O
weeks . . O
, . . O
trametinib . . O
may . . O
be . . O
resumed . . O
at . . O
a . . O
lower . . O
dose . . O
level . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

patients . . O
treated . . O
with . . O
kalbitor . . O
were . . O
between . . O
the . . O
ages . . O
of . . O
10 . . O
and . . O
78 . . O
years . . O
. . . O

overall . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
in . . O
255 . . O
patients . . O
with . . O
hae . . O
were . . O
headache . . B-AdverseReaction
( . . O
16% . . O
) . . O
, . . O
nausea . . B-AdverseReaction
( . . O
13% . . O
) . . O
, . . O
fatigue . . B-AdverseReaction
( . . O
12% . . O
) . . O
, . . O
diarrhea . . B-AdverseReaction
( . . O
11% . . O
) . . O
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
8% . . O
) . . O
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
7% . . O
) . . O
, . . O
nasopharyngitis . . B-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
vomiting . . B-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
pruritus . . B-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
upper . . B-AdverseReaction
abdominal . . I-AdverseReaction
pain . . I-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
and . . O
pyrexia . . B-AdverseReaction
( . . O
5% . . O
) . . O
. . . O

the . . O
median . . O
time . . O
to . . O
onset . . O
of . . O
cardiomyopathy . . B-AdverseReaction
in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
was . . O
86 . . O
days . . O
( . . O
range . . O
: . . O
27 . . O
to . . O
253 . . O
days . . O
) . . O
. . . O

two . . O
percent . . O
demonstrated . . O
a . . O
decrease . . B-AdverseReaction
in . . I-AdverseReaction
lvef . . I-AdverseReaction
below . . O
institutional . . B-Severity
lower . . I-Severity
limits . . I-Severity
of . . I-Severity
normal . . I-Severity
with . . O
an . . O
absolute . . B-AdverseReaction
decrease . . I-AdverseReaction
in . . I-AdverseReaction
lvef . . I-AdverseReaction
of . . O
> . . O
= . . O
20% . . B-Severity
below . . I-Severity
baseline . . I-Severity
. . . O

table . . O
1 . . O
shows . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
3% . . O
of . . O
kalbitor . . O
- . . O
treated . . O
patients . . O
that . . O
also . . O
occurred . . O
at . . O
a . . O
higher . . O
rate . . O
than . . O
in . . O
the . . O
placebo . . O
- . . O
treated . . O
patients . . O
in . . O
the . . O
two . . O
controlled . . O
trials . . O
( . . O
edema3 . . O
and . . O
edema4 . . O
) . . O
of . . O
the . . O
30 . . O
mg . . O
subcutaneous . . O
dose . . O
. . . O

for . . O
symptomatic . . O
cardiomyopathy . . O
or . . O
persistent . . O
, . . O
asymptomatic . . O
lv . . O
dysfunction . . O
that . . O
does . . O
not . . O
resolve . . O
within . . O
4 . . O
weeks . . O
, . . O
permanently . . O
discontinue . . O
trametinib . . O
and . . O
withhold . . O
tafinlar . . O
. . . O

adverse . . O
reactions . . O
reported . . O
by . . O
these . . O
patients . . O
who . . O
received . . O
the . . O
additional . . O
30 . . O
mg . . O
subcutaneous . . O
dose . . O
of . . O
kalbitor . . O
were . . O
consistent . . O
with . . O
those . . O
reported . . O
in . . O
the . . O
patients . . O
receiving . . O
a . . O
single . . O
dose . . O
. . . O

across . . O
clinical . . O
trials . . O
of . . O
tafinlar . . O
administered . . O
in . . O
combination . . O
with . . O
trametinib . . O
( . . O
n . . O
= . . O
202 . . O
) . . O
, . . O
the . . O
incidence . . O
of . . O
rped . . B-AdverseReaction
was . . O
1% . . O
( . . O
2 . . O
/ . . O
202 . . O
) . . O
. . . O

if . . O
tafinlar . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
, . . O
do . . O
not . . O
modify . . O
the . . O
dose . . O
of . . O
tafinlar . . O
. . . O

the . . O
test . . O
results . . O
for . . O
the . . O
ecallantide . . O
program . . O
were . . O
determined . . O
using . . O
one . . O
of . . O
two . . O
assay . . O
formats . . O
: . . O
elisa . . O
and . . O
bridging . . O
electrochemiluminescence . . O
( . . O
ecl . . O
) . . O
. . . O

if . . O
resolution . . O
of . . O
the . . O
rped . . O
is . . O
documented . . O
on . . O
repeat . . O
ophthalmological . . O
evaluation . . O
within . . O
3 . . O
weeks . . O
, . . O
resume . . O
trametinib . . O
at . . O
a . . O
lower . . O
dose . . O
level . . O
. . . O

symptomatic . . O
treatment . . O
employed . . O
in . . O
clinical . . O
trials . . O
included . . O
steroid . . O
and . . O
mydriatic . . O
ophthalmic . . O
drops . . O
. . . O

because . . O
these . . O
events . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
frequency . . O
or . . O
to . . O
establish . . O
a . . O
causal . . O
relationship . . O
with . . O
drug . . O
exposure . . O
. . . O

monitor . . O
patients . . O
for . . O
visual . . O
signs . . O
and . . O
symptoms . . O
of . . O
uveitis . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
change . . O
in . . O
vision . . O
, . . O
photophobia . . O
, . . O
eye . . O
pain . . O
) . . O
. . . O

the . . O
incidence . . O
and . . O
severity . . O
of . . O
pyrexia . . B-AdverseReaction
are . . O
increased . . O
when . . O
tafinlar . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
compared . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

in . . O
trial . . O
1 . . O
, . . O
the . . O
incidence . . O
of . . O
fever . . O
( . . O
serious . . B-Severity
and . . O
non . . O
- . . O
serious . . O
) . . O
was . . O
28% . . O
in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
and . . O
10% . . O
in . . O
patients . . O
treated . . O
with . . O
dacarbazine . . O
. . . O

fever . . B-AdverseReaction
was . . O
complicated . . O
with . . O
chills . . B-AdverseReaction
/ . . O
rigors . . B-AdverseReaction
in . . O
51% . . O
( . . O
28 . . O
/ . . O
55 . . O
) . . O
, . . O
dehydration . . B-AdverseReaction
in . . O
9% . . O
( . . O
5 . . O
/ . . O
55 . . O
) . . O
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
in . . O
4% . . O
( . . O
2 . . O
/ . . O
55 . . O
) . . O
, . . O
and . . O
syncope . . B-AdverseReaction
in . . O
4% . . O
( . . O
2 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
in . . O
trial . . O
2 . . O
. . . O

trial . . O
1 . . O
, . . O
a . . O
multicenter . . O
, . . O
international . . O
, . . O
open . . O
- . . O
label . . O
, . . O
randomized . . O
( . . O
3 . . O
: . . O
1 . . O
) . . O
, . . O
controlled . . O
trial . . O
allocated . . O
250 . . O
patients . . O
with . . O
unresectable . . O
or . . O
metastatic . . O
braf . . O
v600e . . O
mutation . . O
- . . O
positive . . O
melanoma . . O
to . . O
receive . . O
tafinlar . . O
150 . . O
mg . . O
orally . . O
twice . . O
daily . . O
( . . O
n . . O
= . . O
187 . . O
) . . O
or . . O
dacarbazine . . O
1,000 . . O
mg . . O
/ . . O
m . . O
2 . . O
intravenously . . O
every . . O
3 . . O
weeks . . O
( . . O
n . . O
= . . O
63 . . O
) . . O
. . . O

the . . O
trial . . O
excluded . . O
patients . . O
with . . O
abnormal . . O
left . . O
ventricular . . O
ejection . . O
fraction . . O
or . . O
cardiac . . O
valve . . O
morphology . . O
( . . O
> . . O
= . . O
grade . . O
2 . . O
) . . O
, . . O
corrected . . O
qt . . O
interval . . O
> . . O
= . . O
480 . . O
milliseconds . . O
on . . O
electrocardiogram . . O
, . . O
or . . O
a . . O
known . . O
history . . O
of . . O
glucose . . O
- . . O
6 . . O
- . . O
phosphate . . O
dehydrogenase . . O
deficiency . . O
. . . O

withhold . . O
tafinlar . . O
for . . O
fever . . O
of . . O
101.3of . . O
or . . O
higher . . O
. . . O

refer . . O
to . . O
table . . O
2 . . O
for . . O
recommended . . O
dose . . O
modifications . . O
for . . O
adverse . . O
reactions . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

the . . O
most . . O
commonly . . O
occurring . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
were . . O
, . . O
in . . O
order . . O
of . . O
decreasing . . O
frequency . . O
: . . O
hyperkeratosis . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
papilloma . . B-AdverseReaction
, . . O
alopecia . . B-AdverseReaction
, . . O
and . . O
palmar . . B-AdverseReaction
- . . I-AdverseReaction
plantar . . I-AdverseReaction
erythrodysesthesia . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
ppes . . B-AdverseReaction
) . . O
. . . O

prophylaxis . . O
with . . O
antipyretics . . O
may . . O
be . . O
required . . O
when . . O
resuming . . O
tafinlar . . O
or . . O
trametinib . . O
. . . O

selected . . O
common . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
10% . . O
( . . O
all . . O
grades . . O
) . . O
or . . O
> . . O
= . . O
2% . . O
( . . O
grades . . O
3 . . O
or . . O
4 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlara . . O
tafinlarn . . O
= . . O
187 . . O
dacarbazine . . O
n . . O
= . . O
59 . . O
primary . . O
system . . O
organ . . O
class . . O
preferred . . O
term . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grades . . O
3 . . O
and . . O
4b . . O
( . . O
% . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grades . . O
3 . . O
and . . O
4 . . O
( . . O
% . . O
) . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
hyperkeratosis . . B-AdverseReaction
37 . . O
1 . . O
0 . . O
0 . . O
alopecia . . B-AdverseReaction
22 . . O
naf . . O
2 . . O
naf . . O
palmar . . B-AdverseReaction
- . . I-AdverseReaction
plantar . . I-AdverseReaction
erythrodysesthesia . . I-AdverseReaction
syndrome . . I-AdverseReaction
20 . . O
2 . . O
2 . . O
0 . . O
rash . . B-AdverseReaction
17 . . O
0 . . O
0 . . O
0 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
32 . . O
0 . . O
8 . . O
0 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
pyrexia . . B-AdverseReaction
28 . . O
3 . . O
10 . . O
0 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
arthralgia . . B-AdverseReaction
27 . . O
1 . . O
2 . . O
0 . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
12 . . O
3 . . O
7 . . O
0 . . O
myalgia . . B-AdverseReaction
11 . . O
0 . . O
0 . . O
0 . . O
neoplasms . . O
benign . . O
, . . O
malignant . . O
, . . O
and . . O
unspecified . . O
( . . O
including . . O
cysts . . O
and . . O
polyps . . O
) . . O
papilloma . . B-AdverseReaction
c . . O
27 . . O
0 . . O
2 . . O
0 . . O
cuscc . . B-AdverseReaction
d . . O
, . . O
e . . O
7 . . O
4 . . O
0 . . O
0 . . O
respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
12 . . O
0 . . O
5 . . O
0 . . O
gastrointestinal . . O
disorders . . O
constipation . . B-AdverseReaction
11 . . O
2 . . O
14 . . O
0 . . O
infections . . O
and . . O
infestations . . O
nasopharyngitis . . B-AdverseReaction
10 . . O
0 . . O
3 . . O
0 . . O
a . . O
adverse . . O
drug . . O
reactions . . O
, . . O
reported . . O
using . . O
meddra . . O
and . . O
graded . . O
using . . O
ctcae . . O
version . . O
4.0 . . O
for . . O
assessment . . O
of . . O
toxicity . . O
. . . O

across . . O
clinical . . O
trials . . O
of . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
( . . O
n . . O
= . . O
202 . . O
) . . O
, . . O
severe . . B-Severity
skin . . B-AdverseReaction
toxicity . . I-AdverseReaction
and . . O
secondary . . B-AdverseReaction
infections . . I-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
skin . . I-AdverseReaction
requiring . . O
hospitalization . . O
occurred . . O
in . . O
2.5% . . O
( . . O
5 . . O
/ . . O
202 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

f . . O
na . . O
= . . O
not . . O
applicable . . O
. . . O

in . . O
trial . . O
1 . . O
, . . O
5 . . O
of . . O
12 . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
diabetes . . O
required . . O
more . . O
intensive . . O
hypoglycemic . . O
therapy . . O
while . . O
taking . . O
tafinlar . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
pancreatitis . . B-AdverseReaction
. . . O

in . . O
trial . . O
2 . . O
, . . O
the . . O
incidence . . O
of . . O
grade . . B-Severity
3 . . I-Severity
hyperglycemia . . B-AdverseReaction
based . . O
on . . O
laboratory . . O
values . . O
was . . O
5% . . O
( . . O
3 . . O
/ . . O
55 . . O
) . . O
in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
compared . . O
with . . O
2% . . O
( . . O
1 . . O
/ . . O
53 . . O
) . . O
in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

based . . O
on . . O
its . . O
mechanism . . O
of . . O
action . . O
, . . O
tafinlar . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

patients . . O
with . . O
abnormal . . O
lvef . . O
, . . O
history . . O
of . . O
acute . . O
coronary . . O
syndrome . . O
within . . O
6 . . O
months . . O
, . . O
current . . O
evidence . . O
of . . O
class . . O
ii . . O
or . . O
greater . . O
congestive . . O
heart . . O
failure . . O
( . . O
new . . O
york . . O
heart . . O
association . . O
) . . O
, . . O
history . . O
rvo . . O
or . . O
rped . . O
, . . O
qtc . . O
interval . . O
> . . O
= . . O
480 . . O
msec . . O
, . . O
treatment . . O
refractory . . O
hypertension . . O
, . . O
uncontrolled . . O
arrhythmias . . O
, . . O
history . . O
of . . O
pneumonitis . . O
or . . O
interstitial . . O
lung . . O
disease . . O
, . . O
or . . O
a . . O
known . . O
history . . O
of . . O
g6pd . . O
deficiency . . O
were . . O
excluded . . O
. . . O

advise . . O
female . . O
patients . . O
of . . O
reproductive . . O
potential . . O
to . . O
use . . O
a . . O
highly . . O
effective . . O
non . . O
- . . O
hormonal . . O
method . . O
of . . O
contraception . . O
since . . O
tafinlar . . O
can . . O
render . . O
hormonal . . O
contraceptives . . O
ineffective . . O
, . . O
during . . O
treatment . . O
and . . O
for . . O
at . . O
least . . O
2 . . O
weeks . . O
after . . O
treatment . . O
with . . O
tafinlar . . O
or . . O
for . . O
4 . . O
months . . O
after . . O
treatment . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

advise . . O
patients . . O
to . . O
contact . . O
their . . O
healthcare . . O
provider . . O
if . . O
they . . O
become . . O
pregnant . . O
, . . O
or . . O
if . . O
pregnancy . . O
is . . O
suspected . . O
, . . O
while . . O
taking . . O
tafinlar . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
, . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

f . . O
includes . . O
the . . O
following . . O
terms . . O
: . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
and . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
acute . . I-AdverseReaction
. . . O

eye . . O
disorders . . O
: . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
, . . O
transient . . B-AdverseReaction
blindness . . I-AdverseReaction
. . . O

qt . . O
prolongation . . O
: . . O
in . . O
trial . . O
2 . . O
, . . O
qtcf . . B-AdverseReaction
prolongation . . I-AdverseReaction
to . . O
> . . O
500 . . B-Severity
msec . . I-Severity
occurred . . O
in . . O
4% . . O
( . . O
2 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
and . . O
in . . O
2% . . O
( . . O
1 . . O
/ . . O
53 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

if . . O
such . . O
symptoms . . O
occur . . O
, . . O
discontinue . . O
pristiq . . O
and . . O
initiate . . O
supportive . . O
treatment . . O
. . . O

52 . . O
( . . O
0.33 . . O
) . . O
125 . . O
( . . O
0.82 . . O
) . . O
0.41 . . O
( . . O
0.30 . . O
, . . O
0.57 . . O
) . . O
- . . O
hemorrhagic . . B-AdverseReaction
strokes . . O
38 . . O
( . . O
0.24 . . O
) . . O
74 . . O
( . . O
0.49 . . O
) . . O
0.51 . . O
( . . O
0.34 . . O
, . . O
0.75 . . O
) . . O
- . . O
other . . O
ich . . B-AdverseReaction
15 . . O
( . . O
0.10 . . O
) . . O
51 . . O
( . . O
0.34 . . O
) . . O
0.29 . . O
( . . O
0.16 . . O
, . . O
0.51 . . O
) . . O
- . . O
gastrointestinal . . O
( . . O
gi . . O
) . . O
128 . . O
( . . O
0.83 . . O
) . . O
141 . . O
( . . O
0.93 . . O
) . . O
0.89 . . O
( . . O
0.70 . . O
, . . O
1.14 . . O
) . . O
- . . O
fatal . . B-AdverseReaction
* . . O
* . . O
10 . . O
( . . O
0.06 . . O
) . . O
37 . . O
( . . O
0.24 . . O
) . . O
0.27 . . O
( . . O
0.13 . . O
, . . O
0.53 . . O
) . . O
- . . O
intracranial . . O
4 . . O
( . . O
0.03 . . O
) . . O
30 . . O
( . . O
0.20 . . O
) . . O
0.13 . . O
( . . O
0.05 . . O
, . . O
0.37 . . O
) . . O
- . . O
non . . O
- . . O
intracranial . . O
6 . . O
( . . O
0.04 . . O
) . . O
7 . . O
( . . O
0.05 . . O
) . . O
0.84 . . O
( . . O
0.28 . . O
, . . O
2.15 . . O
) . . O
- . . O
in . . O
aristotle . . O
, . . O
the . . O
results . . O
for . . O
major . . B-Severity
bleeding . . B-AdverseReaction
were . . O
generally . . O
consistent . . O
across . . O
most . . O
major . . O
subgroups . . O
including . . O
age . . O
, . . O
weight . . O
, . . O
chads2score . . O
( . . O
a . . O
scale . . O
from . . O
0 . . O
to . . O
6 . . O
used . . O
to . . O
estimate . . O
risk . . O
of . . O
stroke . . O
, . . O
with . . O
higher . . O
scores . . O
predicting . . O
greater . . O
risk . . O
) . . O
, . . O
prior . . O
warfarin . . O
use . . O
, . . O
geographic . . O
region . . O
, . . O
and . . O
aspirin . . O
use . . O
at . . O
randomization . . O
( . . O
figure . . O
1 . . O
) . . O
. . . O

major . . O
45 . . O
( . . O
1.41 . . O
) . . O
29 . . O
( . . O
0.92 . . O
) . . O
1.54 . . O
( . . O
0.96 . . O
, . . O
2.45 . . O
) . . O
0.07 . . O
fatal . . B-AdverseReaction
5 . . O
( . . O
0.16 . . O
) . . O
5 . . O
( . . O
0.16 . . O
) . . O
0.99 . . O
( . . O
0.23 . . O
, . . O
4.29 . . O
) . . O
- . . O
intracranial . . O
11 . . O
( . . O
0.34 . . O
) . . O
11 . . O
( . . O
0.35 . . O
) . . O
0.99 . . O
( . . O
0.39 . . O
, . . O
2.51 . . O
) . . O
- . . O
aristotle . . O
major . . B-Severity
bleeding . . B-AdverseReaction
forest . . O
plot . . O
other . . O
adverse . . O
reactions . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
including . . O
drug . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
, . . O
such . . O
as . . O
skin . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
and . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
such . . O
as . . O
allergic . . B-AdverseReaction
edema . . I-AdverseReaction
) . . O
and . . O
syncope . . B-AdverseReaction
were . . O
reported . . O
in . . O
< . . O
1% . . O
of . . O
patients . . O
receiving . . O
eliquis . . O
. . . O

* . . O
discontinuation . . B-AdverseReaction
syndrome . . I-AdverseReaction
: . . O
taper . . O
dose . . O
when . . O
possible . . O
and . . O
monitor . . O
for . . O
discontinuation . . O
symptoms . . O
( . . O
5.7 . . O
) . . O
. . . O

prophylaxis . . O
of . . O
deep . . O
vein . . O
thrombosis . . O
following . . O
hip . . O
or . . O
knee . . O
replacement . . O
surgery . . O

bleeding . . B-AdverseReaction
was . . O
assessed . . O
in . . O
each . . O
study . . O
beginning . . O
with . . O
the . . O
first . . O
dose . . O
of . . O
double . . O
- . . O
blind . . O
study . . O
drug . . O
. . . O

5.1 . . O
suicidal . . O
thoughts . . O
and . . O
behaviors . . O
in . . O
children . . O
, . . O
adolescents . . O
and . . O
young . . O
adults . . O

events . . O
and . . O
event . . O
rates . . O
include . . O
one . . O
enoxaparin . . O
- . . O
treated . . O
patient . . O
in . . O
advance . . O
- . . O
1 . . O
who . . O
also . . O
had . . O
intracranial . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
. . . O

crnm . . O
= . . O
clinically . . O
relevant . . O
nonmajor . . O
. . . O

vascular . . O
disorders . . O
: . . O
hypotension . . B-AdverseReaction
( . . O
including . . O
procedural . . B-AdverseReaction
hypotension . . I-AdverseReaction
) . . O

common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
1% . . O
) . . O
were . . O
gingival . . B-AdverseReaction
bleeding . . I-AdverseReaction
, . . O
epistaxis . . B-AdverseReaction
, . . O
contusion . . B-AdverseReaction
, . . O
hematuria . . B-AdverseReaction
, . . O
rectal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
hematoma . . B-AdverseReaction
, . . O
menorrhagia . . B-AdverseReaction
, . . O
and . . O
hemoptysis . . B-AdverseReaction
. . . O

prescriptions . . O
for . . O
pristiq . . O
should . . O
be . . O
written . . O
for . . O
the . . O
smallest . . O
quantity . . O
of . . O
tablets . . O
consistent . . O
with . . O
good . . O
patient . . O
management . . O
, . . O
in . . O
order . . O
to . . O
reduce . . O
the . . O
risk . . O
of . . O
overdose . . O
. . . O

the . . O
discontinuation . . O
rate . . O
due . . O
to . . O
bleeding . . B-AdverseReaction
events . . O
was . . O
0.7% . . O
in . . O
the . . O
eliquis . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
1.7% . . O
in . . O
enoxaparin . . O
/ . . O
warfarin . . O
- . . O
treated . . O
patients . . O
in . . O
the . . O
amplify . . O
study . . O
. . . O

whether . . O
any . . O
of . . O
the . . O
symptoms . . O
described . . O
above . . O
represent . . O
such . . O
a . . O
conversion . . O
is . . O
unknown . . O
. . . O

it . . O
should . . O
be . . O
noted . . O
that . . O
pristiq . . O
is . . O
not . . O
approved . . O
for . . O
use . . O
in . . O
treating . . O
bipolar . . O
depression . . O
. . . O

5.2 . . O
serotonin . . O
syndrome . . O

the . . O
concomitant . . O
use . . O
of . . O
pristiq . . O
with . . O
maois . . O
intended . . O
to . . O
treat . . O
psychiatric . . O
disorders . . O
is . . O
contraindicated . . O
. . . O

major . . O
2 . . O
( . . O
0.2 . . O
) . . O
1 . . O
( . . O
0.1 . . O
) . . O
4 . . O
( . . O
0.5 . . O
) . . O
crnm . . B-AdverseReaction
* . . O
25 . . O
( . . O
3.0 . . O
) . . O
34 . . O
( . . O
4.2 . . O
) . . O
19 . . O
( . . O
2.3 . . O
) . . O
major . . O
+ . . O
crnm . . B-AdverseReaction
27 . . O
( . . O
3.2 . . O
) . . O
35 . . O
( . . O
4.3 . . O
) . . O
22 . . O
( . . O
2.7 . . O
) . . O
minor . . O
75 . . O
( . . O
8.9 . . O
) . . O
98 . . O
( . . O
12.1 . . O
) . . O
58 . . O
( . . O
7.0 . . O
) . . O
all . . O
94 . . O
( . . O
11.2 . . O
) . . O
121 . . O
( . . O
14.9 . . O
) . . O
74 . . O
( . . O
9.0 . . O
) . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
patients . . O
in . . O
the . . O
amplify . . O
- . . O
ext . . O
study . . O
are . . O
listed . . O
in . . O
table . . O
8 . . O
. . . O

there . . O
may . . O
be . . O
circumstances . . O
when . . O
it . . O
is . . O
necessary . . O
to . . O
initiate . . O
treatment . . O
with . . O
a . . O
maoi . . O
such . . O
as . . O
linezolid . . O
or . . O
intravenous . . O
methylene . . O
blue . . O
in . . O
a . . O
patient . . O
taking . . O
pristiq . . O
. . . O

if . . O
concomitant . . O
use . . O
of . . O
pristiq . . O
with . . O
other . . O
serotonergic . . O
drugs . . O
, . . O
including . . O
triptans . . O
, . . O
tricyclic . . O
antidepressants . . O
, . . O
fentanyl . . O
, . . O
lithium . . O
, . . O
tramadol . . O
, . . O
buspirone . . O
, . . O
tryptophan . . O
, . . O
and . . O
st . . O
. . . O
john's . . O
wort . . O
is . . O
clinically . . O
warranted . . O
, . . O
patients . . O
should . . O
be . . O
made . . O
aware . . O
of . . O
a . . O
potential . . O
increased . . O
risk . . O
for . . O
serotonin . . O
syndrome . . O
, . . O
particularly . . O
during . . O
treatment . . O
initiation . . O
and . . O
dose . . O
increases . . O
. . . O

treatment . . O
with . . O
pristiq . . O
and . . O
any . . O
concomitant . . O
serotonergic . . O
agents . . O
should . . O
be . . O
discontinued . . O
immediately . . O
if . . O
the . . O
above . . O
events . . O
occur . . O
and . . O
supportive . . O
symptomatic . . O
treatment . . O
should . . O
be . . O
initiated . . O
. . . O

eye . . O
disorders . . O
: . . O
conjunctival . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
retinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
hemorrhage . . I-AdverseReaction

for . . O
patients . . O
who . . O
experience . . O
a . . O
sustained . . O
increase . . O
in . . O
blood . . O
pressure . . O
while . . O
receiving . . O
pristiq . . O
, . . O
either . . O
dose . . O
reduction . . O
or . . O
discontinuation . . O
should . . O
be . . O
considered . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

concomitant . . O
use . . O
of . . O
aspirin . . O
, . . O
nonsteroidal . . O
anti . . O
- . . O
inflammatory . . O
drugs . . O
, . . O
warfarin . . O
, . . O
and . . O
other . . O
anticoagulants . . O
may . . O
add . . O
to . . O
this . . O
risk . . O
. . . O

* . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
( . . O
penile . . B-AdverseReaction
fracture . . I-AdverseReaction
) . . O
and . . O
severe . . B-Severity
penile . . B-AdverseReaction
hematoma . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
in . . O
other . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
, . . O
a . . O
combination . . O
of . . O
penile . . B-AdverseReaction
ecchymoses . . I-AdverseReaction
or . . O
hematoma . . O
, . . O
sudden . . O
penile . . B-AdverseReaction
detumescence . . I-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
a . . O
penile . . B-AdverseReaction
" . . I-AdverseReaction
popping . . I-AdverseReaction
" . . I-AdverseReaction
sound . . I-AdverseReaction
or . . O
sensation . . O
was . . O
reported . . O
, . . O
and . . O
in . . O
these . . O
cases . . O
, . . O
a . . O
diagnosis . . O
of . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
cannot . . B-Factor
be . . I-Factor
excluded . . I-Factor
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
excerpt . . O
: . . O
dupuytren's . . O
contracture . . O
( . . O
6.1 . . O
) . . O

angle . . B-AdverseReaction
- . . I-AdverseReaction
closure . . I-AdverseReaction
glaucoma . . I-AdverseReaction
: . . O
the . . O
pupillary . . O
dilation . . O
that . . O
occurs . . O
following . . O
use . . O
of . . O
many . . O
antidepressant . . O
drugs . . O
including . . O
pristiq . . O
may . . B-Factor
trigger . . O
an . . O
angle . . B-AdverseReaction
closure . . I-AdverseReaction
attack . . I-AdverseReaction
in . . O
a . . O
patient . . O
with . . O
anatomically . . O
narrow . . O
angles . . O
who . . O
does . . O
not . . O
have . . O
a . . O
patent . . O
iridectomy . . O
. . . O

during . . O
all . . O
mdd . . O
phase . . O
2 . . O
and . . O
phase . . O
3 . . O
studies . . O
, . . O
mania . . B-AdverseReaction
was . . O
reported . . O
for . . O
approximately . . O
0.02% . . O
of . . O
patients . . O
treated . . O
with . . O
pristiq . . O
. . . O

these . . O
trials . . O
were . . O
comprised . . O
of . . O
374 . . O
patients . . O
of . . O
whom . . O
249 . . O
and . . O
125 . . O
received . . O
0.58 . . O
mg . . O
of . . O
xiaflex . . O
and . . O
placebo . . O
, . . O
respectively . . O
. . . O

in . . O
general . . O
, . . O
discontinuation . . O
events . . O
occurred . . O
more . . O
frequently . . O
with . . O
longer . . O
duration . . O
of . . O
therapy . . O
. . . O

during . . O
marketing . . O
of . . O
snris . . O
( . . O
serotonin . . O
and . . O
norepinephrine . . O
reuptake . . O
inhibitors . . O
) . . O
, . . O
and . . O
ssris . . O
( . . O
selective . . O
serotonin . . O
reuptake . . O
inhibitors . . O
) . . O
, . . O
there . . O
have . . O
been . . O
spontaneous . . O
reports . . O
of . . O
adverse . . O
events . . O
occurring . . O
upon . . O
discontinuation . . O
of . . O
these . . O
drugs . . O
, . . O
particularly . . O
when . . O
abrupt . . O
, . . O
including . . O
the . . O
following . . O
: . . O
dysphoric . . O
mood . . O
, . . O
irritability . . O
, . . O
agitation . . O
, . . O
dizziness . . O
, . . O
sensory . . O
disturbances . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
paresthesia . . O
, . . O
such . . O
as . . O
electric . . O
shock . . O
sensations . . O
) . . O
, . . O
anxiety . . O
, . . O
confusion . . O
, . . O
headache . . O
, . . O
lethargy . . O
, . . O
emotional . . O
lability . . O
, . . O
insomnia . . O
, . . O
hypomania . . O
, . . O
tinnitus . . O
, . . O
and . . O
seizures . . O
. . . O

table . . O
3 . . O
shows . . O
the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
that . . O
were . . O
reported . . O
in . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
5% . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
and . . O
at . . O
a . . O
frequency . . O
greater . . O
than . . O
placebo . . O
- . . O
treated . . O
patients . . O
after . . O
up . . O
to . . O
3 . . O
injections . . O
in . . O
the . . O
pooled . . O
placebo . . O
- . . O
controlled . . O
trials . . O
through . . O
day . . O
90 . . O
( . . O
studies . . O
1 . . O
and . . O
2 . . O
) . . O
. . . O

subsequently . . O
, . . O
the . . O
physician . . O
may . . O
continue . . O
decreasing . . O
the . . O
dose . . O
, . . O
but . . O
at . . O
a . . O
more . . O
gradual . . O
rate . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.4 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
with . . O
dupuytren's . . O
contracture . . O
and . . O
at . . O
a . . O
greater . . O
incidence . . O
than . . O
placebo . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
trials . . O
through . . O
day . . O
90 . . O
after . . O
up . . O
to . . O
3 . . O
injections . . O
a . . O
most . . O
of . . O
these . . O
events . . O
were . . O
swelling . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
injected . . I-AdverseReaction
hand . . I-AdverseReaction
. . . O
b . . O
includes . . O
the . . O
terms . . O
: . . O
contusion . . B-AdverseReaction
( . . O
any . . O
body . . O
system . . O
) . . O
and . . O
ecchymosis . . B-AdverseReaction
c . . O
includes . . O
the . . O
terms . . O
: . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
erythema . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
inflammation . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
irritation . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
warmth . . I-AdverseReaction
d . . O
includes . . O
the . . O
terms . . O
: . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
swelling . . I-AdverseReaction
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
edema . . I-AdverseReaction
e . . O
includes . . O
the . . O
terms . . O
: . . O
pruritus . . B-AdverseReaction
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pruritus . . I-AdverseReaction
f . . O
includes . . O
the . . O
terms . . O
: . . O
lymphadenopathy . . B-AdverseReaction
and . . O
axillary . . B-AdverseReaction
mass . . I-AdverseReaction
adverse . . O
reaction . . O
xiaflexn . . O
= . . O
249 . . O
placebon . . O
= . . O
125 . . O
all . . O
adverse . . O
reactions . . O
98% . . O
51% . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
a . . O
73% . . O
5% . . O
contusion . . B-AdverseReaction
b . . O
70% . . O
3% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
38% . . O
3% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
c . . O
35% . . O
6% . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
35% . . O
4% . . O
tenderness . . B-AdverseReaction
24% . . O
0% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
swelling . . I-AdverseReaction
d . . O
24% . . O
6% . . O
pruritus . . B-AdverseReaction
e . . O
15% . . O
1% . . O
lymphadenopathy . . B-AdverseReaction
f . . O
13% . . O
0% . . O
skin . . B-AdverseReaction
laceration . . I-AdverseReaction
9% . . O
0% . . O
lymph . . B-AdverseReaction
node . . I-AdverseReaction
pain . . I-AdverseReaction
8% . . O
0% . . O
erythema . . B-AdverseReaction
6% . . O
0% . . O
axillary . . B-AdverseReaction
pain . . I-AdverseReaction
6% . . O
0% . . O
some . . O
patients . . O
developed . . O
vasovagal . . B-AdverseReaction
syncope . . I-AdverseReaction
after . . O
finger . . O
extension . . O
procedures . . O
. . . O

cases . . O
of . . O
seizure . . B-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
pre . . O
- . . O
marketing . . O
clinical . . O
studies . . O
with . . O
pristiq . . O
. . . O

in . . O
study . . O
3 . . O
, . . O
finger . . O
extension . . O
procedures . . O
were . . O
performed . . O
approximately . . O
24 . . O
to . . O
72 . . O
hours . . O
after . . O
injection . . O
. . . O

the . . O
patient . . O
demographics . . O
were . . O
similar . . O
to . . O
studies . . O
1 . . O
and . . O
2 . . O
. . . O

out . . O
of . . O
715 . . O
patients . . O
who . . O
received . . O
two . . O
concurrent . . O
injections . . O
of . . O
xiaflex . . O
0.58 . . O
mg . . O
in . . O
the . . O
same . . O
hand . . O
( . . O
1450 . . O
xiaflex . . O
injections . . O
) . . O
in . . O
study . . O
3 . . O
, . . O
one . . O
( . . O
0.1% . . O
) . . O
patient . . O
experienced . . O
a . . O
tendon . . O
rupture . . O
of . . O
the . . O
treated . . O
finger . . O
within . . O
3 . . O
days . . O
of . . O
the . . O
injection . . O
. . . O

table . . O
4 . . O
. . . O

also . . O
, . . O
patients . . O
taking . . O
diuretics . . O
or . . O
who . . O
are . . O
otherwise . . O
volume . . O
depleted . . O
can . . O
be . . O
at . . O
greater . . O
risk . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.5 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.6 . . O
) . . O
] . . O
. . . O

no . . O
new . . O
safety . . O
signals . . O
were . . O
identified . . O
among . . O
subjects . . O
who . . O
were . . O
retreated . . O
with . . O
xiaflex . . O
. . . O

5.10 . . O
interstitial . . O
lung . . O
disease . . O
and . . O
eosinophilic . . O
pneumonia . . O

5 . . O
warnings . . O
and . . O
precautions . . O

splenic . . B-AdverseReaction
rupture . . I-AdverseReaction
, . . O
including . . O
fatal . . B-AdverseReaction
cases . . O
, . . O
can . . B-Factor
occur . . O
following . . O
administration . . O
of . . O
human . . O
granulocyte . . O
colony . . O
- . . O
stimulating . . O
factors . . O
. . . O

in . . O
patients . . O
who . . O
report . . O
upper . . O
abdominal . . O
or . . O
shoulder . . O
pain . . O
after . . O
receiving . . O
granix . . O
, . . O
discontinue . . O
granix . . O
and . . O
evaluate . . O
for . . O
an . . O
enlarged . . O
spleen . . O
or . . O
splenic . . O
rupture . . O
. . . O

5.2 . . O
acute . . O
respiratory . . O
distress . . O
syndrome . . O
( . . O
ards . . O
) . . O

the . . O
treatment . . O
cycle . . O
was . . O
repeated . . O
at . . O
approximately . . O
6 . . O
- . . O
week . . O
intervals . . O
up . . O
to . . O
three . . O
additional . . O
times . . O
, . . O
for . . O
a . . O
maximum . . O
of . . O
8 . . O
total . . O
injection . . O
procedures . . O
and . . O
4 . . O
total . . O
modeling . . O
procedures . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.2 . . O
) . . O
] . . O
. . . O

5.3 . . O
allergic . . O
reactions . . O

reports . . O
of . . O
penile . . O
" . . O
popping . . O
" . . O
sounds . . O
or . . O
sensations . . O
a . . O
popping . . O
noise . . O
or . . O
popping . . B-AdverseReaction
sensation . . I-AdverseReaction
in . . I-AdverseReaction
the . . I-AdverseReaction
penis . . I-AdverseReaction
, . . O
sometimes . . O
described . . O
as . . O
" . . O
snapping . . O
" . . O
or . . O
" . . O
cracking . . O
" . . O
, . . O
and . . O
sometimes . . O
accompanied . . O
by . . O
detumescence . . B-AdverseReaction
, . . O
hematoma . . B-AdverseReaction
and . . O
/ . . O
or . . O
pain . . B-AdverseReaction
, . . O
were . . O
reported . . O
in . . O
73 . . O
/ . . O
551 . . O
( . . O
13.2% . . O
) . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
and . . O
1 . . O
/ . . O
281 . . O
( . . O
0.3% . . O
) . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

consider . . O
the . . O
potential . . O
risks . . O
and . . O
benefits . . O
prior . . O
to . . O
the . . O
administration . . O
of . . O
human . . O
granulocyte . . O
colony . . O
- . . O
stimulating . . O
factors . . O
in . . O
patients . . O
with . . O
sickle . . O
cell . . O
disease . . O
. . . O

patients . . O
who . . O
develop . . O
symptoms . . O
of . . O
capillary . . O
leak . . O
syndrome . . O
should . . O
be . . O
closely . . O
monitored . . O
and . . O
receive . . O
standard . . O
symptomatic . . O
treatment . . O
, . . O
which . . O
may . . O
include . . O
a . . O
need . . O
for . . O
intensive . . O
care . . O
. . . O

6 . . O
adverse . . O
reactions . . O

neutralizing . . O
antibodies . . O
were . . O
assayed . . O
for . . O
a . . O
subset . . O
of . . O
70 . . O
samples . . O
selected . . O
to . . O
be . . O
representative . . O
of . . O
high . . O
and . . O
low . . O
titer . . O
binding . . O
antibody . . O
responses . . O
at . . O
week . . O
12 . . O
of . . O
treatment . . O
. . . O

for . . O
each . . O
subject . . O
in . . O
whom . . O
a . . O
week . . O
12 . . O
sample . . O
was . . O
selected . . O
, . . O
the . . O
corresponding . . O
week . . O
6 . . O
, . . O
18 . . O
, . . O
24 . . O
, . . O
and . . O
52 . . O
samples . . O
were . . O
assayed . . O
if . . O
they . . O
were . . O
also . . O
binding . . O
antibody . . O
positive . . O
. . . O

neutralizing . . O
antibodies . . O
to . . O
aux . . O
- . . O
i . . O
or . . O
aux . . O
- . . O
ii . . O
, . . O
were . . O
detected . . O
in . . O
60% . . O
and . . O
51.8% . . O
, . . O
respectively . . O
, . . O
of . . O
patients . . O
tested . . O
. . . O

since . . O
the . . O
protein . . O
components . . O
in . . O
xiaflex . . O
( . . O
aux . . O
- . . O
i . . O
and . . O
aux . . O
- . . O
ii . . O
) . . O
have . . O
some . . O
sequence . . O
homology . . O
with . . O
human . . O
matrix . . O
metalloproteinases . . O
( . . O
mmps . . O
) . . O
, . . O
anti . . O
- . . O
product . . O
antibodies . . O
could . . O
theoretically . . O
interfere . . O
with . . O
human . . O
mmps . . O
. . . O

in . . O
addition . . O
, . . O
no . . O
clinical . . O
safety . . O
concerns . . O
related . . O
to . . O
the . . O
inhibition . . O
of . . O
endogenous . . O
mmps . . O
have . . O
been . . O
observed . . O
. . . O

one . . O
subject . . O
out . . O
of . . O
761 . . O
administered . . O
vizamyl . . O
experienced . . O
a . . O
serious . . B-Severity
hypersensitivity . . B-AdverseReaction
reaction . . I-AdverseReaction
with . . O
flushing . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
and . . O
chest . . B-AdverseReaction
pressure . . I-AdverseReaction
within . . O
minutes . . O
following . . O
vizamyl . . O
administration . . O
and . . O
recovered . . O
with . . O
treatment . . O
. . . O

most . . O
adverse . . O
reactions . . O
were . . O
mild . . O
to . . O
moderate . . O
in . . O
intensity . . O
and . . O
resolved . . O
spontaneously . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

6 . . O
adverse . . O
reactions . . O

* . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
: . . O
monitor . . O
patients . . O
for . . O
the . . O
development . . O
of . . O
systemic . . O
immune . . O
- . . O
mediated . . O
reactions . . O
involving . . O
skin . . O
and . . O
other . . O
organs . . O
( . . O
5.2 . . O
) . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
acorda . . O
therapeutics . . O
at . . O
1-877-900-6479 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

* . . O
risk . . B-Factor
of . . O
cardiac . . B-AdverseReaction
arrhythmia . . I-AdverseReaction
and . . O
sudden . . B-AdverseReaction
cardiac . . I-AdverseReaction
death . . I-AdverseReaction
during . . O
general . . O
anesthesia . . O
for . . O
central . . O
venous . . O
catheter . . O
placement . . O
: . . O
caution . . O
should . . O
be . . O
used . . O
when . . O
administering . . O
general . . O
anesthesia . . O
for . . O
the . . O
placement . . O
of . . O
a . . O
central . . O
venous . . O
catheter . . O
intended . . O
for . . O
alglucosidase . . O
alfa . . O
infusion . . O
( . . O
5.4 . . O
) . . O
. . . O

5.1 . . O
anaphylaxis . . O
and . . O
hypersensitivity . . O
reactions . . O

across . . O
all . . O
controlled . . O
and . . O
uncontrolled . . O
trials . . O
, . . O
more . . O
than . . O
1,600 . . O
patients . . O
have . . O
received . . O
qutenza . . O
. . . O

a . . O
total . . O
of . . O
394 . . O
patients . . O
received . . O
more . . O
than . . O
one . . O
treatment . . O
application . . O
and . . O
274 . . O
patients . . O
were . . O
followed . . O
for . . O
48 . . O
weeks . . O
or . . O
longer . . O
. . . O

in . . O
controlled . . O
clinical . . O
studies . . O
, . . O
98% . . O
of . . O
patients . . O
completed . . O
> . . O
= . . O
90% . . O
of . . O
the . . O
intended . . O
patch . . O
application . . O
duration . . O
. . . O

severe . . O
reactions . . O
are . . O
generally . . O
managed . . O
with . . O
infusion . . O
interruption . . O
, . . O
administration . . O
of . . O
antihistamines . . O
, . . O
corticosteroids . . O
, . . O
intravenous . . O
fluids . . O
, . . O
and . . O
/ . . O
or . . O
oxygen . . O
, . . O
when . . O
clinically . . O
indicated . . O
. . . O

in . . O
some . . O
cases . . O
of . . O
anaphylaxis . . O
, . . O
epinephrine . . O
has . . O
been . . O
administered . . O
. . . O

adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
patients . . O
in . . O
the . . O
qutenza . . O
group . . O
and . . O
at . . O
an . . O
incidence . . O
greater . . O
than . . O
in . . O
the . . O
control . . O
group . . O
were . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
erythema . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pruritus . . I-AdverseReaction
and . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
papules . . I-AdverseReaction
. . . O

the . . O
majority . . O
of . . O
application . . O
site . . O
reactions . . O
were . . O
transient . . B-Severity
and . . O
self . . O
- . . O
limited . . O
. . . O

transient . . B-Severity
increases . . B-AdverseReaction
in . . I-AdverseReaction
pain . . I-AdverseReaction
were . . O
commonly . . O
observed . . O
on . . O
the . . O
day . . O
of . . O
treatment . . O
in . . O
patients . . O
treated . . O
with . . O
qutenza . . O
. . . O

pain . . B-AdverseReaction
increases . . I-AdverseReaction
occurring . . O
during . . O
patch . . O
application . . O
usually . . O
began . . O
to . . O
resolve . . O
after . . O
patch . . O
removal . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
abnormal . . B-AdverseReaction
skin . . I-AdverseReaction
odor . . I-AdverseReaction

6 . . O
adverse . . O
reactions . . O

in . . O
these . . O
patients . . O
, . . O
renal . . O
biopsy . . O
was . . O
consistent . . O
with . . O
immune . . B-AdverseReaction
complex . . I-AdverseReaction
deposition . . I-AdverseReaction
. . . O

other . . O
adverse . . O
reactions . . O
which . . O
occurred . . O
in . . O
2-5% . . O
of . . O
subjects . . O
were . . O
eye . . B-AdverseReaction
irritation . . I-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
and . . O
nasopharyngitis . . B-AdverseReaction
. . . O

patients . . O
improved . . O
following . . O
treatment . . O
interruption . . O
. . . O

therefore . . O
, . . O
patients . . O
receiving . . O
alglucosidase . . O
alfa . . O
should . . O
undergo . . O
periodic . . O
urinalysis . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.3 . . O
) . . O
] . . O
. . . O

patients . . O
with . . O
acute . . O
underlying . . O
respiratory . . O
illness . . O
or . . O
compromised . . O
cardiac . . O
and . . O
/ . . O
or . . O
respiratory . . O
function . . O
may . . B-Factor
be . . O
at . . O
risk . . O
of . . O
serious . . B-Severity
exacerbation . . O
of . . O
their . . O
cardiac . . O
or . . O
respiratory . . O
compromise . . O
during . . O
infusions . . O
. . . O

other . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
2-5% . . O
of . . O
subjects . . O
were . . O
eye . . B-AdverseReaction
irritation . . I-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
and . . O
nasopharyngitis . . B-AdverseReaction
. . . O

administration . . O
of . . O
general . . O
anesthesia . . O
can . . O
be . . O
complicated . . O
by . . O
the . . O
presence . . O
of . . O
severe . . O
cardiac . . O
and . . O
skeletal . . O
( . . O
including . . O
respiratory . . O
) . . O
muscle . . O
weakness . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
increased . . O
mortality . . B-AdverseReaction
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O

although . . O
the . . O
causes . . O
of . . O
death . . B-AdverseReaction
were . . O
varied . . O
, . . O
most . . O
of . . O
the . . O
deaths . . B-AdverseReaction
appeared . . O
to . . O
be . . O
either . . O
cardiovascular . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
sudden . . B-AdverseReaction
death . . I-AdverseReaction
) . . O
or . . O
infectious . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
pneumonia . . B-AdverseReaction
) . . O
in . . O
nature . . O
. . . O

fanapt . . O
is . . O
not . . O
approved . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O

( . . O
5.1 . . O
) . . O

manage . . O
by . . O
dose . . O
reduction . . O
or . . O
discontinuation . . O
until . . O
symptoms . . O
resolve . . O
, . . O
and . . O
consider . . O
use . . O
of . . O
corticosteroids . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
: . . O
prolongs . . B-AdverseReaction
qt . . I-AdverseReaction
interval . . I-AdverseReaction
and . . O
may . . B-Factor
be . . O
associated . . O
with . . O
arrhythmia . . B-AdverseReaction
and . . O
sudden . . B-AdverseReaction
death . . I-AdverseReaction
- . . O
consider . . O
using . . O
other . . O
antipsychotics . . O
first . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
impaired . . B-AdverseReaction
wound . . I-AdverseReaction
healing . . I-AdverseReaction
: . . O
increased . . O
risk . . B-Factor
of . . O
wound . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
complications . . I-AdverseReaction
. . . O

monitor . . O
glucose . . O
regularly . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
diabetes . . O
. . . O

monitor . . O
renal . . O
function . . O
, . . O
blood . . O
glucose . . O
, . . O
lipids . . O
, . . O
and . . O
hematologic . . O
parameters . . O
prior . . O
to . . O
treatment . . O
and . . O
periodically . . O
thereafter . . O
. . . O

apprise . . O
women . . O
of . . O
potential . . O
harm . . O
to . . O
the . . O
fetus . . O
. . . O

the . . O
incidence . . O
of . . O
common . . O
terminology . . O
criteria . . O
( . . O
ctc . . O
) . . O
grade . . B-Severity
3 . . I-Severity
and . . O
4 . . O
non . . O
- . . O
infectious . . O
pneumonitis . . O
was . . O
up . . O
to . . O
4.0% . . O
and . . O
up . . O
to . . O
0.2% . . O
, . . O
respectively . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
, . . O
6.2 . . O
, . . O
6.3 . . O
, . . O
6.4 . . O
, . . O
6.5 . . O
) . . O
] . . O
. . . O

5.1 . . O
increased . . O
risks . . O
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O

increased . . O
mortality . . O

patients . . O
who . . O
develop . . O
radiological . . O
changes . . O
suggestive . . O
of . . O
non . . O
- . . O
infectious . . O
pneumonitis . . O
and . . O
have . . O
few . . O
or . . O
no . . O
symptoms . . O
may . . O
continue . . O
afinitor . . O
therapy . . O
without . . O
dose . . O
alteration . . O
. . . O

fanapt . . O
is . . O
not . . O
approved . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
[ . . O
s . . O
ee . . O
boxed . . O
warning . . O
] . . O
. . . O

afinitor . . O
may . . O
be . . O
re . . O
- . . O
introduced . . O
at . . O
a . . O
daily . . O
dose . . O
approximately . . O
50% . . O
lower . . O
than . . O
the . . O
dose . . O
previously . . O
administered . . O
depending . . O
on . . O
the . . O
individual . . O
clinical . . O
circumstances . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

the . . O
use . . O
of . . O
fanapt . . O
should . . O
be . . O
avoided . . O
in . . O
combination . . O
with . . O
other . . O
drugs . . O
that . . O
are . . O
known . . O
to . . O
prolong . . O
qtc . . O
including . . O
class . . O
1a . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
quinidine . . O
, . . O
procainamide . . O
) . . O
or . . O
class . . O
iii . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
amiodarone . . O
, . . O
sotalol . . O
) . . O
antiarrhythmic . . O
medications . . O
, . . O
antipsychotic . . O
medications . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
chlorpromazine . . O
, . . O
thioridazine . . O
) . . O
, . . O
antibiotics . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
gatifloxacin . . O
, . . O
moxifloxacin . . O
) . . O
, . . O
or . . O
any . . O
other . . O
class . . O
of . . O
medications . . O
known . . O
to . . O
prolong . . O
the . . O
qtc . . O
interval . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
pentamidine . . O
, . . O
levomethadyl . . O
acetate . . O
, . . O
methadone . . O
) . . O
. . . O

afinitor . . O
has . . O
immunosuppressive . . O
properties . . O
and . . O
may . . B-Factor
predispose . . O
patients . . O
to . . O
bacterial . . O
, . . O
fungal . . O
, . . O
viral . . O
, . . O
or . . O
protozoal . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
including . . O
infections . . B-AdverseReaction
with . . I-AdverseReaction
opportunistic . . I-AdverseReaction
pathogens . . I-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
, . . O
6.2 . . O
, . . O
6.3 . . O
, . . O
6.4 . . O
, . . O
6.5 . . O
) . . O
] . . O
. . . O

it . . O
is . . O
recommended . . O
that . . O
patients . . O
being . . O
considered . . O
for . . O
fanapt . . O
treatment . . O
who . . O
are . . O
at . . O
risk . . O
for . . O
significant . . O
electrolyte . . O
disturbances . . O
have . . O
baseline . . O
serum . . O
potassium . . O
and . . O
magnesium . . O
measurements . . O
with . . O
periodic . . O
monitoring . . O
. . . O

localized . . O
and . . O
systemic . . O
infections . . O
, . . O
including . . O
pneumonia . . B-AdverseReaction
, . . O
mycobacterial . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
other . . O
bacterial . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
invasive . . B-AdverseReaction
fungal . . I-AdverseReaction
infections . . I-AdverseReaction
, . . O
such . . O
as . . O
aspergillosis . . B-AdverseReaction
, . . O
candidiasis . . B-AdverseReaction
, . . O
or . . O
pneumocystis . . B-AdverseReaction
jiroveci . . I-AdverseReaction
pneumonia . . I-AdverseReaction
( . . O
pjp . . B-AdverseReaction
) . . O
and . . O
viral . . B-AdverseReaction
infections . . I-AdverseReaction
including . . O
reactivation . . B-AdverseReaction
of . . I-AdverseReaction
hepatitis . . I-AdverseReaction
b . . I-AdverseReaction
virus . . I-AdverseReaction
have . . O
occurred . . O
in . . O
patients . . O
taking . . O
afinitor . . O
. . . O

while . . O
taking . . O
afinitor . . O
, . . O
be . . O
vigilant . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
infection . . O
; . . O
if . . O
a . . O
diagnosis . . O
of . . O
an . . O
infection . . O
is . . O
made . . O
, . . O
institute . . O
appropriate . . O
treatment . . O
promptly . . O
and . . O
consider . . O
interruption . . O
or . . O
discontinuation . . O
of . . O
afinitor . . O
. . . O

a . . O
potentially . . O
fatal . . O
symptom . . O
complex . . O
sometimes . . O
referred . . O
to . . O
as . . O
neuroleptic . . B-AdverseReaction
malignant . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
nms . . B-AdverseReaction
) . . O
has . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
administration . . O
of . . O
antipsychotic . . O
drugs . . O
, . . O
including . . O
fanapt . . O
. . . O

5.3 . . O
angioedema . . O
with . . O
concomitant . . O
use . . O
of . . O
angiotensin . . O
- . . O
converting . . O
enzyme . . O
( . . O
ace . . O
) . . O
inhibitors . . O

patients . . O
taking . . O
concomitant . . O
ace . . O
inhibitor . . O
therapy . . O
may . . O
be . . O
at . . O
increased . . O
risk . . B-Factor
for . . O
angioedema . . B-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
swelling . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
airways . . I-AdverseReaction
or . . O
tongue . . O
, . . O
with . . O
or . . O
without . . O
respiratory . . B-AdverseReaction
impairment . . I-AdverseReaction
) . . O
. . . O

grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
stomatitis . . B-AdverseReaction
was . . O
reported . . O
in . . O
4% . . O
- . . O
9% . . O
of . . O
patients . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
, . . O
6.2 . . O
, . . O
6.3 . . O
, . . O
6.4 . . O
, . . O
6.5 . . O
) . . O
] . . O
. . . O

although . . O
the . . O
prevalence . . O
of . . O
the . . O
syndrome . . O
appears . . O
to . . O
be . . O
highest . . O
among . . O
the . . O
elderly . . O
, . . O
especially . . O
elderly . . O
women . . O
, . . O
it . . O
is . . O
impossible . . O
to . . O
rely . . O
on . . O
prevalence . . O
estimates . . O
to . . O
predict . . O
, . . O
at . . O
the . . O
inception . . O
of . . O
antipsychotic . . O
treatment . . O
, . . O
which . . O
patients . . O
are . . O
likely . . O
to . . O
develop . . O
the . . O
syndrome . . O
. . . O

whether . . O
antipsychotic . . O
drug . . O
products . . O
differ . . O
in . . O
their . . O
potential . . O
to . . O
cause . . O
tardive . . O
dyskinesia . . O
is . . O
unknown . . O
. . . O

5.6 . . O
impaired . . O
wound . . O
healing . . O

exercise . . O
caution . . O
with . . O
the . . O
use . . O
of . . O
afinitor . . O
in . . O
the . . O
peri . . O
- . . O
surgical . . O
period . . O
. . . O

given . . O
these . . O
considerations . . O
, . . O
fanapt . . O
should . . O
be . . O
prescribed . . O
in . . O
a . . O
manner . . O
that . . O
is . . O
most . . O
likely . . O
to . . O
minimize . . O
the . . O
occurrence . . O
of . . O
tardive . . O
dyskinesia . . O
. . . O

chronic . . O
antipsychotic . . O
treatment . . O
should . . O
generally . . O
be . . O
reserved . . O
for . . O
patients . . O
who . . O
suffer . . O
from . . O
a . . O
chronic . . O
illness . . O
that . . O
( . . O
1 . . O
) . . O
is . . O
known . . O
to . . O
respond . . O
to . . O
antipsychotic . . O
drugs . . O
, . . O
and . . O
( . . O
2 . . O
) . . O
for . . O
whom . . O
alternative . . O
, . . O
equally . . O
effective . . O
, . . O
but . . O
potentially . . O
less . . O
harmful . . O
treatments . . O
are . . O
not . . O
available . . O
or . . O
appropriate . . O
. . . O

hyperglycemia . . O
and . . O
diabetes . . O
mellitus . . O

hematologic . . O
parameters . . O

given . . O
these . . O
confounders . . O
, . . O
the . . O
relationship . . O
between . . O
atypical . . O
antipsychotic . . O
use . . O
and . . O
hyperglycemia . . O
- . . O
related . . O
adverse . . O
events . . O
is . . O
not . . O
completely . . O
understood . . O
. . . O

monitoring . . O
of . . O
complete . . O
blood . . O
count . . O
is . . O
recommended . . O
prior . . O
to . . O
the . . O
start . . O
of . . O
afinitor . . O
therapy . . O
and . . O
periodically . . O
thereafter . . O
. . . O

due . . O
to . . O
significant . . O
increases . . O
in . . O
exposure . . O
of . . O
everolimus . . O
, . . O
co . . O
- . . O
administration . . O
with . . O
strong . . O
cyp3a4 . . O
/ . . O
pgp . . O
inhibitors . . O
should . . O
be . . O
avoided . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
, . . O
2.5 . . O
) . . O
and . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

a . . O
reduction . . O
of . . O
the . . O
afinitor . . O
dose . . O
is . . O
recommended . . O
when . . O
co . . O
- . . O
administered . . O
with . . O
a . . O
moderate . . O
cyp3a4 . . O
/ . . O
pgp . . O
inhibitor . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
, . . O
2.5 . . O
) . . O
and . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

an . . O
increase . . O
in . . O
the . . O
afinitor . . O
dose . . O
is . . O
recommended . . O
when . . O
co . . O
- . . O
administered . . O
with . . O
a . . O
strong . . O
cyp3a4 . . O
/ . . O
pgp . . O
inducer . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
, . . O
2.5 . . O
) . . O
and . . O
drug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
] . . O
. . . O

patients . . O
who . . O
develop . . O
symptoms . . O
of . . O
hyperglycemia . . O
during . . O
treatment . . O
with . . O
atypical . . O
antipsychotics . . O
should . . O
undergo . . O
fasting . . O
blood . . O
glucose . . O
testing . . O
. . . O

table . . O
1 . . O
: . . O
change . . O
in . . O
fasting . . O
glucose . . O
fanapt . . O
placebo . . O
24 . . O
mg . . O
/ . . O
day . . O
mean . . O
change . . O
from . . O
baseline . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
n . . O
= . . O
114 . . O
n . . O
= . . O
228 . . O
serum . . O
glucose . . O
change . . O
from . . O
baseline . . O
- . . O
0.5 . . O
6.6 . . O
proportion . . O
of . . O
patients . . O
with . . O
shifts . . O
serum . . O
glucose . . O
normal . . O
to . . O
high . . O
2.5 . . O
% . . O
10.7 . . O
% . . O
( . . O
< . . O
100 . . O
mg . . O
/ . . O
dl . . O
to . . O
> . . O
= . . O
126 . . O
mg . . O
/ . . O
dl . . O
) . . O
( . . O
2 . . O
/ . . O
80 . . O
) . . O
( . . O
18 . . O
/ . . O
169 . . O
) . . O
pooled . . O
analyses . . O
of . . O
glucose . . O
data . . O
from . . O
clinical . . O
studies . . O
including . . O
longer . . O
term . . O
trials . . O
are . . O
shown . . O
in . . O
table . . O
2 . . O
. . . O

during . . O
afinitor . . O
treatment . . O
, . . O
avoid . . O
the . . O
use . . O
of . . O
live . . O
vaccines . . O
and . . O
avoid . . O
close . . O
contact . . O
with . . O
individuals . . O
who . . O
have . . O
received . . O
live . . O
vaccines . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
intranasal . . O
influenza . . O
, . . O
measles . . O
, . . O
mumps . . O
, . . O
rubella . . O
, . . O
oral . . O
polio . . O
, . . O
bcg . . O
, . . O
yellow . . O
fever . . O
, . . O
varicella . . O
, . . O
and . . O
ty21a . . O
typhoid . . O
vaccines . . O
) . . O
. . . O

3-6 . . O
months . . O
6-12 . . O
months . . O
> . . O
12 . . O
months . . O
fanapt . . O
10-16 . . O
mg . . O
/ . . O
day . . O
- . . O
3.9 . . O
( . . O
n . . O
= . . O
783 . . O
) . . O
- . . O
3.9 . . O
( . . O
n . . O
= . . O
726 . . O
) . . O
- . . O
7.7 . . O
( . . O
n . . O
= . . O
428 . . O
) . . O
fanapt . . O
20-24 . . O
mg . . O
/ . . O
day . . O
- . . O
19.4 . . O
( . . O
n . . O
= . . O
34 . . O
) . . O
- . . O
23.2 . . O
( . . O
n . . O
= . . O
31 . . O
) . . O
- . . O
19.4 . . O
( . . O
n . . O
= . . O
20 . . O
) . . O
table . . O
5 . . O
: . . O
change . . O
in . . O
triglycerides . . O
mean . . O
change . . O
from . . O
baseline . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
3-6 . . O
months . . O
6-12 . . O
months . . O
> . . O
12 . . O
months . . O
fanapt . . O
10-16 . . O
mg . . O
/ . . O
day . . O
- . . O
8.9 . . O
( . . O
n . . O
= . . O
783 . . O
) . . O
- . . O
8.9 . . O
( . . O
n . . O
= . . O
726 . . O
) . . O
- . . O
17.7 . . O
( . . O
n . . O
= . . O
428 . . O
) . . O
fanapt . . O
20-24 . . O
mg . . O
/ . . O
day . . O
- . . O
26.6 . . O
( . . O
n . . O
= . . O
34 . . O
) . . O
- . . O
35.4 . . O
( . . O
n . . O
= . . O
31 . . O
) . . O
- . . O
17.7 . . O
( . . O
n . . O
= . . O
20 . . O
) . . O
weight . . O
gain . . O

5.12 . . O
embryo . . O
- . . O
fetal . . O
toxicity . . O

across . . O
all . . O
short . . O
- . . O
and . . O
long . . O
- . . O
term . . O
studies . . O
, . . O
the . . O
overall . . O
mean . . O
change . . O
from . . O
baseline . . O
at . . O
endpoint . . O
was . . O
2.1 . . O
kg . . O
. . . O

6 . . O
adverse . . O
reactions . . O

as . . O
with . . O
other . . O
antipsychotics . . O
, . . O
fanapt . . O
should . . O
be . . O
used . . O
cautiously . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
seizures . . O
or . . O
with . . O
conditions . . O
that . . O
potentially . . O
lower . . O
the . . O
seizure . . O
threshold . . O
, . . O
e . . O
. . . O
g . . O
. . . O
, . . O
alzheimer's . . O
dementia . . O
. . . O

conditions . . O
that . . O
lower . . O
the . . O
seizure . . O
threshold . . O
may . . O
be . . O
more . . O
prevalent . . O
in . . O
a . . O
population . . O
of . . O
65 . . O
years . . O
or . . O
older . . O
. . . O

this . . O
reflects . . O
its . . O
alpha1 . . O
- . . O
adrenergic . . O
antagonist . . O
properties . . O
. . . O

6.1 . . O
clinical . . O
studies . . O
experience . . O

patients . . O
with . . O
neutropenia . . O
should . . O
be . . O
carefully . . O
monitored . . O
for . . O
fever . . O
or . . O
other . . O
symptoms . . O
or . . O
signs . . O
of . . O
infection . . O
and . . O
treated . . O
promptly . . O
if . . O
such . . O
symptoms . . O
or . . O
signs . . O
occur . . O
. . . O

5.9 . . O
hyperprolactinemia . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
in . . O
nulojix . . O
- . . O
treated . . O
patients . . O
were . . O
cytomegalovirus . . B-AdverseReaction
infection . . I-AdverseReaction
( . . O
1.5% . . O
) . . O
and . . O
complications . . B-AdverseReaction
of . . I-AdverseReaction
transplanted . . I-AdverseReaction
kidney . . I-AdverseReaction
( . . O
1.5% . . O
) . . O
. . . O

post . . O
- . . O
transplant . . O
lymphoproliferative . . O
disorder . . O

tissue . . O
culture . . O
experiments . . O
indicate . . O
that . . O
approximately . . O
one . . O
- . . O
third . . O
of . . O
human . . O
breast . . O
cancers . . O
are . . O
prolactin . . O
- . . O
dependent . . O
in . . O
vitro . . O
, . . O
a . . O
factor . . O
of . . O
potential . . O
importance . . O
if . . O
the . . O
prescription . . O
of . . O
these . . O
drugs . . O
is . . O
contemplated . . O
in . . O
a . . O
patient . . O
with . . O
previously . . O
detected . . O
breast . . O
cancer . . O
. . . O

six . . O
of . . O
the . . O
8 . . O
cases . . O
presented . . O
with . . O
cns . . O
involvement . . O
. . . O

in . . O
a . . O
short . . O
- . . O
term . . O
placebo . . O
- . . O
controlled . . O
trial . . O
( . . O
4 . . O
- . . O
weeks . . O
) . . O
, . . O
the . . O
mean . . O
change . . O
from . . O
baseline . . O
to . . O
endpoint . . O
in . . O
plasma . . O
prolactin . . O
levels . . O
for . . O
the . . O
fanapt . . O
24 . . O
mg . . O
/ . . O
day . . O
- . . O
treated . . O
group . . O
was . . O
an . . O
increase . . O
of . . O
2.6 . . B-Severity
ng . . I-Severity
/ . . I-Severity
ml . . I-Severity
compared . . O
to . . O
a . . O
decrease . . O
of . . O
6.3 . . O
ng . . O
/ . . O
ml . . O
in . . O
the . . O
placebo . . O
- . . O
group . . O
. . . O

therefore . . O
, . . O
administration . . O
of . . O
higher . . O
than . . O
the . . O
recommended . . O
doses . . O
or . . O
more . . O
frequent . . O
dosing . . O
of . . O
nulojix . . O
is . . O
not . . O
recommended . . O
. . . O

in . . O
the . . O
short . . O
- . . O
term . . O
trials . . O
, . . O
fanapt . . O
was . . O
associated . . O
with . . O
modest . . B-Severity
levels . . I-Severity
of . . O
prolactin . . B-AdverseReaction
elevation . . I-AdverseReaction
compared . . O
to . . O
greater . . B-Severity
prolactin . . B-AdverseReaction
elevations . . I-AdverseReaction
observed . . O
with . . O
some . . O
other . . B-DrugClass
antipsychotic . . I-DrugClass
agents . . I-DrugClass
. . . O

disruption . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
body's . . I-AdverseReaction
ability . . I-AdverseReaction
to . . I-AdverseReaction
reduce . . I-AdverseReaction
core . . I-AdverseReaction
body . . I-AdverseReaction
temperature . . I-AdverseReaction
has . . O
been . . O
attributed . . O
to . . O
antipsychotic . . B-DrugClass
agents . . I-DrugClass
. . . O

aspiration . . O
pneumonia . . O
is . . O
a . . O
common . . O
cause . . O
of . . O
morbidity . . O
and . . O
mortality . . O
in . . O
elderly . . O
patients . . O
, . . O
in . . O
particular . . O
those . . O
with . . O
advanced . . O
alzheimer's . . O
dementia . . O
. . . O

two . . O
fatal . . B-AdverseReaction
cases . . O
of . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
( . . O
pml . . B-AdverseReaction
) . . O
have . . O
been . . O
reported . . O
among . . O
1096 . . O
patients . . O
treated . . O
with . . O
a . . O
nulojix . . O
- . . O
containing . . O
regimen . . O
: . . O
one . . O
patient . . O
in . . O
clinical . . O
trials . . O
of . . O
kidney . . O
transplant . . O
( . . O
studies . . O
1 . . O
, . . O
2 . . O
, . . O
and . . O
3 . . O
described . . O
above . . O
) . . O
and . . O
one . . O
patient . . O
in . . O
a . . O
trial . . O
of . . O
liver . . O
transplant . . O
( . . O
trial . . O
of . . O
250 . . O
patients . . O
) . . O
. . . O

the . . O
kidney . . O
transplant . . O
recipient . . O
was . . O
treated . . O
with . . O
the . . O
nulojix . . O
regimen . . O
of . . O
higher . . O
cumulative . . O
dose . . O
and . . O
more . . O
frequent . . O
dosing . . O
than . . O
recommended . . O
, . . O
mycophenolate . . O
mofetil . . O
( . . O
mmf . . O
) . . O
, . . O
and . . O
corticosteroids . . O
for . . O
2 . . O
years . . O
. . . O

the . . O
liver . . O
transplant . . O
recipient . . O
was . . O
treated . . O
with . . O
6 . . O
months . . O
of . . O
a . . O
nulojix . . O
dosage . . O
regimen . . O
that . . O
was . . O
more . . O
intensive . . O
than . . O
that . . O
studied . . O
in . . O
kidney . . O
transplant . . O
recipients . . O
, . . O
mmf . . O
at . . O
doses . . O
higher . . O
than . . O
the . . O
recommended . . O
dose . . O
, . . O
and . . O
corticosteroids . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
occurring . . O
in . . O
> . . O
= . . O
13% . . O
of . . O
patients . . O
) . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
are . . O
: . . O
infections . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
tonsilitis . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
ear . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
. . . O

because . . O
these . . O
reactions . . O
were . . O
reported . . O
retrospectively . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

excerpt . . O
: . . O
* . . O
neonatal . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
risk . . B-Factor
of . . O
gasping . . B-AdverseReaction
syndrome . . I-AdverseReaction
if . . O
benzyl . . O
alcohol . . O
is . . O
used . . O
in . . O
neonates . . O
. . . O

infusion . . O
reactions . . O

the . . O
most . . O
frequent . . O
reactions . . O
were . . O
hypotension . . B-AdverseReaction
and . . O
hypertension . . B-AdverseReaction
. . . O

neonates . . O
( . . O
i . . O
. . . O
e . . O
. . . O
patients . . O
less . . O
than . . O
1 . . O
month . . O
of . . O
age . . O
or . . O
preterm . . O
infants . . O
with . . O
a . . O
corrected . . O
age . . O
of . . O
less . . O
than . . O
44 . . O
weeks . . O
) . . O
could . . O
be . . O
at . . O
risk . . B-Factor
for . . O
gasping . . B-AdverseReaction
syndrome . . I-AdverseReaction
if . . O
treated . . O
with . . O
ulesfia . . O
( . . O
r . . O
) . . O
lotion . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.4 . . O
) . . O
] . . O
. . . O

the . . O
clinical . . O
significance . . O
of . . O
this . . O
increase . . O
in . . O
early . . B-AdverseReaction
proteinuria . . I-AdverseReaction
is . . O
unknown . . O
. . . O

antibodies . . O
directed . . O
against . . O
the . . O
belatacept . . O
molecule . . O
were . . O
assessed . . O
in . . O
398 . . O
patients . . O
treated . . O
with . . O
the . . O
nulojix . . O
recommended . . O
regimen . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
( . . O
212 . . O
of . . O
these . . O
patients . . O
were . . O
treated . . O
for . . O
at . . O
least . . O
2 . . O
years . . O
) . . O
. . . O

if . . O
irritation . . O
persists . . O
, . . O
consult . . O
a . . O
physician . . O
. . . O

of . . O
the . . O
372 . . O
patients . . O
with . . O
immunogenicity . . O
assessment . . O
at . . O
baseline . . O
( . . O
prior . . O
to . . O
receiving . . O
belatacept . . O
treatment . . O
) . . O
, . . O
29 . . O
patients . . O
tested . . O
positive . . O
for . . O
anti . . O
- . . O
belatacept . . O
antibodies . . O
; . . O
13 . . O
of . . O
these . . O
patients . . O
had . . O
antibodies . . O
to . . O
the . . O
modified . . O
cytotoxic . . O
t . . O
- . . O
lymphocyte . . O
- . . O
associated . . O
antigen . . O
4 . . O
( . . O
ctla . . O
- . . O
4 . . O
) . . O
. . . O

eight . . O
( . . O
2% . . O
) . . O
patients . . O
developed . . O
antibodies . . O
during . . O
treatment . . O
with . . O
the . . O
nulojix . . O
recommended . . O
regimen . . O
. . . O

in . . O
the . . O
patients . . O
who . . O
developed . . O
antibodies . . O
during . . O
treatment . . O
, . . O
the . . O
median . . O
titer . . O
( . . O
by . . O
dilution . . O
method . . O
) . . O
was . . O
8 . . O
, . . O
with . . O
a . . O
range . . O
of . . O
5 . . O
to . . O
80 . . O
. . . O

the . . O
clinical . . O
impact . . O
of . . O
anti . . O
- . . O
belatacept . . O
antibodies . . O
( . . O
including . . O
neutralizing . . O
anti . . O
- . . O
belatacept . . O
antibodies . . O
) . . O
could . . O
not . . O
be . . O
determined . . O
in . . O
the . . O
studies . . O
. . . O

use . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
chronic . . O
infections . . O
. . . O

consider . . O
interrupting . . O
therapy . . O
with . . O
benlysta . . O
if . . O
patients . . O
develop . . O
a . . O
new . . O
infection . . O
during . . O
treatment . . O
with . . O
benlysta . . O
. . . O

the . . O
data . . O
reflect . . O
the . . O
percentage . . O
of . . O
patients . . O
whose . . O
test . . O
results . . O
were . . O
positive . . O
for . . O
antibodies . . O
to . . O
belatacept . . O
in . . O
specific . . O
assays . . O
. . . O

at . . O
one . . O
year . . O
after . . O
transplantation . . O
, . . O
systolic . . O
blood . . O
pressures . . O
were . . O
8 . . O
mmhg . . O
lower . . O
and . . O
diastolic . . O
blood . . O
pressures . . O
were . . O
3 . . O
mmhg . . O
lower . . O
in . . O
patients . . O
treated . . O
with . . O
the . . O
nulojix . . O
recommended . . O
regimen . . O
compared . . O
to . . O
the . . O
cyclosporine . . O
control . . O
regimen . . O
. . . O

5.1 . . O
mortality . . O

serious . . B-Severity
and . . O
sometimes . . O
fatal . . B-AdverseReaction
infections . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
immunosuppressive . . O
agents . . O
, . . O
including . . O
benlysta . . O
. . . O

physicians . . O
should . . O
exercise . . O
caution . . O
when . . O
considering . . O
the . . O
use . . O
of . . O
benlysta . . O
in . . O
patients . . O
with . . O
chronic . . O
infections . . O
. . . O

table . . O
4 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
by . . O
> . . O
= . . O
10% . . O
of . . O
patients . . O
treated . . O
with . . O
either . . O
the . . O
nulojix . . O
recommended . . O
regimen . . O
or . . O
control . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
through . . O
three . . O
years . . O
* . . O
, . . O
adverse . . O
reaction . . O
nulojix . . O
recommended . . O
regimen . . O
n . . O
= . . O
401 . . O
% . . O
cyclosporine . . O
n . . O
= . . O
405 . . O
% . . O
* . . O
all . . O
randomized . . O
and . . O
transplanted . . O
patients . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
. . . O

infections . . O
and . . O
infestations . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
37 . . O
36 . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
infection . . I-AdverseReaction
15 . . O
16 . . O
nasopharyngitis . . B-AdverseReaction
13 . . O
16 . . O
cytomegalovirus . . B-AdverseReaction
infection . . I-AdverseReaction
12 . . O
12 . . O
influenza . . B-AdverseReaction
11 . . O
8 . . O
bronchitis . . B-AdverseReaction
10 . . O
7 . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
39 . . O
36 . . O
constipation . . B-AdverseReaction
33 . . O
35 . . O
nausea . . B-AdverseReaction
24 . . O
27 . . O
vomiting . . B-AdverseReaction
22 . . O
20 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
19 . . O
16 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
9 . . O
10 . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
hyperkalemia . . B-AdverseReaction
20 . . O
20 . . O
hypokalemia . . B-AdverseReaction
21 . . O
14 . . O
hypophosphatemia . . B-AdverseReaction
19 . . O
13 . . O
dyslipidemia . . B-AdverseReaction
19 . . O
24 . . O
hyperglycemia . . B-AdverseReaction
16 . . O
17 . . O
hypocalcemia . . B-AdverseReaction
13 . . O
11 . . O
hypercholesterolemia . . B-AdverseReaction
11 . . O
11 . . O
hypomagnesemia . . B-AdverseReaction
7 . . O
10 . . O
hyperuricemia . . B-AdverseReaction
5 . . O
12 . . O
procedural . . O
complications . . O
graft . . B-AdverseReaction
dysfunction . . I-AdverseReaction
25 . . O
34 . . O
general . . O
disorders . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
34 . . O
42 . . O
pyrexia . . B-AdverseReaction
28 . . O
26 . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
anemia . . B-AdverseReaction
45 . . O
44 . . O
leukopenia . . B-AdverseReaction
20 . . O
23 . . O
renal . . O
and . . O
urinary . . O
disorders . . O
hematuria . . B-AdverseReaction
16 . . O
18 . . O
proteinuria . . B-AdverseReaction
16 . . O
12 . . O
dysuria . . B-AdverseReaction
11 . . O
11 . . O
renal . . B-AdverseReaction
tubular . . I-AdverseReaction
necrosis . . I-AdverseReaction
9 . . O
13 . . O
vascular . . O
disorders . . O
hypertension . . B-AdverseReaction
32 . . O
37 . . O
hypotension . . B-AdverseReaction
18 . . O
12 . . O
respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
24 . . O
18 . . O
dyspnea . . B-AdverseReaction
12 . . O
15 . . O
investigations . . O
blood . . B-AdverseReaction
creatinine . . I-AdverseReaction
increased . . I-AdverseReaction
15 . . O
20 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
arthralgia . . B-AdverseReaction
17 . . O
13 . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
13 . . O
13 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
21 . . O
18 . . O
dizziness . . B-AdverseReaction
9 . . O
10 . . O
tremor . . B-AdverseReaction
8 . . O
17 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
acne . . B-AdverseReaction
8 . . O
11 . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
15 . . O
18 . . O
anxiety . . B-AdverseReaction
10 . . O
11 . . O
selected . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
< . . O
10% . . O
from . . O
nulojix . . O
- . . O
treated . . O
patients . . O
in . . O
either . . O
regimen . . O
through . . O
three . . O
years . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
are . . O
listed . . O
below . . O
: . . O

infections . . O
and . . O
infestations . . O
: . . O
see . . O
table . . O
3 . . O

injury . . O
, . . O
poisoning . . O
, . . O
and . . O
procedural . . O
complications . . O
: . . O
chronic . . B-AdverseReaction
allograft . . I-AdverseReaction
nephropathy . . I-AdverseReaction
, . . O
complications . . B-AdverseReaction
of . . I-AdverseReaction
transplanted . . I-AdverseReaction
kidney . . I-AdverseReaction
, . . O
including . . O
wound . . B-AdverseReaction
dehiscence . . I-AdverseReaction
, . . O
arteriovenous . . B-AdverseReaction
fistula . . I-AdverseReaction
thrombosis . . I-AdverseReaction

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
including . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
artery . . I-AdverseReaction
stenosis . . I-AdverseReaction
, . . O
urinary . . B-AdverseReaction
incontinence . . I-AdverseReaction
, . . O
hydronephrosis . . B-AdverseReaction

cardiac . . O
disorders . . O
: . . O
atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction

the . . O
impact . . O
of . . O
treatment . . O
with . . O
benlysta . . O
on . . O
the . . O
development . . O
of . . O
malignancies . . B-AdverseReaction
is . . O
not . . B-Factor
known . . I-Factor
. . . O

in . . O
the . . O
controlled . . O
clinical . . O
trials . . O
, . . O
malignancies . . B-AdverseReaction
( . . O
including . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
melanoma . . I-AdverseReaction
skin . . I-AdverseReaction
cancers . . I-AdverseReaction
) . . O
were . . O
reported . . O
in . . O
0.4% . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
and . . O
0.4% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
events . . O
( . . O
> . . O
= . . O
4% . . O
) . . O
for . . O
toviaz . . O
were . . O
: . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
( . . O
placebo . . O
, . . O
7% . . O
; . . O
toviaz . . O
4 . . O
mg . . O
, . . O
19% . . O
; . . O
toviaz . . O
8 . . O
mg . . O
, . . O
35% . . O
) . . O
and . . O
constipation . . B-AdverseReaction
( . . O
placebo . . O
, . . O
2% . . O
; . . O
toviaz . . O
4 . . O
mg . . O
, . . O
4% . . O
; . . O
toviaz . . O
8 . . O
mg . . O
, . . O
6% . . O
) . . O
. . . O

( . . O
6 . . O
) . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
pfizer . . O
inc . . O
at . . O
1-800-438-1985 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

acute . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
and . . O
death . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
benlysta . . O
. . . O

these . . O
events . . O
generally . . O
occurred . . O
within . . O
hours . . O
of . . O
the . . O
infusion . . O
; . . O
however . . O
, . . O
they . . O
may . . O
occur . . O
later . . O
. . . O

non . . O
- . . O
acute . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
including . . O
rash . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
and . . O
facial . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
and . . O
typically . . O
occurred . . O
up . . O
to . . O
a . . O
week . . O
following . . O
the . . O
most . . O
recent . . O
infusion . . O
. . . O

hypersensitivity . . O
, . . O
including . . O
serious . . B-Severity
reactions . . O
, . . O
has . . O
occurred . . O
in . . O
patients . . O
who . . O
have . . O
previously . . O
tolerated . . O
infusions . . O
of . . O
benlysta . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

a . . O
total . . O
of . . O
1964 . . O
patients . . O
participated . . O
in . . O
two . . O
12 . . O
- . . O
week . . O
, . . O
phase . . O
3 . . O
efficacy . . O
and . . O
safety . . O
studies . . O
and . . O
subsequent . . O
open . . O
- . . O
label . . O
extension . . O
studies . . O
. . . O

due . . O
to . . O
overlap . . O
in . . O
signs . . O
and . . O
symptoms . . O
, . . O
it . . O
was . . O
not . . O
possible . . O
to . . O
distinguish . . O
between . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
in . . O
all . . O
cases . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

the . . O
second . . O
most . . O
commonly . . O
reported . . O
adverse . . O
event . . O
was . . O
constipation . . B-AdverseReaction
. . . O

the . . O
incidence . . O
of . . O
constipation . . B-AdverseReaction
was . . O
2% . . O
in . . O
those . . O
taking . . O
placebo . . O
, . . O
4% . . O
in . . O
those . . O
taking . . O
4 . . O
mg . . O
/ . . O
day . . O
, . . O
and . . O
6% . . O
in . . O
those . . O
taking . . O
8 . . O
mg . . O
/ . . O
day . . O
. . . O

table . . O
1 . . O
lists . . O
adverse . . O
events . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
that . . O
were . . O
reported . . O
in . . O
the . . O
combined . . O
phase . . O
3 . . O
, . . O
randomized . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
at . . O
an . . O
incidence . . O
greater . . O
than . . O
placebo . . O
and . . O
in . . O
1% . . O
or . . O
more . . O
of . . O
patients . . O
treated . . O
with . . O
toviaz . . O
4 . . O
or . . O
8 . . O
mg . . O
once . . O
daily . . O
for . . O
up . . O
to . . O
12 . . O
weeks . . O
. . . O

5.5 . . O
infusion . . O
reactions . . O

table . . O
1 . . O
: . . O
adverse . . O
events . . O
with . . O
an . . O
incidence . . O
exceeding . . O
the . . O
placebo . . O
rate . . O
and . . O
reported . . O
by . . O
> . . O
= . . O
1% . . O
of . . O
patients . . O
from . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
phase . . O
3 . . O
trials . . O
of . . O
12 . . O
weeks . . O
treatment . . O
duration . . O
system . . O
organ . . O
class . . O
/ . . O
preferred . . O
term . . O
placebo . . O
n . . O
= . . O
554 . . O
% . . O
toviaz . . O
4 . . O
mg . . O
/ . . O
day . . O
n . . O
= . . O
554 . . O
% . . O
toviaz . . O
8 . . O
mg . . O
/ . . O
day . . O
n . . O
= . . O
566 . . O
% . . O
alt . . O
= . . O
alanine . . O
aminotransferase . . O
; . . O
ggt . . O
= . . O
gamma . . O
glutamyltransferase . . O
gastrointestinal . . O
disorders . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
7.0 . . O
18.8 . . O
34.6 . . O
constipation . . B-AdverseReaction
2.0 . . O
4.2 . . O
6.0 . . O
dyspepsia . . B-AdverseReaction
0.5 . . O
1.6 . . O
2.3 . . O
nausea . . B-AdverseReaction
1.3 . . O
0.7 . . O
1.9 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
0.5 . . O
1.1 . . O
0.5 . . O
infections . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
3.1 . . O
3.2 . . O
4.2 . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
2.2 . . O
2.5 . . O
1.8 . . O
eye . . O
disorders . . O
dry . . B-AdverseReaction
eyes . . I-AdverseReaction
0 . . O
1.4 . . O
3.7 . . O
renal . . O
and . . O
urinary . . O
disorders . . O
dysuria . . B-AdverseReaction
0.7 . . O
1.3 . . O
1.6 . . O
urinary . . B-AdverseReaction
retention . . I-AdverseReaction
0.2 . . O
1.1 . . O
1.4 . . O
respiratory . . O
disorders . . O
cough . . B-AdverseReaction
0.5 . . O
1.6 . . O
0.9 . . O
dry . . B-AdverseReaction
throat . . I-AdverseReaction
0.4 . . O
0.9 . . O
2.3 . . O
general . . O
disorders . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
0.7 . . O
0.7 . . O
1.2 . . O
musculoskeletal . . O
disorders . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
0.4 . . O
2.0 . . O
0.9 . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
0.5 . . O
1.3 . . O
0.4 . . O
investigations . . O
alt . . B-AdverseReaction
increased . . I-AdverseReaction
0.9 . . O
0.5 . . O
1.2 . . O
ggt . . B-AdverseReaction
increased . . I-AdverseReaction
0.4 . . O
0.4 . . O
1.2 . . O
skin . . O
disorders . . O
rash . . B-AdverseReaction
0.5 . . O
0.7 . . O
1.1 . . O
patients . . O
also . . O
received . . O
toviaz . . O
for . . O
up . . O
to . . O
three . . O
years . . O
in . . O
open . . O
- . . O
label . . O
extension . . O
phases . . O
of . . O
one . . O
phase . . O
2 . . O
and . . O
two . . O
phase . . O
3 . . O
controlled . . O
trials . . O
. . . O

due . . O
to . . O
overlap . . O
in . . O
signs . . O
and . . O
symptoms . . O
, . . O
it . . O
was . . O
not . . O
possible . . O
to . . O
distinguish . . O
between . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
in . . O
all . . O
cases . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

serious . . B-Severity
psychiatric . . B-AdverseReaction
events . . I-AdverseReaction
were . . O
reported . . O
in . . O
0.8% . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
( . . O
0.6% . . O
and . . O
1.2% . . O
with . . O
1 . . O
and . . O
10 . . O
mg . . O
/ . . O
kg . . O
, . . O
respectively . . O
) . . O
and . . O
0.4% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

interrupt . . O
and . . O
then . . O
reduce . . O
or . . O
discontinue . . O
zydelig . . O
as . . O
recommended . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

monitor . . O
for . . O
pulmonary . . O
symptoms . . O
and . . O
bilateral . . O
interstitial . . O
infiltrates . . O
. . . O

live . . O
vaccines . . O
should . . O
not . . O
be . . O
given . . O
for . . O
30 . . O
days . . O
before . . O
or . . O
concurrently . . O
with . . O
benlysta . . O
as . . O
clinical . . O
safety . . O
has . . O
not . . O
been . . O
established . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
wound . . B-AdverseReaction
complications . . I-AdverseReaction
: . . O
withhold . . O
cometriq . . O
for . . O
dehiscence . . O
or . . O
complications . . O
requiring . . O
medical . . O
intervention . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
fatal . . B-AdverseReaction
and . . O
/ . . O
or . . O
serious . . B-Severity
and . . O
severe . . B-Severity
diarrhea . . B-AdverseReaction
or . . O
colitis . . B-AdverseReaction
occurred . . O
in . . O
14% . . O
of . . O
zydelig . . O
- . . O
treated . . O
patients . . O
. . . O

monitor . . O
for . . O
the . . O
development . . O
of . . O
severe . . O
diarrhea . . O
or . . O
colitis . . O
. . . O

advise . . O
women . . O
of . . O
potential . . O
risk . . O
to . . O
a . . O
fetus . . O
. . . O

5.1 . . O
perforations . . O
and . . O
fistulas . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
pharmacyclics . . O
at . . O
1-877-877-3536 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

mantle . . O
cell . . O
lymphoma . . O

monitor . . O
patients . . O
for . . O
symptoms . . O
of . . O
perforations . . O
and . . O
fistulas . . O
. . . O

the . . O
most . . O
frequent . . O
adverse . . O
reaction . . O
leading . . O
to . . O
treatment . . O
discontinuation . . O
was . . O
subdural . . B-AdverseReaction
hematoma . . I-AdverseReaction
( . . O
1.8% . . O
) . . O
. . . O

however . . O
, . . O
some . . O
of . . O
these . . O
cases . . O
were . . O
in . . O
the . . O
setting . . O
of . . O
disease . . O
progression . . O
. . . O

chronic . . O
lymphocytic . . O
leukemia . . O

resume . . O
cometriq . . O
therapy . . O
after . . O
surgery . . O
based . . O
on . . O
clinical . . O
judgment . . O
of . . O
adequate . . O
wound . . O
healing . . O
. . . O

these . . O
included . . O
infections . . B-AdverseReaction
, . . O
subdural . . B-AdverseReaction
hematomas . . I-AdverseReaction
and . . O
diarrhea . . B-AdverseReaction
. . . O

discontinue . . O
cometriq . . O
for . . O
severe . . O
hypertension . . O
that . . O
cannot . . O
be . . O
controlled . . O
with . . O
anti . . O
- . . O
hypertensive . . O
therapy . . O
. . . O

adverse . . O
reactions . . O
and . . O
laboratory . . O
abnormalities . . O
described . . O
below . . O
in . . O
tables . . O
5 . . O
and . . O
6 . . O
reflect . . O
exposure . . O
to . . O
imbruvica . . O
with . . O
a . . O
median . . O
duration . . O
of . . O
8.6 . . O
months . . O
and . . O
exposure . . O
to . . O
ofatumumab . . O
with . . O
a . . O
median . . O
of . . O
5.3 . . O
months . . O
in . . O
study . . O
2 . . O
. . . O

perform . . O
an . . O
oral . . O
examination . . O
prior . . O
to . . O
initiation . . O
of . . O
cometriq . . O
and . . O
periodically . . O
during . . O
cometriq . . O
therapy . . O
. . . O

5.7 . . O
palmar . . O
- . . O
plantar . . O
erythrodysesthesia . . O
syndrome . . O

palmar . . O
- . . O
plantar . . O
erythrodysesthesia . . O
syndrome . . O
( . . O
ppes . . O
) . . O
occurred . . O
in . . O
50% . . O
of . . O
patients . . O
treated . . O
with . . O
cometriq . . O
and . . O
was . . O
severe . . B-Severity
( . . O
> . . O
= . . O
grade . . B-Severity
3 . . I-Severity
) . . O
in . . O
13% . . O
of . . O
patients . . O
. . . O

adverse . . O
reactions . . O
and . . O
laboratory . . O
abnormalities . . O
described . . O
below . . O
in . . O
tables . . O
7 . . O
and . . O
8 . . O
reflect . . O
exposure . . O
to . . O
imbruvica . . O
with . . O
a . . O
median . . O
duration . . O
of . . O
11.7 . . O
months . . O
in . . O
the . . O
wm . . O
trial . . O
. . . O

table . . O
7 . . O
: . . O
non . . O
- . . O
hematologic . . O
adverse . . O
reactions . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
patients . . O
with . . O
waldenstrom's . . O
macroglobulinemia . . O
( . . O
n . . O
= . . O
63 . . O
) . . O
system . . O
organ . . O
class . . O
preferred . . O
term . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
or . . O
4 . . O
( . . O
% . . O
) . . O
the . . O
system . . O
organ . . O
class . . O
and . . O
individual . . O
adr . . O
terms . . O
are . . O
sorted . . O
in . . O
descending . . O
frequency . . O
order . . O
. . . O

discontinue . . O
cometriq . . O
in . . O
patients . . O
who . . O
develop . . O
nephrotic . . O
syndrome . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
including . . O
anaphylactic . . B-AdverseReaction
shock . . I-AdverseReaction
( . . O
fatal . . B-AdverseReaction
) . . O
, . . O
urticaria . . B-AdverseReaction
, . . O
and . . O
angioedema . . B-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

5.10 . . O
drug . . O
interactions . . O

this . . O
finding . . O
with . . O
salmeterol . . O
is . . O
considered . . O
a . . O
class . . O
effect . . O
of . . O
laba . . O
. . . O

cabozantinib . . O
was . . O
embryolethal . . B-AdverseReaction
in . . O
rats . . B-Animal
at . . O
exposures . . O
below . . O
the . . O
recommended . . O
human . . O
dose . . O
, . . O
with . . O
increased . . O
incidences . . O
of . . O
skeletal . . B-AdverseReaction
variations . . I-AdverseReaction
in . . O
rats . . B-Animal
and . . O
visceral . . B-AdverseReaction
variations . . I-AdverseReaction
and . . O
malformations . . O
in . . O
rabbits . . B-Animal
. . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
, . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
this . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

6 . . O
adverse . . O
reactions . . O

do . . O
not . . O
use . . O
breo . . O
ellipta . . O
for . . O
patients . . O
whose . . O
asthma . . O
is . . O
adequately . . O
controlled . . O
on . . O
low . . O
- . . O
or . . O
medium . . O
- . . O
dose . . O
inhaled . . O
corticosteroids . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

* . . O
hypersensitivity . . B-AdverseReaction
reactions . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

currently . . O
available . . O
data . . O
are . . O
inadequate . . O
to . . O
determine . . O
whether . . O
concurrent . . O
use . . O
of . . O
inhaled . . O
corticosteroids . . O
( . . O
ics . . O
) . . O
or . . O
other . . O
long . . O
- . . O
term . . O
asthma . . O
control . . O
drugs . . O
mitigates . . O
the . . O
increased . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
from . . O
laba . . B-DrugClass
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
of . . O
moderate . . B-Severity
to . . O
severe . . B-Severity
intensity . . O
and . . O
incidence . . O
at . . O
least . . O
2% . . O
( . . O
in . . O
those . . O
receiving . . O
tivicay . . O
in . . O
any . . O
one . . O
adult . . O
trial . . O
) . . O
are . . O
insomnia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
. . . O

once . . O
asthma . . O
control . . O
is . . O
achieved . . O
and . . O
maintained . . O
, . . O
assess . . O
the . . O
patient . . O
at . . O
regular . . O
intervals . . O
and . . O
step . . O
down . . O
therapy . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
discontinue . . O
breo . . O
ellipta . . O
) . . O
if . . O
possible . . O
without . . O
loss . . O
of . . O
asthma . . O
control . . O
and . . O
maintain . . O
the . . O
patient . . O
on . . O
a . . O
long . . O
- . . O
term . . O
asthma . . O
control . . O
medication . . O
, . . O
such . . O
as . . O
an . . O
ics . . O
. . . O

clinical . . O
correlation . . O
, . . O
including . . O
histopathological . . O
evaluation . . O
of . . O
the . . O
suspected . . O
recurrence . . O
site . . O
, . . O
is . . O
essential . . O
to . . O
proper . . O
use . . O
of . . O
the . . O
pet . . O
imaging . . O
information . . O
. . . O

one . . O
published . . O
report . . O
of . . O
18 . . O
f . . O
- . . O
methylcholine . . O
pet . . O
imaging . . O
indicated . . O
that . . O
discontinuation . . O
of . . O
colchicine . . O
for . . O
two . . O
weeks . . O
resolved . . O
the . . O
colchicine . . O
effect . . O
. . . O

there . . O
were . . O
484 . . O
subjects . . O
included . . O
in . . O
the . . O
efficacy . . O
and . . O
safety . . O
analyses . . O
. . . O

through . . O
48 . . O
weeks . . O
, . . O
the . . O
rates . . O
of . . O
adverse . . O
events . . O
leading . . O
to . . O
discontinuation . . O
were . . O
2% . . O
in . . O
subjects . . O
receiving . . O
tivicay . . O
and . . O
4% . . O
in . . O
subjects . . O
receiving . . O
darunavir . . O
/ . . O
ritonavir . . O
. . . O

less . . O
common . . O
adverse . . O
reactions . . O
observed . . O
in . . O
treatment . . O
- . . O
naive . . O
and . . O
treatment . . O
- . . O
experienced . . O
trials . . O

the . . O
following . . O
adrs . . O
occurred . . O
in . . O
less . . O
than . . O
2% . . O
of . . O
treatment . . O
- . . O
naive . . O
or . . O
treatment . . O
- . . O
experienced . . O
subjects . . O
receiving . . O
tivicay . . O
in . . O
a . . O
combination . . O
regimen . . O
in . . O
any . . O
one . . O
trial . . O
. . . O

these . . O
events . . O
have . . O
been . . O
included . . O
because . . O
of . . O
their . . O
seriousness . . O
and . . O
assessment . . O
of . . O
potential . . O
causal . . O
relationship . . O
. . . O

nsf . . B-AdverseReaction
has . . O
not . . B-Negation
been . . O
reported . . O
in . . O
patients . . O
with . . O
a . . O
clear . . O
history . . O
of . . O
exposure . . O
to . . O
dotarem . . O
alone . . O
. . . O

these . . O
events . . O
were . . O
observed . . O
primarily . . O
in . . O
subjects . . O
with . . O
a . . O
pre . . O
- . . O
existing . . O
history . . O
of . . O
depression . . O
or . . O
other . . O
psychiatric . . O
illness . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

overall . . O
, . . O
55% . . O
of . . O
the . . O
patients . . O
were . . O
men . . O
. . . O

table . . O
3 . . O
. . . O

table . . O
2 . . O
lists . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
> . . O
= . . O
0.2% . . O
patients . . O
who . . O
received . . O
dotarem . . O
. . . O

table . . O
4 . . O
. . . O

adverse . . O
reactions . . O
in . . O
pediatric . . O
patients . . O

seventy . . O
- . . O
seven . . O
subjects . . O
initiated . . O
a . . O
lipid . . O
- . . O
lowering . . O
agent . . O
post . . O
- . . O
baseline . . O
; . . O
their . . O
last . . O
fasted . . O
on . . O
- . . O
treatment . . O
values . . O
( . . O
prior . . O
to . . O
starting . . O
the . . O
agent . . O
) . . O
were . . O
used . . O
regardless . . O
if . . O
they . . O
discontinued . . O
the . . O
agent . . O
( . . O
spring . . O
- . . O
2 . . O
: . . O
tivicay . . O
n . . O
= . . O
9 . . O
, . . O
raltegravir . . O
n . . O
= . . O
13 . . O
; . . O
single . . O
: . . O
tivicay . . O
n . . O
= . . O
25 . . O
and . . O
atripla . . O
: . . O
n . . O
= . . O
30 . . O
) . . O
. . . O

the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
reaction . . O
was . . O
headache . . B-AdverseReaction
( . . O
1.5% . . O
) . . O
. . . O

the . . O
following . . O
additional . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
postmarketing . . O
use . . O
of . . O
dotarem . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

grades . . B-Severity
2 . . I-Severity
to . . I-Severity
4 . . I-Severity
alt . . B-AdverseReaction
abnormalities . . I-AdverseReaction
in . . O
hepatitis . . O
b . . O
and . . O
/ . . O
or . . O
c . . O
co . . O
- . . O
infected . . O
compared . . O
with . . O
hiv . . O
mono . . O
- . . O
infected . . O
subjects . . O
receiving . . O
tivicay . . O
were . . O
observed . . O
in . . O
18% . . O
vs . . O
. . . O
3% . . O
with . . O
the . . O
50 . . O
- . . O
mg . . O
once . . O
- . . O
daily . . O
dose . . O
and . . O
13% . . O
vs . . O
. . . O
8% . . O
with . . O
the . . O
50 . . O
- . . O
mg . . O
twice . . O
- . . O
daily . . O
dose . . O
. . . O

increases . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
occurred . . O
within . . O
the . . O
first . . O
4 . . O
weeks . . O
of . . O
treatment . . O
and . . O
remained . . O
stable . . O
through . . O
48 . . O
to . . O
96 . . O
weeks . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
serious . . B-Severity
hypersensitivity . . O
( . . O
anaphylactic . . O
) . . O
reactions . . O
have . . O
been . . O
reported . . O
with . . O
beta . . B-DrugClass
- . . I-DrugClass
lactam . . I-DrugClass
antibacterial . . I-DrugClass
drugs . . I-DrugClass
. . . O

( . . O
5.3 . . O
) . . O

5.1 . . O
decreased . . O
efficacy . . O
in . . O
patients . . O
with . . O
baseline . . O
creatinine . . O
clearance . . O
of . . O
30 . . O
to . . O
< . . O
= . . O
50 . . O
ml . . O
/ . . O
min . . O

in . . O
a . . O
subgroup . . O
analysis . . O
of . . O
a . . O
phase . . O
3 . . O
ciai . . O
trial . . O
, . . O
clinical . . O
cure . . O
rates . . O
were . . O
lower . . O
in . . O
patients . . O
with . . O
baseline . . O
creatinine . . O
clearance . . O
( . . O
crcl . . O
) . . O
of . . O
30 . . O
to . . O
< . . O
= . . O
50 . . O
ml . . O
/ . . O
min . . O
compared . . O
to . . O
those . . O
with . . O
crcl . . O
> . . O
= . . O
50 . . O
ml . . O
/ . . O
min . . O
( . . O
table . . O
4 . . O
) . . O
. . . O

no . . O
grade . . O
4 . . O
laboratory . . O
abnormalities . . O
were . . O
reported . . O
. . . O

* . . O
cardiovascular . . B-AdverseReaction
disorders . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
malignant . . B-AdverseReaction
neoplasms . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
gallbladder . . B-AdverseReaction
disease . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
hypertriglyceridemia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
excerpt . . O
: . . O
in . . O
four . . O
prospective . . O
, . . O
randomized . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
the . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
5% . . O
) . . O
were . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
, . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
and . . O
neck . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
6.1 . . O
) . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
pfizer . . O
inc . . O
. . . O
at . . O
1-800-438-1985 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

serious . . B-Severity
and . . O
occasionally . . O
fatal . . B-AdverseReaction
hypersensitivity . . O
( . . O
anaphylactic . . O
) . . O
reactions . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
beta . . B-DrugClass
- . . I-DrugClass
lactam . . I-DrugClass
antibacterial . . I-DrugClass
drugs . . I-DrugClass
. . . O

5.3 . . O
clostridium . . O
difficile . . O
- . . O
associated . . O
diarrhea . . O

women . . O
enrolled . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
received . . O
calcium . . O
( . . O
600-1200 . . O
mg . . O
) . . O
and . . O
vitamin . . O
d . . O
( . . O
200-400 . . O
iu . . O
) . . O
daily . . O
, . . O
while . . O
women . . O
in . . O
studies . . O
3 . . O
and . . O
4 . . O
received . . O
no . . O
calcium . . O
and . . O
vitamin . . O
d . . O
supplementation . . O
as . . O
part . . O
of . . O
the . . O
protocol . . O
. . . O

treatment . . O
with . . O
antibacterial . . O
agents . . O
alters . . O
the . . O
normal . . O
flora . . O
of . . O
the . . O
colon . . O
and . . O
may . . O
permit . . O
overgrowth . . O
of . . O
c . . O
. . . O
difficile . . O
. . . O

cdad . . O
must . . O
be . . O
considered . . O
in . . O
all . . O
patients . . O
who . . O
present . . O
with . . O
diarrhea . . O
following . . O
antibacterial . . O
use . . O
. . . O

the . . O
percentage . . O
of . . O
patients . . O
who . . O
withdrew . . O
from . . O
treatment . . O
due . . O
to . . O
adverse . . O
reactions . . O
was . . O
7.5% . . O
in . . O
the . . O
duavee . . O
group . . O
and . . O
10.0% . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

if . . O
cdad . . O
is . . O
confirmed . . O
, . . O
discontinue . . O
antibacterials . . O
not . . O
directed . . O
against . . O
c . . O
. . . O
difficile . . O
, . . O
if . . O
possible . . O
. . . O

the . . O
most . . O
commonly . . O
observed . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
5% . . O
) . . O
more . . O
frequently . . O
reported . . O
in . . O
women . . O
treated . . O
with . . O
duavee . . O
than . . O
placebo . . O
are . . O
presented . . O
in . . O
table . . O
1 . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
5% . . O
) . . O
more . . O
common . . O
in . . O
the . . O
duavee . . O
treatment . . O
group . . O
in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
duavee . . O
( . . O
n . . O
= . . O
1224 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
1069 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
100 . . O
( . . O
8 . . O
) . . O
58 . . O
( . . O
5 . . O
) . . O
diarrhea . . B-AdverseReaction
96 . . O
( . . O
8 . . O
) . . O
57 . . O
( . . O
5 . . O
) . . O
dyspepsia . . B-AdverseReaction
84 . . O
( . . O
7 . . O
) . . O
59 . . O
( . . O
6 . . O
) . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
81 . . O
( . . O
7 . . O
) . . O
58 . . O
( . . O
5 . . O
) . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
110 . . O
( . . O
9 . . O
) . . O
63 . . O
( . . O
6 . . O
) . . O
neck . . B-AdverseReaction
pain . . I-AdverseReaction
62 . . O
( . . O
5 . . O
) . . O
46 . . O
( . . O
4 . . O
) . . O
nervous . . O
system . . O
disorders . . O
dizziness . . B-AdverseReaction
65 . . O
( . . O
5 . . O
) . . O
37 . . O
( . . O
3 . . O
) . . O
respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
80 . . O
( . . O
7 . . O
) . . O
61 . . O
( . . O
6 . . O
) . . O
venous . . O
thromboembolism . . O
: . . O
in . . O
the . . O
clinical . . O
studies . . O
with . . O
duavee . . O
, . . O
the . . O
reporting . . O
rates . . O
for . . O
venous . . B-AdverseReaction
thromboembolism . . I-AdverseReaction
( . . O
deep . . B-AdverseReaction
venous . . I-AdverseReaction
thrombosis . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
, . . O
and . . O
retinal . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
) . . O
were . . O
low . . O
in . . O
all . . O
treatment . . O
groups . . O
. . . O

excerpt . . O
: . . O
* . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
can . . B-Factor
occur . . O
with . . O
sirturo . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

withhold . . O
kyprolis . . O
and . . O
evaluate . . O
promptly . . O
. . . O

sirturo . . O
prolongs . . B-AdverseReaction
the . . I-AdverseReaction
qt . . I-AdverseReaction
interval . . I-AdverseReaction
. . . O

( . . O
5.3 . . O
) . . O
* . . O
pulmonary . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
including . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
and . . O
acute . . B-AdverseReaction
diffuse . . I-AdverseReaction
infiltrative . . I-AdverseReaction
pulmonary . . I-AdverseReaction
disease . . I-AdverseReaction
: . . O
withhold . . O
kyprolis . . O
and . . O
evaluate . . O
promptly . . O
( . . O
5.4 . . O
) . . O
* . . O
pulmonary . . B-AdverseReaction
hypertension . . I-AdverseReaction
: . . O
withhold . . O
kyprolis . . O
and . . O
evaluate . . O
( . . O
5.5 . . O
) . . O
* . . O
dyspnea . . B-AdverseReaction
: . . O
for . . O
severe . . O
or . . O
life . . O
threatening . . O
dyspnea . . O
, . . O
withhold . . O
kyprolis . . O
and . . O
evaluate . . O
. . . O

if . . O
hypertension . . O
cannot . . O
be . . O
adequately . . O
controlled . . O
, . . O
a . . O
risk . . O
- . . O
benefit . . O
decision . . O
on . . O
continued . . O
kyprolis . . O
therapy . . O
is . . O
needed . . O
. . . O

alcohol . . O
and . . O
other . . O
hepatotoxic . . O
drugs . . O
should . . O
be . . O
avoided . . O
while . . O
on . . O
sirturo . . O
, . . O
especially . . O
in . . O
patients . . O
with . . O
impaired . . O
hepatic . . O
function . . O
. . . O

monitor . . O
symptoms . . O
( . . O
such . . O
as . . O
fatigue . . O
, . . O
anorexia . . O
, . . O
nausea . . O
, . . O
jaundice . . O
, . . O
dark . . O
urine . . O
, . . O
liver . . O
tenderness . . O
and . . O
hepatomegaly . . O
) . . O
and . . O
laboratory . . O
tests . . O
( . . O
alt . . O
, . . O
ast . . O
, . . O
alkaline . . O
phosphatase . . O
, . . O
and . . O
bilirubin . . O
) . . O
at . . O
baseline . . O
, . . O
monthly . . O
while . . O
on . . O
treatment . . O
, . . O
and . . O
as . . O
needed . . O
. . . O

appropriate . . O
clinical . . O
monitoring . . O
for . . O
sirturo . . O
- . . O
related . . O
adverse . . O
reactions . . O
is . . O
recommended . . O
. . . O

see . . O
the . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
prescribing . . O
information . . O
for . . O
description . . O
of . . O
adverse . . O
reactions . . O
associated . . O
with . . O
their . . O
use . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
( . . O
greater . . O
than . . O
35% . . O
of . . O
subjects . . O
) . . O
in . . O
clinical . . O
trials . . O
in . . O
adult . . O
subjects . . O
receiving . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
and . . O
rebetol . . O
were . . O
fatigue . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
and . . O
dysgeusia . . B-AdverseReaction
. . . O

in . . O
patients . . O
> . . O
= . . O
75 . . O
years . . O
of . . O
age . . O
, . . O
the . . O
risk . . O
of . . O
cardiac . . O
failure . . O
is . . O
increased . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
merck . . O
sharp . . O
& . . O
dohme . . O
corp . . O
. . . O
, . . O
a . . O
subsidiary . . O
of . . O
merck . . O
& . . O
co . . O
. . . O
, . . O
inc . . O
. . . O
, . . O
at . . O
1-877-888-4231 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
clinical . . O
trials . . O
of . . O
victrelis . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

sprint . . O
- . . O
1 . . O
( . . O
subjects . . O
who . . O
were . . O
previously . . O
untreated . . O
) . . O
evaluated . . O
the . . O
use . . O
of . . O
victrelis . . O
in . . O
combination . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
with . . O
or . . O
without . . O
a . . O
four . . O
- . . O
week . . O
lead . . O
- . . O
in . . O
period . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
compared . . O
to . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
. . . O

during . . O
the . . O
four . . O
week . . O
lead . . O
- . . O
in . . O
period . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
in . . O
subjects . . O
treated . . O
with . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
, . . O
28 . . O
/ . . O
1263 . . O
( . . O
2% . . O
) . . O
subjects . . O
experienced . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
of . . O
treatment . . O
. . . O

ensure . . O
that . . O
patients . . O
are . . O
well . . O
hydrated . . O
before . . O
administration . . O
of . . O
kyprolis . . O
in . . O
cycle . . O
1 . . O
, . . O
and . . O
in . . O
subsequent . . O
cycles . . O
as . . O
needed . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

consider . . O
uric . . O
acid . . O
lowering . . O
drugs . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
tls . . O
. . . O

only . . O
anemia . . B-AdverseReaction
and . . O
fatigue . . B-AdverseReaction
were . . O
reported . . O
as . . O
events . . O
that . . O
led . . O
to . . O
discontinuation . . O
in . . O
more . . O
than . . O
1% . . O
of . . O
subjects . . O
in . . O
any . . O
arm . . O
. . . O

serious . . O
adverse . . O
events . . O
were . . O
reported . . O
in . . O
11% . . O
of . . O
subjects . . O
receiving . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
and . . O
in . . O
8% . . O
of . . O
subjects . . O
receiving . . O
pegintron . . O
/ . . O
rebetol . . O
. . . O

gastrointestinal . . O
disorders . . O

5.6 . . O
dyspnea . . O

stop . . O
kyprolis . . O
for . . O
grade . . O
3 . . O
or . . O
4 . . O
dyspnea . . O
until . . O
resolved . . O
or . . O
returned . . O
to . . O
baseline . . O
. . . O

hypertension . . B-AdverseReaction
, . . O
including . . O
hypertensive . . B-AdverseReaction
crisis . . I-AdverseReaction
and . . O
hypertensive . . B-AdverseReaction
emergency . . I-AdverseReaction
, . . O
has . . O
been . . O
observed . . O
with . . O
kyprolis . . O
. . . O

the . . O
proportion . . O
of . . O
subjects . . O
with . . O
decreased . . O
neutrophil . . O
and . . O
platelet . . O
counts . . O
was . . O
higher . . O
in . . O
subjects . . O
treated . . O
with . . O
victrelis . . O
in . . O
combination . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
compared . . O
to . . O
subjects . . O
receiving . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
. . . O

monitor . . O
blood . . O
pressure . . O
regularly . . O
in . . O
all . . O
patients . . O
. . . O

decreases . . O
in . . O
neutrophils . . O
or . . O
platelets . . O
may . . O
require . . O
a . . O
decrease . . O
in . . O
dosage . . O
or . . O
interruption . . O
of . . O
peginterferon . . O
alfa . . O
, . . O
or . . O
discontinuation . . O
of . . O
therapy . . O
[ . . O
see . . O
prescribing . . O
information . . O
for . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
] . . O
. . . O

if . . O
peginterferon . . O
alfa . . O
is . . O
permanently . . O
discontinued . . O
, . . O
then . . O
ribavirin . . O
and . . O
victrelis . . O
must . . O
also . . O
be . . O
discontinued . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

5.8 . . O
venous . . O
thrombosis . . O

infections . . O
and . . O
infestations . . O
: . . O
pneumonia . . B-AdverseReaction
, . . O
sepsis . . B-AdverseReaction

5.9 . . O
infusion . . O
reactions . . O

symptoms . . O
include . . O
fever . . B-AdverseReaction
, . . O
chills . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
, . . O
facial . . B-AdverseReaction
flushing . . I-AdverseReaction
, . . O
facial . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
weakness . . B-AdverseReaction
, . . O
shortness . . B-AdverseReaction
of . . I-AdverseReaction
breath . . I-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
syncope . . B-AdverseReaction
, . . O
chest . . B-AdverseReaction
tightness . . I-AdverseReaction
, . . O
or . . O
angina . . B-AdverseReaction
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

monitor . . O
platelet . . O
counts . . O
frequently . . O
during . . O
treatment . . O
with . . O
kyprolis . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
from . . O
northera . . O
were . . O
hypertension . . B-AdverseReaction
or . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
and . . O
nausea . . B-AdverseReaction
. . . O

monitor . . O
liver . . O
enzymes . . O
regularly . . O
. . . O

5.12 . . O
thrombotic . . O
thrombocytopenic . . O
purpura . . O
/ . . O
hemolytic . . O
uremic . . O
syndrome . . O

cases . . O
of . . O
thrombotic . . B-AdverseReaction
thrombocytopenic . . I-AdverseReaction
purpura . . I-AdverseReaction
/ . . O
hemolytic . . B-AdverseReaction
uremic . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
ttp . . B-AdverseReaction
/ . . O
hus . . B-AdverseReaction
) . . O
including . . O
fatal . . B-AdverseReaction
outcome . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
who . . O
received . . O
kyprolis . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

females . . O
of . . O
reproductive . . O
potential . . O
should . . O
be . . O
advised . . O
to . . O
avoid . . O
becoming . . O
pregnant . . O
while . . O
being . . O
treated . . O
with . . O
kyprolis . . O
. . . O

growth . . O
of . . O
resistant . . O
organisms . . O
with . . O
prolonged . . O
use . . O
. . . O

avoidance . . O
of . . O
contact . . O
lenses . . O
. . . O

5.1 . . O
topical . . O
ophthalmic . . O
use . . O
only . . O

not . . O
for . . O
injection . . O
into . . O
the . . O
eye . . O
. . . O

as . . O
with . . O
other . . O
anti . . O
- . . O
infectives . . O
, . . O
prolonged . . O
use . . O
of . . O
besivance . . O
( . . O
besifloxacin . . O
ophthalmic . . O
suspension . . O
) . . O
0.6% . . O
may . . B-Factor
result . . O
in . . O
overgrowth . . B-AdverseReaction
of . . I-AdverseReaction
non . . I-AdverseReaction
- . . I-AdverseReaction
susceptible . . I-AdverseReaction
organisms . . I-AdverseReaction
, . . O
including . . O
fungi . . O
. . . O

whenever . . O
clinical . . O
judgment . . O
dictates . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
examined . . O
with . . O
the . . O
aid . . O
of . . O
magnification . . O
, . . O
such . . O
as . . O
slit . . O
- . . O
lamp . . O
biomicroscopy . . O
, . . O
and . . O
, . . O
where . . O
appropriate . . O
, . . O
fluorescein . . O
staining . . O
. . . O

5.3 . . O
avoidance . . O
of . . O
contact . . O
lenses . . O

excerpt . . O
: . . O
* . . O
serious . . B-Severity
infections . . B-AdverseReaction
- . . O
do . . O
not . . O
start . . O
cimzia . . O
during . . O
an . . O
active . . O
infection . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

if . . O
reactivation . . O
occurs . . O
, . . O
stop . . O
cimzia . . O
and . . O
begin . . O
anti . . O
- . . O
viral . . O
therapy . . O
( . . O
5.5 . . O
) . . O
* . . O
demyelinating . . B-AdverseReaction
disease . . I-AdverseReaction
, . . O
exacerbation . . O
or . . O
new . . O
onset . . O
, . . O
may . . B-Factor
occur . . O
( . . O
5.6 . . O
) . . O
* . . O
cytopenias . . B-AdverseReaction
, . . O
pancytopenia . . B-AdverseReaction
- . . O
advise . . O
patients . . O
to . . O
seek . . O
immediate . . O
medical . . O
attention . . O
if . . O
symptoms . . O
develop . . O
, . . O
and . . O
consider . . O
stopping . . O
cimzia . . O
( . . O
5.7 . . O
) . . O
* . . O
lupus . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
syndrome . . I-AdverseReaction
- . . O
stop . . O
cimzia . . O
if . . O
syndrome . . O
develops . . O
( . . O
5.9 . . O
) . . O

[ . . O
see . . O
boxed . . O
warning . . O
] . . O

opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
due . . O
to . . O
bacterial . . O
, . . O
mycobacterial . . O
, . . O
invasive . . O
fungal . . O
, . . O
viral . . O
, . . O
parasitic . . O
, . . O
or . . O
other . . O
opportunistic . . O
pathogens . . O
including . . O
aspergillosis . . B-AdverseReaction
, . . O
blastomycosis . . B-AdverseReaction
, . . O
candidiasis . . B-AdverseReaction
, . . O
coccidioidomycosis . . B-AdverseReaction
, . . O
histoplasmosis . . B-AdverseReaction
, . . O
legionellosis . . B-AdverseReaction
, . . O
listeriosis . . B-AdverseReaction
, . . O
pneumocystosis . . B-AdverseReaction
and . . O
tuberculosis . . B-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
. . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
gd1 . . O
patients . . O
switching . . O
from . . O
enzyme . . O
replacement . . O
therapy . . O
to . . O
cerdelga . . O
and . . O
more . . O
frequently . . O
than . . O
imiglucerase . . O
( . . O
trial . . O
2 . . O
) . . O
trial . . O
2 . . O
was . . O
not . . O
designed . . O
to . . O
support . . O
comparative . . O
claims . . O
for . . O
cerdelga . . O
for . . O
the . . O
adverse . . O
reactions . . O
reported . . O
in . . O
this . . O
table . . O
. . . O

the . . O
risks . . O
and . . O
benefits . . O
of . . O
treatment . . O
should . . O
be . . O
considered . . O
prior . . O
to . . O
initiating . . O
therapy . . O
in . . O
patients . . O
: . . O

induration . . O
of . . O
5 . . O
mm . . O
or . . O
greater . . O
with . . O
tuberculin . . O
skin . . O
testing . . O
should . . O
be . . O
considered . . O
a . . O
positive . . O
test . . O
result . . O
when . . O
assessing . . O
if . . O
treatment . . O
for . . O
latent . . O
tuberculosis . . O
is . . O
needed . . O
prior . . O
to . . O
initiating . . O
cimzia . . O
, . . O
even . . O
for . . O
patients . . O
previously . . O
vaccinated . . O
with . . O
bacille . . O
calmette . . O
- . . O
guerin . . O
( . . O
bcg . . O
) . . O
. . . O

consultation . . O
with . . O
a . . O
physician . . O
with . . O
expertise . . O
in . . O
the . . O
treatment . . O
of . . O
tuberculosis . . O
is . . O
recommended . . O
to . . O
aid . . O
in . . O
the . . O
decision . . O
of . . O
whether . . O
initiating . . O
anti . . O
- . . O
tuberculosis . . O
therapy . . O
is . . O
appropriate . . O
for . . O
an . . O
individual . . O
patient . . O
. . . O

tuberculosis . . O
should . . O
be . . O
strongly . . O
considered . . O
in . . O
patients . . O
who . . O
develop . . O
a . . O
new . . O
infection . . O
during . . O
cimzia . . O
treatment . . O
, . . O
especially . . O
in . . O
patients . . O
who . . O
have . . O
previously . . O
or . . O
recently . . O
traveled . . O
to . . O
countries . . O
with . . O
a . . O
high . . O
prevalence . . O
of . . O
tuberculosis . . O
, . . O
or . . O
who . . O
have . . O
had . . O
close . . O
contact . . O
with . . O
a . . O
person . . O
with . . O
active . . O
tuberculosis . . O
. . . O

immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
presenting . . O
as . . O
proteinuria . . B-AdverseReaction
, . . O
nephrotic . . B-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
and . . O
necrotizing . . B-AdverseReaction
skin . . I-AdverseReaction
lesions . . I-AdverseReaction
have . . O
occurred . . O
in . . O
some . . O
patients . . O
following . . O
alglucosidase . . O
alfa . . O
treatment . . O
. . . O

inform . . O
patients . . O
of . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
anaphylaxis . . O
, . . O
hypersensitivity . . O
reactions . . O
, . . O
and . . O
immune . . O
- . . O
mediated . . O
reactions . . O
and . . O
have . . O
them . . O
seek . . O
immediate . . O
medical . . O
care . . O
should . . O
signs . . O
and . . O
symptoms . . O
occur . . O
( . . O
5.1 . . O
, . . O
5.2 . . O
) . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
drug . . O
reactions . . O
of . . O
moderate . . B-Severity
to . . I-Severity
severe . . I-Severity
intensity . . O
( . . O
at . . O
least . . O
2% . . O
) . . O
which . . O
occurred . . O
at . . O
a . . O
higher . . O
rate . . O
than . . O
placebo . . O
in . . O
adults . . O
are . . O
rash . . B-AdverseReaction
and . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O

during . . O
controlled . . O
and . . O
open . . O
- . . O
labeled . . O
portions . . O
of . . O
cimzia . . O
studies . . O
of . . O
crohn's . . O
disease . . O
and . . O
other . . O
diseases . . O
, . . O
malignancies . . B-AdverseReaction
( . . O
excluding . . B-Negation
non . . B-AdverseReaction
- . . I-AdverseReaction
melanoma . . I-AdverseReaction
skin . . I-AdverseReaction
cancer . . I-AdverseReaction
) . . O
were . . O
observed . . O
at . . O
a . . O
rate . . O
( . . O
95% . . O
confidence . . O
interval . . O
) . . O
of . . O
0.5 . . O
( . . O
0.4 . . O
, . . O
0.7 . . O
) . . O
per . . O
100 . . O
patient . . O
- . . O
years . . O
among . . O
4,650 . . O
cimzia . . O
- . . O
treated . . O
patients . . O
versus . . O
a . . O
rate . . O
of . . O
0.6 . . O
( . . O
0.1 . . O
, . . O
1.7 . . O
) . . O
per . . O
100 . . O
patient . . O
- . . O
years . . O
among . . O
1,319 . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
janssen . . O
products . . O
, . . O
lp . . O
at . . O
1-800 . . O
- . . O
janssen . . O
( . . O
1-800-526-7736 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

the . . O
other . . O
cases . . O
represented . . O
a . . O
variety . . O
of . . O
different . . O
malignancies . . B-AdverseReaction
and . . O
included . . O
rare . . B-AdverseReaction
malignancies . . I-AdverseReaction
usually . . O
associated . . O
with . . O
immunosuppression . . O
and . . O
malignancies . . B-AdverseReaction
that . . O
are . . O
not . . O
usually . . O
observed . . O
in . . O
children . . O
and . . O
adolescents . . O
. . . O

in . . O
these . . O
pooled . . O
trials . . O
, . . O
the . . O
median . . O
exposure . . O
for . . O
subjects . . O
in . . O
the . . O
intelence . . O
( . . O
r . . O
) . . O
arm . . O
and . . O
placebo . . O
arm . . O
was . . O
52.3 . . O
and . . O
51.0 . . O
weeks . . O
, . . O
respectively . . O
. . . O

these . . O
cases . . O
were . . O
reported . . O
post . . O
- . . O
marketing . . O
and . . O
are . . O
derived . . O
from . . O
a . . O
variety . . O
of . . O
sources . . O
including . . O
registries . . O
and . . O
spontaneous . . O
post . . O
- . . O
marketing . . O
reports . . O
. . . O

patients . . O
with . . O
a . . O
history . . O
of . . O
nnrti . . B-DrugClass
- . . O
related . . O
rash . . B-AdverseReaction
did . . O
not . . O
appear . . O
to . . O
be . . O
at . . O
increased . . O
risk . . O
for . . O
the . . O
development . . O
of . . O
intelence . . O
( . . O
r . . O
) . . O
- . . O
related . . O
rash . . B-AdverseReaction
compared . . O
to . . O
patients . . O
without . . O
a . . O
history . . O
of . . O
nnrti . . B-DrugClass
- . . O
related . . O
rash . . B-AdverseReaction
. . . O

rates . . O
in . . O
clinical . . O
studies . . O
for . . O
cimzia . . O
cannot . . O
be . . O
compared . . O
to . . O
the . . O
rates . . O
of . . O
clinical . . O
trials . . O
of . . O
other . . O
tnf . . O
blockers . . O
and . . O
may . . O
not . . O
predict . . O
the . . O
rates . . O
observed . . O
when . . O
cimzia . . O
is . . O
used . . O
in . . O
a . . O
broader . . O
patient . . O
population . . O
. . . O

patients . . O
with . . O
crohn's . . O
disease . . O
that . . O
require . . O
chronic . . O
exposure . . O
to . . O
immunosuppressant . . B-DrugClass
therapies . . I-DrugClass
may . . O
be . . O
at . . O
higher . . O
risk . . O
than . . O
the . . O
general . . O
population . . O
for . . O
the . . O
development . . O
of . . O
lymphoma . . B-AdverseReaction
, . . O
even . . O
in . . O
the . . O
absence . . O
of . . O
tnf . . O
blocker . . O
therapy . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

laboratory . . O
abnormalities . . O
considered . . O
adrs . . O
are . . O
included . . O
in . . O
table . . O
2 . . O
. . . O

( . . O
grades . . O
2 . . O
to . . O
4 . . O
) . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
adult . . O
subjects . . O
in . . O
the . . O
intelence . . O
( . . O
r . . O
) . . O
treatment . . O
groups . . O
and . . O
at . . O
a . . O
higher . . O
rate . . O
compared . . O
to . . O
placebo . . O
( . . O
excess . . O
of . . O
1% . . O
) . . O
system . . O
organ . . O
class . . O
, . . O
preferred . . O
term . . O
, . . O
% . . O
pooled . . O
tmc125 . . O
- . . O
c206 . . O
and . . O
tmc125 . . O
- . . O
c216 . . O
trials . . O
intelence . . O
( . . O
r . . O
) . . O
+ . . O
brn . . O
= . . O
599 . . O
placebo . . O
+ . . O
brn . . O
= . . O
604 . . O
n . . O
= . . O
total . . O
number . . O
of . . O
subjects . . O
per . . O
treatment . . O
group . . O
, . . O
br . . O
= . . O
background . . O
regimen . . O
nervous . . O
system . . O
disorders . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
4% . . O
2% . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
10% . . O
3% . . O
less . . O
common . . O
adverse . . O
reactions . . O

it . . O
is . . O
uncertain . . O
whether . . O
the . . O
occurrence . . O
of . . O
hstcl . . O
is . . O
related . . O
to . . O
use . . O
of . . O
a . . O
tnf . . O
blocker . . O
or . . O
a . . O
tnf . . O
blocker . . O
in . . O
combination . . O
with . . O
these . . O
other . . O
immunosuppressants . . O
. . . O

the . . O
potential . . O
risk . . O
of . . O
using . . O
a . . O
tnf . . O
blocker . . O
in . . O
combination . . O
with . . O
azathioprine . . O
or . . O
6 . . O
- . . O
mp . . O
should . . O
be . . O
carefully . . O
considered . . O
. . . O

cases . . O
of . . O
acute . . O
and . . O
chronic . . B-AdverseReaction
leukemia . . I-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
post . . O
- . . O
marketing . . O
tnf . . B-DrugClass
- . . I-DrugClass
blocker . . I-DrugClass
use . . O
in . . O
ra . . O
and . . O
other . . O
indications . . O
. . . O

nervous . . O
system . . O
disorders . . O
: . . O
paraesthesia . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
convulsion . . B-AdverseReaction
, . . O
hypoesthesia . . B-AdverseReaction
, . . O
amnesia . . B-AdverseReaction
, . . O
syncope . . B-AdverseReaction
, . . O
disturbance . . B-AdverseReaction
in . . I-AdverseReaction
attention . . I-AdverseReaction
, . . O
hypersomnia . . B-AdverseReaction
, . . O
tremor . . B-AdverseReaction

reproductive . . O
system . . O
and . . O
breast . . O
disorders . . O
: . . O
gynecomastia . . O

selected . . O
grade . . O
2 . . O
to . . O
grade . . O
4 . . O
laboratory . . O
abnormalities . . O
that . . O
represent . . O
a . . O
worsening . . O
from . . O
baseline . . O
observed . . O
in . . O
adult . . O
subjects . . O
treated . . O
with . . O
intelence . . O
( . . O
r . . O
) . . O
are . . O
presented . . O
in . . O
table . . O
2 . . O
. . . O

the . . O
majority . . O
of . . O
reports . . O
have . . O
occurred . . O
in . . O
patients . . O
concomitantly . . O
receiving . . O
other . . O
medications . . O
that . . O
suppress . . O
the . . O
immune . . O
system . . O
, . . O
which . . O
may . . O
also . . O
contribute . . O
to . . O
hbv . . B-AdverseReaction
reactivation . . I-AdverseReaction
. . . O

ast . . O
and . . O
alt . . B-AdverseReaction
abnormalities . . I-AdverseReaction
occurred . . O
more . . O
frequently . . O
in . . O
hepatitis . . O
b . . O
and . . O
/ . . O
or . . O
hepatitis . . O
c . . O
virus . . O
co . . O
- . . O
infected . . O
subjects . . O
for . . O
both . . O
treatment . . O
groups . . O
. . . O

for . . O
patients . . O
who . . O
test . . O
positive . . O
for . . O
hbv . . O
infection . . O
, . . O
consultation . . O
with . . O
a . . O
physician . . O
with . . O
expertise . . O
in . . O
the . . O
treatment . . O
of . . O
hepatitis . . O
b . . O
is . . O
recommended . . O
. . . O

in . . O
patients . . O
who . . O
develop . . O
hbv . . O
reactivation . . O
, . . O
discontinue . . O
cimzia . . O
and . . O
initiate . . O
effective . . O
anti . . O
- . . O
viral . . O
therapy . . O
with . . O
appropriate . . O
supportive . . O
treatment . . O
. . . O

therefore . . O
, . . O
exercise . . O
caution . . O
when . . O
considering . . O
resumption . . O
of . . O
cimzia . . O
therapy . . O
in . . O
this . . O
situation . . O
and . . O
monitor . . O
patients . . O
closely . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
drug . . O
reactions . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
pediatric . . O
subjects . . O
were . . O
rash . . B-AdverseReaction
and . . O
diarrhea . . B-AdverseReaction
. . . O

use . . O
of . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
, . . O
of . . O
which . . O
cimzia . . O
is . . O
a . . O
member . . O
, . . O
has . . O
been . . O
associated . . O
with . . O
rare . . O
cases . . O
of . . O
new . . O
onset . . O
or . . O
exacerbation . . O
of . . O
clinical . . O
symptoms . . O
and . . O
/ . . O
or . . O
radiographic . . O
evidence . . O
of . . O
central . . B-AdverseReaction
nervous . . I-AdverseReaction
system . . I-AdverseReaction
demyelinating . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
including . . O
multiple . . B-AdverseReaction
sclerosis . . I-AdverseReaction
, . . O
and . . O
with . . O
peripheral . . B-AdverseReaction
demyelinating . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
including . . O
guillain . . B-AdverseReaction
- . . I-AdverseReaction
barre . . I-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

rash . . B-AdverseReaction
( . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
grade . . B-Severity
2 . . I-Severity
) . . O
occurred . . O
in . . O
15% . . O
of . . O
pediatric . . O
subjects . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
clostridium . . B-AdverseReaction
difficile . . I-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
diarrhea . . I-AdverseReaction
( . . O
cdad . . B-AdverseReaction
) . . O
has . . O
been . . O
reported . . O
with . . O
nearly . . O
all . . O
systemic . . O
antibacterial . . O
agents . . O
, . . O
including . . O
teflaro . . O
. . . O

treatment . . O
with . . O
cimzia . . O
may . . B-Factor
result . . O
in . . O
the . . O
formation . . B-AdverseReaction
of . . I-AdverseReaction
autoantibodies . . I-AdverseReaction
and . . O
rarely . . O
, . . O
in . . O
the . . O
development . . O
of . . O
a . . O
lupus . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

( . . O
5.3 . . O
) . . O

maintain . . O
clinical . . O
supervision . . O
if . . O
this . . O
product . . O
is . . O
to . . O
be . . O
given . . O
to . . O
a . . O
penicillin . . O
- . . O
or . . O
other . . O
beta . . O
- . . O
lactam . . O
- . . O
allergic . . O
patient . . O
, . . O
because . . O
cross . . O
sensitivity . . O
among . . O
beta . . O
- . . O
lactam . . O
antibacterial . . O
agents . . O
has . . O
been . . O
clearly . . O
established . . O
. . . O

the . . O
clinical . . O
significance . . O
of . . O
this . . O
is . . O
unknown . . O
. . . O

5.2 . . O
clostridium . . O
difficile . . O
- . . O
associated . . O
diarrhea . . O

( . . O
5.1 . . O
) . . O
* . . O
patients . . O
with . . O
underlying . . O
hepatitis . . O
b . . O
or . . O
c . . O
may . . O
be . . O
at . . O
increased . . O
risk . . B-Factor
for . . O
worsening . . O
or . . O
development . . O
of . . O
transaminase . . B-AdverseReaction
elevations . . I-AdverseReaction
with . . O
use . . O
of . . O
tivicay . . O
. . . O

if . . O
anemia . . O
develops . . O
during . . O
or . . O
after . . O
treatment . . O
with . . O
teflaro . . O
, . . O
drug . . O
- . . O
induced . . O
hemolytic . . O
anemia . . O
should . . O
be . . O
considered . . O
. . . O

clinical . . O
status . . O
, . . O
including . . O
liver . . O
aminotransferases . . O
, . . O
should . . O
be . . O
monitored . . O
and . . O
appropriate . . O
therapy . . O
initiated . . O
. . . O

prescribing . . O
teflaro . . O
in . . O
the . . O
absence . . O
of . . O
a . . O
proven . . O
or . . O
strongly . . O
suspected . . O
bacterial . . O
infection . . O
is . . O
unlikely . . O
to . . O
provide . . O
benefit . . O
to . . O
the . . O
patient . . O
and . . O
increases . . O
the . . O
risk . . O
of . . O
the . . O
development . . O
of . . O
drug . . O
- . . O
resistant . . O
bacteria . . O
. . . O

instruct . . O
patients . . O
to . . O
consult . . O
a . . O
physician . . O
immediately . . O
should . . O
any . . O
of . . O
these . . O
signs . . O
or . . O
symptoms . . O
develop . . O
. . . O

gadolinium . . B-DrugClass
- . . I-DrugClass
based . . I-DrugClass
contrast . . I-DrugClass
agents . . I-DrugClass
( . . O
gbcas . . O
) . . O
increase . . O
the . . O
risk . . B-Factor
for . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O
among . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
the . . O
drugs . . O
. . . O

the . . O
gbca . . B-DrugClass
- . . O
associated . . O
nsf . . B-AdverseReaction
risk . . O
appears . . O
highest . . O
for . . O
patients . . O
with . . O
chronic . . O
, . . O
severe . . O
kidney . . O
disease . . O
( . . O
gfr . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73m . . O
2 . . O
) . . O
as . . O
well . . O
as . . O
patients . . O
with . . O
acute . . O
kidney . . O
injury . . O
. . . O

nsf . . B-AdverseReaction
may . . B-Factor
result . . O
in . . O
fatal . . B-AdverseReaction
or . . O
debilitating . . B-Severity
fibrosis . . B-AdverseReaction
affecting . . O
the . . O
skin . . O
, . . O
muscle . . O
and . . O
internal . . O
organs . . O
. . . O

for . . O
patients . . O
at . . O
risk . . O
for . . O
chronically . . O
reduced . . O
renal . . O
function . . O
( . . O
for . . O
example . . O
, . . O
age . . O
> . . O
60 . . O
years . . O
, . . O
diabetes . . O
mellitus . . O
or . . O
chronic . . O
hypertension . . O
) . . O
, . . O
estimate . . O
the . . O
gfr . . O
through . . O
laboratory . . O
testing . . O
. . . O

most . . O
hypersensitivity . . O
reactions . . O
to . . O
eovist . . O
have . . O
occurred . . O
within . . O
half . . O
an . . O
hour . . O
after . . O
administration . . O
. . . O

delayed . . O
reactions . . O
can . . B-Factor
occur . . O
up . . O
to . . O
several . . O
days . . O
after . . O
eovist . . O
administration . . O
. . . O

observe . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
hypersensitivity . . O
reactions . . O
during . . O
and . . O
following . . O
eovist . . O
administration . . O
. . . O

5.3 . . O
acute . . O
kidney . . O
injury . . O

do . . O
not . . O
exceed . . O
the . . O
recommended . . O
dose . . O
; . . O
the . . O
risk . . O
of . . O
acute . . O
kidney . . O
injury . . O
may . . O
increase . . O
with . . O
higher . . O
than . . O
recommended . . O
doses . . O
. . . O

ensure . . O
catheter . . O
and . . O
venous . . O
patency . . O
before . . O
the . . O
injection . . O
of . . O
eovist . . O
. . . O

in . . O
patients . . O
with . . O
end . . O
- . . O
stage . . O
renal . . O
failure . . O
, . . O
hepatic . . O
contrast . . O
was . . O
markedly . . O
reduced . . O
and . . O
was . . O
attributed . . O
to . . O
elevated . . O
serum . . O
ferritin . . O
levels . . O
. . . O

carefully . . O
weigh . . O
risks . . O
and . . O
benefits . . O
of . . O
treatment . . O
with . . O
otezla . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
depression . . O
and . . O
/ . . O
or . . O
suicidal . . O
thoughts . . O
or . . O
behavior . . O
. . . O

patients . . O
, . . O
their . . O
caregivers . . O
, . . O
and . . O
families . . O
should . . O
be . . O
advised . . O
of . . O
the . . O
need . . O
to . . O
be . . O
alert . . O
for . . O
the . . O
emergence . . O
or . . O
worsening . . O
of . . O
depression . . O
, . . O
suicidal . . O
thoughts . . O
or . . O
other . . O
mood . . O
changes . . O
, . . O
and . . O
if . . O
such . . O
changes . . O
occur . . O
to . . O
contact . . O
their . . O
healthcare . . O
provider . . O
. . . O

during . . O
the . . O
clinical . . O
trials . . O
, . . O
0.3% . . O
( . . O
4 . . O
/ . . O
1441 . . O
) . . O
of . . O
subjects . . O
treated . . O
with . . O
otezla . . O
discontinued . . O
treatment . . O
due . . O
to . . O
depression . . B-AdverseReaction
or . . O
depressed . . B-AdverseReaction
mood . . I-AdverseReaction
compared . . O
with . . O
none . . O
in . . O
placebo . . O
treated . . O
subjects . . O
( . . O
0 . . O
/ . . O
495 . . O
) . . O
. . . O

depression . . B-AdverseReaction
was . . O
reported . . O
as . . O
serious . . B-Severity
in . . O
0.2% . . O
( . . O
3 . . O
/ . . O
1441 . . O
) . . O
of . . O
subjects . . O
exposed . . O
to . . O
otezla . . O
, . . O
compared . . O
to . . O
none . . O
in . . O
placebo . . O
- . . O
treated . . O
subjects . . O
( . . O
0 . . O
/ . . O
495 . . O
) . . O
. . . O

psoriasis . . O
: . . O
during . . O
the . . O
0 . . O
to . . O
16 . . O
week . . O
placebo . . O
- . . O
controlled . . O
period . . O
of . . O
the . . O
3 . . O
controlled . . O
clinical . . O
trials . . O
, . . O
1.3% . . O
( . . O
12 . . O
/ . . O
920 . . O
) . . O
of . . O
subjects . . O
treated . . O
with . . O
otezla . . O
reported . . O
depression . . B-AdverseReaction
compared . . O
to . . O
0.4% . . O
( . . O
2 . . O
/ . . O
506 . . O
) . . O
treated . . O
with . . O
placebo . . O
. . . O

in . . O
the . . O
clinical . . O
trials . . O
, . . O
one . . O
subject . . O
treated . . O
with . . O
otezla . . O
attempted . . B-AdverseReaction
suicide . . I-AdverseReaction
while . . O
one . . O
who . . O
received . . O
placebo . . B-Factor
committed . . O
suicide . . B-AdverseReaction
. . . O

5.2 . . O
weight . . O
decrease . . O

during . . O
the . . O
controlled . . O
period . . O
of . . O
the . . O
studies . . O
in . . O
psoriatic . . O
arthritis . . O
( . . O
psa . . O
) . . O
, . . O
weight . . B-AdverseReaction
decrease . . I-AdverseReaction
between . . O
5% . . O
- . . O
10% . . O
of . . O
body . . O
weight . . O
was . . O
reported . . O
in . . O
10% . . O
( . . O
49 . . O
/ . . O
497 . . O
) . . O
of . . O
subjects . . O
treated . . O
with . . O
otezla . . O
30 . . O
mg . . O
twice . . O
daily . . O
compared . . O
to . . O
3.3% . . O
( . . O
16 . . O
/ . . O
495 . . O
) . . O
treated . . O
with . . O
placebo . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

weight . . B-AdverseReaction
decrease . . I-AdverseReaction
of . . O
> . . O
= . . O
10% . . B-Severity
of . . I-Severity
body . . I-Severity
weight . . I-Severity
occurred . . O
in . . O
2% . . O
( . . O
16 . . O
/ . . O
784 . . O
) . . O
of . . O
subjects . . O
treated . . O
with . . O
otezla . . O
30 . . O
mg . . O
twice . . O
daily . . O
compared . . O
to . . O
1% . . O
( . . O
3 . . O
/ . . O
382 . . O
) . . O
subjects . . O
treated . . O
with . . O
placebo . . O
. . . O

6 . . O
adverse . . O
reactions . . O

* . . O
hypotension . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
impairment . . B-AdverseReaction
in . . I-AdverseReaction
renal . . I-AdverseReaction
function . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
hypoglycemia . . B-AdverseReaction
with . . O
concomitant . . O
use . . O
with . . O
insulin . . O
and . . O
insulin . . O
secretagogues . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
increased . . B-AdverseReaction
low . . I-AdverseReaction
- . . I-AdverseReaction
density . . I-AdverseReaction
lipoprotein . . I-AdverseReaction
cholesterol . . I-AdverseReaction
( . . O
ldl . . O
- . . O
c . . O
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
associated . . O
with . . O
jardiance . . O
( . . O
5% . . O
or . . O
greater . . O
incidence . . O
) . . O
were . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
and . . O
female . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
6.1 . . O
) . . O
excerpt . . O
: . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
boehringer . . O
ingelheim . . O
pharmaceuticals . . O
, . . O
inc . . O
. . . O
at . . O
1-800-542-6257 . . O
or . . O
1-800-459-9906 . . O
tty . . O
, . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

table . . O
1 . . O
adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
jardiance . . O
and . . O
greater . . O
than . . O
placebo . . O
in . . O
pooled . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
studies . . O
of . . O
jardiance . . O
monotherapy . . O
or . . O
combination . . O
therapy . . O
a . . O
predefined . . O
adverse . . O
event . . O
grouping . . O
, . . O
including . . O
, . . O
but . . O
not . . O
limited . . O
to . . O
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
asymptomatic . . B-AdverseReaction
bacteriuria . . I-AdverseReaction
, . . O
cystitis . . B-AdverseReaction
b . . O
female . . B-AdverseReaction
genital . . I-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
include . . O
the . . O
following . . O
adverse . . O
reactions . . O
: . . O
vulvovaginal . . B-AdverseReaction
mycotic . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
vaginal . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
vulvitis . . B-AdverseReaction
, . . O
vulvovaginal . . B-AdverseReaction
candidiasis . . I-AdverseReaction
, . . O
genital . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
genital . . B-AdverseReaction
candidiasis . . I-AdverseReaction
, . . O
genital . . B-AdverseReaction
infection . . I-AdverseReaction
fungal . . I-AdverseReaction
, . . O
genitourinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
vulvovaginitis . . B-AdverseReaction
, . . O
cervicitis . . B-AdverseReaction
, . . O
urogenital . . B-AdverseReaction
infection . . I-AdverseReaction
fungal . . I-AdverseReaction
, . . O
vaginitis . . B-AdverseReaction
bacterial . . I-AdverseReaction
. . . O

the . . O
incidence . . O
of . . O
hypoglycemia . . B-AdverseReaction
increased . . O
when . . O
jardiance . . O
was . . O
administered . . O
with . . O
insulin . . O
or . . O
sulfonylurea . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
occurred . . O
more . . O
frequently . . O
in . . O
female . . O
than . . O
male . . O
patients . . O
( . . O
see . . O
table . . O
1 . . O
) . . O
. . . O

phimosis . . B-AdverseReaction
occurred . . O
more . . O
frequently . . O
in . . O
male . . O
patients . . O
treated . . O
with . . O
jardiance . . O
10 . . O
mg . . O
( . . O
less . . O
than . . O
0.1% . . O
) . . O
and . . O
jardiance . . O
25 . . O
mg . . O
( . . O
0.1% . . O
) . . O
than . . O
placebo . . O
( . . O
0% . . O
) . . O
. . . O

urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
in . . O
the . . O
pool . . O
of . . O
five . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
, . . O
the . . O
incidence . . O
of . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
asymptomatic . . B-AdverseReaction
bacteriuria . . I-AdverseReaction
, . . O
and . . O
cystitis . . B-AdverseReaction
) . . O
was . . O
increased . . O
in . . O
patients . . O
treated . . O
with . . O
jardiance . . O
compared . . O
to . . O
placebo . . O
( . . O
see . . O
table . . O
1 . . O
) . . O
. . . O

urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
occurred . . O
more . . O
frequently . . O
in . . O
female . . O
patients . . O
. . . O

the . . O
range . . O
of . . O
mean . . O
baseline . . O
ldl . . O
- . . O
c . . O
levels . . O
was . . O
90.3 . . O
to . . O
90.6 . . O
mg . . O
/ . . O
dl . . O
across . . O
treatment . . O
groups . . O
. . . O

at . . O
the . . O
end . . O
of . . O
treatment . . O
, . . O
0.6% . . O
, . . O
2.7% . . O
, . . O
and . . O
3.5% . . O
of . . O
patients . . O
with . . O
hematocrits . . O
initially . . O
within . . O
the . . O
reference . . O
range . . O
had . . O
values . . O
above . . O
the . . O
upper . . O
limit . . O
of . . O
the . . O
reference . . O
range . . O
with . . O
placebo . . O
, . . O
jardiance . . O
10 . . O
mg . . O
, . . O
and . . O
jardiance . . O
25 . . O
mg . . O
, . . O
respectively . . O
. . . O

* . . O
? . . O

immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
hepatitis . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

* . . O
? . . O

* . . O
? . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
the . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
rates . . O
in . . O
other . . O
clinical . . O
trials . . O
or . . O
experience . . O
with . . O
therapeutics . . O
in . . O
the . . O
same . . O
class . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
. . . O
] . . O
one . . O
hundred . . O
thirty . . O
- . . O
one . . O
patients . . O
( . . O
median . . O
age . . O
57 . . O
years . . O
, . . O
60% . . O
male . . O
) . . O
received . . O
yervoy . . O
as . . O
a . . O
single . . O
agent . . O
, . . O
380 . . O
patients . . O
( . . O
median . . O
age . . O
56 . . O
years . . O
, . . O
61% . . O
male . . O
) . . O
received . . O
yervoy . . O
with . . O
an . . O
investigational . . O
gp100 . . O
peptide . . O
vaccine . . O
( . . O
gp100 . . O
) . . O
, . . O
and . . O
132 . . O
patients . . O
( . . O
median . . O
age . . O
57 . . O
years . . O
, . . O
54% . . O
male . . O
) . . O
received . . O
gp100 . . O
peptide . . O
vaccine . . O
alone . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
drug . . B-AdverseReaction
reaction . . I-AdverseReaction
with . . I-AdverseReaction
eosinophilia . . I-AdverseReaction
and . . I-AdverseReaction
systemic . . I-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
dress . . B-AdverseReaction
syndrome . . I-AdverseReaction
) . . O

this . . O
assay . . O
has . . O
substantial . . O
limitations . . O
in . . O
detecting . . O
anti . . O
- . . O
ipilimumab . . O
antibodies . . O
in . . O
the . . O
presence . . O
of . . O
ipilimumab . . O
. . . O

infusion . . O
- . . O
related . . O
or . . O
peri . . B-AdverseReaction
- . . I-AdverseReaction
infusional . . I-AdverseReaction
reactions . . I-AdverseReaction
consistent . . O
with . . O
hypersensitivity . . B-AdverseReaction
or . . O
anaphylaxis . . B-AdverseReaction
were . . O
not . . B-Negation
reported . . O
in . . O
these . . O
11 . . O
patients . . O
nor . . O
were . . O
neutralizing . . O
antibodies . . O
against . . O
ipilimumab . . O
detected . . O
. . . O

males . . O
represented . . O
73% . . O
and . . O
53% . . O
of . . O
the . . O
adult . . O
and . . O
pediatric . . O
populations . . O
, . . O
respectively . . O
. . . O

discontinuation . . O
of . . O
coartem . . O
tablets . . O
due . . O
to . . O
adverse . . O
drug . . O
reactions . . O
occurred . . O
in . . O
1.1% . . O
of . . O
patients . . O
treated . . O
with . . O
the . . O
6 . . O
- . . O
dose . . O
regimen . . O
overall . . O
: . . O
0.2% . . O
( . . O
1 . . O
/ . . O
647 . . O
) . . O
in . . O
adults . . O
and . . O
1.6% . . O
( . . O
21 . . O
/ . . O
1,332 . . O
) . . O
in . . O
children . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
3% . . O
or . . O
more . . O
of . . O
adult . . O
patients . . O
treated . . O
in . . O
clinical . . O
trials . . O
with . . O
the . . O
6 . . O
- . . O
dose . . O
regimen . . O
of . . O
coartem . . O
tablets . . O
system . . O
organ . . O
class . . O
preferred . . O
term . . O
adults . . O
* . . O
n . . O
= . . O
647 . . O
( . . O
% . . O
) . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
360 . . O
( . . O
56 . . O
) . . O
dizziness . . B-AdverseReaction
253 . . O
( . . O
39 . . O
) . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
anorexia . . B-AdverseReaction
260 . . O
( . . O
40 . . O
) . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
asthenia . . B-AdverseReaction
243 . . O
( . . O
38 . . O
) . . O
pyrexia . . B-AdverseReaction
159 . . O
( . . O
25 . . O
) . . O
chills . . B-AdverseReaction
147 . . O
( . . O
23 . . O
) . . O
fatigue . . B-AdverseReaction
111 . . O
( . . O
17 . . O
) . . O
malaise . . B-AdverseReaction
20 . . O
( . . O
3 . . O
) . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
arthralgia . . B-AdverseReaction
219 . . O
( . . O
34 . . O
) . . O
myalgia . . B-AdverseReaction
206 . . O
( . . O
32 . . O
) . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
169 . . O
( . . O
26 . . O
) . . O
vomiting . . B-AdverseReaction
113 . . O
( . . O
17 . . O
) . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
112 . . O
( . . O
17 . . O
) . . O
diarrhea . . B-AdverseReaction
46 . . O
( . . O
7 . . O
) . . O
psychiatric . . O
disorders . . O
sleep . . B-AdverseReaction
disorder . . I-AdverseReaction
144 . . O
( . . O
22 . . O
) . . O
insomnia . . B-AdverseReaction
32 . . O
( . . O
5 . . O
) . . O
cardiac . . O
disorders . . O
palpitations . . B-AdverseReaction
115 . . O
( . . O
18 . . O
) . . O
hepatobiliary . . O
disorders . . O
hepatomegaly . . B-AdverseReaction
59 . . O
( . . O
9 . . O
) . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
splenomegaly . . B-AdverseReaction
57 . . O
( . . O
9 . . O
) . . O
anemia . . B-AdverseReaction
23 . . O
( . . O
4 . . O
) . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
37 . . O
( . . O
6 . . O
) . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
pruritus . . B-AdverseReaction
24 . . O
( . . O
4 . . O
) . . O
rash . . B-AdverseReaction
21 . . O
( . . O
3 . . O
) . . O
ear . . O
and . . O
labyrinth . . O
disorders . . O
vertigo . . B-AdverseReaction
21 . . O
( . . O
3 . . O
) . . O
infections . . O
and . . O
infestations . . O
malaria . . B-AdverseReaction
18 . . O
( . . O
3 . . O
) . . O
nasopharyngitis . . B-AdverseReaction
17 . . O
( . . O
3 . . O
) . . O
* . . O
adult . . O
patients . . O
defined . . O
as . . O
> . . O
16 . . O
years . . O
of . . O
age . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
3% . . O
or . . O
more . . O
of . . O
pediatric . . O
patients . . O
treated . . O
in . . O
clinical . . O
trials . . O
with . . O
the . . O
6 . . O
- . . O
dose . . O
regimen . . O
of . . O
coartem . . O
tablets . . O
system . . O
organ . . O
class . . O
preferred . . O
term . . O
children . . O
* . . O
n . . O
= . . O
1,332 . . O
( . . O
% . . O
) . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
pyrexia . . B-AdverseReaction
381 . . O
( . . O
29 . . O
) . . O
chills . . B-AdverseReaction
72 . . O
( . . O
5 . . O
) . . O
asthenia . . B-AdverseReaction
63 . . O
( . . O
5 . . O
) . . O
fatigue . . B-AdverseReaction
46 . . O
( . . O
3 . . O
) . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
302 . . O
( . . O
23 . . O
) . . O
gastrointestinal . . O
disorders . . O
vomiting . . B-AdverseReaction
242 . . O
( . . O
18 . . O
) . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
112 . . O
( . . O
8 . . O
) . . O
diarrhea . . B-AdverseReaction
100 . . O
( . . O
8 . . O
) . . O
nausea . . B-AdverseReaction
61 . . O
( . . O
5 . . O
) . . O
infections . . O
and . . O
infestations . . O
plasmodium . . B-AdverseReaction
falciparum . . I-AdverseReaction
infection . . I-AdverseReaction
224 . . O
( . . O
17 . . O
) . . O
rhinitis . . B-AdverseReaction
51 . . O
( . . O
4 . . O
) . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
anorexia . . B-AdverseReaction
175 . . O
( . . O
13 . . O
) . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
168 . . O
( . . O
13 . . O
) . . O
dizziness . . B-AdverseReaction
56 . . O
( . . O
4 . . O
) . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
splenomegaly . . B-AdverseReaction
124 . . O
( . . O
9 . . O
) . . O
anemia . . B-AdverseReaction
115 . . O
( . . O
9 . . O
) . . O
hepatobiliary . . O
disorders . . O
hepatomegaly . . B-AdverseReaction
75 . . O
( . . O
6 . . O
) . . O
investigations . . O
aspartate . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
51 . . O
( . . O
4 . . O
) . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
arthralgia . . B-AdverseReaction
39 . . O
( . . O
3 . . O
) . . O
myalgia . . B-AdverseReaction
39 . . O
( . . O
3 . . O
) . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
38 . . O
( . . O
3 . . O
) . . O
* . . O
children . . O
defined . . O
as . . O
patients . . O
< . . O
= . . O
16 . . O
years . . O
of . . O
age . . O

clinically . . O
significant . . O
adverse . . O
reactions . . O
reported . . O
in . . O
adults . . O
and . . O
/ . . O
or . . O
children . . O
treated . . O
with . . O
the . . O
6 . . O
- . . O
dose . . O
regimen . . O
of . . O
coartem . . O
tablets . . O
which . . O
occurred . . O
in . . O
clinical . . O
studies . . O
at . . O
< . . O
3% . . O
regardless . . O
of . . O
causality . . O
are . . O
listed . . O
below . . O
: . . O

general . . O
disorders . . O
: . . O
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction

metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
hypokalemia . . B-AdverseReaction

avoid . . O
administering . . O
stribild . . O
with . . O
concurrent . . O
or . . O
recent . . O
use . . O
of . . O
nephrotoxic . . O
drugs . . O
. . . O

do . . O
not . . O
administer . . O
in . . O
combination . . O
with . . O
hepsera . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
decreases . . B-AdverseReaction
in . . I-AdverseReaction
bone . . I-AdverseReaction
mineral . . I-AdverseReaction
density . . I-AdverseReaction
( . . O
bmd . . O
) . . O
: . . O
consider . . O
monitoring . . O
bmd . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
pathologic . . O
fracture . . O
or . . O
other . . O
risk . . O
factors . . O
of . . O
osteoporosis . . O
or . . O
bone . . O
loss . . O
. . . O

lactic . . B-AdverseReaction
acidosis . . I-AdverseReaction
and . . O
severe . . B-Severity
hepatomegaly . . B-AdverseReaction
with . . O
steatosis . . B-AdverseReaction
, . . O
including . . O
fatal . . B-AdverseReaction
cases . . O
, . . O
have . . O
been . . O
reported . . O
with . . O
the . . O
use . . O
of . . O
nucleoside . . O
analogs . . O
, . . O
including . . O
tenofovir . . O
df . . O
, . . O
a . . O
component . . O
of . . O
stribild . . O
, . . O
in . . O
combination . . O
with . . O
other . . O
antiretrovirals . . O
. . . O

a . . O
majority . . O
of . . O
these . . O
cases . . O
have . . O
been . . O
in . . O
women . . O
. . . O

particular . . O
caution . . O
should . . O
be . . O
exercised . . O
when . . O
administering . . O
nucleoside . . O
analogs . . O
to . . O
any . . O
patient . . O
with . . O
known . . O
risk . . O
factors . . O
for . . O
liver . . O
disease . . O
; . . O
however . . O
, . . O
cases . . O
have . . O
also . . O
been . . O
reported . . O
in . . O
patients . . O
with . . O
no . . O
known . . O
risk . . O
factors . . O
. . . O

in . . O
the . . O
clinical . . O
trials . . O
of . . O
stribild . . O
over . . O
144 . . O
weeks . . O
, . . O
13 . . O
( . . O
1.9% . . O
) . . O
subjects . . O
in . . O
the . . O
stribild . . O
group . . O
( . . O
n . . O
= . . O
701 . . O
) . . O
, . . O
8 . . O
( . . O
2.3% . . O
) . . O
subjects . . O
in . . O
the . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
group . . O
( . . O
n . . O
= . . O
355 . . O
) . . O
and . . O
no . . O
subjects . . O
in . . O
the . . O
atripla . . O
group . . O
( . . O
n . . O
= . . O
352 . . O
) . . O
discontinued . . O
study . . O
drug . . O
due . . O
to . . O
a . . O
renal . . B-AdverseReaction
adverse . . I-AdverseReaction
reaction . . I-AdverseReaction
. . . O

four . . O
( . . O
0.6% . . O
) . . O
subjects . . O
who . . O
received . . O
stribild . . O
developed . . O
laboratory . . O
findings . . O
consistent . . O
with . . O
proximal . . B-AdverseReaction
renal . . I-AdverseReaction
tubular . . I-AdverseReaction
dysfunction . . I-AdverseReaction
leading . . O
to . . O
discontinuation . . O
of . . O
stribild . . O
during . . O
the . . O
first . . O
48 . . O
weeks . . O
of . . O
treatment . . O
. . . O

alternatives . . O
to . . O
nsaids . . O
should . . O
be . . O
considered . . O
, . . O
if . . O
needed . . O
, . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
renal . . O
dysfunction . . O
. . . O

the . . O
emtricitabine . . O
and . . O
tenofovir . . O
df . . O
components . . O
of . . O
stribild . . O
are . . O
primarily . . O
excreted . . O
by . . O
the . . O
kidney . . O
. . . O

* . . O
loss . . O
of . . O
therapeutic . . O
effect . . O
of . . O
stribild . . O
and . . O
possible . . O
development . . O
of . . O
resistance . . O
. . . O

see . . O
table . . O
6 . . O
for . . O
steps . . O
to . . O
prevent . . O
or . . O
manage . . O
these . . O
possible . . O
and . . O
known . . O
significant . . O
drug . . O
interactions . . O
, . . O
including . . O
dosing . . O
recommendations . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.5 . . O
) . . O
] . . O
. . . O

serum . . O
parathyroid . . O
hormone . . O
levels . . O
and . . O
1.25 . . O
vitamin . . O
d . . O
levels . . O
were . . O
also . . O
higher . . O
in . . O
subjects . . O
receiving . . O
tenofovir . . O
df . . O
. . . O

the . . O
effects . . O
of . . O
tenofovir . . O
df . . O
- . . O
associated . . O
changes . . O
in . . O
bmd . . O
and . . O
biochemical . . O
markers . . O
on . . O
long . . O
- . . O
term . . O
bone . . O
health . . O
and . . O
future . . O
fracture . . O
risk . . O
are . . O
unknown . . O
. . . O

assessment . . O
of . . O
bmd . . O
should . . O
be . . O
considered . . O
for . . O
hiv . . O
- . . O
1 . . O
infected . . O
patients . . O
who . . O
have . . O
a . . O
history . . O
of . . O
pathologic . . O
bone . . O
fracture . . O
or . . O
other . . O
risk . . O
factors . . O
for . . O
osteoporosis . . O
or . . O
bone . . O
loss . . O
. . . O

cases . . O
of . . O
osteomalacia . . B-AdverseReaction
associated . . O
with . . O
proximal . . B-AdverseReaction
renal . . I-AdverseReaction
tubulopathy . . I-AdverseReaction
, . . O
manifested . . O
as . . O
bone . . B-AdverseReaction
pain . . I-AdverseReaction
or . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremities . . I-AdverseReaction
and . . O
which . . O
may . . B-Factor
contribute . . O
to . . O
fractures . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
the . . O
use . . O
of . . O
tenofovir . . O
df . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

a . . O
causal . . O
relationship . . O
has . . O
not . . O
been . . O
established . . O
. . . O

stendra . . O
was . . O
administered . . O
to . . O
2215 . . O
men . . O
during . . O
clinical . . O
trials . . O
. . . O

in . . O
trials . . O
of . . O
stendra . . O
for . . O
use . . O
as . . O
needed . . O
, . . O
a . . O
total . . O
of . . O
493 . . O
patients . . O
were . . O
exposed . . O
for . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
6 . . O
months . . O
, . . O
and . . O
153 . . O
patients . . O
were . . O
treated . . O
for . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
12 . . O
months . . O
. . . O

the . . O
discontinuation . . O
rate . . O
due . . O
to . . O
adverse . . O
reactions . . O
for . . O
patients . . O
treated . . O
with . . O
stendra . . O
50 . . O
mg . . O
, . . O
100 . . O
mg . . O
, . . O
or . . O
200 . . O
mg . . O
was . . O
1.4% . . O
, . . O
2.0% . . O
, . . O
and . . O
2.0% . . O
, . . O
respectively . . O
, . . O
compared . . O
to . . O
1.7% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

table . . O
1 . . O
presents . . O
the . . O
adverse . . O
reactions . . O
reported . . O
when . . O
stendra . . O
was . . O
taken . . O
as . . O
recommended . . O
( . . O
on . . O
an . . O
as . . O
- . . O
needed . . O
basis . . O
) . . O
from . . O
these . . O
3 . . O
clinical . . O
trials . . O
. . . O

the . . O
discontinuation . . O
rate . . O
due . . O
to . . O
adverse . . O
reactions . . O
for . . O
patients . . O
treated . . O
with . . O
stendra . . O
( . . O
50 . . O
mg . . O
, . . O
100 . . O
mg . . O
, . . O
or . . O
200 . . O
mg . . O
) . . O
was . . O
2.8% . . O
. . . O

at . . O
any . . O
point . . O
during . . O
the . . O
trial . . O
, . . O
patients . . O
could . . O
request . . O
to . . O
have . . O
their . . O
dose . . O
of . . O
stendra . . O
increased . . O
to . . O
200 . . O
mg . . O
or . . O
decreased . . O
to . . O
50 . . O
mg . . O
based . . O
on . . O
their . . O
individual . . O
response . . O
to . . O
treatment . . O
. . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
by . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
stendra . . O
in . . O
an . . O
open . . O
- . . O
label . . O
extension . . O
trial . . O
adverse . . O
reaction . . O
stendra . . O
( . . O
n . . O
= . . O
711 . . O
) . . O
headache . . B-AdverseReaction
5.6% . . O
flushing . . B-AdverseReaction
3.5% . . O
nasopharyngitis . . B-AdverseReaction
3.4% . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
2.1% . . O
adverse . . O
reactions . . O
reported . . O
by . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
1% . . O
, . . O
but . . O
less . . O
than . . O
2% . . O
of . . O
patients . . O
in . . O
the . . O
open . . O
- . . O
label . . O
extension . . O
study . . O
included . . O
: . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
uri . . B-AdverseReaction
) . . O
, . . O
influenza . . B-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
bronchitis . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
and . . O
diarrhea . . B-AdverseReaction
. . . O

6.2 . . O
postmarketing . . O
experience . . O

ophthalmologic . . O
: . . O

it . . O
is . . O
not . . O
possible . . O
to . . O
determine . . O
whether . . O
these . . O
events . . O
are . . O
related . . O
directly . . O
to . . O
the . . O
use . . O
of . . O
pde5 . . O
inhibitors . . O
, . . O
to . . O
the . . O
patient's . . O
underlying . . O
vascular . . O
risk . . O
factors . . O
or . . O
anatomical . . O
defects . . O
, . . O
to . . O
a . . O
combination . . O
of . . O
these . . O
factors . . O
, . . O
or . . O
to . . O
other . . O
factors . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
andpatient . . O
counseling . . O
information . . O
( . . O
17.6 . . O
) . . O
] . . O
. . . O

in . . O
clinical . . O
studies . . O
, . . O
leukocytosis . . B-AdverseReaction
( . . O
wbc . . B-AdverseReaction
counts . . I-AdverseReaction
> . . I-AdverseReaction
100,000 . . I-AdverseReaction
x . . I-AdverseReaction
10 . . I-AdverseReaction
6 . . I-AdverseReaction
/ . . I-AdverseReaction
l . . I-AdverseReaction
) . . O
was . . O
observed . . O
in . . O
less . . O
than . . O
1% . . O
patients . . O
with . . O
non . . O
- . . O
myeloid . . O
malignancies . . O
receiving . . O
granix . . O
. . . O

other . . O
adverse . . O
reactions . . O
known . . O
to . . O
occur . . O
following . . O
administration . . O
of . . O
human . . B-DrugClass
granulocyte . . I-DrugClass
colony . . I-DrugClass
- . . I-DrugClass
stimulating . . I-DrugClass
factors . . I-DrugClass
include . . O
myalgia . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
sweet's . . B-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
acute . . B-AdverseReaction
febrile . . I-AdverseReaction
neutrophilic . . I-AdverseReaction
dermatosis . . I-AdverseReaction
) . . O
, . . O
cutaneous . . B-AdverseReaction
vasculitis . . I-AdverseReaction
and . . O
thrombocytopenia . . B-AdverseReaction
. . . O

6.2 . . O
immunogenicity . . O

among . . O
these . . O
subjects . . O
, . . O
42% . . O
were . . O
women . . O
and . . O
99% . . O
caucasian . . O
. . . O

other . . O
adverse . . O
reactions . . O
occurred . . O
at . . O
a . . O
rate . . O
of . . O
1% . . O
or . . O
less . . O
and . . O
the . . O
reported . . O
events . . O
consisted . . O
of . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vertigo . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
or . . O
dizziness . . B-AdverseReaction
. . . O

these . . O
reactions . . O
were . . O
of . . O
mild . . O
to . . O
moderate . . O
severity . . O
. . . O

the . . O
reactions . . O
either . . O
resolved . . O
spontaneously . . O
or . . O
following . . O
the . . O
administration . . O
of . . O
corticosteroids . . O
and . . O
antihistamines . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
boehringer . . O
ingelheim . . O
pharmaceuticals . . O
, . . O
inc . . O
. . . O
at . . O
( . . O
800 . . O
) . . O
542-6257 . . O
or . . O
( . . O
800 . . O
) . . O
459-9906 . . O
tty . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

the . . O
re . . O
- . . O
ly . . O
( . . O
randomized . . O
evaluation . . O
of . . O
long . . O
- . . O
term . . O
anticoagulant . . O
therapy . . O
) . . O
study . . O
provided . . O
safety . . O
information . . O
on . . O
the . . O
use . . O
of . . O
two . . O
doses . . O
of . . O
pradaxa . . O
and . . O
warfarin . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

the . . O
risk . . B-Factor
of . . O
major . . B-Severity
bleeds . . B-AdverseReaction
was . . O
similar . . O
with . . O
pradaxa . . O
150 . . O
mg . . O
and . . O
warfarin . . O
across . . O
major . . O
subgroups . . O
defined . . O
by . . O
baseline . . O
characteristics . . O
( . . O
see . . O
figure . . O
1 . . O
) . . O
, . . O
with . . O
the . . O
exception . . O
of . . O
age . . O
, . . O
where . . O
there . . O
was . . O
a . . O
trend . . O
towards . . O
a . . O
higher . . O
incidence . . O
of . . O
major . . B-Severity
bleeding . . B-AdverseReaction
on . . O
pradaxa . . O
( . . O
hazard . . O
ratio . . O
1.2 . . O
, . . O
95% . . O
ci . . O
: . . O
1.0 . . O
to . . O
1.5 . . O
) . . O
for . . O
patients . . O
> . . O
= . . O
75 . . O
years . . O
of . . O
age . . O
. . . O

patients . . O
on . . O
pradaxa . . O
150 . . O
mg . . O
had . . O
an . . O
increased . . O
incidence . . O
of . . O
gastrointestinal . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
35% . . O
vs . . O
. . . O
24% . . O
on . . O
warfarin . . O
) . . O
. . . O

hypersensitivity . . O
reactions . . O

three . . O
of . . O
these . . O
trials . . O
were . . O
active . . O
- . . O
controlled . . O
( . . O
warfarin . . O
) . . O
( . . O
re . . O
- . . O
cover . . O
, . . O
re . . O
- . . O
cover . . O
ii . . O
, . . O
and . . O
re . . O
- . . O
medy . . O
) . . O
, . . O
and . . O
one . . O
study . . O
( . . O
re . . O
- . . O
sonate . . O
) . . O
was . . O
placebo . . O
- . . O
controlled . . O
. . . O

the . . O
demographic . . O
characteristics . . O
were . . O
similar . . O
among . . O
the . . O
4 . . O
pivotal . . O
studies . . O
and . . O
between . . O
the . . O
treatment . . O
groups . . O
within . . O
these . . O
studies . . O
. . . O

re . . O
- . . O
cover . . O
and . . O
re . . O
- . . O
cover . . O
ii . . O
studies . . O
compared . . O
pradaxa . . O
150 . . O
mg . . O
twice . . O
daily . . O
and . . O
warfarin . . O
for . . O
the . . O
treatment . . O
of . . O
deep . . O
vein . . O
thrombosis . . O
and . . O
pulmonary . . O
embolism . . O
. . . O

table . . O
4 . . O
shows . . O
the . . O
number . . O
of . . O
patients . . O
experiencing . . O
bleeding . . B-AdverseReaction
events . . O
in . . O
the . . O
study . . O
. . . O

patients . . O
can . . O
have . . O
more . . O
than . . O
one . . O
site . . O
of . . O
bleeding . . B-AdverseReaction
. . . O
c . . O
confidence . . O
interval . . O
patients . . O
major . . B-Severity
bleeding . . B-AdverseReaction
event . . O
a . . O
bleeding . . B-AdverseReaction
sites . . O
for . . O
mbe . . B-AdverseReaction
b . . O
clinically . . O
relevant . . O
non . . B-Severity
- . . I-Severity
major . . I-Severity
bleeding . . B-AdverseReaction
any . . O
bleeding . . B-AdverseReaction
in . . O
the . . O
re . . O
- . . O
medy . . O
study . . O
, . . O
the . . O
rate . . O
of . . O
any . . O
gastrointestinal . . B-AdverseReaction
bleeds . . I-AdverseReaction
in . . O
patients . . O
receiving . . O
pradaxa . . O
150 . . O
mg . . O
was . . O
3.1% . . O
( . . O
2.2% . . O
on . . O
warfarin . . O
) . . O
. . . O

table . . O
5 . . O
shows . . O
the . . O
number . . O
of . . O
patients . . O
experiencing . . O
bleeding . . B-AdverseReaction
events . . O
in . . O
the . . O
study . . O
. . . O

table . . O
5 . . O
bleeding . . B-AdverseReaction
events . . O
in . . O
re . . O
- . . O
sonate . . O
treated . . O
patients . . O
note . . O
: . . O
mbe . . B-AdverseReaction
can . . O
belong . . O
to . . O
more . . O
than . . O
one . . O
criterion . . O
. . . O
a . . O
patients . . O
with . . O
at . . O
least . . O
one . . O
mbe . . B-AdverseReaction
. . . O
b . . O
bleeding . . B-AdverseReaction
site . . O
based . . O
on . . O
investigator . . O
assessment . . O
. . . O

in . . O
the . . O
placebo . . O
- . . O
controlled . . O
study . . O
, . . O
a . . O
similar . . O
rate . . O
of . . O
non . . B-Severity
- . . I-Severity
fatal . . I-Severity
and . . O
fatal . . B-AdverseReaction
clinical . . O
myocardial . . O
infarction . . O
was . . O
reported . . O
in . . O
patients . . O
who . . O
received . . O
pradaxa . . O
[ . . O
1 . . O
( . . O
0.32 . . O
per . . O
100 . . O
patient . . O
- . . O
years . . O
) . . O
] . . O
and . . O
in . . O
those . . O
who . . O
received . . O
placebo . . O
[ . . O
1 . . O
( . . O
0.34 . . O
per . . O
100 . . O
patient . . O
- . . O
years . . O
) . . O
] . . O
. . . O

dyspepsia . . B-AdverseReaction
( . . O
including . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
and . . O
epigastric . . B-AdverseReaction
discomfort . . I-AdverseReaction
) . . O
occurred . . O
in . . O
patients . . O
on . . O
pradaxa . . O
in . . O
7.5% . . O
vs . . O
. . . O
5.5% . . O
on . . O
warfarin . . O
, . . O
and . . O
gastritis . . B-AdverseReaction
- . . O
like . . O
symptoms . . O
( . . O
including . . O
gastritis . . B-AdverseReaction
, . . O
gerd . . B-AdverseReaction
, . . O
esophagitis . . B-AdverseReaction
, . . O
erosive . . B-AdverseReaction
gastritis . . I-AdverseReaction
and . . O
gastric . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
) . . O
occurred . . O
at . . O
3.0% . . O
vs . . O
. . . O
1.7% . . O
, . . O
respectively . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

duavee . . O
contains . . O
conjugated . . O
estrogens . . O
and . . O
bazedoxifene . . O
, . . O
an . . O
estrogen . . O
agonist . . O
/ . . O
antagonist . . O
. . . O

women . . O
taking . . O
duavee . . O
should . . O
not . . O
take . . O
progestins . . O
, . . O
additional . . O
estrogens . . O
or . . O
additional . . O
estrogen . . O
agonist . . O
/ . . O
antagonists . . O
. . . O

5.2 . . O
cardiovascular . . O
disorders . . O

an . . O
increased . . O
risk . . O
of . . O
stroke . . B-AdverseReaction
and . . O
dvt . . B-AdverseReaction
has . . O
been . . O
reported . . O
with . . O
estrogen . . B-DrugClass
- . . O
alone . . O
therapy . . O
. . . O

risk . . O
factors . . O
for . . O
arterial . . O
vascular . . O
disease . . O
( . . O
for . . O
example . . O
, . . O
hypertension . . O
, . . O
diabetes . . O
mellitus . . O
, . . O
tobacco . . O
use . . O
, . . O
hypercholesterolemia . . O
, . . O
and . . O
obesity . . O
) . . O
and . . O
/ . . O
or . . O
vte . . O
( . . O
for . . O
example . . O
, . . O
personal . . O
history . . O
or . . O
family . . O
history . . O
of . . O
vte . . O
, . . O
obesity . . O
, . . O
and . . O
systemic . . O
lupus . . O
erythematosus . . O
) . . O
should . . O
be . . O
managed . . O
appropriately . . O
. . . O

the . . O
increase . . O
in . . O
risk . . O
was . . O
demonstrated . . O
in . . O
year . . O
1 . . O
and . . O
persisted . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.5 . . O
) . . O
] . . O
. . . O

should . . O
a . . O
stroke . . O
occur . . O
or . . O
be . . O
suspected . . O
, . . O
duavee . . O
should . . O
be . . O
discontinued . . O
immediately . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

coronary . . O
heart . . O
disease . . O

in . . O
the . . O
whi . . O
estrogen . . O
- . . O
alone . . O
substudy . . O
, . . O
the . . O
risk . . O
of . . O
vte . . B-AdverseReaction
[ . . O
dvt . . B-AdverseReaction
and . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
( . . O
pe . . B-AdverseReaction
) . . O
] . . O
was . . O
increased . . O
for . . O
women . . O
receiving . . O
daily . . O
conjugated . . B-DrugClass
estrogens . . I-DrugClass
( . . O
0.625 . . O
mg . . O
) . . O
- . . O
alone . . O
compared . . O
to . . O
placebo . . O
( . . O
30 . . O
versus . . O
22 . . O
per . . O
10,000 . . O
women . . O
- . . O
years . . O
) . . O
, . . O
although . . O
only . . O
the . . O
increased . . O
risk . . O
of . . O
dvt . . B-AdverseReaction
reached . . O
statistical . . O
significance . . O
( . . O
23 . . O
versus . . O
15 . . O
per . . O
10,000 . . O
women . . O
- . . O
years . . O
) . . O
. . . O

5.3 . . O
malignant . . O
neoplasms . . O

endometrial . . O
hyperplasia . . O
may . . O
be . . O
a . . O
precursor . . O
to . . O
endometrial . . O
cancer . . O
. . . O

women . . O
taking . . O
duavee . . O
should . . O
not . . O
take . . O
additional . . O
estrogens . . O
as . . O
this . . O
may . . O
increase . . O
the . . O
risk . . O
of . . O
endometrial . . O
hyperplasia . . O
. . . O

adequate . . O
diagnostic . . O
measures . . O
, . . O
including . . O
directed . . O
or . . O
random . . O
endometrial . . O
sampling . . O
when . . O
indicated . . O
, . . O
should . . O
be . . O
undertaken . . O
to . . O
rule . . O
out . . O
malignancy . . O
in . . O
postmenopausal . . O
women . . O
with . . O
undiagnosed . . O
persistent . . O
or . . O
recurring . . O
abnormal . . O
genital . . O
bleeding . . O
. . . O

in . . O
addition . . O
, . . O
mammography . . O
examinations . . O
should . . O
be . . O
scheduled . . O
based . . O
on . . O
patient . . O
age . . O
, . . O
risk . . O
factors . . O
, . . O
and . . O
prior . . O
mammogram . . O
results . . O
. . . O

in . . O
some . . O
epidemiological . . O
studies . . O
, . . O
the . . O
use . . O
of . . O
estrogen . . B-DrugClass
- . . O
only . . O
products . . O
, . . O
in . . O
particular . . O
for . . O
5 . . O
or . . O
more . . O
years . . O
, . . O
has . . O
been . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . O
of . . O
ovarian . . B-AdverseReaction
cancer . . I-AdverseReaction
. . . O

in . . O
the . . O
whims . . O
estrogen . . O
- . . O
alone . . O
ancillary . . O
study . . O
of . . O
whi . . O
, . . O
a . . O
population . . O
of . . O
2,947 . . O
hysterectomized . . O
women . . O
65 . . O
to . . O
79 . . O
years . . O
of . . O
age . . O
was . . O
randomized . . O
to . . O
daily . . O
ce . . O
( . . O
0.625 . . O
mg . . O
) . . O
- . . O
alone . . O
or . . O
placebo . . O
. . . O

5.6 . . O
visual . . O
abnormalities . . O

in . . O
a . . O
small . . O
number . . O
of . . O
case . . O
reports . . O
in . . O
women . . O
receiving . . O
estrogens . . O
, . . O
substantial . . B-Severity
increases . . B-AdverseReaction
in . . I-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
have . . O
been . . O
attributed . . O
to . . O
idiosyncratic . . O
reactions . . O
to . . O
estrogens . . O
. . . O

for . . O
women . . O
with . . O
a . . O
history . . O
of . . O
cholestatic . . O
jaundice . . O
associated . . O
with . . O
past . . O
estrogen . . O
use . . O
or . . O
with . . O
pregnancy . . O
, . . O
caution . . O
should . . O
be . . O
exercised . . O
; . . O
and . . O
in . . O
the . . O
case . . O
of . . O
recurrence . . O
, . . O
duavee . . O
should . . O
be . . O
discontinued . . O
. . . O

5.12 . . O
hypocalcemia . . O

estrogen . . O
therapy . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
women . . O
with . . O
hypoparathyroidism . . O
as . . O
estrogen . . O
- . . O
induced . . O
hypocalcemia . . O
may . . O
occur . . O
. . . O

exogenous . . O
estrogens . . O
may . . B-Factor
exacerbate . . O
symptoms . . O
of . . O
angioedema . . O
in . . O
women . . O
with . . O
hereditary . . O
angioedema . . O
. . . O

accelerated . . B-AdverseReaction
prothrombin . . I-AdverseReaction
time . . I-AdverseReaction
, . . O
partial . . O
thromboplastin . . O
time . . O
, . . O
and . . O
platelet . . O
aggregation . . O
time . . O
; . . O
increased . . B-AdverseReaction
platelet . . I-AdverseReaction
count . . I-AdverseReaction
; . . O
increased . . B-AdverseReaction
factors . . I-AdverseReaction
ii . . I-AdverseReaction
, . . O
vii . . O
antigen . . O
, . . O
viii . . O
antigen . . O
, . . O
viii . . O
coagulant . . O
activity . . O
, . . O
ix . . O
, . . O
x . . O
, . . O
xii . . O
, . . O
vii . . O
- . . O
x . . O
complex . . O
, . . O
ii . . O
- . . O
vii . . O
- . . O
x . . O
complex . . O
, . . O
and . . O
beta . . O
- . . O
thromboglobulin . . O
; . . O
decreased . . B-AdverseReaction
levels . . I-AdverseReaction
of . . I-AdverseReaction
antifactor . . I-AdverseReaction
xa . . I-AdverseReaction
and . . O
antithrombin . . O
iii . . O
, . . O
decreased . . B-AdverseReaction
antithrombin . . I-AdverseReaction
iii . . I-AdverseReaction
activity . . I-AdverseReaction
; . . O
increased . . B-AdverseReaction
levels . . I-AdverseReaction
of . . I-AdverseReaction
fibrinogen . . I-AdverseReaction
and . . O
fibrinogen . . O
activity . . O
; . . O
increased . . B-AdverseReaction
plasminogen . . I-AdverseReaction
antigen . . I-AdverseReaction
and . . O
activity . . O
. . . O

free . . O
hormone . . O
concentrations . . O
, . . O
such . . O
as . . O
testosterone . . O
and . . O
estradiol . . O
, . . O
may . . B-Factor
be . . O
decreased . . O
. . . O

other . . O
plasma . . O
proteins . . O
may . . B-Factor
be . . O
increased . . O
( . . O
angiotensinogen . . O
/ . . O
renin . . O
substrate . . O
, . . O
alpha . . O
- . . O
1 . . O
- . . O
antitrypsin . . O
, . . O
ceruloplasmin . . O
) . . O
. . . O

increased . . B-AdverseReaction
plasma . . I-AdverseReaction
high . . I-AdverseReaction
- . . I-AdverseReaction
density . . I-AdverseReaction
lipoprotein . . I-AdverseReaction
( . . O
hdl . . O
) . . O
and . . O
hdl2 . . O
cholesterol . . O
subfraction . . O
concentrations . . O
, . . O
reduced . . O
low . . O
- . . O
density . . O
lipoprotein . . O
( . . O
ldl . . O
) . . O
cholesterol . . O
concentrations . . O
, . . O
increased . . B-AdverseReaction
triglyceride . . I-AdverseReaction
levels . . I-AdverseReaction
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
and . . O
behaviors . . O

* . . O
pristiq . . O
is . . O
not . . O
approved . . O
for . . O
use . . O
in . . O
pediatric . . O
patients . . O
( . . O
8.4 . . O
) . . O
. . . O

do . . O
not . . O
restart . . O
if . . O
pancreatitis . . O
is . . O
confirmed . . O
. . . O

monitor . . O
and . . O
treat . . O
promptly . . O
per . . O
standard . . O
of . . O
care . . O
until . . O
signs . . O
and . . O
symptoms . . O
resolve . . O
( . . O
5.4 . . O
) . . O
. . . O

glucagon . . O
- . . O
like . . O
peptide . . O
( . . O
glp . . O
- . . O
1 . . O
) . . O
receptor . . O
agonists . . O
have . . O
induced . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
adenomas . . I-AdverseReaction
and . . O
carcinomas . . O
in . . O
mice . . B-Animal
and . . O
rats . . B-Animal
at . . O
clinically . . O
relevant . . O
exposures . . O
. . . O

routine . . O
monitoring . . O
of . . O
serum . . O
calcitonin . . O
or . . O
using . . O
thyroid . . O
ultrasound . . O
is . . O
of . . O
uncertain . . O
value . . O
for . . O
early . . O
detection . . O
of . . O
mtc . . O
in . . O
patients . . O
treated . . O
with . . O
trulicity . . O
. . . O

if . . O
a . . O
hypersensitivity . . O
reaction . . O
occurs . . O
, . . O
the . . O
patient . . O
should . . O
discontinue . . O
trulicity . . O
and . . O
promptly . . O
seek . . O
medical . . O
advice . . O
. . . O

excerpt . . O
: . . O
* . . O
somnolence . . B-AdverseReaction
or . . O
sedation . . B-AdverseReaction
: . . O
monitor . . O
for . . O
central . . O
nervous . . O
system . . O
( . . O
cns . . O
) . . O
depression . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
somnolence . . B-AdverseReaction
or . . O
sedation . . B-AdverseReaction
was . . O
reported . . O
at . . O
all . . O
effective . . O
doses . . O
and . . O
was . . O
dose . . O
- . . O
related . . O
. . . O

prescribers . . O
should . . O
monitor . . O
patients . . O
for . . O
somnolence . . O
and . . O
sedation . . O
, . . O
particularly . . O
with . . O
concomitant . . O
use . . O
of . . O
other . . O
central . . O
nervous . . O
system . . O
depressants . . O
. . . O

prescribers . . O
should . . O
caution . . O
patients . . O
against . . O
engaging . . O
in . . O
hazardous . . O
activities . . O
requiring . . O
mental . . O
alertness . . O
, . . O
such . . O
as . . O
operating . . O
dangerous . . O
machinery . . O
or . . O
motor . . O
vehicles . . O
, . . O
until . . O
the . . O
effect . . O
of . . O
onfi . . O
is . . O
known . . O
. . . O

the . . O
more . . O
severe . . O
withdrawal . . O
symptoms . . O
have . . O
usually . . O
been . . O
limited . . O
to . . O
patients . . O
who . . O
received . . O
excessive . . O
doses . . O
over . . O
an . . O
extended . . O
period . . O
of . . O
time . . O
, . . O
followed . . O
by . . O
an . . O
abrupt . . O
discontinuation . . O
. . . O

patients . . O
should . . O
be . . O
closely . . O
monitored . . O
for . . O
signs . . O
or . . O
symptoms . . O
of . . O
sjs . . O
/ . . O
ten . . O
, . . O
especially . . O
during . . O
the . . O
first . . O
8 . . O
weeks . . O
of . . O
treatment . . O
initiation . . O
or . . O
when . . O
re . . O
- . . O
introducing . . O
therapy . . O
. . . O

5.5 . . O
physical . . O
and . . O
psychological . . O
dependence . . O

because . . O
most . . O
trials . . O
included . . O
in . . O
the . . O
analysis . . O
did . . O
not . . O
extend . . O
beyond . . O
24 . . O
weeks . . O
, . . O
the . . O
risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
beyond . . O
24 . . O
weeks . . O
could . . O
not . . O
be . . O
assessed . . O
. . . O

the . . O
finding . . O
of . . O
increased . . O
risk . . O
with . . O
aeds . . O
of . . O
varying . . O
mechanisms . . O
of . . O
action . . O
and . . O
across . . O
a . . O
range . . O
of . . O
indications . . O
suggests . . O
that . . O
the . . O
risk . . O
applies . . O
to . . O
all . . O
aeds . . O
used . . O
for . . O
any . . O
indication . . O
. . . O

risk . . O
by . . O
indication . . O
for . . O
antiepileptic . . O
drugs . . O
in . . O
the . . O
pooled . . O
analysis . . O
indication . . O
placebo . . O
patients . . O
with . . O
events . . O
per . . O
1000 . . O
patients . . O
drug . . O
patients . . O
with . . O
events . . O
per . . O
1000 . . O
patients . . O
relative . . O
risk . . O
: . . O
incidence . . O
of . . O
drug . . O
events . . O
in . . O
drug . . O
patients . . O
/ . . O
incidencein . . O
placebo . . O
patients . . O
risk . . O
difference . . O
: . . O
additional . . O
drug . . O
patients . . O
with . . O
events . . O
per . . O
1000 . . O
patients . . O
epilepsy . . O
1.0 . . O
3.4 . . O
3.5 . . O
2.4 . . O
psychiatric . . O
5.7 . . O
8.5 . . O
1.5 . . O
2.9 . . O
other . . O
1.0 . . O
1.8 . . O
1.9 . . O
0.9 . . O
total . . O
2.4 . . O
4.3 . . O
1.8 . . O
1.9 . . O
the . . O
relative . . O
risk . . B-Factor
for . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
was . . O
higher . . O
in . . O
clinical . . O
trials . . O
for . . O
epilepsy . . O
than . . O
in . . O
clinical . . O
trials . . O
for . . O
psychiatric . . O
or . . O
other . . O
conditions . . O
, . . O
but . . O
the . . O
absolute . . O
risk . . O
differences . . O
were . . O
similar . . O
for . . O
the . . O
epilepsy . . O
and . . O
psychiatric . . O
indications . . O
. . . O

should . . O
suicidal . . O
thoughts . . O
and . . O
behavior . . O
emerge . . O
during . . O
treatment . . O
, . . O
the . . O
prescriber . . O
needs . . O
to . . O
consider . . O
whether . . O
the . . O
emergence . . O
of . . O
these . . O
symptoms . . O
in . . O
any . . O
given . . O
patient . . O
may . . O
be . . O
related . . O
to . . O
the . . O
illness . . O
being . . O
treated . . O
. . . O

behaviors . . O
of . . O
concern . . O
should . . O
be . . O
reported . . O
immediately . . O
to . . O
healthcare . . O
providers . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
that . . O
led . . O
to . . O
treatment . . O
discontinuations . . O
were . . O
hepatotoxicity . . B-AdverseReaction
and . . O
diarrhea . . B-AdverseReaction
/ . . O
colitis . . B-AdverseReaction
. . . O

thirty . . O
- . . O
nine . . O
subjects . . O
( . . O
35% . . O
) . . O
had . . O
dose . . O
interruptions . . O
and . . O
sixteen . . O
subjects . . O
( . . O
15% . . O
) . . O
had . . O
dose . . O
reductions . . O
due . . O
to . . O
adverse . . O
reactions . . O
or . . O
laboratory . . O
abnormalities . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
benlysta . . O
plus . . O
standard . . O
of . . O
care . . O
compared . . O
with . . O
placebo . . O
plus . . O
standard . . O
of . . O
care . . O
in . . O
2,133 . . O
patients . . O
in . . O
3 . . O
controlled . . O
trials . . O
. . . O

the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
positivity . . O
in . . O
an . . O
assay . . O
is . . O
highly . . O
dependent . . O
on . . O
several . . O
factors . . O
, . . O
including . . O
assay . . O
sensitivity . . O
and . . O
specificity . . O
, . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

voraxaze . . O
was . . O
given . . O
at . . O
a . . O
dose . . O
of . . O
50 . . O
units . . O
/ . . O
kg . . O
as . . O
an . . O
intravenous . . O
injection . . O
over . . O
5 . . O
minutes . . O
. . . O

this . . O
information . . O
was . . O
abstracted . . O
and . . O
categorized . . O
using . . O
the . . O
national . . O
cancer . . O
institute . . O
( . . O
nci . . O
) . . O
" . . O
common . . O
terminology . . O
criteria . . O
for . . O
adverse . . O
events . . O
" . . O

the . . O
study . . O
1 . . O
population . . O
enrolled . . O
patients . . O
with . . O
a . . O
median . . O
age . . O
of . . O
18 . . O
years . . O
( . . O
1 . . O
month . . O
to . . O
85 . . O
years . . O
) . . O
; . . O
63% . . O
were . . O
male . . O
, . . O
and . . O
the . . O
underlying . . O
malignancies . . O
were . . O
osteosarcoma . . O
/ . . O
sarcomas . . O
in . . O
32% . . O
, . . O
and . . O
leukemia . . O
or . . O
lymphoma . . O
in . . O
63% . . O
of . . O
patients . . O
. . . O

at . . O
the . . O
time . . O
of . . O
data . . O
cut . . O
- . . O
off . . O
, . . O
243 . . O
patients . . O
were . . O
enrolled . . O
and . . O
safety . . O
data . . O
was . . O
available . . O
for . . O
141 . . O
patients . . O
. . . O

one . . O
( . . O
n . . O
= . . O
122 . . O
) . . O
or . . O
2 . . O
( . . O
n . . O
= . . O
18 . . O
) . . O
doses . . O
of . . O
voraxaze . . O
were . . O
administered . . O
intravenously . . O
; . . O
the . . O
number . . O
of . . O
doses . . O
was . . O
not . . O
specified . . O
for . . O
1 . . O
patient . . O
. . . O

twenty . . O
- . . O
one . . O
of . . O
290 . . O
patients . . O
( . . O
7% . . O
) . . O
experienced . . O
adverse . . O
reactions . . O
that . . O
were . . O
assessed . . O
as . . O
related . . O
to . . O
voraxaze . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O

* . . O
for . . O
patients . . O
at . . O
highest . . O
risk . . O
for . . O
nsf . . O
, . . O
do . . O
not . . O
exceed . . O
the . . O
recommended . . O
dotarem . . O
dose . . O
and . . O
allow . . O
a . . O
sufficient . . O
period . . O
of . . O
time . . O
for . . O
elimination . . O
of . . O
the . . O
drug . . O
from . . O
the . . O
body . . O
prior . . O
to . . O
any . . O
re . . O
- . . O
administration . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

( . . O
6.1 . . O
) . . O
excerpt . . O
: . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
xenoport . . O
at . . O
1-877 . . O
- . . O
xenoprt . . O
( . . O
1-877-936-6778 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

the . . O
600 . . O
- . . O
mg . . O
dose . . O
was . . O
studied . . O
in . . O
2 . . O
of . . O
the . . O
3 . . O
studies . . O
. . . O

eleven . . O
out . . O
of . . O
163 . . O
( . . O
7% . . O
) . . O
patients . . O
treated . . O
with . . O
600 . . O
mg . . O
of . . O
horizant . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
reactions . . O
compared . . O
with . . O
10 . . O
of . . O
the . . O
245 . . O
( . . O
4% . . O
) . . O
patients . . O
who . . O
received . . O
placebo . . O
. . . O

the . . O
most . . O
commonly . . O
observed . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
and . . O
at . . O
least . . O
2 . . O
times . . O
the . . O
rate . . O
of . . O
placebo . . O
) . . O
in . . O
these . . O
trials . . O
for . . O
the . . O
600 . . O
mg . . O
dose . . O
of . . O
horizant . . O
were . . O
somnolence . . B-AdverseReaction
/ . . O
sedation . . B-AdverseReaction
and . . O
dizziness . . B-AdverseReaction
( . . O
see . . O
table . . O
4 . . O
) . . O
. . . O

adverse . . O
reactions . . O
reported . . O
in . . O
these . . O
three . . O
12 . . O
week . . O
studies . . O
in . . O
< . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
600 . . O
mg . . O
of . . O
horizant . . O
and . . O
numerically . . O
greater . . O
than . . O
placebo . . O
were . . O
balance . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
disorientation . . B-AdverseReaction
, . . O
feeling . . B-AdverseReaction
drunk . . I-AdverseReaction
, . . O
lethargy . . B-AdverseReaction
, . . O
and . . O
vertigo . . B-AdverseReaction
. . . O

dizziness . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
and . . O
insomnia . . B-AdverseReaction
appeared . . O
to . . O
show . . O
a . . O
dose . . O
relationship . . O
. . . O

6.2 . . O
adverse . . O
events . . O
associated . . O
with . . O
gabapentin . . O

the . . O
following . . O
adverse . . O
events . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
gabapentin . . O
, . . O
either . . O
in . . O
clinical . . O
trials . . O
or . . O
postmarketing . . O
: . . O
breast . . B-AdverseReaction
enlargement . . I-AdverseReaction
, . . O
gynecomastia . . B-AdverseReaction
, . . O
and . . O
elevated . . B-AdverseReaction
creatine . . I-AdverseReaction
kinase . . I-AdverseReaction
. . . O

adverse . . O
reactions . . O
associated . . O
with . . O
ophthalmic . . B-DrugClass
steroids . . I-DrugClass
include . . O
elevated . . B-AdverseReaction
intraocular . . I-AdverseReaction
pressure . . I-AdverseReaction
, . . O
which . . O
may . . O
be . . O
associated . . O
with . . O
optic . . B-AdverseReaction
nerve . . I-AdverseReaction
damage . . I-AdverseReaction
, . . O
visual . . O
acuity . . O
and . . O
field . . O
defects . . O
, . . O
posterior . . B-AdverseReaction
subcapsular . . I-AdverseReaction
cataract . . I-AdverseReaction
formation . . I-AdverseReaction
; . . O
secondary . . B-AdverseReaction
ocular . . I-AdverseReaction
infection . . I-AdverseReaction
from . . O
pathogens . . O
including . . O
herpes . . O
simplex . . O
, . . O
and . . O
perforation . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
globe . . I-AdverseReaction
where . . O
there . . O
is . . O
thinning . . O
of . . O
the . . O
cornea . . O
or . . O
sclera . . O
. . . O

ocular . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
< . . O
1% . . O
of . . O
subjects . . O
included . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
discomfort . . I-AdverseReaction
or . . O
irritation . . O
, . . O
corneal . . B-AdverseReaction
pigmentation . . I-AdverseReaction
and . . O
striae . . O
, . . O
episcleritis . . B-AdverseReaction
, . . O
eye . . B-AdverseReaction
pruritis . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
irritation . . I-AdverseReaction
and . . O
crusting . . O
, . . O
foreign . . B-AdverseReaction
body . . I-AdverseReaction
sensation . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
lacrimation . . I-AdverseReaction
, . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
sclera . . B-AdverseReaction
hyperemia . . I-AdverseReaction
, . . O
and . . O
uveitis . . B-AdverseReaction
. . . O

most . . O
of . . O
these . . O
reactions . . O
may . . O
have . . O
been . . O
the . . O
consequence . . O
of . . O
the . . O
surgical . . O
procedure . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction

gadolinium . . B-DrugClass
- . . I-DrugClass
based . . I-DrugClass
contrast . . I-DrugClass
agents . . I-DrugClass
( . . O
gbcas . . O
) . . O
increase . . O
the . . O
risk . . B-Factor
for . . O
nsf . . B-AdverseReaction
among . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
the . . O
drugs . . O
. . . O

for . . O
patients . . O
at . . O
risk . . O
for . . O
chronically . . O
reduced . . O
renal . . O
function . . O
( . . O
for . . O
example . . O
, . . O
age . . O
> . . O
60 . . O
years . . O
, . . O
hypertension . . O
or . . O
diabetes . . O
) . . O
, . . O
estimate . . O
the . . O
glomerular . . O
filtration . . O
rate . . O
( . . O
gfr . . O
) . . O
through . . O
laboratory . . O
testing . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O

* . . O
screen . . O
patients . . O
for . . O
acute . . O
kidney . . O
injury . . O
and . . O
other . . O
conditions . . O
that . . O
may . . O
reduce . . O
renal . . O
function . . O
. . . O

postmarketing . . O
reports . . O
indicate . . O
that . . O
the . . O
effects . . O
of . . O
xeomin . . O
and . . O
all . . O
botulinum . . O
toxin . . O
products . . O
may . . B-Factor
spread . . B-AdverseReaction
from . . I-AdverseReaction
the . . I-AdverseReaction
area . . I-AdverseReaction
of . . I-AdverseReaction
injection . . I-AdverseReaction
to . . O
produce . . O
symptoms . . O
consistent . . O
with . . O
botulinum . . O
toxin . . B-AdverseReaction
effects . . I-AdverseReaction
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
distant . . B-AdverseReaction
spread . . I-AdverseReaction
of . . I-AdverseReaction
toxin . . I-AdverseReaction
effect . . I-AdverseReaction

these . . O
symptoms . . O
have . . O
been . . O
reported . . O
hours . . O
to . . O
weeks . . O
after . . O
injection . . O
. . . O

anaphylaxis . . B-AdverseReaction
occurred . . O
as . . O
late . . O
into . . O
treatment . . O
as . . O
the . . O
47 . . O
th . . O
infusion . . O
. . . O

observe . . O
patients . . O
closely . . O
for . . O
an . . O
appropriate . . O
period . . O
of . . O
time . . O
after . . O
administration . . O
of . . O
vimizim . . O
, . . O
taking . . O
into . . O
account . . O
the . . O
time . . O
to . . O
onset . . O
of . . O
anaphylaxis . . O
seen . . O
in . . O
premarketing . . O
clinical . . O
trials . . O
. . . O

however . . O
, . . O
if . . O
severe . . O
hypersensitivity . . O
reactions . . O
occur . . O
, . . O
immediately . . O
stop . . O
the . . O
infusion . . O
of . . O
vimizim . . O
and . . O
initiate . . O
appropriate . . O
treatment . . O
. . . O

careful . . O
consideration . . O
should . . O
be . . O
given . . O
to . . O
the . . O
patient's . . O
clinical . . O
status . . O
prior . . O
to . . O
administration . . O
of . . O
vimizim . . O
and . . O
consider . . O
delaying . . O
the . . O
vimizim . . O
infusion . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
remove . . O
contact . . O
lenses . . O
prior . . O
to . . O
instillation . . O
of . . O
bepreve . . O
. . . O

5.3 . . O
topical . . O
ophthalmic . . O
use . . O
only . . O

bepreve . . O
is . . O
for . . O
topical . . O
ophthalmic . . O
use . . O
only . . O
. . . O

warning . . O
: . . O
potential . . O
risk . . B-Factor
of . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
with . . O
long . . O
- . . O
term . . O
use . . O
: . . O
for . . O
short . . O
- . . O
term . . O
hospital . . O
use . . O
only . . O

table . . O
1 . . O
displays . . O
adverse . . O
drug . . O
reactions . . O
reported . . O
by . . O
at . . O
least . . O
2% . . O
of . . O
patients . . O
( . . O
and . . O
higher . . O
than . . O
placebo . . O
) . . O
during . . O
a . . O
3 . . O
month . . O
exposure . . O
at . . O
the . . O
recommended . . O
75 . . O
mcg . . O
once . . O
daily . . O
dose . . O
. . . O

adverse . . O
drug . . O
reactions . . O
are . . O
listed . . O
according . . O
to . . O
meddra . . O
( . . O
version . . O
13.0 . . O
) . . O
system . . O
organ . . O
class . . O
and . . O
sorted . . O
in . . O
descending . . O
order . . O
of . . O
frequency . . O
. . . O

table . . O
1 . . O
: . . O
number . . O
and . . O
frequency . . O
of . . O
adverse . . O
drug . . O
reactions . . O
greater . . O
than . . O
2% . . O
( . . O
and . . O
higher . . O
than . . O
placebo . . O
) . . O
in . . O
copd . . O
patients . . O
exposed . . O
to . . O
arcapta . . O
neohaler . . O
75 . . O
mcg . . O
for . . O
up . . O
to . . O
3 . . O
months . . O
in . . O
multiple . . O
dose . . O
, . . O
controlled . . O
trials . . O
indacaterol . . O
75 . . O
mcg . . O
once . . O
daily . . O
placebo . . O
n . . O
= . . O
449 . . O
n . . O
= . . O
445 . . O
n . . O
( . . O
% . . O
) . . O
n . . O
( . . O
% . . O
) . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
- . . O
cough . . B-AdverseReaction
29 . . O
( . . O
6.5 . . O
) . . O
20 . . O
( . . O
4.5 . . O
) . . O
- . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
10 . . O
( . . O
2.2 . . O
) . . O
3 . . O
( . . O
0.7 . . O
) . . O
infections . . O
and . . O
infestations . . O
- . . O
nasopharyngitis . . B-AdverseReaction
24 . . O
( . . O
5.3 . . O
) . . O
12 . . O
( . . O
2.7 . . O
) . . O
nervous . . O
system . . O
disorders . . O
- . . O
headache . . B-AdverseReaction
23 . . O
( . . O
5.1 . . O
) . . O
11 . . O
( . . O
2.5 . . O
) . . O
gastrointestinal . . O
disorders . . O
- . . O
nausea . . B-AdverseReaction
11 . . O
( . . O
2.4 . . O
) . . O
4 . . O
( . . O
0.9 . . O
) . . O
in . . O
these . . O
trials . . O
the . . O
overall . . O
frequency . . O
of . . O
all . . O
cardiovascular . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
was . . O
2.5% . . O
for . . O
arcapta . . O
neohaler . . O
75 . . O
mcg . . O
and . . O
1.6% . . O
for . . O
placebo . . O
during . . O
a . . O
3 . . O
month . . O
exposure . . O
. . . O

of . . O
these . . O
patients . . O
, . . O
there . . O
were . . O
2 . . O
respiratory . . O
- . . O
related . . O
deaths . . B-AdverseReaction
in . . O
the . . O
arcapta . . O
neohaler . . O
300 . . O
mcg . . O
dose . . O
group . . O
. . . O

excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
drug . . O
reactions . . O
to . . O
stribild . . O
( . . O
incidence . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
10% . . O
, . . O
all . . O
grades . . O
) . . O
are . . O
nausea . . B-AdverseReaction
and . . O
diarrhea . . B-AdverseReaction
. . . O

the . . O
safety . . O
assessment . . O
of . . O
stribild . . O
is . . O
based . . O
on . . O
the . . O
week . . O
144 . . O
pooled . . O
data . . O
from . . O
1408 . . O
subjects . . O
in . . O
two . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
active . . O
- . . O
controlled . . O
clinical . . O
trials . . O
, . . O
study . . O
102 . . O
and . . O
study . . O
103 . . O
, . . O
in . . O
antiretroviral . . O
treatment . . O
- . . O
naive . . O
hiv . . O
- . . O
1 . . O
infected . . O
adult . . O
subjects . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

additional . . O
adverse . . O
drug . . O
reactions . . O
observed . . O
with . . O
stribild . . O
included . . O
suicidal . . B-AdverseReaction
ideation . . I-AdverseReaction
and . . O
suicide . . B-AdverseReaction
attempt . . I-AdverseReaction
( . . O
0.3% . . O
) . . O
, . . O
all . . O
in . . O
subjects . . O
with . . O
a . . O
pre . . O
- . . O
existing . . O
history . . O
of . . O
depression . . O
or . . O
psychiatric . . O
illness . . O
. . . O

no . . O
new . . O
adverse . . O
reactions . . O
to . . O
stribild . . O
through . . O
week . . O
48 . . O
were . . O
identified . . O
in . . O
584 . . O
virologically . . O
stably . . O
suppressed . . O
subjects . . O
switching . . O
to . . O
stribild . . O
from . . O
a . . O
regimen . . O
containing . . O
a . . O
rtv . . O
- . . O
boosted . . O
protease . . O
inhibitor . . O
( . . O
pi . . O
) . . O
or . . O
a . . O
non . . O
- . . O
nucleoside . . O
reverse . . O
transcriptase . . O
inhibitor . . O
( . . O
nnrti . . O
) . . O
. . . O

table . . O
3 . . O
laboratory . . O
abnormalities . . O
( . . O
grades . . O
3-4 . . O
) . . O
reported . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
subjects . . O
receiving . . O
stribild . . O
in . . O
studies . . O
102 . . O
and . . O
103 . . O
( . . O
week . . O
144 . . O
analysis . . O
) . . O
stribild . . O
atripla . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
laboratory . . O
parameter . . O
abnormality . . O
, . . O
n . . O
= . . O
701 . . O
n . . O
= . . O
352 . . O
n . . O
= . . O
355 . . O
ast . . O
( . . O
> . . O
5.0 . . O
* . . O
uln . . O
) . . O
3% . . O
6% . . O
6% . . O
alt . . O
( . . O
> . . O
3.0 . . O
* . . O
uln . . O
) . . O
2% . . O
5% . . O
4% . . O
amylase . . O
( . . O
> . . O
2.0 . . O
* . . O
uln . . O
) . . O
3% . . O
3% . . O
5% . . O
creatine . . O
kinase . . O
( . . O
> . . O
= . . O
10.0 . . O
* . . O
uln . . O
) . . O
8% . . O
15% . . O
11% . . O
urine . . B-AdverseReaction
rbc . . I-AdverseReaction
( . . O
hematuria . . B-AdverseReaction
) . . O
( . . O
> . . O
75 . . O
rbc . . O
/ . . O
hpf . . O
) . . O
4% . . O
2% . . O
4% . . O
in . . O
study . . O
103 . . O
, . . O
bmd . . O
was . . O
assessed . . O
by . . O
dexa . . O
in . . O
a . . O
non . . O
- . . O
random . . O
subset . . O
of . . O
120 . . O
subjects . . O
( . . O
stribild . . O
group . . O
n . . O
= . . O
54 . . O
; . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
group . . O
n . . O
= . . O
66 . . O
) . . O
. . . O

in . . O
studies . . O
102 . . O
and . . O
103 . . O
, . . O
bone . . B-AdverseReaction
fractures . . I-AdverseReaction
occurred . . O
in . . O
27 . . O
subjects . . O
( . . O
3.9% . . O
) . . O
in . . O
the . . O
stribild . . O
group . . O
, . . O
8 . . O
subjects . . O
( . . O
2.3% . . O
) . . O
in . . O
the . . O
atripla . . O
group . . O
, . . O
and . . O
19 . . O
subjects . . O
( . . O
5.4% . . O
) . . O
in . . O
the . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
group . . O
. . . O

table . . O
5 . . O
lipid . . O
values . . O
, . . O
mean . . O
change . . O
from . . O
baseline . . O
at . . O
week . . O
144 . . O
in . . O
subjects . . O
receiving . . O
stribild . . O
or . . O
comparator . . O
in . . O
studies . . O
102 . . O
and . . O
103 . . O
stribildn . . O
= . . O
701 . . O
atriplan . . O
= . . O
352 . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvadan . . O
= . . O
355 . . O
baseline . . O
week . . O
144 . . O
baseline . . O
week . . O
144 . . O
baseline . . O
week . . O
144 . . O
mg . . O
/ . . O
dl . . O
change . . O
mg . . O
/ . . O
dl . . O
change . . O
mg . . O
/ . . O
dl . . O
change . . O
total . . O
cholesterol . . O
( . . O
fasted . . O
) . . O
166[n . . O
= . . O
675 . . O
] . . O
+ . . O
17[n . . O
= . . O
535 . . O
] . . O
161[n . . O
= . . O
343 . . O
] . . O
+ . . O
22[n . . O
= . . O
262 . . O
] . . O
168[n . . O
= . . O
337 . . O
] . . O
+ . . O
16[n . . O
= . . O
243 . . O
] . . O
hdl . . O
- . . O
cholesterol . . O
( . . O
fasted . . O
) . . O
43[n . . O
= . . O
675 . . O
] . . O
+ . . O
7[n . . O
= . . O
535 . . O
] . . O
43[n . . O
= . . O
343 . . O
] . . O
+ . . O
9[n . . O
= . . O
262 . . O
] . . O
42[n . . O
= . . O
335 . . O
] . . O
+ . . O
7[n . . O
= . . O
242 . . O
] . . O
ldl . . O
- . . O
cholesterol . . O
( . . O
fasted . . O
) . . O
100[n . . O
= . . O
675 . . O
] . . O
+ . . O
15[n . . O
= . . O
535 . . O
] . . O
97[n . . O
= . . O
343 . . O
] . . O
+ . . O
19[n . . O
= . . O
262 . . O
] . . O
101[n . . O
= . . O
337 . . O
] . . O
+ . . O
18[n . . O
= . . O
242 . . O
] . . O
triglycerides . . O
( . . O
fasted . . O
) . . O
122[n . . O
= . . O
675 . . O
] . . O
+ . . O
12[n . . O
= . . O
535 . . O
] . . O
121[n . . O
= . . O
343 . . O
] . . O
+ . . O
5[n . . O
= . . O
262 . . O
] . . O
132[n . . O
= . . O
337 . . O
] . . O
+ . . O
22[n . . O
= . . O
242 . . O
] . . O
6.2 . . O
postmarketing . . O
experience . . O
the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
approval . . O
use . . O
of . . O
tenofovir . . O
df . . O
. . . O

respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O

dyspnea . . B-AdverseReaction

excerpt . . O
: . . O
* . . O
if . . O
the . . O
following . . O
occur . . O
, . . O
discontinue . . O
erwinaze . . O
: . . O
serious . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
( . . O
5.1 . . O
) . . O
severe . . B-Severity
or . . O
hemorrhagic . . B-AdverseReaction
pancreatitis . . I-AdverseReaction
( . . O
5.2 . . O
) . . O
* . . O
glucose . . O
intolerance . . O
can . . B-Factor
occur . . O
and . . O
, . . O
in . . O
some . . O
cases . . O
, . . O
may . . O
be . . O
irreversible . . B-Severity
. . . O

evaluate . . O
patients . . O
with . . O
symptoms . . O
compatible . . O
with . . O
pancreatitis . . O
to . . O
establish . . O
a . . O
diagnosis . . O
. . . O

in . . O
the . . O
case . . O
of . . O
mild . . O
pancreatitis . . O
, . . O
hold . . O
erwinaze . . O
until . . O
the . . O
signs . . O
and . . O
symptoms . . O
subside . . O
and . . O
amylase . . O
levels . . O
return . . O
to . . O
normal . . O
. . . O

5.4 . . O
thrombosis . . O
and . . O
hemorrhage . . O

assess . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
enterocolitis . . O
, . . O
dermatitis . . O
, . . O
neuropathy . . O
, . . O
and . . O
endocrinopathy . . O
and . . O
evaluate . . O
clinical . . O
chemistries . . O
including . . O
liver . . O
function . . O
tests . . O
and . . O
thyroid . . O
function . . O
tests . . O
at . . O
baseline . . O
and . . O
before . . O
each . . O
dose . . O
. . . O

( . . O
2.2 . . O
) . . O

assess . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
enterocolitis . . O
, . . O
dermatitis . . O
, . . O
neuropathy . . O
, . . O
and . . O
endocrinopathy . . O
and . . O
evaluate . . O
clinical . . O
chemistries . . O
including . . O
liver . . O
function . . O
tests . . O
and . . O
thyroid . . O
function . . O
tests . . O
at . . O
baseline . . O
and . . O
before . . O
each . . O
dose . . O
. . . O

( . . O
5.1 . . O
, . . O
5.2 . . O
, . . O
5.3 . . O
, . . O
5.4 . . O
, . . O
5.5 . . O
) . . O

5 . . O
warnings . . O
and . . O
precautions . . O

ampyra . . O
can . . B-Factor
cause . . O
seizures . . B-AdverseReaction
. . . O

in . . O
the . . O
post . . O
- . . O
marketing . . O
period . . O
seizures . . B-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

the . . O
majority . . O
of . . O
seizures . . B-AdverseReaction
occurred . . O
at . . O
the . . O
recommended . . O
dose . . O
and . . O
in . . O
patients . . O
without . . O
a . . O
history . . O
of . . O
seizures . . O
, . . O
and . . O
generally . . O
within . . O
days . . O
to . . O
weeks . . O
of . . O
starting . . O
therapy . . O
. . . O

signs . . O
and . . O
symptoms . . O
have . . O
included . . O
respiratory . . B-AdverseReaction
compromise . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
and . . O
angioedema . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
throat . . I-AdverseReaction
and . . O
or . . O
tongue . . O
. . . O

patients . . O
should . . O
be . . O
informed . . O
of . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
anaphylaxis . . O
and . . O
instructed . . O
to . . O
discontinue . . O
ampyra . . O
and . . O
seek . . O
immediate . . O
medical . . O
care . . O
should . . O
these . . O
signs . . O
and . . O
symptoms . . O
occur . . O
( . . O
17.3 . . O
) . . O
. . . O

* . . O
oral . . B-AdverseReaction
ulceration . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

the . . O
median . . O
age . . O
of . . O
patients . . O
was . . O
61 . . O
years . . O
( . . O
range . . O
28-93 . . O
years . . O
) . . O
, . . O
and . . O
75% . . O
were . . O
caucasian . . O
. . . O

safety . . O
results . . O
are . . O
based . . O
on . . O
a . . O
median . . O
follow . . O
- . . O
up . . O
of . . O
approximately . . O
13 . . O
months . . O
. . . O

dose . . O
adjustments . . O
( . . O
interruptions . . O
or . . O
reductions . . O
) . . O
were . . O
more . . O
frequent . . O
among . . O
patients . . O
in . . O
the . . O
afinitor . . O
plus . . O
exemestane . . O
arm . . O
than . . O
in . . O
the . . O
placebo . . O
plus . . O
exemestane . . O
arm . . O
( . . O
63% . . O
versus . . O
14% . . O
) . . O
. . . O

the . . O
most . . O
common . . O
grade . . B-Severity
3-4 . . I-Severity
laboratory . . O
abnormalities . . O
( . . O
incidence . . O
> . . O
= . . O
3% . . O
) . . O
were . . O
hyperglycemia . . B-AdverseReaction
, . . O
lymphopenia . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
hemoglobin . . I-AdverseReaction
, . . O
hypophosphatemia . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
alkaline . . I-AdverseReaction
phosphatase . . I-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
aspartate . . I-AdverseReaction
transaminase . . I-AdverseReaction
( . . O
ast . . O
) . . O
, . . O
potassium . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
and . . O
thrombocytopenia . . B-AdverseReaction
. . . O

dose . . O
delay . . O
or . . O
reduction . . O
was . . O
necessary . . O
in . . O
61% . . O
of . . O
everolimus . . O
patients . . O
and . . O
29% . . O
of . . O
placebo . . O
patients . . O
. . . O

thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
included . . O
five . . O
patients . . O
with . . O
pulmonary . . B-AdverseReaction
embolus . . I-AdverseReaction
in . . O
the . . O
everolimus . . O
arm . . O
and . . O
one . . O
in . . O
the . . O
placebo . . O
arm . . O
as . . O
well . . O
as . . O
three . . O
patients . . O
with . . O
thrombosis . . B-AdverseReaction
in . . O
the . . O
everolimus . . O
arm . . O
and . . O
two . . O
in . . O
the . . O
placebo . . O
arm . . O
. . . O

table . . O
4 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
> . . O
= . . O
10% . . O
of . . O
patients . . O
with . . O
advanced . . O
pnet . . O
grading . . O
according . . O
to . . O
ctcae . . O
version . . O
3.0 . . O
a . . O
includes . . O
stomatitis . . B-AdverseReaction
, . . O
aphthous . . B-AdverseReaction
stomatitis . . I-AdverseReaction
, . . O
gingival . . B-AdverseReaction
pain . . I-AdverseReaction
/ . . O
swelling . . O
/ . . O
ulceration . . O
, . . O
glossitis . . B-AdverseReaction
, . . O
glossodynia . . B-AdverseReaction
, . . O
lip . . B-AdverseReaction
ulceration . . I-AdverseReaction
, . . O
mouth . . B-AdverseReaction
ulceration . . I-AdverseReaction
, . . O
tongue . . B-AdverseReaction
ulceration . . I-AdverseReaction
, . . O
and . . O
mucosal . . B-AdverseReaction
inflammation . . I-AdverseReaction
. . . O
b . . O
includes . . O
diarrhea . . B-AdverseReaction
, . . O
enteritis . . B-AdverseReaction
, . . O
enterocolitis . . B-AdverseReaction
, . . O
colitis . . B-AdverseReaction
, . . O
defecation . . B-AdverseReaction
urgency . . I-AdverseReaction
, . . O
and . . O
steatorrhea . . B-AdverseReaction
. . . O
c . . O
includes . . O
pneumonitis . . B-AdverseReaction
, . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
fibrosis . . I-AdverseReaction
and . . O
restrictive . . B-AdverseReaction
pulmonary . . I-AdverseReaction
disease . . I-AdverseReaction
. . . O

key . . O
observed . . O
laboratory . . O
abnormalities . . O
are . . O
presented . . O
in . . O
table . . O
5 . . O
. . . O

the . . O
most . . O
common . . O
grade . . B-Severity
3-4 . . I-Severity
laboratory . . O
abnormalities . . O
( . . O
incidence . . O
> . . O
= . . O
3% . . O
) . . O
were . . O
lymphopenia . . B-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
hypophosphatemia . . B-AdverseReaction
, . . O
and . . O
hypercholesterolemia . . B-AdverseReaction
. . . O

infections . . B-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction
, . . O
and . . O
pneumonitis . . B-AdverseReaction
were . . O
the . . O
most . . O
common . . O
reasons . . O
for . . O
treatment . . O
delay . . O
or . . O
dose . . O
reduction . . O
. . . O

table . . O
6 . . O
compares . . O
the . . O
incidence . . O
of . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reactions . . O
reported . . O
with . . O
an . . O
incidence . . O
of . . O
> . . O
= . . O
10% . . O
for . . O
patients . . O
receiving . . O
afinitor . . O
10 . . O
mg . . O
daily . . O
versus . . O
placebo . . O
. . . O

within . . O
each . . O
meddra . . O
system . . O
organ . . O
class . . O
, . . O
the . . O
adverse . . O
reactions . . O
are . . O
presented . . O
in . . O
order . . O
of . . O
decreasing . . O
frequency . . O
. . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
exacerbation . . O
of . . O
pre . . O
- . . O
existing . . O
diabetes . . O
mellitus . . O
( . . O
2% . . O
) . . O
, . . O
new . . B-AdverseReaction
onset . . I-AdverseReaction
of . . I-AdverseReaction
diabetes . . I-AdverseReaction
mellitus . . I-AdverseReaction
( . . O
< . . O
1% . . O
) . . O

nervous . . O
system . . O
disorders . . O
: . . O
dizziness . . B-AdverseReaction
( . . O
7% . . O
) . . O
, . . O
paresthesia . . B-AdverseReaction
( . . O
5% . . O
) . . O

the . . O
most . . O
common . . O
grade . . O
3-4 . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
2% . . O
) . . O
were . . O
stomatitis . . B-AdverseReaction
and . . O
amenorrhea . . B-AdverseReaction
. . . O

dose . . O
adjustments . . O
( . . O
interruptions . . O
or . . O
reductions . . O
) . . O
due . . O
to . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
52% . . O
of . . O
afinitor . . O
- . . O
treated . . O
patients . . O
. . . O

afinitor . . O
n . . O
= . . O
79 . . O
placebo . . O
n . . O
= . . O
39 . . O
all . . O
grades . . O
% . . O
grade . . O
3 . . O
% . . O
grade . . O
4 . . O
% . . O
all . . O
grades . . O
% . . O
grade . . O
3 . . O
% . . O
grade . . O
4 . . O
% . . O
any . . O
adverse . . O
reaction . . O
100 . . O
25 . . O
5 . . O
97 . . O
8 . . O
5 . . O
gastrointestinal . . O
disorders . . O
stomatitis . . B-AdverseReaction
a . . O
78 . . O
6 . . O
0 . . O
23 . . O
0 . . O
0 . . O
vomiting . . B-AdverseReaction
15 . . O
0 . . O
0 . . O
5 . . O
0 . . O
0 . . O
diarrhea . . B-AdverseReaction
14 . . O
0 . . O
0 . . O
5 . . O
0 . . O
0 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
13 . . O
0 . . O
0 . . O
8 . . O
0 . . O
0 . . O
infections . . O
and . . O
infestations . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
11 . . O
0 . . O
0 . . O
5 . . O
0 . . O
0 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
arthralgia . . B-AdverseReaction
13 . . O
0 . . O
0 . . O
5 . . O
0 . . O
0 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
20 . . O
0 . . O
0 . . O
13 . . O
0 . . O
0 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
acne . . B-AdverseReaction
22 . . O
0 . . O
0 . . O
5 . . O
0 . . O
0 . . O
amenorrhea . . B-AdverseReaction
occurred . . O
in . . O
15% . . O
of . . O
afinitor . . O
- . . O
treated . . O
females . . O
( . . O
8 . . O
of . . O
52 . . O
) . . O
and . . O
4% . . O
( . . O
1 . . O
of . . O
26 . . O
) . . O
of . . O
females . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

other . . O
adverse . . O
reactions . . O
involving . . O
the . . O
female . . O
reproductive . . O
system . . O
were . . O
menorrhagia . . B-AdverseReaction
( . . O
10% . . O
) . . O
, . . O
menstrual . . B-AdverseReaction
irregularities . . I-AdverseReaction
( . . O
10% . . O
) . . O
, . . O
and . . O
vaginal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
( . . O
8% . . O
) . . O
. . . O

there . . O
were . . O
no . . O
adverse . . O
reactions . . O
resulting . . O
in . . O
permanent . . O
discontinuation . . O
. . . O

laboratory . . O
abnormalities . . O
are . . O
described . . O
separately . . O
in . . O
table . . O
11 . . O
. . . O

the . . O
following . . O
is . . O
discussed . . O
in . . O
more . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

* . . O
seizure . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
are . . O
asthenia . . B-AdverseReaction
/ . . O
fatigue . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
and . . O
dizziness . . B-AdverseReaction
/ . . O
vertigo . . B-AdverseReaction
. . . O

study . . O
1 . . O
: . . O
metastatic . . O
castration . . O
- . . O
resistant . . O
prostate . . O
cancer . . O
following . . O
chemotherapy . . O
study . . O
1 . . O
enrolled . . O
1199 . . O
patients . . O
with . . O
metastatic . . O
crpc . . O
who . . O
had . . O
previously . . O
received . . O
docetaxel . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
treatment . . O
was . . O
17.5 . . O
months . . O
with . . O
xtandi . . O
and . . O
4.6 . . O
months . . O
with . . O
placebo . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reaction . . O
leading . . O
to . . O
treatment . . O
discontinuation . . O
was . . O
fatigue . . B-AdverseReaction
/ . . O
asthenia . . B-AdverseReaction
, . . O
which . . O
occurred . . O
in . . O
1% . . O
of . . O
patients . . O
on . . O
each . . O
treatment . . O
arm . . O
. . . O

the . . O
incidence . . O
of . . O
grade . . B-Severity
1-4 . . I-Severity
thrombocytopenia . . O
was . . O
6% . . O
of . . O
patients . . O
treated . . O
with . . O
xtandi . . O
( . . O
0.3% . . O
grade . . O
3-4 . . O
) . . O
and . . O
5% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
( . . O
0.5% . . O
grade . . O
3-4 . . O
) . . O
. . . O

grade . . B-Severity
1-4 . . I-Severity
elevations . . O
in . . O
alt . . O
occurred . . O
in . . O
10% . . O
of . . O
patients . . O
treated . . O
with . . O
xtandi . . O
( . . O
0.2% . . O
grade . . O
3-4 . . O
) . . O
and . . O
16% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
( . . O
0.2% . . O
grade . . O
3-4 . . O
) . . O
. . . O

hypertension . . B-AdverseReaction
in . . O
the . . O
two . . O
randomized . . O
trials . . O
, . . O
hypertension . . B-AdverseReaction
was . . O
reported . . O
in . . O
11% . . O
of . . O
patients . . O
receiving . . O
xtandi . . O
and . . O
4% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

in . . O
patients . . O
with . . O
symptomatic . . O
heart . . O
failure . . O
and . . O
recent . . O
decompensation . . O
requiring . . O
hospitalization . . O
or . . O
nyha . . O
class . . O
iv . . O
heart . . O
failure . . O
; . . O
multaq . . O
doubles . . O
the . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
. . . O

in . . O
patients . . O
with . . O
permanent . . O
atrial . . O
fibrillation . . O
, . . O
multaq . . O
doubles . . O
the . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
, . . O
stroke . . B-AdverseReaction
and . . O
hospitalization . . O
for . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
increased . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
, . . O
stroke . . B-AdverseReaction
and . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
in . . O
patients . . O
with . . O
decompensated . . O
heart . . O
failure . . O
or . . O
permanent . . O
atrial . . O
fibrillation . . O

( . . O
4 . . O
, . . O
5.2 . . O
, . . O
14.4 . . O
) . . O

6 . . O
adverse . . O
reactions . . O

* . . O
diarrhea . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
bullous . . O
and . . O
exfoliative . . B-AdverseReaction
skin . . I-AdverseReaction
disorders . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
hepatic . . B-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
keratitis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
are . . O
diarrhea . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
/ . . O
dermatitis . . B-AdverseReaction
acneiform . . I-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction
, . . O
paronychia . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
skin . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
( . . O
6.1 . . O
) . . O

the . . O
most . . O
frequent . . O
serious . . O
adverse . . O
reactions . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
gilotrif . . O
were . . O
diarrhea . . B-AdverseReaction
( . . O
6.6% . . O
) . . O
; . . O
vomiting . . B-AdverseReaction
( . . O
4.8% . . O
) . . O
; . . O
and . . O
dyspnea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
and . . O
hypokalemia . . B-AdverseReaction
( . . O
1.7% . . O
each . . O
) . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
all . . O
patients . . O
were . . O
evaluated . . O
for . . O
lvef . . O
at . . O
screening . . O
and . . O
every . . O
9 . . O
weeks . . O
thereafter . . O
in . . O
the . . O
gilotrif . . O
- . . O
treated . . O
group . . O
and . . O
as . . O
needed . . O
in . . O
the . . O
pemetrexed . . O
/ . . O
cisplatin . . O
group . . O
. . . O

* . . O
none . . O
of . . O
the . . O
adverse . . O
reactions . . O
in . . O
this . . O
table . . O
except . . O
stomatitis . . B-AdverseReaction
( . . O
one . . O
patient . . O
on . . O
gilotrif . . O
[ . . O
0.4% . . O
] . . O
) . . O
were . . O
grade . . B-Severity
4 . . I-Severity
in . . O
severity . . O
1 . . O
includes . . O
stomatitis . . B-AdverseReaction
, . . O
aphthous . . B-AdverseReaction
stomatitis . . I-AdverseReaction
, . . O
mucosal . . B-AdverseReaction
inflammation . . I-AdverseReaction
, . . O
mouth . . B-AdverseReaction
ulceration . . I-AdverseReaction
, . . O
oral . . B-AdverseReaction
mucosa . . I-AdverseReaction
erosion . . I-AdverseReaction
, . . O
mucosal . . B-AdverseReaction
erosion . . I-AdverseReaction
, . . O
mucosal . . B-AdverseReaction
ulceration . . I-AdverseReaction
2 . . O
includes . . O
group . . O
of . . O
rash . . B-AdverseReaction
preferred . . O
terms . . O
, . . O
acne . . B-AdverseReaction
, . . O
acne . . B-AdverseReaction
pustular . . I-AdverseReaction
, . . O
dermatitis . . B-AdverseReaction
acneiform . . I-AdverseReaction
3 . . O
includes . . O
paronychia . . B-AdverseReaction
, . . O
nail . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
nail . . B-AdverseReaction
bed . . I-AdverseReaction
infection . . I-AdverseReaction
gilotrifn . . O
= . . O
229 . . O
pemetrexed . . O
/ . . O
cisplatinn . . O
= . . O
111 . . O
adverse . . O
reaction . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
* . . O
( . . O
% . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
* . . O
( . . O
% . . O
) . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
96 . . O
15 . . O
23 . . O
2 . . O
stomatitis . . B-AdverseReaction
1 . . O
71 . . O
9 . . O
15 . . O
1 . . O
nausea . . B-AdverseReaction
25 . . O
4 . . O
68 . . O
4 . . O
vomiting . . B-AdverseReaction
23 . . O
4 . . O
47 . . O
3 . . O
cheilitis . . B-AdverseReaction
12 . . O
0 . . O
1 . . O
0 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
/ . . O
dermatitis . . B-AdverseReaction
acneiform . . I-AdverseReaction
2 . . O
90 . . O
16 . . O
11 . . O
0 . . O
pruritus . . B-AdverseReaction
21 . . O
0 . . O
1 . . O
0 . . O
dry . . B-AdverseReaction
skin . . I-AdverseReaction
31 . . O
0 . . O
2 . . O
0 . . O
infections . . O
and . . O
infestations . . O
paronychia . . B-AdverseReaction
3 . . O
58 . . O
11 . . O
0 . . O
0 . . O
cystitis . . B-AdverseReaction
13 . . O
1 . . O
5 . . O
0 . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
29 . . O
4 . . O
55 . . O
4 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
epistaxis . . B-AdverseReaction
17 . . O
0 . . O
2 . . O
1 . . O
rhinorrhea . . B-AdverseReaction
11 . . O
0 . . O
6 . . O
0 . . O
investigations . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
17 . . O
1 . . O
14 . . O
1 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
pyrexia . . B-AdverseReaction
12 . . O
0 . . O
6 . . O
0 . . O
eye . . O
disorders . . O
conjunctivitis . . B-AdverseReaction
11 . . O
0 . . O
3 . . O
0 . . O
table . . O
2 . . O
adverse . . O
reactions . . O
of . . O
laboratory . . O
abnormalities . . O
from . . O
the . . O
investigations . . O
soc . . O
reported . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
gilotrif . . O
- . . O
treated . . O
patients . . O
in . . O
study . . O
1 . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

* . . O
adrenocortical . . B-AdverseReaction
insufficiency . . I-AdverseReaction
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

study . . O
1 . . O
: . . O
metastatic . . O
crpc . . O
following . . O
chemotherapy . . O

patients . . O
were . . O
not . . O
eligible . . O
if . . O
ast . . O
and . . O
/ . . O
or . . O
alt . . O
> . . O
= . . O
2.5 . . O
* . . O
uln . . O
in . . O
the . . O
absence . . O
of . . O
liver . . O
metastases . . O
. . . O

table . . O
1 . . O
shows . . O
adverse . . O
reactions . . O
on . . O
the . . O
zytiga . . O
arm . . O
in . . O
study . . O
1 . . O
that . . O
occurred . . O
with . . O
a . . O
> . . O
= . . O
2% . . O
absolute . . O
increase . . O
in . . O
frequency . . O
compared . . O
to . . O
placebo . . O
or . . O
were . . O
events . . O
of . . O
special . . O
interest . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
treatment . . O
with . . O
zytiga . . O
was . . O
8 . . O
months . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
treatment . . O
with . . O
zytiga . . O
was . . O
13.8 . . O
months . . O
. . . O

there . . O
was . . O
one . . O
death . . B-AdverseReaction
associated . . O
with . . O
arrhythmia . . B-AdverseReaction
and . . O
one . . O
patient . . O
with . . O
sudden . . B-AdverseReaction
death . . I-AdverseReaction
in . . O
the . . O
zytiga . . O
arms . . O
and . . O
no . . B-Negation
deaths . . B-AdverseReaction
in . . O
the . . O
placebo . . B-Factor
arms . . O
. . . O

6.2 . . O
post . . O
marketing . . O
experience . . O

excerpt . . O
: . . O
avoid . . O
treatment . . O
in . . O
the . . O
periocular . . O
area . . O
. . . O

avoid . . O
accidental . . O
transfer . . O
of . . O
the . . O
drug . . O
into . . O
the . . O
eyes . . O
and . . O
to . . O
the . . O
periocular . . O
area . . O
. . . O

eye . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
including . . O
severe . . B-Severity
eye . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
chemical . . B-AdverseReaction
conjunctivitis . . I-AdverseReaction
, . . O
corneal . . B-AdverseReaction
burn . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
ptosis . . I-AdverseReaction
, . . O
periorbital . . B-AdverseReaction
edema . . I-AdverseReaction
can . . B-Factor
occur . . O
after . . O
exposure . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

severe . . B-Severity
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
in . . I-AdverseReaction
the . . I-AdverseReaction
treated . . I-AdverseReaction
area . . I-AdverseReaction
, . . O
including . . O
erythema . . O
, . . O
crusting . . O
, . . O
swelling . . O
, . . O
vesiculation . . O
/ . . O
postulation . . O
, . . O
and . . O
erosion . . O
/ . . O
ulceration . . O
, . . O
can . . B-Factor
occur . . O
after . . O
topical . . O
application . . O
of . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

glabellar . . O
lines . . O

upper . . O
limb . . O
spasticity . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

the . . O
population . . O
was . . O
almost . . O
entirely . . O
caucasian . . O
( . . O
99% . . O
) . . O
with . . O
a . . O
median . . O
age . . O
of . . O
51 . . O
years . . O
( . . O
range . . O
18-82 . . O
years . . O
) . . O
. . . O

common . . O
adverse . . O
reactions . . O

table . . O
3 . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
5% . . O
) . . O
and . . O
greater . . O
than . . O
placebo . . O
in . . O
the . . O
pooled . . O
, . . O
double . . O
- . . O
blind . . O
phase . . O
of . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
cervical . . O
dystonia . . O
adverse . . O
reaction . . O
preferred . . O
term . . O
dysport . . O
( . . O
r . . O
) . . O
500 . . O
units . . O
( . . O
n . . O
= . . O
173 . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
182 . . O
) . . O
% . . O
% . . O
any . . O
adverse . . O
reaction . . O
61 . . O
51 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
30 . . O
23 . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
discomfort . . I-AdverseReaction
13 . . O
8 . . O
fatigue . . B-AdverseReaction
12 . . O
10 . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
5 . . O
4 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
30 . . O
18 . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
16 . . O
4 . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
7 . . O
3 . . O
gastrointestinal . . O
disorders . . O
28 . . O
15 . . O
dysphagia . . B-AdverseReaction
15 . . O
4 . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
13 . . O
7 . . O
nervous . . O
system . . O
disorders . . O
16 . . O
13 . . O
headache . . B-AdverseReaction
11 . . O
9 . . O
infections . . O
and . . O
infestations . . O
13 . . O
9 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
12 . . O
8 . . O
dysphonia . . B-AdverseReaction
6 . . O
2 . . O
eye . . O
disorders . . O
7 . . O
2 . . O
dose . . O
- . . O
response . . O
relationships . . O
for . . O
common . . O
adverse . . O
reactions . . O
in . . O
a . . O
randomized . . O
multiple . . O
fixed . . O
- . . O
dose . . O
study . . O
in . . O
which . . O
the . . O
total . . O
dose . . O
was . . O
divided . . O
between . . O
two . . O
muscles . . O
( . . O
the . . O
sternocleidomastoid . . O
and . . O
splenius . . O
capitis . . O
) . . O
are . . O
shown . . O
in . . O
table . . O
4 . . O
. . . O

injection . . B-AdverseReaction
site . . I-AdverseReaction
discomfort . . I-AdverseReaction
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
were . . O
common . . O
adverse . . O
reactions . . O
following . . O
dysport . . O
( . . O
r . . O
) . . O
administration . . O
. . . O

this . . O
was . . O
not . . O
clinically . . O
significant . . O
among . . O
patients . . O
in . . O
the . . O
development . . O
program . . O
but . . O
could . . O
be . . O
a . . O
factor . . O
in . . O
patients . . O
whose . . O
diabetes . . O
is . . O
difficult . . O
to . . O
control . . O
. . . O

the . . O
majority . . O
of . . O
the . . O
reports . . O
of . . O
eyelid . . O
ptosis . . O
were . . O
mild . . B-Severity
to . . O
moderate . . B-Severity
in . . O
severity . . O
and . . O
resolved . . O
over . . O
several . . O
weeks . . O
. . . O

in . . O
a . . O
pooled . . O
analysis . . O
of . . O
clinical . . O
studies . . O
, . . O
adverse . . O
reactions . . O
with . . O
an . . O
incidence . . O
of . . O
less . . O
than . . O
2% . . O
reported . . O
in . . O
dysport . . O
( . . O
r . . O
) . . O
treatment . . O
groups . . O
included . . O
dysphagia . . B-AdverseReaction
0.5% . . O
, . . O
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction
0.5% . . O
, . . O
hypertonia . . B-AdverseReaction
0.5% . . O
, . . O
and . . O
sensation . . B-AdverseReaction
of . . I-AdverseReaction
heaviness . . I-AdverseReaction
0.3% . . O
. . . O

6.3 . . O
immunogenicity . . O

testing . . O
for . . O
antibodies . . O
to . . O
dysport . . O
( . . O
r . . O
) . . O
was . . O
performed . . O
for . . O
1554 . . O
subjects . . O
who . . O
had . . O
up . . O
to . . O
nine . . O
cycles . . O
of . . O
treatment . . O
. . . O

two . . O
subjects . . O
( . . O
0.13% . . O
) . . O
tested . . O
positive . . O
for . . O
binding . . O
antibodies . . O
at . . O
baseline . . O
. . . O

* . . O
the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
elsewhere . . O
in . . O
labeling . . O
: . . O
* . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O
[ . . O
see . . O
boxed . . O
warning . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

the . . O
average . . O
age . . O
was . . O
55 . . O
years . . O
( . . O
range . . O
from1 . . O
week . . O
to . . O
93 . . O
years . . O
) . . O
. . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
reaction . . O
rate . . O
( . . O
% . . O
) . . O
n . . O
= . . O
6330 . . O
headache . . B-AdverseReaction
1.5 . . O
nausea . . B-AdverseReaction
1.2 . . O
dizziness . . B-AdverseReaction
0.5 . . O
dysgeusia . . B-AdverseReaction
0.4 . . O
feeling . . B-AdverseReaction
hot . . I-AdverseReaction
0.4 . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
0.4 . . O
vomiting . . B-AdverseReaction
0.4 . . O
rash . . B-AdverseReaction
( . . O
includes . . O
generalized . . O
, . . O
macular . . O
, . . O
papular . . O
, . . O
pruritic . . O
) . . O
0.3 . . O
pruritus . . B-AdverseReaction
( . . O
includes . . O
generalized . . O
) . . O
0.2 . . O
erythema . . B-AdverseReaction
0.2 . . O
hypersensitivity . . B-AdverseReaction
/ . . O
anaphylactoid . . B-AdverseReaction
* . . O
0.1 . . O
dyspnea . . B-AdverseReaction
0.1 . . O
paresthesia . . B-AdverseReaction
0.1 . . O
* . . O
hypersensitivity . . B-AdverseReaction
/ . . O
anaphylactoid . . B-AdverseReaction
reaction . . I-AdverseReaction
may . . O
occur . . O
with . . O
one . . O
or . . O
more . . O
of . . O
the . . O
following . . O
adverse . . O
reactions . . O
: . . O
for . . O
example . . O
, . . O
hypotension . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
face . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
flushing . . B-AdverseReaction

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

the . . O
risk . . O
appears . . O
lower . . O
for . . O
patients . . O
with . . O
chronic . . O
, . . O
moderate . . O
kidney . . O
disease . . O
( . . O
gfr . . O
30 . . O
to . . O
59 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73m . . O
2 . . O
) . . O
and . . O
little . . O
, . . O
if . . O
any . . O
, . . O
for . . O
patients . . O
with . . O
chronic . . O
, . . O
mild . . O
kidney . . O
disease . . O
( . . O
gfr . . O
60 . . O
to . . O
89 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73m . . O
2 . . O
) . . O
. . . O

screen . . O
patients . . O
for . . O
acute . . O
kidney . . O
injury . . O
and . . O
other . . O
conditions . . O
that . . O
may . . O
reduce . . O
renal . . O
function . . O
. . . O

for . . O
patients . . O
at . . O
risk . . O
for . . O
chronically . . O
reduced . . O
renal . . O
function . . O
( . . O
for . . O
example . . O
, . . O
age . . O
> . . O
60 . . O
years . . O
, . . O
diabetes . . O
mellitus . . O
or . . O
chronic . . O
hypertension . . O
) . . O
, . . O
estimate . . O
the . . O
gfr . . O
through . . O
laboratory . . O
testing . . O
. . . O

record . . O
the . . O
specific . . O
gbca . . O
and . . O
the . . O
dose . . O
administered . . O
to . . O
a . . O
patient . . O
. . . O

observe . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
hypersensitivity . . O
reactions . . O
during . . O
and . . O
following . . O
gadavist . . O
administration . . O
. . . O

in . . O
patients . . O
with . . O
chronic . . O
renal . . O
impairment . . O
, . . O
acute . . B-AdverseReaction
kidney . . I-AdverseReaction
injury . . I-AdverseReaction
sometimes . . O
requiring . . O
dialysis . . O
has . . O
been . . O
observed . . O
with . . O
the . . O
use . . O
of . . O
some . . O
gbcas . . B-DrugClass
. . . O

5.5 . . O
overestimation . . O
of . . O
extent . . O
of . . O
malignant . . O
disease . . O
in . . O
mri . . O
of . . O
the . . O
breast . . O

6 . . O
adverse . . O
reactions . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
25% . . O
) . . O
are . . O
nausea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
and . . O
vomiting . . B-AdverseReaction
. . . O

( . . O
6 . . O
) . . O

one . . O
treatment . . O
- . . O
related . . O
death . . B-AdverseReaction
associated . . O
with . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
was . . O
reported . . O
in . . O
the . . O
trial . . O
. . . O

one . . O
patient . . O
with . . O
baseline . . O
hyperuricemia . . O
and . . O
bulky . . O
disease . . O
experienced . . O
grade . . B-Severity
4 . . I-Severity
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
during . . O
the . . O
first . . O
cycle . . O
of . . O
treatment . . O
and . . O
died . . B-AdverseReaction
due . . O
to . . O
multi . . B-AdverseReaction
- . . I-AdverseReaction
organ . . I-AdverseReaction
failure . . I-AdverseReaction
. . . O

discontinuations . . O
due . . O
to . . O
adverse . . O
reactions . . O

* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
pancreatitis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
glucose . . B-AdverseReaction
intolerance . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
thrombosis . . B-AdverseReaction
and . . O
hemorrhage . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
1% . . O
or . . O
greater . . O
) . . O
with . . O
erwinaze . . O
treatment . . O
are . . O
systemic . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
transaminases . . B-AdverseReaction
abnormal . . I-AdverseReaction
, . . O
fever . . B-AdverseReaction
, . . O
pancreatitis . . B-AdverseReaction
, . . O
local . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
thrombosis . . B-AdverseReaction
, . . O
hyperbilirubinemia . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
/ . . O
discomfort . . O
, . . O
and . . O
diarrhea . . B-AdverseReaction
. . . O

the . . O
study . . O
1 . . O
population . . O
included . . O
patients . . O
with . . O
a . . O
median . . O
age . . O
of . . O
11 . . O
years . . O
( . . O
2 . . O
to . . O
18 . . O
years . . O
) . . O
; . . O
59% . . O
were . . O
male . . O
, . . O
78% . . O
were . . O
white . . O
, . . O
10% . . O
were . . O
black . . O
/ . . O
african . . O
american . . O
, . . O
5% . . O
were . . O
asian . . O
, . . O
and . . O
7% . . O
were . . O
other . . O
or . . O
unknown . . O
. . . O

the . . O
emtp . . O
trial . . O
enrolled . . O
1368 . . O
patients . . O
with . . O
all . . O
or . . O
lymphoblastic . . O
lymphoma . . O
who . . O
received . . O
erwinaze . . O
after . . O
developing . . O
systemic . . O
hypersensitivity . . O
to . . O
an . . O
e . . O
. . . O
coli . . O
- . . O
derived . . O
asparaginase . . O
. . . O

the . . O
route . . O
of . . O
administration . . O
was . . O
intramuscular . . O
n . . O
= . . O
852 . . O
, . . O
intravenous . . O
n . . O
= . . O
29 . . O
, . . O
other . . O
or . . O
unknown . . O
n . . O
= . . O
59 . . O
. . . O

seventy . . O
- . . O
eight . . O
percent . . O
of . . O
patients . . O
( . . O
693 . . O
of . . O
893 . . O
) . . O
were . . O
able . . O
to . . O
receive . . O
all . . O
planned . . O
doses . . O
to . . O
complete . . O
their . . O
prescribed . . O
treatment . . O
regimen . . O
. . . O

because . . O
clinical . . O
studies . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

the . . O
data . . O
in . . O
table . . O
1 . . O
are . . O
derived . . O
from . . O
the . . O
placebo . . O
- . . O
controlled . . O
trials . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

these . . O
data . . O
reflect . . O
exposure . . O
of . . O
1670 . . O
patients . . O
to . . O
trulicity . . O
and . . O
a . . O
mean . . O
duration . . O
of . . O
exposure . . O
to . . O
trulicity . . O
of . . O
23.8 . . O
weeks . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
reported . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
trulicity . . O
- . . O
treated . . O
patients . . O
a . . O
includes . . O
diarrhea . . B-AdverseReaction
, . . O
fecal . . B-AdverseReaction
volume . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
frequent . . B-AdverseReaction
bowel . . I-AdverseReaction
movements . . I-AdverseReaction
. . . O
b . . O
includes . . O
retching . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
projectile . . I-AdverseReaction
. . . O
c . . O
includes . . O
abdominal . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
lower . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
tenderness . . I-AdverseReaction
, . . O
gastrointestinal . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O
d . . O
includes . . O
fatigue . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
malaise . . B-AdverseReaction
. . . O

adverse . . O
reaction . . O
placebo . . O
( . . O
n . . O
= . . O
568 . . O
) . . O
% . . O
trulicity . . O
0.75 . . O
mg . . O
( . . O
n . . O
= . . O
836 . . O
) . . O
% . . O
trulicity . . O
1.5 . . O
mg . . O
( . . O
n . . O
= . . O
834 . . O
) . . O
% . . O
nausea . . B-AdverseReaction
5.3 . . O
12.4 . . O
21.1 . . O
diarrhea . . B-AdverseReaction
a . . O
6.7 . . O
8.9 . . O
12.6 . . O
vomiting . . B-AdverseReaction
b . . O
2.3 . . O
6.0 . . O
12.7 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
c . . O
4.9 . . O
6.5 . . O
9.4 . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
1.6 . . O
4.9 . . O
8.6 . . O
dyspepsia . . B-AdverseReaction
2.3 . . O
4.1 . . O
5.8 . . O
fatigue . . B-AdverseReaction
d . . O
2.6 . . O
4.2 . . O
5.6 . . O
gastrointestinal . . O
adverse . . O
reactions . . O

in . . O
addition . . O
to . . O
the . . O
reactions . . O
in . . O
table . . O
1 . . O
, . . O
the . . O
following . . O
adverse . . O
reactions . . O
were . . O
reported . . O
more . . O
frequently . . O
in . . O
trulicity . . O
- . . O
treated . . O
patients . . O
than . . O
placebo . . O
( . . O
frequencies . . O
listed . . O
, . . O
respectively . . O
, . . O
as . . O
: . . O
placebo . . O
; . . O
0.75 . . O
mg . . O
; . . O
1.5 . . O
mg . . O
) . . O
: . . O
constipation . . B-AdverseReaction
( . . O
0.7% . . O
, . . O
3.9% . . O
, . . O
3.7% . . O
) . . O
, . . O
flatulence . . B-AdverseReaction
( . . O
1.4% . . O
, . . O
1.4% . . O
, . . O
3.4% . . O
) . . O
, . . O
abdominal . . B-AdverseReaction
distension . . I-AdverseReaction
( . . O
0.7% . . O
, . . O
2.9% . . O
, . . O
2.3% . . O
) . . O
, . . O
gastroesophageal . . B-AdverseReaction
reflux . . I-AdverseReaction
disease . . I-AdverseReaction
( . . O
0.5% . . O
, . . O
1.7% . . O
, . . O
2.0% . . O
) . . O
, . . O
and . . O
eructation . . B-AdverseReaction
( . . O
0.2% . . O
, . . O
0.6% . . O
, . . O
1.6% . . O
) . . O
. . . O

in . . O
this . . O
pool . . O
, . . O
a . . O
total . . O
of . . O
3342 . . O
patients . . O
with . . O
type . . O
2 . . O
diabetes . . O
were . . O
treated . . O
with . . O
trulicity . . O
for . . O
a . . O
mean . . O
duration . . O
of . . O
52 . . O
weeks . . O
. . . O

baseline . . O
estimated . . O
renal . . O
function . . O
was . . O
normal . . O
or . . O
mildly . . O
impaired . . O
( . . O
egfr . . O
> . . O
= . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m2 . . O
) . . O
in . . O
95.7% . . O
of . . O
the . . O
trulicity . . O
population . . O
. . . O

table . . O
2 . . O
summarizes . . O
the . . O
incidence . . O
of . . O
documented . . O
symptomatic . . O
( . . O
< . . O
= . . O
70 . . O
mg . . O
/ . . O
dl . . O
glucose . . O
threshold . . O
) . . O
and . . O
severe . . B-Severity
hypoglycemia . . B-AdverseReaction
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
studies . . O
. . . O

severe . . B-Severity
hypoglycemia . . B-AdverseReaction
occurred . . O
in . . O
2.4% . . O
and . . O
3.4% . . O
of . . O
patients . . O
when . . O
trulicity . . O
0.75 . . O
mg . . O
and . . O
1.5 . . O
mg . . O
, . . O
respectively . . O
, . . O
was . . O
co . . O
- . . O
administered . . O
with . . O
prandial . . O
insulin . . O
. . . O

persistence . . B-AdverseReaction
of . . I-AdverseReaction
sinus . . I-AdverseReaction
tachycardia . . I-AdverseReaction
( . . O
reported . . O
at . . O
more . . O
than . . O
2 . . O
visits . . O
) . . O
was . . O
reported . . O
in . . O
0.2% . . O
, . . O
0.4% . . O
and . . O
1.6% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
, . . O
trulicity . . O
0.75 . . O
mg . . O
and . . O
trulicity . . O
1.5 . . O
mg . . O
, . . O
respectively . . O
. . . O

systemic . . O
hypersensitivity . . O
adverse . . O
reactions . . O
sometimes . . O
severe . . B-Severity
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
severe . . B-Severity
urticaria . . B-AdverseReaction
, . . O
systemic . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
facial . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
lip . . B-AdverseReaction
swelling . . I-AdverseReaction
) . . O
occurred . . O
in . . O
0.5% . . O
of . . O
patients . . O
on . . O
trulicity . . O
in . . O
the . . O
four . . O
phase . . O
2 . . O
and . . O
five . . O
phase . . O
3 . . O
studies . . O
. . . O

in . . O
the . . O
placebo . . O
- . . O
controlled . . O
studies . . O
, . . O
injection . . B-AdverseReaction
- . . I-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
injection . . B-AdverseReaction
- . . I-AdverseReaction
site . . I-AdverseReaction
rash . . I-AdverseReaction
, . . O
erythema . . O
) . . O
were . . O
reported . . O
in . . O
0.5% . . O
of . . O
trulicity . . O
- . . O
treated . . O
patients . . O
and . . O
in . . O
0.0% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

on . . O
electrocardiograms . . O
, . . O
a . . O
pr . . B-AdverseReaction
interval . . I-AdverseReaction
increase . . I-AdverseReaction
to . . O
at . . O
least . . O
220 . . O
milliseconds . . O
was . . O
observed . . O
in . . O
0.7% . . O
, . . O
2.5% . . O
and . . O
3.2% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
, . . O
trulicity . . O
0.75 . . O
mg . . O
and . . O
trulicity . . O
1.5 . . O
mg . . O
, . . O
respectively . . O
. . . O

patients . . O
exposed . . O
to . . O
trulicity . . O
had . . O
mean . . O
increases . . O
from . . O
baseline . . O
in . . O
lipase . . O
and . . O
/ . . O
or . . O
pancreatic . . O
amylase . . O
of . . O
14% . . O
to . . O
20% . . O
, . . O
while . . O
placebo . . O
- . . O
treated . . O
patients . . O
had . . O
mean . . O
increases . . O
of . . O
up . . O
to . . O
3% . . O
. . . O

the . . O
mean . . O
exposure . . O
across . . O
studies . . O
was . . O
12 . . O
months . . O
. . . O

in . . O
athena . . O
, . . O
the . . O
maximum . . O
follow . . O
- . . O
up . . O
was . . O
30 . . O
months . . O
. . . O

the . . O
most . . O
common . . O
reasons . . O
for . . O
discontinuation . . O
of . . O
therapy . . O
with . . O
multaq . . O
were . . O
gastrointestinal . . B-AdverseReaction
disorders . . I-AdverseReaction
( . . O
3.2 . . O
% . . O
versus . . O
1.8% . . O
in . . O
the . . O
placebo . . O
group . . O
) . . O
and . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
( . . O
1.5% . . O
versus . . O
0.5% . . O
in . . O
the . . O
placebo . . O
group . . O
) . . O
. . . O

the . . O
following . . O
laboratory . . O
data . . O
/ . . O
ecg . . O
parameters . . O
were . . O
reported . . O
with . . O
multaq . . O
400 . . O
mg . . O
twice . . O
daily . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
multaq . . O
. . . O

cardiac . . O
: . . O
new . . O
or . . O
worsening . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O

respiratory . . O
: . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
including . . O
pneumonitis . . B-AdverseReaction
and . . O
pulmonary . . B-AdverseReaction
fibrosis . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O

vascular . . O
: . . O
vasculitis . . B-AdverseReaction
, . . O
including . . O
leukocytoclastic . . B-AdverseReaction
vasculitis . . I-AdverseReaction

excerpt . . O
: . . O
* . . O
hypotension . . B-AdverseReaction
: . . O
before . . O
initiating . . O
invokana . . O
, . . O
assess . . O
volume . . O
status . . O
and . . O
correct . . O
hypovolemia . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
, . . O
the . . O
elderly . . O
, . . O
in . . O
patients . . O
with . . O
low . . O
systolic . . O
blood . . O
pressure . . O
, . . O
or . . O
if . . O
on . . O
diuretics . . O
, . . O
acei . . O
, . . O
or . . O
arb . . O
. . . O

symptomatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
can . . B-Factor
occur . . O
after . . O
initiating . . O
invokana . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
particularly . . O
in . . O
patients . . O
with . . O
impaired . . O
renal . . O
function . . O
( . . O
egfr . . O
less . . O
than . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
, . . O
elderly . . O
patients . . O
, . . O
patients . . O
on . . O
either . . O
diuretics . . O
or . . O
medications . . O
that . . O
interfere . . O
with . . O
the . . O
renin . . O
- . . O
angiotensin . . O
- . . O
aldosterone . . O
system . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
angiotensin . . O
- . . O
converting . . O
- . . O
enzyme . . O
[ . . O
ace . . O
] . . O
inhibitors . . O
, . . O
angiotensin . . O
receptor . . O
blockers . . O
[ . . O
arbs . . O
] . . O
) . . O
, . . O
or . . O
patients . . O
with . . O
low . . O
systolic . . O
blood . . O
pressure . . O
. . . O

5.2 . . O
impairment . . O
in . . O
renal . . O
function . . O

invokana . . O
increases . . B-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
and . . O
decreases . . B-AdverseReaction
egfr . . I-AdverseReaction
. . . O

invokana . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
. . . O

consider . . O
factors . . O
that . . O
contribute . . O
to . . O
fracture . . O
risk . . O
prior . . O
to . . O
initiating . . O
invokana . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

monitor . . O
ldl . . O
- . . O
c . . O
and . . O
treat . . O
if . . O
appropriate . . O
after . . O
initiating . . O
invokana . . O
. . . O

the . . O
most . . O
serious . . O
adverse . . O
reactions . . O
were . . O
: . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contactjanssen . . O
biotech . . O
, . . O
inc . . O
. . . O
at . . O
1-800 . . O
- . . O
janssen . . O
( . . O
1-800-526-7736 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

the . . O
safety . . O
data . . O
described . . O
below . . O
are . . O
based . . O
on . . O
one . . O
, . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
controlled . . O
phase . . O
3 . . O
trial . . O
in . . O
patients . . O
with . . O
ra . . O
receiving . . O
simponi . . O
aria . . O
by . . O
intravenous . . O
infusion . . O
( . . O
trial . . O
1 . . O
) . . O
. . . O

the . . O
protocol . . O
included . . O
provisions . . O
for . . O
patients . . O
taking . . O
placebo . . O
to . . O
receive . . O
treatment . . O
with . . O
simponi . . O
aria . . O
at . . O
week . . O
16 . . O
or . . O
week . . O
24 . . O
either . . O
by . . O
patient . . O
response . . O
( . . O
based . . O
on . . O
uncontrolled . . O
disease . . O
activity . . O
) . . O
or . . O
by . . O
design . . O
, . . O
so . . O
that . . O
adverse . . O
events . . O
cannot . . O
always . . O
be . . O
unambiguously . . O
attributed . . O
to . . O
a . . O
given . . O
treatment . . O
. . . O

comparisons . . O
between . . O
placebo . . O
and . . O
simponi . . O
aria . . O
were . . O
based . . O
on . . O
the . . O
first . . O
24 . . O
weeks . . O
of . . O
exposure . . O
. . . O

serious . . B-Severity
infections . . B-AdverseReaction
observed . . O
in . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
included . . O
sepsis . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
cellulitis . . B-AdverseReaction
, . . O
abscess . . B-AdverseReaction
, . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
tuberculosis . . B-AdverseReaction
( . . O
tb . . B-AdverseReaction
) . . O
, . . O
and . . O
invasive . . B-AdverseReaction
fungal . . I-AdverseReaction
infections . . I-AdverseReaction
. . . O

malignancies . . O

in . . O
the . . O
controlled . . O
and . . O
uncontrolled . . O
portions . . O
through . . O
approximately . . O
92 . . O
weeks . . O
, . . O
the . . O
incidence . . O
of . . O
malignancies . . B-AdverseReaction
per . . O
100 . . O
patient . . O
- . . O
years . . O
, . . O
other . . O
than . . O
lymphoma . . B-AdverseReaction
and . . O
nmsc . . B-AdverseReaction
, . . O
in . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
was . . O
0.31 . . O
( . . O
ci . . O
: . . O
0.06 . . O
, . . O
0.92 . . O
) . . O
and . . O
the . . O
incidence . . O
of . . O
nmsc . . B-AdverseReaction
was . . O
0.1 . . O
( . . O
95% . . O
ci . . O
: . . O
0.00 . . O
, . . O
0.58 . . O
) . . O
. . . O

liver . . O
enzyme . . O
elevations . . O

the . . O
use . . O
of . . O
tnf . . B-DrugClass
- . . I-DrugClass
blockers . . I-DrugClass
, . . O
of . . O
which . . O
simponi . . O
aria . . O
is . . O
a . . O
member . . O
, . . O
has . . O
been . . O
associated . . O
with . . O
the . . O
formation . . B-AdverseReaction
of . . I-AdverseReaction
autoantibodies . . I-AdverseReaction
and . . O
, . . O
rarely . . O
, . . O
with . . O
the . . O
development . . O
of . . O
a . . O
lupus . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

immunogenicity . . O

6.2 . . O
post . . O
- . . O
marketing . . O
experience . . O

5.1 . . O
increased . . O
risk . . O
of . . O
thrombotic . . O
events . . O
after . . O
premature . . O
discontinuation . . O

5.2 . . O
risk . . O
of . . O
bleeding . . O

pradaxa . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
bleeding . . B-AdverseReaction
and . . O
can . . B-Factor
cause . . O
significant . . B-Severity
and . . O
, . . O
sometimes . . O
, . . O
fatal . . B-AdverseReaction
bleeding . . O
. . . O

promptly . . O
evaluate . . O
any . . O
signs . . O
or . . O
symptoms . . O
of . . O
blood . . O
loss . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
a . . O
drop . . O
in . . O
hemoglobin . . O
and . . O
/ . . O
or . . O
hematocrit . . O
or . . O
hypotension . . O
) . . O
. . . O

5.3 . . O
spinal . . O
/ . . O
epidural . . O
anesthesia . . O
or . . O
puncture . . O

5.5 . . O
effect . . O
of . . O
p . . O
- . . O
gp . . O
inducers . . O
and . . O
inhibitors . . O
on . . O
dabigatran . . O
exposure . . O

avoid . . O
use . . O
of . . O
pradaxa . . O
and . . O
concomitant . . O
p . . O
- . . O
gp . . O
inhibitors . . O
in . . O
patients . . O
with . . O
crcl . . O
< . . O
50 . . O
ml . . O
/ . . O
min . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
and . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

6 . . O
adverse . . O
reactions . . O

adverse . . O
reactions . . O
were . . O
similar . . O
in . . O
patients . . O
who . . O
received . . O
doses . . O
greater . . O
than . . O
250 . . O
mg . . O
daily . . O
. . . O

6 . . O
adverse . . O
reactions . . O

three . . O
hundred . . O
ninety . . O
- . . O
five . . O
patients . . O
, . . O
including . . O
approximately . . O
250 . . O
children . . O
( . . O
aged . . O
2 . . O
to . . O
17 . . O
years . . O
) . . O
have . . O
been . . O
treated . . O
with . . O
ilaris . . O
in . . O
interventional . . O
trials . . O
in . . O
caps . . O
or . . O
sjia . . O
. . . O

excerpt . . O
: . . O
caps . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
greater . . O
than . . O
10% . . O
reported . . O
by . . O
patients . . O
with . . O
caps . . O
treated . . O
with . . O
ilaris . . O
are . . O
nasopharyngitis . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
influenza . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
and . . O
nausea . . B-AdverseReaction
. . . O

( . . O
6 . . O
) . . O

sjia . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
drug . . O
reactions . . O
greater . . O
than . . O
10% . . O
reported . . O
by . . O
patients . . O
with . . O
sjia . . O
treated . . O
with . . O
ilaris . . O
are . . O
infections . . B-AdverseReaction
( . . O
nasopharyngitis . . B-AdverseReaction
and . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
) . . O
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
novartis . . O
pharmaceuticals . . O
corporation . . O
at . . O
1-888-669-6682 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

one . . O
patient . . O
discontinued . . O
treatment . . O
due . . O
to . . O
potential . . B-Factor
infection . . B-AdverseReaction
. . . O

since . . O
all . . O
caps . . O
patients . . O
received . . O
ilaris . . O
in . . O
part . . O
1 . . O
, . . O
there . . O
are . . O
no . . O
controlled . . O
data . . O
on . . O
adverse . . O
events . . O
( . . O
aes . . O
) . . O
. . . O

serious . . B-Severity
infections . . B-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
pneumonia . . B-AdverseReaction
, . . O
varicella . . B-AdverseReaction
, . . O
gastroenteritis . . B-AdverseReaction
, . . O
measles . . B-AdverseReaction
, . . O
sepsis . . B-AdverseReaction
, . . O
otitis . . B-AdverseReaction
media . . I-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
adenovirus . . B-AdverseReaction
, . . O
lymph . . B-AdverseReaction
node . . I-AdverseReaction
abscess . . I-AdverseReaction
, . . O
pharyngitis . . B-AdverseReaction
) . . O
were . . O
observed . . O
in . . O
approximately . . O
4% . . O
to . . O
5% . . O
( . . O
0.02 . . O
to . . O
0.17 . . O
per . . O
100 . . O
patient . . O
- . . O
days . . O
) . . O
of . . O
patients . . O
receiving . . O
ilaris . . O
in . . O
both . . O
studies . . O
. . . O

6.3 . . O
immunogenicity . . O

no . . O
neutralizing . . O
antibodies . . O
were . . O
detected . . O
. . . O

the . . O
data . . O
obtained . . O
in . . O
an . . O
assay . . O
are . . O
highly . . O
dependent . . O
on . . O
several . . O
factors . . O
including . . O
assay . . O
sensitivity . . O
and . . O
specificity . . O
, . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
underlying . . O
disease . . O
, . . O
and . . O
the . . O
number . . O
of . . O
patients . . O
tested . . O
. . . O

transient . . B-Severity
decreases . . B-AdverseReaction
in . . I-AdverseReaction
absolute . . I-AdverseReaction
neutrophil . . I-AdverseReaction
count . . I-AdverseReaction
( . . O
anc . . O
) . . O
to . . O
less . . O
than . . O
1 . . B-Severity
x . . I-Severity
10 . . I-Severity
9 . . I-Severity
/ . . I-Severity
l . . I-Severity
were . . O
reported . . O
in . . O
3 . . O
patients . . O
( . . O
6.0% . . O
) . . O
in . . O
the . . O
ilaris . . O
group . . O
compared . . O
to1 . . O
patient . . O
( . . O
2.0% . . O
) . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

all . . O
patients . . O
had . . O
normal . . O
values . . O
at . . O
the . . O
next . . O
visit . . O
. . . O

other . . O
serious . . B-Severity
penile . . B-AdverseReaction
injury . . I-AdverseReaction
in . . O
the . . O
treatment . . O
of . . O
peyronie's . . O
disease . . O

corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
( . . O
penile . . B-AdverseReaction
fracture . . I-AdverseReaction
) . . O
or . . O

severe . . B-Severity
penile . . B-AdverseReaction
hematoma . . I-AdverseReaction
was . . O
also . . O
reported . . O
as . . O
an . . O
adverse . . O
reaction . . O
in . . O
39 . . O
of . . O
1044 . . O
( . . O
3.7% . . O
) . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

signs . . O
or . . O
symptoms . . O
that . . O
may . . O
reflect . . O
serious . . O
penile . . O
injury . . O
should . . O
be . . O
promptly . . O
evaluated . . O
to . . O
assess . . O
for . . O
corporal . . O
rupture . . O
or . . O
severe . . O
penile . . O
hematoma . . O
which . . O
may . . O
require . . O
surgical . . O
intervention . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
( . . O
penile . . B-AdverseReaction
fracture . . I-AdverseReaction
) . . O
or . . O
other . . O
serious . . B-Severity
penile . . B-AdverseReaction
injury . . I-AdverseReaction
in . . O
the . . O
treatment . . O
of . . O
peyronie's . . O
disease . . O

6 . . O
adverse . . O
reactions . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trial . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

across . . O
the . . O
3 . . O
studies . . O
, . . O
there . . O
were . . O
1493 . . O
patients . . O
randomized . . O
equally . . O
to . . O
placebo . . O
, . . O
otezla . . O
20 . . O
mg . . O
twice . . O
daily . . O
or . . O
otezla . . O
30 . . O
mg . . O
twice . . O
daily . . O
. . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
patients . . O
on . . O
otezla . . O
30 . . O
mg . . O
twice . . O
daily . . O
and . . O
> . . O
= . . O
1% . . O
than . . O
that . . O
observed . . O
in . . O
patients . . O
on . . O
placebo . . O
for . . O
up . . O
to . . O
day . . O
112 . . O
( . . O
week . . O
16 . . O
) . . O
a . . O
of . . O
the . . O
reported . . O
gastrointestinal . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
1 . . O
subject . . O
experienced . . O
a . . O
serious . . B-Severity
adverse . . O
reaction . . O
of . . O
nausea . . B-AdverseReaction
and . . O
vomiting . . B-AdverseReaction
in . . O
otezla . . O
30 . . O
mg . . O
twice . . O
daily . . O
; . . O
1 . . O
subject . . O
treated . . O
with . . O
otezla . . O
20 . . O
mg . . O
twice . . O
daily . . O
experienced . . O
a . . O
serious . . B-Severity
adverse . . O
reaction . . O
of . . O
diarrhea . . B-AdverseReaction
; . . O
1 . . O
patient . . O
treated . . O
with . . O
otezla . . O
30 . . O
mg . . O
twice . . O
daily . . O
experienced . . O
a . . O
serious . . B-Severity
adverse . . O
reaction . . O
of . . O
headache . . B-AdverseReaction
. . . O
b . . O
of . . O
the . . O
reported . . O
adverse . . O
drug . . O
reactions . . O
none . . O
were . . O
serious . . O
. . . O
c . . O
n . . O
( . . O
% . . O
) . . O
indicates . . O
number . . O
of . . O
patients . . O
and . . O
percent . . O
. . . O

subjects . . O
were . . O
randomized . . O
to . . O
receive . . O
otezla . . O
30 . . O
mg . . O
twice . . O
daily . . O
or . . O
placebo . . O
twice . . O
daily . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
for . . O
subjects . . O
taking . . O
otezla . . O
were . . O
nausea . . B-AdverseReaction
( . . O
1.6% . . O
) . . O
, . . O
diarrhea . . B-AdverseReaction
( . . O
1.0% . . O
) . . O
, . . O
and . . O
headache . . B-AdverseReaction
( . . O
0.8% . . O
) . . O
. . . O

the . . O
proportion . . O
of . . O
subjects . . O
with . . O
psoriasis . . O
who . . O
discontinued . . O
treatment . . O
due . . O
to . . O
any . . O
adverse . . O
reaction . . O
was . . O
6.1% . . O
for . . O
subjects . . O
treated . . O
with . . O
otezla . . O
30 . . O
mg . . O
twice . . O
daily . . O
and . . O
4.1% . . O
for . . O
placebo . . O
- . . O
treated . . O
subjects . . O
. . . O

since . . O
there . . O
is . . O
minimal . . O
systemic . . O
absorption . . O
of . . O
fidaxomicin . . O
, . . O
dificid . . O
is . . O
not . . O
effective . . O
for . . O
treatment . . O
of . . O
systemic . . O
infections . . O
. . . O

5.2 . . O
hypersensitivity . . O
reactions . . O

physicians . . O
prescribing . . O
dificid . . O
to . . O
patients . . O
with . . O
a . . O
known . . O
macrolide . . O
allergy . . O
should . . O
be . . O
aware . . O
of . . O
the . . O
possibility . . O
of . . O
hypersensitivity . . O
reactions . . O
. . . O

consider . . O
other . . O
antidiabetic . . O
therapies . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
pancreatitis . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
discontinue . . O
tanzeum . . O
if . . O
suspected . . O
. . . O

monitor . . O
and . . O
treat . . O
promptly . . O
per . . O
standard . . O
of . . O
care . . O
until . . O
signs . . O
and . . O
symptoms . . O
resolve . . O
. . . O

human . . O
relevance . . O
of . . O
glp . . B-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
receptor . . I-DrugClass
agonist . . I-DrugClass
induced . . O
c . . B-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
in . . O
rodents . . B-Animal
has . . O
not . . O
been . . O
determined . . O
. . . O

the . . O
risk . . B-Factor
of . . O
hypoglycemia . . B-AdverseReaction
is . . O
increased . . O
when . . O
tanzeum . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
insulin . . O
secretagogues . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
sulfonylureas . . O
) . . O
or . . O
insulin . . O
. . . O

therefore . . O
, . . O
patients . . O
may . . O
require . . O
a . . O
lower . . O
dose . . O
of . . O
sulfonylurea . . O
or . . O
insulin . . O
to . . O
reduce . . O
the . . O
risk . . B-Factor
of . . O
hypoglycemia . . B-AdverseReaction
in . . O
this . . O
setting . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
, . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

across . . O
8 . . O
phase . . O
iii . . O
clinical . . O
trials . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
, . . O
a . . O
serious . . B-Severity
hypersensitivity . . B-AdverseReaction
reaction . . I-AdverseReaction
with . . O
pruritus . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
dyspnea . . B-AdverseReaction
occurred . . O
in . . O
a . . O
patient . . O
treated . . O
with . . O
tanzeum . . O
. . . O

5.5 . . O
renal . . O
impairment . . O

some . . O
of . . O
these . . O
events . . O
were . . O
reported . . O
in . . O
patients . . O
without . . O
known . . O
underlying . . O
renal . . O
disease . . O
. . . O

( . . O
6.1 . . O
) . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

serious . . O
adverse . . O
reactions . . O
and . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O

table . . O
4 . . O
lists . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
patients . . O
receiving . . O
teflaro . . O
in . . O
the . . O
pooled . . O
phase . . O
3 . . O
clinical . . O
trials . . O
. . . O

following . . O
is . . O
a . . O
list . . O
of . . O
additional . . O
adverse . . O
reactions . . O
reported . . O
by . . O
the . . O
1740 . . O
patients . . O
who . . O
received . . O
teflaro . . O
in . . O
any . . O
clinical . . O
trial . . O
with . . O
incidences . . O
less . . O
than . . O
2% . . O
. . . O

immune . . O
system . . O
disorders . . O
- . . O
hypersensitivity . . B-AdverseReaction
, . . O
anaphylaxis . . B-AdverseReaction

5.1 . . O
peripheral . . O
neuropathy . . O

adcetris . . O
treatment . . O
causes . . O
a . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
that . . O
is . . O
predominantly . . O
sensory . . O
. . . O

cases . . O
of . . O
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
have . . O
also . . O
been . . O
reported . . O
. . . O

of . . O
these . . O
patients . . O
, . . O
49% . . O
had . . O
complete . . O
resolution . . O
, . . O
31% . . O
had . . O
partial . . O
improvement . . O
, . . O
and . . O
20% . . O
had . . O
no . . O
improvement . . O
. . . O

of . . O
the . . O
patients . . O
who . . O
reported . . O
neuropathy . . B-AdverseReaction
, . . O
51% . . O
had . . O
residual . . B-AdverseReaction
neuropathy . . I-AdverseReaction
at . . O
the . . O
time . . O
of . . O
their . . O
last . . O
evaluation . . O
. . . O

patients . . O
experiencing . . O
new . . O
or . . O
worsening . . O
peripheral . . O
neuropathy . . O
may . . O
require . . O
a . . O
delay . . O
, . . O
change . . O
in . . O
dose . . O
, . . O
or . . O
discontinuation . . O
of . . O
adcetris . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

5.3 . . O
hematologic . . O
toxicities . . O

serious . . B-Severity
cases . . O
of . . O
hepatotoxicity . . B-AdverseReaction
, . . O
including . . O
fatal . . B-AdverseReaction
outcomes . . O
, . . O
have . . O
occurred . . O
in . . O
patients . . O
receiving . . O
adcetris . . O
. . . O

preexisting . . O
liver . . O
disease . . O
, . . O
elevated . . O
baseline . . O
liver . . O
enzymes . . O
, . . O
and . . O
concomitant . . O
medications . . O
may . . O
also . . O
increase . . O
the . . O
risk . . O
. . . O

first . . O
onset . . O
of . . O
symptoms . . O
occurred . . O
at . . O
various . . O
times . . O
from . . O
initiation . . O
of . . O
adcetris . . O
therapy . . O
, . . O
with . . O
some . . O
cases . . O
occurring . . O
within . . O
3 . . O
months . . O
of . . O
initial . . O
exposure . . O
. . . O

however . . O
, . . O
based . . O
on . . O
its . . O
mechanism . . O
of . . O
action . . O
and . . O
findings . . O
in . . O
animals . . O
, . . O
adcetris . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

brentuximab . . O
vedotin . . O
caused . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicities . . I-AdverseReaction
, . . O
including . . O
significantly . . B-Severity
decreased . . B-AdverseReaction
embryo . . I-AdverseReaction
viability . . I-AdverseReaction
and . . O
fetal . . B-AdverseReaction
malformations . . I-AdverseReaction
, . . O
in . . O
animals . . B-Animal
at . . O
maternal . . O
exposures . . O
that . . O
were . . O
similar . . O
to . . O
human . . O
exposures . . O
at . . O
the . . O
recommended . . O
doses . . O
for . . O
patients . . O
with . . O
classical . . O
hl . . O
and . . O
salcl . . O
. . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
, . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
receiving . . O
the . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

fatal . . B-AdverseReaction
and . . O
/ . . O
or . . O
serious . . B-Severity
hepatotoxicity . . B-AdverseReaction
occurred . . O
in . . O
14% . . O
of . . O
patients . . O
treated . . O
with . . O
zydelig . . O
. . . O

elevations . . B-AdverseReaction
in . . I-AdverseReaction
alt . . I-AdverseReaction
or . . O
ast . . O
greater . . O
than . . O
5 . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
have . . O
occurred . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

patients . . O
with . . O
pneumonitis . . O
thought . . O
to . . O
be . . O
caused . . O
by . . O
zydelig . . O
have . . O
been . . O
treated . . O
with . . O
discontinuation . . O
of . . O
zydelig . . O
and . . O
administration . . O
of . . O
corticosteroids . . O
. . . O

advise . . O
patients . . O
to . . O
promptly . . O
report . . O
any . . O
new . . O
or . . O
worsening . . O
abdominal . . O
pain . . O
, . . O
chills . . O
, . . O
fever . . O
, . . O
nausea . . O
, . . O
or . . O
vomiting . . O
. . . O

discontinue . . O
zydelig . . O
permanently . . O
in . . O
patients . . O
who . . O
experience . . O
intestinal . . O
perforation . . O
. . . O

5.5 . . O
severe . . O
cutaneous . . O
reactions . . O

5.6 . . O
anaphylaxis . . O

serious . . B-Severity
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
on . . O
zydelig . . O
. . . O

based . . O
on . . O
findings . . O
in . . O
animals . . B-Animal
, . . O
zydelig . . O
may . . O
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

warning . . O
: . . O
risk . . B-Factor
of . . O
anaphylaxis . . B-AdverseReaction

patients . . O
with . . O
acute . . O
respiratory . . O
illness . . O
may . . O
be . . O
at . . O
risk . . O
of . . O
serious . . O
acute . . O
exacerbation . . O
of . . O
their . . O
respiratory . . O
compromise . . O
due . . O
to . . O
hypersensitivity . . O
reactions . . O
, . . O
and . . O
require . . O
additional . . O
monitoring . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
, . . O
5.2 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

inform . . O
patients . . O
of . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
anaphylaxis . . O
and . . O
have . . O
them . . O
seek . . O
immediate . . O
medical . . O
care . . O
should . . O
symptoms . . O
occur . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
hypoglycemia . . B-AdverseReaction
: . . O
when . . O
an . . O
insulin . . O
secretagogue . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
sulfonylurea . . O
) . . O
or . . O
insulin . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
nesina . . O
, . . O
a . . O
lower . . O
dose . . O
of . . O
the . . O
insulin . . O
secretagogue . . O
or . . O
insulin . . O
may . . O
be . . O
required . . O
to . . O
minimize . . O
the . . O
risk . . O
of . . O
hypoglycemia . . O
. . . O

( . . O
5.6 . . O
) . . O
5.1 . . O
pancreatitis . . O

there . . O
have . . O
been . . O
postmarketing . . O
reports . . O
of . . O
fatal . . B-AdverseReaction
and . . O
nonfatal . . B-Severity
hepatic . . O
failure . . O
in . . O
patients . . O
taking . . O
nesina . . O
, . . O
although . . O
some . . O
of . . O
the . . O
reports . . O
contain . . O
insufficient . . O
information . . O
necessary . . O
to . . O
establish . . O
the . . O
probable . . O
cause . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

patients . . O
with . . O
type . . O
2 . . O
diabetes . . O
may . . O
have . . O
fatty . . O
liver . . O
disease . . O
, . . O
which . . O
may . . O
cause . . O
liver . . O
test . . O
abnormalities . . O
, . . O
and . . O
they . . O
may . . O
also . . O
have . . O
other . . O
forms . . O
of . . O
liver . . O
disease . . O
, . . O
many . . O
of . . O
which . . O
can . . O
be . . O
treated . . O
or . . O
managed . . O
. . . O

measure . . O
liver . . O
tests . . O
promptly . . O
in . . O
patients . . O
who . . O
report . . O
symptoms . . O
that . . O
may . . O
indicate . . O
liver . . O
injury . . O
, . . O
including . . O
fatigue . . O
, . . O
anorexia . . O
, . . O
right . . O
upper . . O
abdominal . . O
discomfort . . O
, . . O
dark . . O
urine . . O
or . . O
jaundice . . O
. . . O

in . . O
this . . O
clinical . . O
context . . O
, . . O
if . . O
the . . O
patient . . O
is . . O
found . . O
to . . O
have . . O
clinically . . O
significant . . O
liver . . O
enzyme . . O
elevations . . O
and . . O
if . . O
abnormal . . O
liver . . O
tests . . O
persist . . O
or . . O
worsen . . O
, . . O
nesina . . O
should . . O
be . . O
interrupted . . O
and . . O
investigation . . O
done . . O
to . . O
establish . . O
the . . O
probable . . O
cause . . O
. . . O

insulin . . O
and . . O
insulin . . O
secretagogues . . O
, . . O
such . . O
as . . O
sulfonylureas . . O
, . . O
are . . O
known . . O
to . . O
cause . . O
hypoglycemia . . O
. . . O

therefore . . O
, . . O
a . . O
lower . . O
dose . . O
of . . O
insulin . . O
or . . O
insulin . . O
secretagogue . . O
may . . O
be . . O
required . . O
to . . O
minimize . . O
the . . O
risk . . O
of . . O
hypoglycemia . . O
when . . O
used . . O
in . . O
combination . . O
with . . O
nesina . . O
. . . O

there . . O
have . . O
been . . O
postmarketing . . O
reports . . O
of . . O
severe . . B-Severity
and . . O
disabling . . B-Severity
arthralgia . . B-AdverseReaction
in . . O
patients . . O
taking . . O
dpp . . B-DrugClass
- . . I-DrugClass
4 . . I-DrugClass
inhibitors . . I-DrugClass
. . . O

glabellar . . O
lines . . O
: . . O
the . . O
most . . O
commonly . . O
observed . . O
adverse . . O
reaction . . O
( . . O
> . . O
1% . . O
of . . O
patients . . O
and . . O
> . . O
placebo . . O
) . . O
is . . O
headache . . B-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
a . . O
single . . O
intramuscular . . O
dose . . O
of . . O
xeomin . . O
in . . O
a . . O
placebo . . O
- . . O
controlled . . O
, . . O
phase . . O
3 . . O
trial . . O
in . . O
patients . . O
with . . O
cervical . . O
dystonia . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

table . . O
2 . . O
: . . O
most . . O
common . . O
teaes . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
and . . O
greater . . O
than . . O
placebo . . O
: . . O
double . . O
- . . O
blind . . O
phase . . O
of . . O
clinical . . O
trial . . O
double . . O
- . . O
blind . . O
phase . . O
system . . O
organ . . O
classpreferred . . O
term . . O
xeomin . . O
120 . . O
units . . O
( . . O
n . . O
= . . O
77 . . O
) . . O
xeomin . . O
240 . . O
units . . O
( . . O
n . . O
= . . O
82 . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
74 . . O
) . . O
any . . O
teaes . . O
57% . . O
55% . . O
42% . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
23% . . O
32% . . O
11% . . O
neck . . B-AdverseReaction
pain . . I-AdverseReaction
7% . . O
15% . . O
4% . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
7% . . O
11% . . O
1% . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
7% . . O
4% . . O
1% . . O
gastrointestinal . . O
disorders . . O
18% . . O
24% . . O
4% . . O
dysphagia . . B-AdverseReaction
13% . . O
18% . . O
3% . . O
nervous . . O
system . . O
disorders . . O
16% . . O
17% . . O
7% . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
16% . . O
11% . . O
11% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
9% . . O
4% . . O
7% . . O
infections . . O
and . . O
infestations . . O
14% . . O
13% . . O
11% . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
13% . . O
10% . . O
3% . . O
blepharospasm . . O

no . . O
serious . . O
adverse . . O
events . . O
occurred . . O
in . . O
patients . . O
who . . O
received . . O
xeomin . . O
; . . O
one . . O
placebo . . B-Factor
- . . O
treated . . O
patient . . O
experienced . . O
a . . O
serious . . B-Severity
adverse . . O
event . . O
( . . O
dyspnea . . B-AdverseReaction
) . . O
. . . O

xeomin . . O
treated . . O
subjects . . O
were . . O
24 . . O
to . . O
74 . . O
years . . O
old . . O
, . . O
and . . O
were . . O
predominantly . . O
female . . O
( . . O
88% . . O
) . . O
. . . O

four . . O
serious . . O
adverse . . O
events . . O
occurred . . O
in . . O
two . . O
placebo . . O
- . . O
treated . . O
subjects . . O
. . . O

all . . O
serious . . O
adverse . . O
events . . O
were . . O
assessed . . O
as . . O
unrelated . . O
to . . O
study . . O
drug . . O
. . . O

adverse . . O
reactions . . O
are . . O
adverse . . O
events . . O
in . . O
which . . O
there . . O
is . . O
some . . O
basis . . O
to . . O
believe . . O
there . . O
is . . O
a . . O
causal . . O
relationship . . O
between . . O
the . . O
drug . . O
and . . O
the . . O
occurrence . . O
of . . O
the . . O
adverse . . O
event . . O
. . . O

headache . . B-AdverseReaction
was . . O
the . . O
most . . O
common . . O
adverse . . O
reaction . . O
, . . O
reported . . O
for . . O
57 . . O
subjects . . O
( . . O
7.1% . . O
) . . O
, . . O
followed . . O
by . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hematoma . . I-AdverseReaction
in . . O
8 . . O
subjects . . O
( . . O
1.0% . . O
) . . O
. . . O

6.2 . . O
immunogenicity . . O

the . . O
incidence . . O
of . . O
antibody . . O
formation . . O
is . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

in . . O
addition . . O
, . . O
the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
positivity . . O
in . . O
an . . O
assay . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
including . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

* . . O
cardiac . . B-AdverseReaction
toxicities . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
pulmonary . . B-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
pulmonary . . B-AdverseReaction
hypertension . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
dyspnea . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
hypertension . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
* . . O
venous . . B-AdverseReaction
thrombosis . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
* . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
] . . O
* . . O
thrombocytopenia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.10 . . O
) . . O
] . . O
* . . O
hepatic . . B-AdverseReaction
toxicity . . I-AdverseReaction
and . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.11 . . O
) . . O
] . . O
* . . O
thrombotic . . B-AdverseReaction
thrombocytopenic . . I-AdverseReaction
purpura . . I-AdverseReaction
/ . . O
hemolytic . . B-AdverseReaction
uremic . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.12 . . O
) . . O
] . . O
* . . O
posterior . . B-AdverseReaction
reversible . . I-AdverseReaction
encephalopathy . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
pres . . B-AdverseReaction
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.13 . . O
) . . O
] . . O
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
events . . O
occurring . . O
in . . O
at . . O
least . . O
20% . . O
of . . O
patients . . O
treated . . O
with . . O
kyprolis . . O
in . . O
monotherapy . . O
trials . . O
: . . O
anemia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
platelets . . I-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
lymphocyte . . I-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
hemoglobin . . I-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
. . . O

6.1.1 . . O
safety . . O
experience . . O
with . . O
kyprolis . . O
in . . O
combination . . O
with . . O
lenalidomide . . O
and . . O
dexamethasone . . O
in . . O
patients . . O
with . . O
multiple . . O
myeloma . . O

the . . O
safety . . O
of . . O
kyprolis . . O
in . . O
combination . . O
with . . O
lenalidomide . . O
and . . O
dexamethasone . . O
( . . O
krd . . O
) . . O
was . . O
evaluated . . O
in . . O
an . . O
open . . O
- . . O
label . . O
randomized . . O
study . . O
in . . O
patients . . O
with . . O
relapsed . . O
multiple . . O
myeloma . . O
. . . O

laboratory . . O
abnormalities . . O

the . . O
median . . O
number . . O
of . . O
cycles . . O
initiated . . O
was . . O
4 . . O
( . . O
range . . O
1-35 . . O
) . . O
. . . O

the . . O
most . . O
common . . O
serious . . O
adverse . . O
events . . O
were . . O
: . . O
pneumonia . . B-AdverseReaction
( . . O
8% . . O
) . . O
, . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
disease . . B-AdverseReaction
progression . . I-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
pyrexia . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
hypercalcemia . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
congestive . . B-AdverseReaction
heart . . I-AdverseReaction
failure . . I-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
multiple . . B-AdverseReaction
myeloma . . I-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
anemia . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
and . . O
dyspnea . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

these . . O
adverse . . O
events . . O
were . . O
related . . O
to . . O
cardiac . . B-AdverseReaction
disorders . . I-AdverseReaction
in . . O
10 . . O
( . . O
2% . . O
) . . O
patients . . O
, . . O
infections . . B-AdverseReaction
in . . O
8 . . O
( . . O
1% . . O
) . . O
patients . . O
, . . O
renal . . B-AdverseReaction
disorders . . I-AdverseReaction
in . . O
4 . . O
( . . O
< . . O
1% . . O
) . . O
patients . . O
, . . O
and . . O
other . . O
adverse . . O
events . . O
in . . O
8 . . O
( . . O
1% . . O
) . . O
patients . . O
. . . O

* . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
* . . O
cardiac . . O
disorders . . O
: . . O
cardiac . . B-AdverseReaction
arrest . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
congestive . . I-AdverseReaction
, . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
, . . O
myocardial . . B-AdverseReaction
ischemia . . I-AdverseReaction
* . . O
eye . . O
disorders . . O
: . . O
cataract . . B-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
* . . O
gastrointestinal . . O
disorders . . O
: . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
toothache . . B-AdverseReaction
* . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
infusion . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
multi . . B-AdverseReaction
- . . I-AdverseReaction
organ . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
pain . . B-AdverseReaction
* . . O
hepatobiliary . . O
disorders . . O
: . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
* . . O
infections . . O
and . . O
infestations . . O
: . . O
bronchitis . . B-AdverseReaction
, . . O
influenza . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
sepsis . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
* . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
hyperglycemia . . B-AdverseReaction
, . . O
hyperkalemia . . B-AdverseReaction
, . . O
hyperuricemia . . B-AdverseReaction
, . . O
hypoalbuminemia . . B-AdverseReaction
, . . O
hypocalcemia . . B-AdverseReaction
, . . O
hypomagnesemia . . B-AdverseReaction
, . . O
hyponatremia . . B-AdverseReaction
, . . O
hypophosphatemia . . B-AdverseReaction
, . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
* . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
musculoskeletal . . B-AdverseReaction
chest . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
* . . O
nervous . . O
system . . O
disorders . . O
: . . O
hypoesthesia . . B-AdverseReaction
, . . O
paresthesia . . B-AdverseReaction
* . . O
psychiatric . . O
disorders . . O
: . . O
anxiety . . B-AdverseReaction
* . . O
renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
* . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
dysphonia . . B-AdverseReaction
, . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
edema . . I-AdverseReaction
* . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
erythema . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
* . . O
vascular . . O
disorders . . O
: . . O
embolic . . B-AdverseReaction
and . . I-AdverseReaction
thrombotic . . I-AdverseReaction
events . . I-AdverseReaction
, . . I-AdverseReaction
venous . . I-AdverseReaction
( . . O
including . . O
deep . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
and . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
) . . O
, . . O
hypotension . . B-AdverseReaction
grade . . B-Severity
3 . . I-Severity
and . . O
higher . . O
adverse . . O
reactions . . O
occurring . . O
at . . O
an . . O
incidence . . O
of . . O
> . . O
1% . . O
include . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
arrest . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
congestive . . I-AdverseReaction
, . . O
pain . . B-AdverseReaction
, . . O
sepsis . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
hyperkalemia . . B-AdverseReaction
, . . O
hyperuricemia . . B-AdverseReaction
, . . O
hypoalbuminemia . . B-AdverseReaction
, . . O
hypocalcemia . . B-AdverseReaction
, . . O
hyponatremia . . B-AdverseReaction
, . . O
hypophosphatemia . . B-AdverseReaction
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
acute . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
and . . O
hypotension . . B-AdverseReaction
. . . O

table . . O
8 . . O
: . . O
grade . . O
3-4 . . O
laboratory . . O
abnormalities . . O
( . . O
> . . O
10% . . O
) . . O
( . . O
monotherapy . . O
) . . O
adverse . . O
reaction . . O
kyprolis . . O
( . . O
n . . O
= . . O
598 . . O
) . . O
decreased . . B-AdverseReaction
platelets . . I-AdverseReaction
184 . . O
( . . O
31% . . O
) . . O
decreased . . B-AdverseReaction
lymphocytes . . I-AdverseReaction
151 . . O
( . . O
25% . . O
) . . O
decreased . . B-AdverseReaction
hemoglobin . . I-AdverseReaction
132 . . O
( . . O
22% . . O
) . . O
decreased . . B-AdverseReaction
total . . I-AdverseReaction
white . . I-AdverseReaction
blood . . I-AdverseReaction
cell . . I-AdverseReaction
count . . I-AdverseReaction
71 . . O
( . . O
12% . . O
) . . O
decreased . . B-AdverseReaction
sodium . . I-AdverseReaction
69 . . O
( . . O
12% . . O
) . . O
decreased . . B-AdverseReaction
absolute . . I-AdverseReaction
neutrophil . . I-AdverseReaction
count . . I-AdverseReaction
67 . . O
( . . O
11% . . O
) . . O
6.2 . . O
post . . O
- . . O
marketing . . O
experience . . O
the . . O
following . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
the . . O
post . . O
- . . O
marketing . . O
experience . . O
with . . O
kyprolis . . O
. . . O

excerpt . . O
: . . O
* . . O
neutropenia . . B-AdverseReaction
: . . O
monitor . . O
peripheral . . O
blood . . O
cell . . O
counts . . O
and . . O
adjust . . O
dose . . O
as . . O
appropriate . . O
( . . O
2.2 . . O
, . . O
5.1 . . O
, . . O
6 . . O
) . . O
* . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
: . . O
monitor . . O
for . . O
signs . . O
of . . O
neuropathy . . O
. . . O

clinical . . O
studies . . O
of . . O
halaven . . O
did . . O
not . . O
include . . O
patients . . O
with . . O
baseline . . O
neutrophil . . O
counts . . O
below . . O
1,500 . . O
/ . . O
mm . . O
3 . . O
. . . O

correct . . O
hypokalemia . . O
or . . O
hypomagnesemia . . O
prior . . O
to . . O
initiating . . O
halaven . . O
and . . O
monitor . . O
these . . O
electrolytes . . O
periodically . . O
during . . O
therapy . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

in . . O
some . . O
cases . . O
angioedema . . O
occurred . . O
after . . O
the . . O
first . . O
dose . . O
. . . O

toviaz . . O
should . . O
be . . O
administered . . O
with . . O
caution . . O
to . . O
patients . . O
with . . O
clinically . . O
significant . . O
bladder . . O
outlet . . O
obstruction . . O
because . . O
of . . O
the . . O
risk . . O
of . . O
urinary . . O
retention . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

toviaz . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
being . . O
treated . . O
for . . O
narrow . . O
- . . O
angle . . O
glaucoma . . O
, . . O
and . . O
only . . O
where . . O
the . . O
potential . . O
benefits . . O
outweigh . . O
the . . O
risks . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

5.9 . . O
myasthenia . . O
gravis . . O

( . . O
5.1 . . O
, . . O
6 . . O
) . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
apopharma . . O
inc . . O
. . . O
at . . O
: . . O
telephone . . O
: . . O
1-866-949-0995 . . O

} . . O
} . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
reported . . O
during . . O
clinical . . O
trials . . O
were . . O
chromaturia . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
alanine . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
and . . O
neutropenia . . B-AdverseReaction
. . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
metabolic . . B-AdverseReaction
acidosis . . I-AdverseReaction
, . . O
dehydration . . B-AdverseReaction
. . . O

skin . . O
, . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
hyperhidrosis . . B-AdverseReaction
, . . O
periorbital . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
photosensitivity . . B-AdverseReaction
reaction . . I-AdverseReaction
, . . O
pruritis . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
henoch . . B-AdverseReaction
- . . I-AdverseReaction
schonlein . . I-AdverseReaction
purpura . . I-AdverseReaction
. . . O

management . . O
of . . O
hyperammonemia . . O
due . . O
to . . O
nags . . O
deficiency . . O
should . . O
be . . O
done . . O
in . . O
coordination . . O
with . . O
medical . . O
personnel . . O
experienced . . O
in . . O
metabolic . . O
disorders . . O
. . . O

ongoing . . O
monitoring . . O
of . . O
plasma . . O
ammonia . . O
levels . . O
, . . O
neurological . . O
status . . O
, . . O
laboratory . . O
tests . . O
and . . O
clinical . . O
responses . . O
in . . O
patients . . O
receiving . . O
carbaglu . . O
is . . O
crucial . . O
to . . O
assess . . O
patient . . O
response . . O
to . . O
treatment . . O
. . . O

( . . O
4 . . O
) . . O
* . . O
cigarette . . O
smoking . . O
increases . . O
the . . O
risk . . O
of . . O
serious . . O
cardiovascular . . B-AdverseReaction
events . . I-AdverseReaction
from . . O
combination . . B-DrugClass
oral . . I-DrugClass
contraceptive . . I-DrugClass
( . . O
coc . . O
) . . O
use . . O
. . . O

if . . O
this . . O
product . . O
is . . O
used . . O
for . . O
10 . . O
days . . O
or . . O
longer . . O
, . . O
iop . . O
should . . O
be . . O
monitored . . O
. . . O

( . . O
5.3 . . O
) . . O

if . . O
signs . . O
and . . O
symptoms . . O
fail . . O
to . . O
improve . . O
after . . O
2 . . O
days . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
re . . O
- . . O
evaluated . . O
. . . O

item{ . . O
viral . . O
infections . . O
- . . O
employment . . O
of . . O
a . . O
corticosteroid . . O
medication . . O
in . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
herpes . . O
simplex . . O
requires . . O
great . . O
caution . . O
. . . O

( . . O
5.5 . . O
) . . O

steroids . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
the . . O
presence . . O
of . . O
glaucoma . . O
. . . O

use . . O
of . . O
corticosteroids . . B-DrugClass
may . . O
result . . O
in . . O
posterior . . B-AdverseReaction
subcapsular . . I-AdverseReaction
cataract . . I-AdverseReaction
formation . . O
. . . O

the . . O
use . . O
of . . O
steroids . . B-DrugClass
after . . O
cataract . . O
surgery . . O
may . . O
delay . . B-AdverseReaction
healing . . I-AdverseReaction
and . . O
increase . . O
the . . O
incidence . . O
of . . O
bleb . . O
formation . . O
. . . O

if . . O
signs . . O
and . . O
symptoms . . O
fail . . O
to . . O
improve . . O
after . . O
2 . . O
days . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
re . . O
- . . O
evaluated . . O
. . . O

fungal . . B-AdverseReaction
infections . . I-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
cornea . . I-AdverseReaction
are . . O
particularly . . O
prone . . O
to . . O
develop . . O
coincidentally . . O
with . . O
long . . O
- . . O
term . . O
local . . O
steroid . . B-DrugClass
application . . O
. . . O

durezol . . O
should . . O
not . . O
be . . O
instilled . . O
while . . O
wearing . . O
contact . . O
lenses . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
serious . . B-Severity
infections . . B-AdverseReaction
and . . O
malignancy . . B-AdverseReaction

excerpt . . O
: . . O
warning . . O
: . . O
serious . . B-Severity
infections . . B-AdverseReaction
and . . O
malignancy . . B-AdverseReaction

* . . O
monitor . . O
all . . O
patients . . O
for . . O
active . . O
tb . . O
during . . O
treatment . . O
, . . O
even . . O
if . . O
initial . . O
latent . . O
tb . . O
test . . O
is . . O
negative . . O
( . . O
5.1 . . O
) . . O
. . . O

discontinue . . O
simponi . . O
aria . . O
if . . O
a . . O
patient . . O
develops . . O
a . . O
serious . . O
infection . . O
. . . O

reported . . O
infections . . O
with . . O
tnf . . O
- . . O
blockers . . O
, . . O
of . . O
which . . O
simponi . . O
aria . . O
is . . O
a . . O
member . . O
, . . O
include . . O
: . . O

monitor . . O
patients . . O
closely . . O
for . . O
the . . O
development . . O
of . . O
signs . . O
and . . O
symptoms . . O
of . . O
infection . . O
during . . O
and . . O
after . . O
treatment . . O
with . . O
simponi . . O
aria . . O
, . . O
including . . O
the . . O
possible . . O
development . . O
of . . O
tuberculosis . . O
in . . O
patients . . O
who . . O
tested . . O
negative . . O
for . . O
latent . . O
tuberculosis . . O
infection . . O
prior . . O
to . . O
initiating . . O
therapy . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

malignancy . . O

excerpt . . O
: . . O
* . . O
determine . . O
cardiac . . O
rhythm . . O
at . . O
least . . O
once . . O
every . . O
3 . . O
months . . O
. . . O

5.2 . . O
cardiovascular . . O
death . . O
and . . O
heart . . O
failure . . O
in . . O
permanent . . O
af . . O

multaq . . O
offers . . O
no . . O
benefit . . O
in . . O
subjects . . O
in . . O
permanent . . O
af . . O
. . . O

5.5 . . O
liver . . O
injury . . O

* . . O
hepatocellular . . B-AdverseReaction
liver . . I-AdverseReaction
injury . . I-AdverseReaction
, . . O
including . . O
acute . . B-AdverseReaction
liver . . I-AdverseReaction
failure . . I-AdverseReaction
requiring . . O
transplant . . O
, . . O
has . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
multaq . . O
in . . O
the . . O
postmarketing . . O
setting . . O
. . . O

onset . . O
of . . O
dyspnea . . O
or . . O
non . . O
- . . O
productive . . O
cough . . O
may . . O
be . . O
related . . O
to . . O
pulmonary . . O
toxicity . . O
and . . O
patients . . O
should . . O
be . . O
carefully . . O
evaluated . . O
clinically . . O
. . . O

dronedarone . . O
induces . . O
a . . O
moderate . . B-Severity
( . . O
average . . O
of . . O
about . . O
10 . . O
ms . . O
but . . O
much . . O
greater . . O
effects . . O
have . . O
been . . O
observed . . O
) . . O
qtc . . O
( . . O
bazett . . O
) . . O
prolongation . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
and . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

small . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
creatinine . . I-AdverseReaction
levels . . I-AdverseReaction
( . . O
about . . O
0.1 . . B-Severity
mg . . I-Severity
/ . . I-Severity
dl . . I-Severity
) . . O
following . . O
dronedarone . . O
treatment . . O
initiation . . O
have . . O
been . . O
shown . . O
to . . O
be . . O
a . . O
result . . O
of . . O
inhibition . . O
of . . O
creatinine's . . O
tubular . . O
secretion . . O
. . . O

5.10 . . O
women . . O
of . . O
childbearing . . O
potential . . O

premenopausal . . O
women . . O
who . . O
have . . O
not . . O
undergone . . O
a . . O
hysterectomy . . O
or . . O
oophorectomy . . O
must . . O
use . . O
effective . . O
contraception . . O
while . . O
using . . O
multaq . . O
. . . O

( . . O
6.1 . . O
) . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
regeneron . . O
at . . O
1-855-395-3248 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

serious . . O
adverse . . O
reactions . . O
related . . O
to . . O
the . . O
injection . . O
procedure . . O
have . . O
occurred . . O
in . . O
< . . O
0.1% . . O
of . . O
intravitreal . . O
injections . . O
with . . O
eylea . . O
including . . O
endophthalmitis . . B-AdverseReaction
and . . O
retinal . . B-AdverseReaction
detachment . . I-AdverseReaction
. . . O

diabetic . . O
macular . . O
edema . . O
( . . O
dme . . O
) . . O

there . . O
were . . O
no . . O
differences . . O
in . . O
efficacy . . O
or . . O
safety . . O
between . . O
patients . . O
with . . O
or . . O
without . . O
immunoreactivity . . O
. . . O

warning . . O
: . . O
risk . . B-Factor
for . . O
hepatic . . B-AdverseReaction
decompensation . . I-AdverseReaction
in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O

in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
, . . O
promacta . . O
( . . O
r . . O
) . . O
in . . O
combination . . O
with . . O
interferon . . O
and . . O
ribavirin . . O
may . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
hepatic . . B-AdverseReaction
decompensation . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

patient . . O
informationduavee . . O
( . . O
r . . O
) . . O
( . . O
dew . . O
' . . O
ah . . O
- . . O
vee . . O
) . . O
( . . O
conjugated . . O
estrogens . . O
/ . . O
bazedoxifene . . O
) . . O
tablets . . O

what . . O
is . . O
duavee . . O
? . . O

* . . O
reduce . . O
moderate . . O
to . . O
severe . . O
hot . . O
flushesestrogens . . O
are . . O
hormones . . O
made . . O
by . . O
a . . O
woman's . . O
ovaries . . O
. . . O

your . . O
healthcare . . O
provider . . O
should . . O
check . . O
any . . O
unusual . . O
vaginal . . O
bleeding . . O
to . . O
find . . O
out . . O
the . . O
cause . . O
. . . O

do . . O
not . . O
take . . O
duavee . . O
if . . O
the . . O
test . . O
is . . O
positive . . O
and . . O
talk . . O
to . . O
your . . O
healthcare . . O
provider . . O
. . . O

your . . O
healthcare . . O
provider . . O
may . . O
need . . O
to . . O
check . . O
you . . O
more . . O
carefully . . O
if . . O
you . . O
have . . O
certain . . O
conditions . . O
, . . O
such . . O
as . . O
asthma . . O
( . . O
wheezing . . O
) . . O
, . . O
epilepsy . . O
( . . O
seizures . . O
) . . O
, . . O
diabetes . . O
, . . O
migraine . . O
, . . O
endometriosis . . O
, . . O
lupus . . O
, . . O
or . . O
problems . . O
with . . O
your . . O
heart . . O
, . . O
liver . . O
, . . O
thyroid . . O
, . . O
kidneys . . O
, . . O
or . . O
have . . O
high . . O
calcium . . O
levels . . O
in . . O
your . . O
blood . . O
. . . O

tell . . O
your . . O
healthcare . . O
provider . . O
about . . O
all . . O
the . . O
medicines . . O
you . . O
take . . O
, . . O
including . . O
prescription . . O
and . . O
over . . O
- . . O
the . . O
- . . O
counter . . O
medicines . . O
, . . O
vitamins . . O
, . . O
and . . O
herbal . . O
supplements . . O
. . . O

how . . O
should . . O
i . . O
take . . O
duavee . . O
? . . O

* . . O
record . . O
the . . O
date . . O
you . . O
open . . O
the . . O
foil . . O
pouch . . O
in . . O
the . . O
space . . O
provided . . O
on . . O
the . . O
blister . . O
package . . O
label . . O
. . . O

* . . O
take . . O
duavee . . O
exactly . . O
as . . O
your . . O
healthcare . . O
provider . . O
tells . . O
you . . O
to . . O
take . . O
it . . O
. . . O

* . . O
if . . O
you . . O
miss . . O
a . . O
dose . . O
of . . O
duavee . . O
, . . O
take . . O
it . . O
as . . O
soon . . O
as . . O
you . . O
remember . . O
. . . O

side . . O
effects . . O
are . . O
grouped . . O
by . . O
how . . O
serious . . O
they . . O
are . . O
and . . O
how . . O
often . . O
they . . O
happen . . O
when . . O
you . . O
are . . O
treated . . O
. . . O

tell . . O
your . . O
healthcare . . O
provider . . O
if . . O
you . . O
have . . O
any . . O
side . . O
effects . . O
that . . O
bother . . O
you . . O
or . . O
do . . O
not . . O
go . . O
away . . O
. . . O

call . . O
your . . O
doctor . . O
for . . O
medical . . O
advice . . O
about . . O
side . . O
effects . . O
. . . O

what . . O
can . . O
i . . O
do . . O
to . . O
lower . . O
my . . O
chances . . O
of . . O
a . . O
serious . . O
side . . O
effect . . O
with . . O
duavee . . O
? . . O

do . . O
not . . O
use . . O
duavee . . O
for . . O
a . . O
condition . . O
for . . O
which . . O
it . . O
was . . O
not . . O
prescribed . . O
. . . O

it . . O
may . . O
harm . . O
them . . O
. . . O

the . . O
following . . O
serious . . O
reactions . . O
are . . O
described . . O
in . . O
greater . . O
detail . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
section . . O
: . . O

( . . O
6.1 . . O
) . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
merck . . O
sharp . . O
& . . O
dohme . . O
corp . . O
. . . O
, . . O
a . . O
subsidiary . . O
of . . O
merck . . O
& . . O
co . . O
. . . O
, . . O
inc . . O
. . . O
, . . O
at . . O
1-877-888-4231 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

most . . O
patients . . O
( . . O
75% . . O
) . . O
enrolled . . O
in . . O
the . . O
cuti . . O
trial . . O
were . . O
female . . O
, . . O
and . . O
most . . O
patients . . O
( . . O
58% . . O
) . . O
enrolled . . O
in . . O
the . . O
ciai . . O
trial . . O
were . . O
male . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
5% . . O
or . . O
greater . . O
in . . O
either . . O
indication . . O
) . . O
occurring . . O
in . . O
patients . . O
receiving . . O
zerbaxa . . O
were . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
and . . O
pyrexia . . B-AdverseReaction
. . . O

table . . O
5 . . O
lists . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
1% . . O
or . . O
greater . . O
of . . O
patients . . O
receiving . . O
zerbaxa . . O
in . . O
phase . . O
3 . . O
clinical . . O
trials . . O
. . . O

renal . . B-AdverseReaction
impairment . . I-AdverseReaction
( . . O
including . . O
the . . O
terms . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
and . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
acute . . I-AdverseReaction
) . . O
led . . O
to . . O
discontinuation . . O
of . . O
treatment . . O
in . . O
5 . . O
/ . . O
1015 . . O
( . . O
0.5% . . O
) . . O
subjects . . O
receiving . . O
zerbaxa . . O
and . . O
none . . O
in . . O
the . . O
comparator . . O
arms . . O
. . . O

in . . O
three . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
of . . O
up . . O
to . . O
14 . . O
weeks . . O
duration . . O
, . . O
4% . . O
( . . O
15 . . O
/ . . O
400 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
ampyra . . O
10 . . O
mg . . O
twice . . O
daily . . O
experienced . . O
one . . O
or . . O
more . . O
treatment . . O
emergent . . O
adverse . . O
events . . O
leading . . O
to . . O
discontinuation . . O
, . . O
compared . . O
to . . O
2% . . O
( . . O
5 . . O
/ . . O
238 . . O
) . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

the . . O
experience . . O
in . . O
open . . O
- . . O
label . . O
clinical . . O
trials . . O
is . . O
consistent . . O
with . . O
the . . O
safety . . O
profile . . O
observed . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
piramal . . O
at . . O
1-855-545-5245 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rate . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
neutropenia . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction

in . . O
order . . O
to . . O
monitor . . O
the . . O
occurrence . . O
of . . O
neutropenia . . O
, . . O
frequent . . O
blood . . O
cell . . O
counts . . O
should . . O
be . . O
performed . . O
on . . O
all . . O
patients . . O
receiving . . O
jevtana . . O
. . . O

( . . O
2.2 . . O
, . . O
5.1 . . O
) . . O
* . . O
hepatotoxicity . . B-AdverseReaction
: . . O
zykadia . . O
can . . B-Factor
cause . . O
hepatotoxicity . . B-AdverseReaction
. . . O

monitor . . O
liver . . O
laboratory . . O
tests . . O
at . . O
least . . O
monthly . . O
. . . O

( . . O
2.2 . . O
, . . O
5.2 . . O
) . . O
* . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
( . . O
ild . . B-AdverseReaction
) . . O
/ . . O
pneumonitis . . B-AdverseReaction
: . . O
occurred . . O
in . . O
4% . . O
of . . O
patients . . O
. . . O

( . . O
2.2 . . O
, . . O
5.3 . . O
) . . O
* . . O
qt . . B-AdverseReaction
interval . . I-AdverseReaction
prolongation . . I-AdverseReaction
: . . O
zykadia . . O
can . . B-Factor
cause . . O
qtc . . B-AdverseReaction
interval . . I-AdverseReaction
prolongation . . I-AdverseReaction
. . . O

withhold . . O
then . . O
dose . . O
reduce . . O
, . . O
or . . O
permanently . . O
discontinue . . O
zykadia . . O
. . . O

initiate . . O
or . . O
optimize . . O
anti . . O
- . . O
hyperglycemic . . O
medications . . O
as . . O
indicated . . O
. . . O

5.1 . . O
severe . . O
or . . O
persistent . . O
gastrointestinal . . O
toxicity . . O

drug . . O
- . . O
induced . . O
hepatotoxicity . . B-AdverseReaction
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
zykadia . . O
. . . O

5.5 . . O
hyperglycemia . . O

initiate . . O
or . . O
optimize . . O
anti . . O
- . . O
hyperglycemic . . O
medications . . O
as . . O
indicated . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
sinus . . B-AdverseReaction
bradycardia . . I-AdverseReaction
, . . O
defined . . O
as . . O
a . . O
heart . . B-AdverseReaction
rate . . I-AdverseReaction
of . . I-AdverseReaction
less . . I-AdverseReaction
than . . I-AdverseReaction
50 . . I-AdverseReaction
beats . . I-AdverseReaction
per . . I-AdverseReaction
minute . . I-AdverseReaction
, . . O
was . . O
noted . . O
as . . O
a . . O
new . . O
finding . . O
in . . O
1% . . O
of . . O
255 . . O
patients . . O
. . . O

in . . O
cases . . O
of . . O
symptomatic . . O
bradycardia . . O
that . . O
is . . O
not . . O
life . . O
- . . O
threatening . . O
, . . O
withhold . . O
zykadia . . O
until . . O
recovery . . O
to . . O
asymptomatic . . O
bradycardia . . O
or . . O
to . . O
a . . O
heart . . O
rate . . O
of . . O
60 . . O
bpm . . O
or . . O
above . . O
, . . O
evaluate . . O
the . . O
use . . O
of . . O
concomitant . . O
medications . . O
, . . O
and . . O
adjust . . O
the . . O
dose . . O
of . . O
zykadia . . O
. . . O

permanently . . O
discontinue . . O
zykadia . . O
for . . O
life . . O
- . . O
threatening . . O
bradycardia . . O
if . . O
no . . O
contributing . . O
concomitant . . O
medication . . O
is . . O
identified . . O
; . . O
however . . O
, . . O
if . . O
associated . . O
with . . O
a . . O
concomitant . . O
medication . . O
known . . O
to . . O
cause . . O
bradycardia . . O
or . . O
hypotension . . O
, . . O
withhold . . O
zykadia . . O
until . . O
recovery . . O
to . . O
asymptomatic . . O
bradycardia . . O
or . . O
to . . O
a . . O
heart . . O
rate . . O
of . . O
60 . . O
bpm . . O
or . . O
above . . O
, . . O
and . . O
if . . O
the . . O
concomitant . . O
medication . . O
can . . O
be . . O
adjusted . . O
or . . O
discontinued . . O
, . . O
resume . . O
zykadia . . O
at . . O
a . . O
reduced . . O
dose . . O
as . . O
described . . O
in . . O
table . . O
1 . . O
upon . . O
recovery . . O
to . . O
asymptomatic . . O
bradycardia . . O
or . . O
to . . O
a . . O
heart . . O
rate . . O
of . . O
60 . . O
bpm . . O
or . . O
above . . O
, . . O
with . . O
frequent . . O
monitoring . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

( . . O
2.3,5.3 . . O
) . . O
* . . O
hepatic . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
fatal . . B-AdverseReaction
hepatic . . B-AdverseReaction
impairment . . I-AdverseReaction
occurs . . O
in . . O
0.18% . . O
of . . O
patients . . O
. . . O

withhold . . O
gilotrif . . O
for . . O
keratitis . . O
evaluation . . O
. . . O

withhold . . O
or . . O
discontinue . . O
gilotrif . . O
for . . O
confirmed . . O
ulcerative . . O
keratitis . . O
. . . O

advise . . O
females . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
and . . O
to . . O
use . . O
highly . . O
effective . . O
contraception . . O
. . . O

renal . . O
impairment . . O
as . . O
a . . O
consequence . . O
of . . O
diarrhea . . B-AdverseReaction
occurred . . O
in . . O
6.1% . . O
of . . O
patients . . O
treated . . O
with . . O
gilotrif . . O
, . . O
out . . O
of . . O
which . . O
3 . . O
( . . O
1.3% . . O
) . . O
were . . O
grade . . B-Severity
3 . . I-Severity
. . . O

withhold . . O
gilotrif . . O
during . . O
evaluation . . O
of . . O
patients . . O
with . . O
suspected . . O
ild . . O
, . . O
and . . O
discontinue . . O
gilotrif . . O
in . . O
patients . . O
with . . O
confirmed . . O
ild . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

5.5 . . O
keratitis . . O

5.6 . . O
embryofetal . . O
toxicity . . O

based . . O
on . . O
its . . O
mechanism . . O
of . . O
action . . O
, . . O
gilotrif . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

chemotherapy . . O
was . . O
given . . O
by . . O
intravenous . . O
infusion . . O
every . . O
3 . . O
weeks . . O
for . . O
up . . O
to . . O
6 . . O
cycles . . O
, . . O
in . . O
the . . O
absence . . O
of . . O
dose . . O
- . . O
limiting . . O
chemotherapy . . O
- . . O
related . . O
toxicities . . O
. . . O

a . . O
total . . O
of . . O
62% . . O
of . . O
patients . . O
were . . O
female . . O
and . . O
46% . . O
were . . O
asian . . O
. . . O

table . . O
4 . . O
. . . O

summary . . O
of . . O
treatment . . O
- . . O
emergent . . O
laboratory . . O
abnormalities . . O
with . . O
grade . . O
3 . . O
or . . O
4 . . O
incidence . . O
of . . O
> . . O
= . . O
4% . . O
in . . O
xalkori . . O
- . . O
treated . . O
patients . . O
in . . O
study . . O
1 . . O
laboratory . . O
abnormality . . O
xalkori . . O
chemotherapy . . O
any . . O
grade . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
/ . . O
4 . . O
( . . O
% . . O
) . . O
any . . O
grade . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
/ . . O
4 . . O
( . . O
% . . O
) . . O
hematology . . O
neutropenia . . B-AdverseReaction
52 . . O
11 . . O
59 . . O
16 . . O
lymphopenia . . B-AdverseReaction
48 . . O
7 . . O
53 . . O
13 . . O
chemistry . . O
alt . . B-AdverseReaction
elevation . . I-AdverseReaction
79 . . O
15 . . O
33 . . O
2 . . O
ast . . B-AdverseReaction
elevation . . I-AdverseReaction
66 . . O
8 . . O
28 . . O
1 . . O
hypophosphatemia . . B-AdverseReaction
32 . . O
10 . . O
21 . . O
6 . . O
previously . . O
treated . . O
alk . . O
- . . O
positive . . O
metastatic . . O
nsclc . . O
- . . O
study . . O
2 . . O

patients . . O
in . . O
the . . O
xalkori . . O
arm . . O
( . . O
n . . O
= . . O
172 . . O
) . . O
received . . O
xalkori . . O
250 . . O
mg . . O
orally . . O
twice . . O
daily . . O
until . . O
documented . . O
disease . . O
progression . . O
, . . O
intolerance . . O
to . . O
therapy . . O
, . . O
or . . O
the . . O
investigator . . O
determined . . O
that . . O
the . . O
patient . . O
was . . O
no . . O
longer . . O
experiencing . . O
clinical . . O
benefit . . O
. . . O

the . . O
most . . O
frequent . . O
serious . . O
adverse . . O
reactions . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
xalkori . . O
were . . O
pneumonia . . B-AdverseReaction
( . . O
4.1% . . O
) . . O
, . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
( . . O
3.5% . . O
) . . O
, . . O
dyspnea . . B-AdverseReaction
( . . O
2.3% . . O
) . . O
, . . O
and . . O
ild . . B-AdverseReaction
( . . O
2.9% . . O
) . . O
. . . O

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
that . . O
led . . O
to . . O
dose . . O
reduction . . O
in . . O
the . . O
patients . . O
treated . . O
with . . O
xalkori . . O
were . . O
alanine . . O
aminotransferase . . O
( . . O
alt . . O
) . . O
elevation . . O
( . . O
7.6% . . O
) . . O
including . . O
some . . O
patients . . O
with . . O
concurrent . . O
aspartate . . O
aminotransferase . . O
( . . O
ast . . O
) . . O
elevation . . O
, . . O
qtc . . B-AdverseReaction
prolongation . . I-AdverseReaction
( . . O
2.9% . . O
) . . O
, . . O
and . . O
neutropenia . . B-AdverseReaction
( . . O
2.3% . . O
) . . O
. . . O

adverse . . O
reactions . . O
reported . . O
at . . O
a . . O
higher . . O
incidence . . O
( . . O
> . . O
= . . O
5% . . O
higher . . O
for . . O
all . . O
grades . . O
or . . O
> . . O
= . . O
2% . . O
higher . . O
for . . O
grades . . O
3 . . O
/ . . O
4 . . O
) . . O
with . . O
xalkori . . O
than . . O
chemotherapy . . O
in . . O
study . . O
2 . . O
adverse . . O
reaction . . O
xalkori . . O
( . . O
n . . O
= . . O
172 . . O
) . . O
chemotherapy . . O
( . . O
pemetrexed . . O
or . . O
docetaxel . . O
) . . O
( . . O
n . . O
= . . O
171 . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
/ . . O
4 . . O
( . . O
% . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
/ . . O
4 . . O
( . . O
% . . O
) . . O
includes . . O
cases . . O
reported . . O
within . . O
the . . O
clustered . . O
terms . . O
: . . O
nervous . . O
system . . O
disorder . . O
dizziness . . B-AdverseReaction
22 . . O
1 . . O
8 . . O
0 . . O
dysgeusia . . B-AdverseReaction
26 . . O
0 . . O
9 . . O
0 . . O
syncope . . B-AdverseReaction
3 . . O
3 . . O
0 . . O
0 . . O
eye . . O
disorders . . O
vision . . B-AdverseReaction
disorder . . I-AdverseReaction
60 . . O
0 . . O
9 . . O
0 . . O
cardiac . . O
disorders . . O
electrocardiogram . . B-AdverseReaction
qt . . I-AdverseReaction
prolonged . . I-AdverseReaction
5 . . O
3 . . O
0 . . O
0 . . O
bradycardia . . B-AdverseReaction
5 . . O
0 . . O
0 . . O
0 . . O
investigations . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
10 . . O
1 . . O
4 . . O
0 . . O
gastrointestinal . . O
disorders . . O
vomiting . . B-AdverseReaction
47 . . O
1 . . O
18 . . O
0 . . O
nausea . . B-AdverseReaction
55 . . O
1 . . O
37 . . O
1 . . O
diarrhea . . B-AdverseReaction
60 . . O
0 . . O
19 . . O
1 . . O
constipation . . B-AdverseReaction
42 . . O
2 . . O
23 . . O
0 . . O
dyspepsia . . B-AdverseReaction
8 . . O
0 . . O
3 . . O
0 . . O
infections . . O
and . . O
infestations . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
infection . . I-AdverseReaction
26 . . O
0 . . O
13 . . O
1 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
6 . . O
5 . . O
2 . . O
2 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
edema . . B-AdverseReaction
31 . . O
0 . . O
16 . . O
0 . . O
additional . . O
adverse . . O
reactions . . O
occurring . . O
at . . O
an . . O
overall . . O
incidence . . O
between . . O
1% . . O
and . . O
30% . . O
in . . O
patients . . O
treated . . O
with . . O
xalkori . . O
included . . O
( . . O
% . . O
) . . O
, . . O
fatigue . . B-AdverseReaction
( . . O
27% . . O
) . . O
, . . O
neuropathy . . B-AdverseReaction
( . . O
19% . . O
; . . O
dysesthesia . . B-AdverseReaction
, . . O
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction
, . . O
hypoesthesia . . B-AdverseReaction
, . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
, . . O
neuralgia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
parasthesia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
polyneuropathy . . B-AdverseReaction
, . . O
burning . . B-AdverseReaction
sensation . . I-AdverseReaction
in . . I-AdverseReaction
skin . . I-AdverseReaction
) . . O
, . . O
rash . . B-AdverseReaction
( . . O
9% . . O
) . . O
, . . O
ild . . B-AdverseReaction
( . . O
4% . . O
; . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
ild . . B-AdverseReaction
, . . O
pneumonitis . . B-AdverseReaction
) . . O
, . . O
renal . . B-AdverseReaction
cyst . . I-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
and . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
( . . O
1% . . O
) . . O
. . . O

vision . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
most . . O
commonly . . O
visual . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
photopsia . . B-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
or . . O
vitreous . . B-AdverseReaction
floaters . . I-AdverseReaction
, . . O
occurred . . O
in . . O
1038 . . O
( . . O
62% . . O
) . . O
of . . O
1669 . . O
patients . . O
. . . O

there . . O
were . . O
13 . . O
( . . O
0.8% . . O
) . . O
patients . . O
with . . O
grade . . B-Severity
3 . . I-Severity
and . . O
4 . . O
( . . O
0.2% . . O
) . . O
patients . . O
with . . O
grade . . B-Severity
4 . . I-Severity
visual . . O
impairment . . O
. . . O

renal . . O
cysts . . O

renal . . B-AdverseReaction
cysts . . I-AdverseReaction
were . . O
experienced . . O
by . . O
50 . . O
( . . O
3% . . O
) . . O
of . . O
1669 . . O
patients . . O
. . . O

renal . . B-AdverseReaction
cysts . . I-AdverseReaction
occurred . . O
in . . O
8 . . O
( . . O
5% . . O
) . . O
patients . . O
treated . . O
with . . O
xalkori . . O
and . . O
1 . . O
( . . O
1% . . O
) . . O
patient . . O
treated . . O
with . . O
chemotherapy . . O
in . . O
study . . O
2 . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

excerpt . . O
: . . O
* . . O
hepatotoxicity . . B-AdverseReaction
: . . O
fatal . . B-AdverseReaction
hepatotoxicity . . B-AdverseReaction
occurred . . O
in . . O
0.1% . . O
of . . O
patients . . O
. . . O

monitor . . O
heart . . O
rate . . O
and . . O
blood . . O
pressure . . O
regularly . . O
. . . O

discontinue . . O
xalkori . . O
in . . O
patients . . O
with . . O
severe . . O
visual . . O
loss . . O
. . . O

advise . . O
females . . O
of . . O
reproductive . . O
potential . . O
of . . O
the . . O
potential . . O
risk . . O
to . . O
a . . O
fetus . . O
and . . O
use . . O
of . . O
effective . . O
contraception . . O
. . . O

across . . O
clinical . . O
trials . . O
( . . O
n . . O
= . . O
1669 . . O
) . . O
, . . O
49 . . O
xalkori . . O
- . . O
treated . . O
patients . . O
( . . O
2.9% . . O
) . . O
had . . O
ild . . B-AdverseReaction
of . . O
any . . O
grade . . O
, . . O
18 . . O
patients . . O
( . . O
1.1% . . O
) . . O
had . . O
grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
ild . . B-AdverseReaction
, . . O
and . . O
8 . . O
patients . . O
( . . O
0.5% . . O
) . . O
had . . O
fatal . . B-AdverseReaction
ild . . B-AdverseReaction
. . . O

these . . O
cases . . O
generally . . O
occurred . . O
within . . O
3 . . O
months . . O
after . . O
the . . O
initiation . . O
of . . O
xalkori . . O
. . . O

avoid . . O
use . . O
of . . O
xalkori . . O
in . . O
patients . . O
with . . O
congenital . . O
long . . O
qt . . O
syndrome . . O
. . . O

5.5 . . O
severe . . O
visual . . O
loss . . O

across . . O
all . . O
clinical . . O
trials . . O
, . . O
the . . O
incidence . . O
of . . O
grade . . B-Severity
4 . . I-Severity
visual . . B-AdverseReaction
field . . I-AdverseReaction
defect . . I-AdverseReaction
with . . O
vision . . B-AdverseReaction
loss . . I-AdverseReaction
was . . O
0.2% . . O
( . . O
4 . . O
/ . . O
1669 . . O
) . . O
. . . O

optic . . B-AdverseReaction
atrophy . . I-AdverseReaction
and . . O
optic . . B-AdverseReaction
nerve . . I-AdverseReaction
disorder . . I-AdverseReaction
have . . O
been . . O
reported . . O
as . . O
potential . . B-Factor
causes . . O
of . . O
vision . . B-AdverseReaction
loss . . I-AdverseReaction
. . . O

based . . O
on . . O
its . . O
mechanism . . O
of . . O
action . . O
, . . O
xalkori . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

the . . O
safety . . O
profile . . O
of . . O
saphris . . O
in . . O
the . . O
maintenance . . O
treatment . . O
of . . O
schizophrenia . . O
in . . O
adults . . O
was . . O
similar . . O
to . . O
that . . O
seen . . O
with . . O
acute . . O
treatment . . O
. . . O

the . . O
adult . . O
information . . O
below . . O
is . . O
derived . . O
from . . O
a . . O
clinical . . O
trial . . O
database . . O
for . . O
saphris . . O
consisting . . O
of . . O
over . . O
4565 . . O
patients . . O
and . . O
/ . . O
or . . O
healthy . . O
subjects . . O
exposed . . O
to . . O
one . . O
or . . O
more . . O
sublingual . . O
doses . . O
of . . O
saphris . . O
. . . O

a . . O
total . . O
of . . O
651 . . O
pediatric . . O
patients . . O
were . . O
treated . . O
with . . O
saphris . . O
. . . O

* . . O
bipolar . . O
disorder . . O
adults . . O
( . . O
adjunctive . . O
) . . O
: . . O
somnolence . . B-AdverseReaction
, . . O
oral . . B-AdverseReaction
hypoesthesia . . I-AdverseReaction
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

adverse . . O
reactions . . O
occurring . . O
at . . O
an . . O
incidence . . O
of . . O
2% . . O
or . . O
more . . O
among . . O
saphris . . O
- . . O
treated . . O
( . . O
monotherapy . . O
) . . O
patients . . O
with . . O
bipolar . . O
i . . O
disorder . . O
: . . O
adverse . . O
reactions . . O
associated . . O
with . . O
the . . O
use . . O
of . . O
saphris . . O
( . . O
incidence . . O
of . . O
2% . . O
or . . O
greater . . O
, . . O
rounded . . O
to . . O
the . . O
nearest . . O
percent . . O
, . . O
and . . O
saphris . . O
incidence . . O
greater . . O
than . . O
placebo . . O
) . . O
that . . O
occurred . . O
during . . O
acute . . O
monotherapy . . O
( . . O
up . . O
to . . O
3 . . O
- . . O
weeks . . O
in . . O
patients . . O
with . . O
bipolar . . O
mania . . O
) . . O
are . . O
shown . . O
in . . O
table . . O
9 . . O
. . . O

adverse . . O
reactions . . O
occurring . . O
with . . O
saphris . . O
at . . O
an . . O
incidence . . O
of . . O
2% . . O
or . . O
more . . O
in . . O
saphris . . O
- . . O
treated . . O
bipolar . . O
patients . . O
: . . O
adverse . . O
reactions . . O
associated . . O
with . . O
the . . O
use . . O
of . . O
saphris . . O
( . . O
incidence . . O
of . . O
> . . O
= . . O
2% . . O
in . . O
any . . O
saphris . . O
dose . . O
group . . O
and . . O
greater . . O
than . . O
placebo . . O
) . . O
that . . O
occurred . . O
during . . O
acute . . O
therapy . . O
are . . O
shown . . O
in . . O
table . . O
10 . . O
. . . O

5includes . . O
the . . O
preferred . . O
terms . . O
hyperinsulinemia . . B-AdverseReaction
and . . O
blood . . B-AdverseReaction
insulin . . I-AdverseReaction
increased . . I-AdverseReaction
. . . O

table . . O
11 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
2% . . O
or . . O
more . . O
of . . O
adult . . O
patients . . O
in . . O
any . . O
saphris . . O
- . . O
dose . . O
group . . O
and . . O
which . . O
occurred . . O
at . . O
greater . . O
incidence . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O
at . . O
3 . . O
weeks . . O
in . . O
adjunctive . . O
bipolar . . O
mania . . O
trials . . O
* . . O
saphris . . O
5 . . O
mg . . O
to . . O
10 . . O
mg . . O
twice . . O
daily . . O
with . . O
flexible . . O
dosing . . O
. . . O

system . . O
organ . . O
class . . O
/ . . O
preferred . . O
term . . O
placebo . . O
n . . O
= . . O
166 . . O
% . . O
saphris . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
* . . O
n . . O
= . . O
158 . . O
% . . O
gastrointestinal . . O
disorders . . O
dyspepsia . . B-AdverseReaction
2 . . O
3 . . O
oral . . B-AdverseReaction
hypoesthesia . . I-AdverseReaction
0 . . O
5 . . O
general . . O
disorders . . O
fatigue . . B-AdverseReaction
2 . . O
4 . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
< . . O
1 . . O
3 . . O
investigations . . O
increased . . B-AdverseReaction
weight . . I-AdverseReaction
0 . . O
3 . . O
nervous . . O
system . . O
disorders . . O
dizziness . . B-AdverseReaction
2 . . O
4 . . O
other . . O
extrapyramidal . . B-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
excluding . . B-Negation
akathisia . . B-AdverseReaction
) . . O
5 . . O
6 . . O
somnolence . . B-AdverseReaction
? . . O

10 . . O
22 . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
8 . . O
10 . . O
vascular . . O
disorders . . O
hypertension . . B-AdverseReaction
< . . O
1 . . O
3 . . O
dystonia . . O
: . . O
symptoms . . O
of . . O
dystonia . . B-AdverseReaction
, . . O
prolonged . . B-AdverseReaction
abnormal . . I-AdverseReaction
contractions . . I-AdverseReaction
of . . I-AdverseReaction
muscle . . I-AdverseReaction
groups . . I-AdverseReaction
, . . O
may . . B-Factor
occur . . O
in . . O
susceptible . . O
individuals . . O
during . . O
the . . O
first . . O
few . . O
days . . O
of . . O
treatment . . O
. . . O

in . . O
a . . O
3 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
pediatric . . O
trial . . O
with . . O
bipolar . . O
i . . O
disorder . . O
, . . O
the . . O
incidences . . O
of . . O
eps . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
events . . I-AdverseReaction
, . . O
excluding . . B-Negation
events . . O
related . . O
to . . O
akathisia . . B-AdverseReaction
, . . O
were . . O
4% . . O
, . . O
3% . . O
, . . O
and . . O
5% . . O
for . . O
patients . . O
treated . . O
with . . O
saphris . . O
2.5 . . O
mg . . O
, . . O
5 . . O
mg . . O
, . . O
and . . O
10 . . O
mg . . O
twice . . O
daily . . O
, . . O
respectively . . O
, . . O
as . . O
compared . . O
to . . O
3% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
with . . O
transaminase . . B-AdverseReaction
elevations . . I-AdverseReaction
> . . O
= . . O
3 . . B-Severity
times . . I-Severity
uln . . I-Severity
( . . O
at . . O
endpoint . . O
) . . O
was . . O
0.9% . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
versus . . O
1.3% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
with . . O
transaminase . . B-AdverseReaction
elevations . . I-AdverseReaction
> . . O
= . . O
3 . . B-Severity
times . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
( . . I-Severity
uln . . I-Severity
) . . I-Severity
( . . O
at . . O
endpoint . . O
) . . O
was . . O
2.5% . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
versus . . O
0.6% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

in . . O
a . . O
3 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
pediatric . . O
trial . . O
with . . O
bipolar . . O
i . . O
disorder . . O
, . . O
transient . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
transaminases . . I-AdverseReaction
( . . O
primarily . . O
alt . . O
) . . O
were . . O
more . . O
common . . O
in . . O
treated . . O
patients . . O
. . . O

the . . O
proportion . . O
of . . O
pediatric . . O
patients . . O
with . . O
alt . . B-AdverseReaction
elevations . . I-AdverseReaction
> . . O
= . . O
3 . . B-Severity
times . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
( . . I-Severity
uln . . I-Severity
) . . I-Severity
was . . O
2.4% . . O
for . . O
patients . . O
treated . . O
with . . O
saphris . . O
10 . . O
mg . . O
twice . . O
daily . . O
versus . . O
none . . O
for . . O
the . . O
other . . O
saphris . . O
dose . . O
groups . . O
and . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
with . . O
prolactin . . B-AdverseReaction
elevations . . I-AdverseReaction
> . . O
= . . O
4 . . B-Severity
times . . I-Severity
uln . . I-Severity
( . . O
at . . O
endpoint . . O
) . . O
were . . O
2.3% . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
versus . . O
0.7% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

in . . O
a . . O
long . . O
- . . O
term . . O
( . . O
52 . . O
- . . O
week . . O
) . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
comparator . . O
- . . O
controlled . . O
adult . . O
trial . . O
that . . O
included . . O
primarily . . O
patients . . O
with . . O
schizophrenia . . O
, . . O
the . . O
mean . . O
decrease . . B-AdverseReaction
in . . I-AdverseReaction
prolactin . . I-AdverseReaction
from . . O
baseline . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
was . . O
26.9 . . O
ng . . O
/ . . O
ml . . O
. . . O

creatine . . O
kinase . . O
( . . O
ck . . O
) . . O
: . . O
the . . O
proportion . . O
of . . O
adult . . O
patients . . O
with . . O
ck . . B-AdverseReaction
elevations . . I-AdverseReaction
> . . O
3 . . B-Severity
times . . I-Severity
uln . . I-Severity
at . . O
any . . O
time . . O
were . . O
6.4% . . O
and . . O
11.1% . . O
for . . O
patients . . O
treated . . O
with . . O
saphris . . O
5 . . O
mg . . O
twice . . O
daily . . O
and . . O
10 . . O
mg . . O
twice . . O
daily . . O
, . . O
respectively . . O
, . . O
as . . O
compared . . O
to . . O
6.7% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
in . . O
short . . O
- . . O
term . . O
, . . O
fixed . . O
- . . O
dose . . O
trials . . O
in . . O
schizophrenia . . O
and . . O
bipolar . . O
mania . . O
. . . O

reactions . . O
are . . O
further . . O
categorized . . O
by . . O
meddra . . O
system . . O
organ . . O
class . . O
and . . O
listed . . O
in . . O
order . . O
of . . O
decreasing . . O
frequency . . O
according . . O
to . . O
the . . O
following . . O
definitions . . O
: . . O
those . . O
occurring . . O
in . . O
at . . O
least . . O
1 . . O
/ . . O
100 . . O
patients . . O
( . . O
frequent . . O
) . . O
( . . O
only . . O
those . . O
not . . O
already . . O
listed . . O
in . . O
the . . O
tabulated . . O
results . . O
from . . O
placebo . . O
- . . O
controlled . . O
trials . . O
appear . . O
in . . O
this . . O
listing . . O
) . . O
; . . O
those . . O
occurring . . O
in . . O
1 . . O
/ . . O
100 . . O
to . . O
1 . . O
/ . . O
1000 . . O
patients . . O
( . . O
infrequent . . O
) . . O
; . . O
and . . O
those . . O
occurring . . O
in . . O
fewer . . O
than . . O
1 . . O
/ . . O
1000 . . O
patients . . O
( . . O
rare . . O
) . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

patients . . O
who . . O
fail . . O
to . . O
show . . O
substantial . . O
clinical . . O
benefit . . O
after . . O
adequate . . O
titration . . O
should . . O
be . . O
discontinued . . O
from . . O
potiga . . O
. . . O

additional . . O
testing . . O
may . . O
include . . O
fluorescein . . O
angiograms . . O
( . . O
fa . . O
) . . O
, . . O
optical . . O
coherence . . O
tomography . . O
( . . O
oct . . O
) . . O
, . . O
perimetry . . O
, . . O
and . . O
electroretinograms . . O
( . . O
erg . . O
) . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
and . . O
potential . . B-Factor
vision . . B-AdverseReaction
loss . . I-AdverseReaction

testing . . O
should . . O
include . . O
visual . . O
acuity . . O
and . . O
dilated . . O
fundus . . O
photography . . O
. . . O

warning . . O
: . . O
serious . . B-Severity
infections . . B-AdverseReaction
and . . O
malignancy . . B-AdverseReaction

antigen . . O
and . . O
antibody . . O
testing . . O
for . . O
histoplasmosis . . O
may . . O
be . . O
negative . . O
in . . O
some . . O
patients . . O
with . . O
active . . O
infection . . O
. . . O

the . . O
risks . . O
and . . O
benefits . . O
of . . O
treatment . . O
with . . O
cimzia . . O
should . . O
be . . O
carefully . . O
considered . . O
prior . . O
to . . O
initiating . . O
therapy . . O
in . . O
patients . . O
with . . O
chronic . . O
or . . O
recurrent . . O
infection . . O
. . . O

patients . . O
should . . O
be . . O
closely . . O
monitored . . O
for . . O
the . . O
development . . O
of . . O
signs . . O
and . . O
symptoms . . O
of . . O
infection . . O
during . . O
and . . O
after . . O
treatment . . O
with . . O
cimzia . . O
, . . O
including . . O
the . . O
possible . . O
development . . O
of . . O
tuberculosis . . O
in . . O
patients . . O
who . . O
tested . . O
negative . . O
for . . O
latent . . O
tuberculosis . . O
infection . . O
prior . . O
to . . O
initiating . . O
therapy . . O
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

cimzia . . O
is . . O
not . . O
indicated . . O
for . . O
use . . O
in . . O
pediatric . . O
patients . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

some . . O
drugs . . O
that . . O
are . . O
inhibitors . . O
of . . O
cyp2d6 . . O
and . . O
cyp3a . . O
are . . O
contraindicated . . O
with . . O
cerdelga . . O
depending . . O
on . . O
the . . O
patient's . . O
cyp2d6 . . O
metabolizer . . O
status . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

5.2 . . O
ecg . . O
changes . . O
and . . O
potential . . O
for . . O
cardiac . . O
arrhythmias . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
one . . O
clinical . . O
trial . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
the . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
the . . O
same . . O
or . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

( . . O
6 . . O
) . . O

excerpt . . O
: . . O
common . . O
adverse . . O
reactions . . O
( . . O
reported . . O
in . . O
> . . O
= . . O
4% . . O
of . . O
patients . . O
treated . . O
with . . O
nesina . . O
25 . . O
mg . . O
and . . O
more . . O
frequently . . O
than . . O
in . . O
patients . . O
who . . O
received . . O
placebo . . O
) . . O
are . . O
: . . O
nasopharyngitis . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
and . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O

6.1 . . O
clinical . . O
studies . . O
experience . . O

the . . O
mean . . O
exposure . . O
to . . O
nesina . . O
was . . O
40 . . O
weeks . . O
with . . O
more . . O
than . . O
2400 . . O
subjects . . O
treated . . O
for . . O
more . . O
than . . O
one . . O
year . . O
. . . O

the . . O
mean . . O
duration . . O
of . . O
diabetes . . O
was . . O
seven . . O
years . . O
, . . O
the . . O
mean . . O
body . . O
mass . . O
index . . O
( . . O
bmi . . O
) . . O
was . . O
31 . . O
kg . . O
/ . . O
m . . O
2 . . O
( . . O
51% . . O
of . . O
patients . . O
had . . O
a . . O
bmi . . O
> . . O
= . . O
30 . . O
kg . . O
/ . . O
m . . O
2 . . O
) . . O
, . . O
and . . O
the . . O
mean . . O
age . . O
was . . O
57 . . O
years . . O
( . . O
24% . . O
of . . O
patients . . O
> . . O
= . . O
65 . . O
years . . O
of . . O
age . . O
) . . O
. . . O

hypoglycemic . . B-AdverseReaction
events . . I-AdverseReaction
were . . O
documented . . O
based . . O
upon . . O
a . . O
blood . . O
glucose . . O
value . . O
and . . O
/ . . O
or . . O
clinical . . O
signs . . O
and . . O
symptoms . . O
of . . O
hypoglycemia . . B-AdverseReaction
. . . O

the . . O
use . . O
of . . O
nesina . . O
as . . O
add . . O
- . . O
on . . O
therapy . . O
to . . O
glyburide . . O
or . . O
insulin . . O
did . . O
not . . O
increase . . O
the . . O
incidence . . O
of . . O
hypoglycemia . . B-AdverseReaction
compared . . O
to . . O
placebo . . O
. . . O

no . . B-Negation
clinically . . O
meaningful . . O
changes . . B-AdverseReaction
in . . I-AdverseReaction
vital . . I-AdverseReaction
signs . . I-AdverseReaction
or . . O
in . . O
electrocardiograms . . O
were . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
nesina . . O
. . . O

excerpt . . O
: . . O
* . . O
bone . . B-AdverseReaction
marrow . . I-AdverseReaction
suppression . . I-AdverseReaction
( . . O
particularly . . O
neutropenia . . B-AdverseReaction
) . . O
and . . O
its . . O
clinical . . O
consequences . . O
( . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
, . . O
neutropenic . . B-AdverseReaction
infections . . I-AdverseReaction
) . . O
: . . O
monitor . . O
blood . . O
counts . . O
frequently . . O
to . . O
determine . . O
if . . O
dosage . . O
modification . . O
or . . O
initiation . . O
of . . O
g . . O
- . . O
csf . . O
is . . O
needed . . O
. . . O

identify . . O
cause . . O
and . . O
manage . . O
aggressively . . O
. . . O

( . . O
2.3 . . O
) . . O
* . . O
jevtana . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

5.1 . . O
bone . . O
marrow . . O
suppression . . O

neutropenic . . B-AdverseReaction
deaths . . B-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

in . . O
the . . O
randomized . . O
trial . . O
, . . O
five . . O
patients . . O
( . . O
1.3% . . O
) . . O
experienced . . O
fatal . . B-AdverseReaction
infectious . . B-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
sepsis . . B-AdverseReaction
or . . O
septic . . B-AdverseReaction
shock . . I-AdverseReaction
) . . O
. . . O

all . . O
had . . O
grade . . B-Severity
4 . . I-Severity
neutropenia . . B-AdverseReaction
and . . O
one . . O
had . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
. . . O

therapeutic . . O
use . . O
of . . O
g . . O
- . . O
csf . . O
and . . O
secondary . . O
prophylaxis . . O
should . . O
be . . O
considered . . O
in . . O
all . . O
patients . . O
considered . . O
to . . O
be . . O
at . . O
increased . . O
risk . . O
for . . O
neutropenia . . O
complications . . O
. . . O

jevtana . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
neutrophils . . O
< . . O
= . . O
1,500 . . O
/ . . O
mm . . O
3 . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

caution . . O
is . . O
recommended . . O
in . . O
patients . . O
with . . O
hemoglobin . . O
< . . O
10 . . O
g . . O
/ . . O
dl . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
may . . B-Factor
occur . . O
within . . O
a . . O
few . . O
minutes . . O
following . . O
the . . O
initiation . . O
of . . O
the . . O
infusion . . O
of . . O
jevtana . . O
, . . O
thus . . O
facilities . . O
and . . O
equipment . . O
for . . O
the . . O
treatment . . O
of . . O
hypotension . . O
and . . O
bronchospasm . . O
should . . O
be . . O
available . . O
. . . O

observe . . O
patients . . O
closely . . O
for . . O
hypersensitivity . . O
reactions . . O
, . . O
especially . . O
during . . O
the . . O
first . . O
and . . O
second . . O
infusions . . O
. . . O

most . . O
cases . . O
occurred . . O
in . . O
association . . O
with . . O
sepsis . . B-AdverseReaction
, . . O
dehydration . . B-AdverseReaction
, . . O
or . . O
obstructive . . B-AdverseReaction
uropathy . . I-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

appropriate . . O
measures . . O
should . . O
be . . O
taken . . O
to . . O
identify . . O
causes . . O
of . . O
renal . . O
failure . . O
and . . O
treat . . O
aggressively . . O
. . . O

in . . O
the . . O
randomized . . O
clinical . . O
trial . . O
, . . O
3 . . O
of . . O
131 . . O
( . . O
2% . . O
) . . O
patients . . O
< . . O
65 . . O
years . . O
of . . O
age . . O
and . . O
15 . . O
of . . O
240 . . O
( . . O
6% . . O
) . . O
> . . O
= . . O
65 . . O
years . . O
of . . O
age . . O
died . . B-AdverseReaction
of . . O
causes . . O
other . . O
than . . O
disease . . O
progression . . O
within . . O
30 . . O
days . . O
of . . O
the . . O
last . . O
cabazitaxel . . O
dose . . O
. . . O

5.6 . . O
use . . O
in . . O
patients . . O
with . . O
hepatic . . O
impairment . . O

jevtana . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
severe . . O
hepatic . . O
impairment . . O
( . . O
total . . O
bilirubin . . O
> . . O
3 . . O
* . . O
uln . . O
) . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

dose . . O
should . . O
be . . O
reduced . . O
for . . O
patients . . O
with . . O
mild . . O
( . . O
total . . O
bilirubin . . O
> . . O
1 . . O
to . . O
< . . O
= . . O
1.5 . . O
* . . O
uln . . O
or . . O
ast . . O
> . . O
1.5 . . O
* . . O
uln . . O
) . . O
and . . O
moderate . . O
( . . O
total . . O
bilirubin . . O
> . . O
1.5 . . O
to . . O
< . . O
= . . O
3.0 . . O
* . . O
uln . . O
and . . O
any . . O
ast . . O
) . . O
hepatic . . O
impairment . . O
, . . O
based . . O
on . . O
tolerability . . O
data . . O
in . . O
these . . O
patients . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
and . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.7 . . O
) . . O
] . . O
. . . O

5.7 . . O
embryo . . O
- . . O
fetal . . O
toxicity . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
, . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
this . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

( . . O
5.2 . . O
) . . O
* . . O
continue . . O
therapy . . O
with . . O
leucovorin . . O
until . . O
the . . O
methotrexate . . O
concentration . . O
has . . O
been . . O
maintained . . O
below . . O
the . . O
leucovorin . . O
treatment . . O
threshold . . O
for . . O
a . . O
minimum . . O
of . . O
3 . . O
days . . O
. . . O

( . . O
5.3 . . O
) . . O

5.2 . . O
monitoring . . O
methotrexate . . O
concentration . . O
/ . . O
interference . . O
with . . O
assay . . O

due . . O
to . . O
the . . O
long . . O
half . . O
- . . O
life . . O
of . . O
dampa . . O
( . . O
t1 . . O
/ . . O
2of . . O
approximately . . O
9 . . O
hours . . O
) . . O
, . . O
measurement . . O
of . . O
methotrexate . . O
using . . O
immunoassays . . O
is . . O
unreliable . . O
for . . O
samples . . O
collected . . O
within . . O
48 . . O
hours . . O
following . . O
voraxaze . . O
administration . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.1 . . O
) . . O
] . . O
. . . O

5.3 . . O
continuation . . O
and . . O
timing . . O
of . . O
leucovorin . . O
rescue . . O

for . . O
the . . O
first . . O
48 . . O
hours . . O
after . . O
voraxaze . . O
, . . O
administer . . O
the . . O
same . . O
leucovorin . . O
dose . . O
as . . O
given . . O
prior . . O
to . . O
voraxaze . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

( . . O
2.3 . . O
, . . O
5.1 . . O
) . . O
* . . O
myelosuppression . . B-AdverseReaction
: . . O
monitor . . O
blood . . O
counts . . O
and . . O
manage . . O
as . . O
necessary . . O
. . . O

withhold . . O
, . . O
dose . . O
reduce . . O
, . . O
or . . O
discontinue . . O
bosulif . . O
. . . O

withhold . . O
, . . O
dose . . O
reduce . . O
, . . O
or . . O
discontinue . . O
bosulif . . O
. . . O

in . . O
the . . O
single . . O
- . . O
arm . . O
phase . . O
1 . . O
/ . . O
2 . . O
clinical . . O
trial . . O
, . . O
the . . O
median . . O
time . . O
to . . O
onset . . O
for . . O
diarrhea . . O
( . . O
all . . O
grades . . O
) . . O
was . . O
2 . . O
days . . O
and . . O
the . . O
median . . O
duration . . O
per . . O
event . . O
was . . O
1 . . O
day . . O
. . . O

thrombocytopenia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
and . . O
neutropenia . . B-AdverseReaction
occur . . O
with . . O
bosulif . . O
treatment . . O
. . . O

this . . O
case . . O
represented . . O
1 . . O
out . . O
of . . O
1209 . . O
patients . . O
in . . O
bosulif . . O
clinical . . O
trials . . O
. . . O

in . . O
the . . O
546 . . O
patients . . O
from . . O
the . . O
safety . . O
population . . O
, . . O
the . . O
incidence . . O
of . . O
alt . . B-AdverseReaction
elevation . . I-AdverseReaction
was . . O
17% . . O
and . . O
ast . . B-AdverseReaction
elevation . . I-AdverseReaction
was . . O
14% . . O
. . . O

interrupt . . O
, . . O
dose . . O
reduce . . O
or . . O
discontinue . . O
bosulif . . O
as . . O
necessary . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

bosutinib . . O
caused . . O
embryofetal . . B-AdverseReaction
toxicities . . I-AdverseReaction
in . . O
rabbits . . B-Animal
at . . O
maternal . . O
exposures . . O
that . . O
were . . O
greater . . O
than . . O
the . . O
clinical . . O
exposure . . O
at . . O
the . . O
recommended . . O
bosutinib . . O
dose . . O
of . . O
500 . . O
mg . . O
/ . . O
day . . O
. . . O

more . . O
frequent . . O
monitoring . . O
is . . O
recommended . . O
in . . O
patients . . O
with . . O
egfr . . O
below . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
( . . O
5.2 . . O
) . . O
* . . O
hypoglycemia . . B-AdverseReaction
: . . O
consider . . O
lowering . . O
the . . O
dose . . O
of . . O
insulin . . O
secretagogue . . O
or . . O
insulin . . O
to . . O
reduce . . O
the . . O
risk . . O
of . . O
hypoglycemia . . O
when . . O
initiating . . O
jardiance . . O
( . . O
5.3 . . O
) . . O
* . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
: . . O
monitor . . O
and . . O
treat . . O
as . . O
appropriate . . O
( . . O
5.4 . . O
) . . O
* . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
: . . O
monitor . . O
and . . O
treat . . O
as . . O
appropriate . . O
( . . O
5.5 . . O
) . . O
* . . O
increased . . B-AdverseReaction
ldl . . I-AdverseReaction
- . . I-AdverseReaction
c . . I-AdverseReaction
: . . O
monitor . . O
and . . O
treat . . O
as . . O
appropriate . . O
( . . O
5.6 . . O
) . . O
* . . O
macrovascular . . O
outcomes . . O
: . . O
there . . O
have . . O
been . . O
no . . O
clinical . . O
studies . . O
establishing . . O
conclusive . . O
evidence . . O
of . . O
macrovascular . . O
risk . . O
reduction . . O
with . . O
jardiance . . O
( . . O
5.7 . . O
) . . O

5.1 . . O
hypotension . . O

jardiance . . O
causes . . O
intravascular . . B-AdverseReaction
volume . . I-AdverseReaction
contraction . . I-AdverseReaction
. . . O

symptomatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
may . . B-Factor
occur . . O
after . . O
initiating . . O
jardiance . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
particularly . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
, . . O
the . . O
elderly . . O
, . . O
in . . O
patients . . O
with . . O
low . . O
systolic . . O
blood . . O
pressure . . O
, . . O
and . . O
in . . O
patients . . O
on . . O
diuretics . . O
. . . O

more . . O
frequent . . O
monitoring . . O
of . . O
renal . . O
function . . O
is . . O
recommended . . O
in . . O
these . . O
patients . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.5 . . O
, . . O
8.6 . . O
) . . O
] . . O
. . . O

renal . . O
function . . O
should . . O
be . . O
evaluated . . O
prior . . O
to . . O
initiating . . O
jardiance . . O
and . . O
periodically . . O
thereafter . . O
. . . O

there . . O
have . . O
been . . O
no . . O
clinical . . O
studies . . O
establishing . . O
conclusive . . O
evidence . . O
of . . O
macrovascular . . O
risk . . O
reduction . . O
with . . O
jardiance . . O
or . . O
any . . O
other . . O
antidiabetic . . O
drug . . O
. . . O

excerpt . . O
: . . O
* . . O
elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
( . . O
alt . . O
or . . O
ast . . O
) . . O
: . . O
transaminases . . O
( . . O
alt . . O
and . . O
ast . . O
) . . O
should . . O
be . . O
assessed . . O
prior . . O
to . . O
initiating . . O
kalydeco . . O
, . . O
every . . O
3 . . O
months . . O
during . . O
the . . O
first . . O
year . . O
of . . O
treatment . . O
, . . O
and . . O
annually . . O
thereafter . . O
. . . O

( . . O
5.2 . . O
, . . O
7.2 . . O
, . . O
12.3 . . O
) . . O
* . . O
cataracts . . B-AdverseReaction
: . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
congenital . . I-AdverseReaction
lens . . I-AdverseReaction
opacities . . I-AdverseReaction
/ . . O
cataracts . . O
have . . O
been . . O
reported . . O
in . . O
pediatric . . O
patients . . O
treated . . O
with . . O
kalydeco . . O
. . . O

excerpt . . O
: . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
following . . O
datscan . . O
administration . . O
. . . O

( . . O
5.2 . . O
) . . O

5.1 . . O
hypersensitivity . . O
reactions . . O

6 . . O
adverse . . O
reactions . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
, . . O
dizziness . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
pruritis . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
occurred . . O
in . . O
< . . O
1.3% . . O
of . . O
patients . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

during . . O
clinical . . O
development . . O
1346 . . O
patients . . O
were . . O
exposed . . O
to . . O
adreview . . O
, . . O
251 . . O
patients . . O
with . . O
known . . O
or . . O
suspected . . O
pheochromocytoma . . O
or . . O
neuroblastoma . . O
, . . O
985 . . O
patients . . O
with . . O
heart . . O
failure . . O
, . . O
and . . O
110 . . O
control . . O
patients . . O
. . . O

all . . O
patients . . O
were . . O
monitored . . O
for . . O
adverse . . O
reactions . . O
over . . O
a . . O
24 . . O
hour . . O
period . . O
following . . O
adreview . . O
administration . . O
. . . O

congestive . . O
heart . . O
failure . . O

* . . O
transaminase . . B-AdverseReaction
elevations . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
drug . . O
reactions . . O
to . . O
kalydeco . . O
( . . O
occurring . . O
in . . O
> . . O
= . . O
8% . . O
of . . O
patients . . O
with . . O
cf . . O
who . . O
have . . O
a . . O
g551d . . O
mutation . . O
in . . O
the . . O
cftr . . O
gene . . O
) . . O
were . . O
headache . . B-AdverseReaction
, . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
dizziness . . B-AdverseReaction
. . . O

* . . O
an . . O
8 . . O
- . . O
week . . O
crossover . . O
design . . O
trial . . O
( . . O
trial . . O
4 . . O
) . . O
involving . . O
39 . . O
patients . . O
between . . O
the . . O
ages . . O
of . . O
6 . . O
and . . O
57 . . O
years . . O
with . . O
a . . O
g1244e . . O
, . . O
g1349d . . O
, . . O
g178r . . O
, . . O
g551s . . O
, . . O
g970r . . O
, . . O
s1251n . . O
, . . O
s1255p . . O
, . . O
s549n . . O
, . . O
or . . O
s549r . . O
mutation . . O
in . . O
the . . O
cftr . . O
gene . . O
. . . O

* . . O
a . . O
24 . . O
- . . O
week . . O
open . . O
- . . O
label . . O
trial . . O
( . . O
trial . . O
6 . . O
) . . O
in . . O
34 . . O
patients . . O
2 . . O
to . . O
less . . O
than . . O
6 . . O
years . . O
of . . O
age . . O
. . . O

patients . . O
eligible . . O
for . . O
trial . . O
6 . . O
were . . O
those . . O
with . . O
the . . O
g551d . . O
, . . O
g1244e . . O
, . . O
g1349d . . O
, . . O
g178r . . O
, . . O
g551s . . O
, . . O
g970r . . O
, . . O
s1251n . . O
, . . O
s1255p . . O
, . . O
s549n . . O
, . . O
or . . O
s549r . . O
mutation . . O
in . . O
the . . O
cftr . . O
gene . . O
. . . O

table . . O
2 . . O
: . . O
incidence . . O
of . . O
adverse . . O
drug . . O
reactions . . O
in . . O
> . . O
= . . O
8% . . O
of . . O
kalydeco . . O
- . . O
treated . . O
patients . . O
with . . O
a . . O
g551d . . O
mutation . . O
in . . O
the . . O
cftr . . O
gene . . O
and . . O
greater . . O
than . . O
placebo . . O
in . . O
2 . . O
placebo . . O
- . . O
controlled . . O
phase . . O
3 . . O
clinical . . O
trials . . O
of . . O
48 . . O
weeks . . O
duration . . O
adverse . . O
reaction . . O
( . . O
preferred . . O
term . . O
) . . O
incidence . . O
: . . O
pooled . . O
48 . . O
- . . O
week . . O
trials . . O
kalydecon . . O
= . . O
109n . . O
( . . O
% . . O
) . . O
placebon . . O
= . . O
104n . . O
( . . O
% . . O
) . . O
headache . . B-AdverseReaction
26 . . O
( . . O
24 . . O
) . . O
17 . . O
( . . O
16 . . O
) . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
24 . . O
( . . O
22 . . O
) . . O
19 . . O
( . . O
18 . . O
) . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
24 . . O
( . . O
22 . . O
) . . O
14 . . O
( . . O
14 . . O
) . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
22 . . O
( . . O
20 . . O
) . . O
16 . . O
( . . O
15 . . O
) . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
17 . . O
( . . O
16 . . O
) . . O
13 . . O
( . . O
13 . . O
) . . O
nasopharyngitis . . B-AdverseReaction
16 . . O
( . . O
15 . . O
) . . O
12 . . O
( . . O
12 . . O
) . . O
diarrhea . . B-AdverseReaction
14 . . O
( . . O
13 . . O
) . . O
10 . . O
( . . O
10 . . O
) . . O
rash . . B-AdverseReaction
14 . . O
( . . O
13 . . O
) . . O
7 . . O
( . . O
7 . . O
) . . O
nausea . . B-AdverseReaction
13 . . O
( . . O
12 . . O
) . . O
11 . . O
( . . O
11 . . O
) . . O
dizziness . . B-AdverseReaction
10 . . O
( . . O
9 . . O
) . . O
1 . . O
( . . O
1 . . O
) . . O
adverse . . O
reactions . . O
in . . O
the . . O
48 . . O
- . . O
week . . O
clinical . . O
trials . . O
that . . O
occurred . . O
in . . O
the . . O
kalydeco . . O
group . . O
at . . O
a . . O
frequency . . O
of . . O
4 . . O
to . . O
7% . . O
where . . O
rates . . O
exceeded . . O
that . . O
in . . O
the . . O
placebo . . O
group . . O
include . . O
: . . O

laboratory . . O
abnormalities . . O

transaminase . . O
elevations . . O
: . . O
in . . O
trials . . O
1 . . O
, . . O
2 . . O
, . . O
and . . O
3 . . O
the . . O
incidence . . O
of . . O
maximum . . O
transaminase . . O
( . . O
alt . . O
or . . O
ast . . O
) . . O
> . . O
8 . . O
, . . O
> . . O
5 . . O
, . . O
or . . O
> . . O
3 . . O
* . . O
uln . . O
was . . O
2% . . O
, . . O
2% . . O
, . . O
and . . O
6% . . O
in . . O
kalydeco . . O
- . . O
treated . . O
patients . . O
and . . O
2% . . O
, . . O
2% . . O
, . . O
and . . O
8% . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
respectively . . O
. . . O

monitor . . O
platelet . . O
counts . . O
regularly . . O
. . . O

in . . O
two . . O
controlled . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
and . . O
thrombocytopenia . . O
, . . O
ascites . . B-AdverseReaction
and . . O
encephalopathy . . B-AdverseReaction
occurred . . O
more . . O
frequently . . O
on . . O
the . . O
arm . . O
receiving . . O
treatment . . O
with . . O
promacta . . O
plus . . O
antivirals . . O
( . . O
7% . . O
) . . O
than . . O
the . . O
placebo . . O
plus . . O
antivirals . . O
arm . . O
( . . O
4% . . O
) . . O
. . . O

if . . O
the . . O
abnormalities . . O
are . . O
confirmed . . O
, . . O
monitor . . O
serum . . O
liver . . O
tests . . O
weekly . . O
until . . O
resolved . . O
or . . O
stabilized . . O
. . . O

5.3 . . O
thrombotic . . O
/ . . O
thromboembolic . . O
complications . . O

the . . O
majority . . O
of . . O
events . . O
were . . O
of . . O
the . . O
portal . . O
venous . . O
system . . O
( . . O
1% . . O
in . . O
patients . . O
treated . . O
with . . O
promacta . . O
versus . . O
less . . O
than . . O
1% . . O
for . . O
placebo . . O
) . . O
. . . O

seven . . O
thrombotic . . B-AdverseReaction
complications . . I-AdverseReaction
( . . O
six . . O
patients . . O
) . . O
were . . O
reported . . O
in . . O
the . . O
group . . O
that . . O
received . . O
promacta . . O
and . . O
three . . O
thrombotic . . B-AdverseReaction
complications . . I-AdverseReaction
were . . O
reported . . O
in . . O
the . . O
placebo . . B-Factor
group . . O
( . . O
two . . O
patients . . O
) . . O
. . . O

perform . . O
a . . O
baseline . . O
ocular . . O
examination . . O
prior . . O
to . . O
administration . . O
of . . O
promacta . . O
and . . O
, . . O
during . . O
therapy . . O
with . . O
promacta . . O
, . . O
regularly . . O
monitor . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
cataracts . . O
. . . O

( . . O
6.1 . . O
) . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
arbor . . O
pharmaceuticals . . O
, . . O
llc . . O
at . . O
1-866-516-4950 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

a . . O
total . . O
of . . O
4814 . . O
patients . . O
were . . O
evaluated . . O
for . . O
safety . . O
when . . O
treated . . O
with . . O
edarbi . . O
at . . O
doses . . O
of . . O
20 . . O
, . . O
40 . . O
, . . O
or . . O
80 . . O
mg . . O
in . . O
clinical . . O
trials . . O
. . . O

this . . O
includes . . O
1704 . . O
patients . . O
treated . . O
for . . O
at . . O
least . . O
six . . O
months . . O
; . . O
of . . O
these . . O
, . . O
588 . . O
were . . O
treated . . O
for . . O
at . . O
least . . O
one . . O
year . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
event . . O
leading . . O
to . . O
discontinuation . . O
, . . O
hypotension . . B-AdverseReaction
/ . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
, . . O
was . . O
reported . . O
by . . O
0.4% . . O
( . . O
8 . . O
/ . . O
2146 . . O
) . . O
patients . . O
randomized . . O
to . . O
edarbi . . O
40 . . O
mg . . O
or . . O
80 . . O
mg . . O
compared . . O
to . . O
0% . . O
( . . O
0 . . O
/ . . O
801 . . O
) . . O
patients . . O
randomized . . O
to . . O
placebo . . O
. . . O

in . . O
placebo . . O
- . . O
controlled . . O
monotherapy . . O
trials . . O
, . . O
diarrhea . . B-AdverseReaction
was . . O
reported . . O
up . . O
to . . O
2% . . O
in . . O
patients . . O
treated . . O
with . . O
edarbi . . O
80 . . O
mg . . O
daily . . O
compared . . O
with . . O
0.5% . . O
of . . O
patients . . O
on . . O
placebo . . O
. . . O

other . . O
adverse . . O
reactions . . O
with . . O
a . . O
plausible . . O
relationship . . O
to . . O
treatment . . O
that . . O
have . . O
been . . O
reported . . O
with . . O
an . . O
incidence . . O
of . . O
> . . O
= . . O
0.3% . . O
and . . O
greater . . O
than . . O
placebo . . O
in . . O
more . . O
than . . O
3300 . . O
patients . . O
treated . . O
with . . O
edarbi . . O
in . . O
controlled . . O
trials . . O
are . . O
listed . . O
below . . O
: . . O

hemoglobin . . O
/ . . O
hematocrit . . O

none . . O
of . . O
these . . O
abnormalities . . O
were . . O
reported . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

6.3 . . O
postmarketing . . O
experience . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
the . . O
postmarketing . . O
use . . O
of . . O
edarbi . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

excerpt . . O
: . . O
* . . O
the . . O
potency . . O
units . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
are . . O
not . . O
interchangeable . . O
with . . O
other . . O
preparations . . O
of . . O
botulinum . . O
toxin . . O
products . . O
and . . O
, . . O
therefore . . O
, . . O
units . . O
of . . O
biological . . O
activity . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
cannot . . O
be . . O
compared . . O
to . . O
or . . O
converted . . O
into . . O
units . . O
of . . O
any . . O
other . . O
botulinum . . O
toxin . . O
products . . O
( . . O
5.1 . . O
) . . O
* . . O
recommended . . O
dose . . O
and . . O
frequency . . O
of . . O
administration . . O
should . . O
not . . O
be . . O
exceeded . . O
( . . O
5.4 . . O
) . . O
* . . O
immediate . . O
medical . . O
attention . . O
may . . O
be . . O
required . . O
in . . O
cases . . O
of . . O
respiratory . . O
, . . O
speech . . O
or . . O
swallowing . . B-AdverseReaction
difficulties . . I-AdverseReaction
( . . O
5.3 . . O
) . . O
* . . O
concomitant . . O
neuromuscular . . O
disorder . . O
may . . O
exacerbate . . O
clinical . . O
effects . . O
of . . O
treatment . . O
( . . O
5.5 . . O
) . . O
* . . O
dysport . . O
( . . O
r . . O
) . . O
contains . . O
human . . O
albumin . . O
. . . O

there . . O
is . . O
a . . O
risk . . B-Factor
for . . O
transmission . . O
of . . O
creutzfeldt . . B-AdverseReaction
- . . I-AdverseReaction
jakob . . I-AdverseReaction
disease . . I-AdverseReaction
( . . O
cjd . . B-AdverseReaction
) . . O
however . . O
, . . O
no . . O
cases . . O
of . . O
transmission . . O
of . . O
viral . . B-AdverseReaction
diseases . . I-AdverseReaction
or . . O
cjd . . B-AdverseReaction
have . . O
ever . . O
been . . O
identified . . O
for . . O
albumin . . O
( . . O
5.6 . . O
) . . O
5.1 . . O
lack . . O
of . . O
interchangeability . . O
between . . O
botulinum . . O
toxin . . O
products . . O

post . . O
- . . O
marketing . . O
safety . . O
data . . O
from . . O
dysport . . O
( . . O
r . . O
) . . O
and . . O
other . . O
approved . . O
botulinum . . O
toxins . . O
suggest . . O
that . . O
botulinum . . O
toxin . . O
effects . . O
may . . B-Factor
, . . O
in . . O
some . . O
cases . . O
, . . O
be . . O
observed . . O
beyond . . O
the . . O
site . . O
of . . O
local . . O
injection . . O
. . . O

deaths . . B-AdverseReaction
as . . O
a . . O
complication . . O
of . . O
severe . . B-Severity
dysphagia . . B-AdverseReaction
have . . O
been . . O
reported . . O
after . . O
treatment . . O
with . . O
botulinum . . O
toxin . . O
. . . O

patients . . O
with . . O
neuromuscular . . O
disorders . . O
may . . O
be . . O
at . . O
increased . . O
risk . . B-Factor
of . . O
clinically . . O
significant . . O
effects . . O
including . . O
severe . . B-Severity
dysphagia . . B-AdverseReaction
and . . O
respiratory . . B-AdverseReaction
compromise . . I-AdverseReaction
from . . O
typical . . O
doses . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

5.6 . . O
human . . O
albumin . . O

excerpt . . O
: . . O
* . . O
serious . . B-Severity
hypersensitivity . . O
( . . O
anaphylactic . . O
) . . O
and . . O
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
glycopeptide . . O
antibacterial . . O
agents . . O
, . . O
including . . O
dalvance . . O
; . . O
exercise . . O
caution . . O
in . . O
patients . . O
with . . O
known . . O
hypersensitivity . . O
to . . O
glycopeptides . . O
. . . O

if . . O
an . . O
allergic . . O
reaction . . O
occurs . . O
, . . O
treatment . . O
with . . O
dalvance . . O
should . . O
be . . O
discontinued . . O
. . . O

stopping . . O
or . . O
slowing . . O
the . . O
infusion . . O
may . . O
result . . O
in . . O
cessation . . O
of . . O
these . . O
reactions . . O
. . . O

clostridium . . B-AdverseReaction
difficile . . I-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
diarrhea . . I-AdverseReaction
( . . O
cdad . . B-AdverseReaction
) . . O
has . . O
been . . O
reported . . O
in . . O
users . . O
of . . O
nearly . . O
all . . O
systemic . . O
antibacterial . . O
drugs . . O
, . . O
including . . O
dalvance . . O
, . . O
with . . O
severity . . O
ranging . . O
from . . O
mild . . B-Severity
diarrhea . . B-AdverseReaction
to . . O
fatal . . B-AdverseReaction
colitis . . B-AdverseReaction
. . . O

cdad . . O
must . . O
be . . O
considered . . O
in . . O
all . . O
patients . . O
who . . O
present . . O
with . . O
diarrhea . . O
following . . O
antibacterial . . O
use . . O
. . . O

5.5 . . O
development . . O
of . . O
drug . . O
- . . O
resistant . . O
bacteria . . O

prescribing . . O
dalvance . . O
in . . O
the . . O
absence . . O
of . . O
a . . O
proven . . O
or . . O
strongly . . O
suspected . . O
bacterial . . O
infection . . O
is . . O
unlikely . . O
to . . O
provide . . O
benefit . . O
to . . O
the . . O
patient . . O
and . . O
increases . . O
the . . O
risk . . O
of . . O
the . . O
development . . O
of . . O
drug . . O
- . . O
resistant . . O
bacteria . . O
. . . O

in . . O
controlled . . O
and . . O
uncontrolled . . O
studies . . O
, . . O
1,564 . . O
patients . . O
received . . O
cimzia . . O
at . . O
some . . O
dose . . O
level . . O
, . . O
of . . O
whom . . O
1,350 . . O
patients . . O
received . . O
400 . . O
mg . . O
cimzia . . O
. . . O

other . . O
adverse . . O
reactions . . O

the . . O
most . . O
commonly . . O
occurring . . O
adverse . . O
reactions . . O
in . . O
controlled . . O
trials . . O
of . . O
crohn's . . O
disease . . O
were . . O
described . . O
above . . O
. . . O

eye . . O
disorders . . O
: . . O
optic . . B-AdverseReaction
neuritis . . I-AdverseReaction
, . . O
retinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
and . . O
uveitis . . B-AdverseReaction
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
nephrotic . . B-AdverseReaction
syndrome . . I-AdverseReaction
and . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
. . . O

cimzia . . O
was . . O
studied . . O
primarily . . O
in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
and . . O
in . . O
long . . O
- . . O
term . . O
follow . . O
- . . O
up . . O
studies . . O
. . . O

in . . O
placebo . . O
- . . O
controlled . . O
studies . . O
, . . O
the . . O
population . . O
had . . O
a . . O
median . . O
age . . O
of . . O
53 . . O
years . . O
at . . O
entry . . O
; . . O
approximately . . O
80% . . O
were . . O
females . . O
, . . O
93% . . O
were . . O
caucasian . . O
and . . O
all . . O
patients . . O
were . . O
suffering . . O
from . . O
active . . O
rheumatoid . . O
arthritis . . O
, . . O
with . . O
a . . O
median . . O
disease . . O
duration . . O
of . . O
6.2 . . O
years . . O
. . . O

most . . O
patients . . O
received . . O
the . . O
recommended . . O
dose . . O
of . . O
cimzia . . O
or . . O
higher . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
by . . O
> . . O
= . . O
3% . . O
of . . O
patients . . O
treated . . O
with . . O
cimzia . . O
dosed . . O
every . . O
other . . O
week . . O
during . . O
placebo . . O
- . . O
controlled . . O
period . . O
of . . O
rheumatoid . . O
arthritis . . O
studies . . O
, . . O
with . . O
concomitant . . O
methotrexate . . O
. . . O

adverse . . O
reaction . . O
( . . O
preferred . . O
term . . O
) . . O
placebo+ . . O
mtx . . O
( . . O
% . . O
) . . O
n . . O
= . . O
324 . . O
cimzia . . O
200 . . O
mg . . O
eow . . O
+ . . O
mtx . . O
( . . O
% . . O
) . . O
n . . O
= . . O
640 . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
2 . . O
6 . . O
headache . . B-AdverseReaction
4 . . O
5 . . O
hypertension . . B-AdverseReaction
2 . . O
5 . . O
nasopharyngitis . . B-AdverseReaction
1 . . O
5 . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
1 . . O
4 . . O
pyrexia . . B-AdverseReaction
2 . . O
3 . . O
pharyngitis . . B-AdverseReaction
1 . . O
3 . . O
rash . . B-AdverseReaction
1 . . O
3 . . O
acute . . B-AdverseReaction
bronchitis . . I-AdverseReaction
1 . . O
3 . . O
fatigue . . B-AdverseReaction
2 . . O
3 . . O
hypertensive . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
observed . . O
more . . O
frequently . . O
in . . O
patients . . O
receiving . . O
cimzia . . O
than . . O
in . . O
controls . . O
. . . O

these . . O
adverse . . O
reactions . . O
occurred . . O
more . . O
frequently . . O
among . . O
patients . . O
with . . O
a . . O
baseline . . O
history . . O
of . . O
hypertension . . O
and . . O
among . . O
patients . . O
receiving . . O
concomitant . . O
corticosteroids . . O
and . . O
non . . O
- . . O
steroidal . . O
anti . . O
- . . O
inflammatory . . O
drugs . . O
. . . O

infections . . O

there . . O
is . . O
no . . O
evidence . . O
of . . O
increased . . O
risk . . O
of . . O
infections . . O
with . . O
continued . . O
exposure . . O
over . . O
time . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

in . . O
the . . O
studies . . O
with . . O
cimzia . . O
in . . O
ra . . O
, . . O
there . . O
were . . O
36 . . O
cases . . O
of . . O
tb . . B-AdverseReaction
among . . O
2,367 . . O
exposed . . O
patients . . O
, . . O
including . . O
some . . O
fatal . . B-AdverseReaction
cases . . O
. . . O

malignancies . . O

in . . O
clinical . . O
studies . . O
in . . O
crohn's . . O
disease . . O
, . . O
4% . . O
of . . O
patients . . O
treated . . O
with . . O
cimzia . . O
and . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
that . . O
had . . O
negative . . O
baseline . . O
ana . . O
titers . . O
developed . . O
positive . . O
titers . . O
during . . O
the . . O
studies . . O
. . . O

patients . . O
treated . . O
with . . O
concomitant . . O
immunosuppressants . . O
had . . O
a . . O
lower . . O
rate . . O
of . . O
antibody . . O
development . . O
than . . O
patients . . O
not . . O
taking . . O
immunosuppressants . . O
at . . O
baseline . . O
( . . O
3% . . O
and . . O
11% . . O
, . . O
respectively . . O
) . . O
. . . O

in . . O
study . . O
ra . . O
- . . O
iii . . O
, . . O
too . . O
few . . O
patients . . O
developed . . O
antibodies . . O
to . . O
allow . . O
for . . O
meaningful . . O
analysis . . O
of . . O
acr20 . . O
response . . O
by . . O
antibody . . O
status . . O
. . . O

the . . O
following . . O
symptoms . . O
that . . O
could . . O
be . . O
compatible . . O
with . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
rarely . . O
following . . O
cimzia . . O
administration . . O
to . . O
patients . . O
: . . O
angioedema . . B-AdverseReaction
, . . O
dermatitis . . B-AdverseReaction
allergic . . I-AdverseReaction
, . . O
dizziness . . O
( . . O
postural . . O
) . . O
, . . O
dyspnea . . B-AdverseReaction
, . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
malaise . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
serum . . B-AdverseReaction
sickness . . I-AdverseReaction
, . . O
and . . O
( . . O
vasovagal . . O
) . . O
syncope . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
estimate . . O
reliably . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

immune . . O
system . . O
disorders . . O
: . . O
sarcoidosis . . B-AdverseReaction

monitor . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
bleeding . . O
. . . O

* . . O
radiation . . B-AdverseReaction
risk . . I-AdverseReaction
: . . O
amyvid . . O
, . . O
similar . . O
to . . O
all . . O
radiopharmaceuticals . . O
, . . O
contributes . . O
to . . O
a . . O
patient's . . O
long . . B-AdverseReaction
- . . I-AdverseReaction
term . . I-AdverseReaction
cumulative . . I-AdverseReaction
radiation . . I-AdverseReaction
exposure . . I-AdverseReaction
. . . O

5.2 . . O
radiation . . O
risk . . O

ensure . . O
safe . . O
handling . . O
to . . O
protect . . O
patients . . O
and . . O
health . . O
care . . O
workers . . O
from . . O
unintentional . . O
radiation . . O
exposure . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
. . . O

pool . . O
of . . O
placebo . . O
- . . O
controlled . . O
trials . . O

fifty . . O
percent . . O
( . . O
50% . . O
) . . O
of . . O
the . . O
population . . O
was . . O
male . . O
and . . O
72% . . O
were . . O
caucasian . . O
, . . O
12% . . O
were . . O
asian . . O
, . . O
and . . O
5% . . O
were . . O
black . . O
or . . O
african . . O
american . . O
. . . O

these . . O
adverse . . O
reactions . . O
were . . O
not . . O
present . . O
at . . O
baseline . . O
, . . O
occurred . . O
more . . O
commonly . . O
on . . O
invokana . . O
than . . O
on . . O
placebo . . O
, . . O
and . . O
occurred . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
either . . O
invokana . . O
100 . . O
mg . . O
or . . O
invokana . . O
300 . . O
mg . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
from . . O
pool . . O
of . . O
four . . O
26 . . O
- . . O
week . . O
placebo . . O
- . . O
controlled . . O
studies . . O
reported . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
invokana . . O
- . . O
treated . . O
patientsthe . . O
four . . O
placebo . . O
- . . O
controlled . . O
trials . . O
included . . O
one . . O
monotherapy . . O
trial . . O
and . . O
three . . O
add . . O
- . . O
on . . O
combination . . O
trials . . O
with . . O
metformin . . O
, . . O
metformin . . O
and . . O
sulfonylurea . . O
, . . O
or . . O
metformin . . O
and . . O
pioglitazone . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
eight . . O
clinical . . O
trials . . O
, . . O
hypersensitivity . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
including . . O
erythema . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
and . . O
angioedema . . B-AdverseReaction
) . . O
occurred . . O
in . . O
3.0% . . O
, . . O
3.8% . . O
, . . O
and . . O
4.2% . . O
of . . O
patients . . O
receiving . . O
comparator . . O
, . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
. . . O

five . . O
patients . . O
experienced . . O
serious . . B-Severity
adverse . . O
reactions . . O
of . . O
hypersensitivity . . B-AdverseReaction
with . . O
invokana . . O
, . . O
which . . O
included . . O
4 . . O
patients . . O
with . . O
urticaria . . B-AdverseReaction
and . . O
1 . . O
patient . . O
with . . O
a . . O
diffuse . . B-AdverseReaction
rash . . I-AdverseReaction
and . . O
urticaria . . B-AdverseReaction
occurring . . O
within . . O
hours . . O
of . . O
exposure . . O
to . . O
invokana . . O
. . . O

photosensitivity . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
including . . O
photosensitivity . . B-AdverseReaction
reaction . . I-AdverseReaction
, . . O
polymorphic . . B-AdverseReaction
light . . I-AdverseReaction
eruption . . I-AdverseReaction
, . . O
and . . O
sunburn . . B-AdverseReaction
) . . O
occurred . . O
in . . O
0.1% . . O
, . . O
0.2% . . O
, . . O
and . . O
0.2% . . O
of . . O
patients . . O
receiving . . O
comparator . . O
, . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
. . . O

table . . O
3 . . O
: . . O
changes . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
and . . O
egfr . . O
associated . . O
with . . O
invokana . . O
in . . O
the . . O
pool . . O
of . . O
four . . O
placebo . . O
- . . O
controlled . . O
trials . . O
and . . O
moderate . . O
renal . . O
impairment . . O
trial . . O
placebon . . O
= . . O
646 . . O
invokana . . O
100 . . O
mgn . . O
= . . O
833 . . O
invokana . . O
300 . . O
mgn . . O
= . . O
834 . . O
pool . . O
of . . O
four . . O
placebo . . O
- . . O
controlled . . O
trials . . O
baseline . . O
creatinine . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
0.84 . . O
0.82 . . O
0.82 . . O
egfr . . O
( . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
87.0 . . O
88.3 . . O
88.8 . . O
week . . O
6 . . O
change . . O
creatinine . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
0.01 . . O
0.03 . . O
0.05 . . O
egfr . . O
( . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
- . . O
1.6 . . O
- . . O
3.8 . . O
- . . O
5.0 . . O
end . . O
of . . O
treatment . . O
change . . O
creatinine . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
0.01 . . O
0.02 . . O
0.03 . . O
egfr . . O
( . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
- . . O
1.6 . . O
- . . O
2.3 . . O
- . . O
3.4 . . O
placebon . . O
= . . O
90 . . O
invokana . . O
100 . . O
mgn . . O
= . . O
90 . . O
invokana . . O
300 . . O
mgn . . O
= . . O
89 . . O
moderate . . O
renal . . O
impairment . . O
trial . . O
baseline . . O
creatinine . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
1.61 . . O
1.62 . . O
1.63 . . O
egfr . . O
( . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
40.1 . . O
39.7 . . O
38.5 . . O
week . . O
3 . . O
change . . O
creatinine . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
0.03 . . O
0.18 . . O
0.28 . . O
egfr . . O
( . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
- . . O
0.7 . . O
- . . O
4.6 . . O
- . . O
6.2 . . O
end . . O
of . . O
treatment . . O
change . . O
creatinine . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
0.07 . . O
0.16 . . O
0.18 . . O
egfr . . O
( . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
- . . O
1.5 . . O
- . . O
3.6 . . O
- . . O
4.0 . . O
in . . O
the . . O
pool . . O
of . . O
four . . O
placebo . . O
- . . O
controlled . . O
trials . . O
where . . O
patients . . O
had . . O
normal . . O
or . . O
mildly . . O
impaired . . O
baseline . . O
renal . . O
function . . O
, . . O
the . . O
proportion . . O
of . . O
patients . . O
who . . O
experienced . . O
at . . O
least . . O
one . . O
event . . O
of . . O
significant . . B-Severity
renal . . B-AdverseReaction
function . . I-AdverseReaction
decline . . I-AdverseReaction
, . . O
defined . . O
as . . O
an . . O
egfr . . B-AdverseReaction
below . . I-AdverseReaction
80 . . I-AdverseReaction
ml . . I-AdverseReaction
/ . . I-AdverseReaction
min . . I-AdverseReaction
/ . . I-AdverseReaction
1.73 . . I-AdverseReaction
m . . I-AdverseReaction
2 . . I-AdverseReaction
and . . O
30% . . O
lower . . O
than . . O
baseline . . O
, . . O
was . . O
2.1% . . O
with . . O
placebo . . O
, . . O
2.0% . . O
with . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
4.1% . . O
with . . O
invokana . . O
300 . . O
mg . . O
. . . O

discontinuations . . O
due . . O
to . . O
renal . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
occurred . . O
in . . O
1.0% . . O
with . . O
placebo . . O
, . . O
1.2% . . O
with . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
1.6% . . O
with . . O
invokana . . O
300 . . O
mg . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

female . . O
patients . . O
who . . O
developed . . O
genital . . O
mycotic . . O
infections . . O
on . . O
invokana . . O
were . . O
more . . O
likely . . O
to . . O
experience . . O
recurrence . . O
and . . O
require . . O
treatment . . O
with . . O
oral . . O
or . . O
topical . . O
antifungal . . O
agents . . O
and . . O
anti . . O
- . . O
microbial . . O
agents . . O
. . . O

in . . O
all . . O
clinical . . O
trials . . O
, . . O
hypoglycemia . . O
was . . O
defined . . O
as . . O
any . . O
event . . O
regardless . . O
of . . O
symptoms . . O
, . . O
where . . O
biochemical . . O
hypoglycemia . . O
was . . O
documented . . O
( . . O
any . . O
glucose . . O
value . . O
below . . O
or . . O
equal . . O
to . . O
70 . . O
mg . . O
/ . . O
dl . . O
) . . O
. . . O

among . . O
patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
, . . O
approximately . . O
84% . . O
were . . O
taking . . O
medications . . O
that . . O
interfere . . O
with . . O
potassium . . O
excretion . . O
, . . O
such . . O
as . . O
potassium . . O
- . . O
sparing . . O
diuretics . . O
, . . O
angiotensin . . O
- . . O
converting . . O
- . . O
enzyme . . O
inhibitors . . O
, . . O
and . . O
angiotensin . . O
- . . O
receptor . . O
blockers . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
and . . O
5.3 . . O
) . . O
and . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

increases . . O
in . . O
serum . . O
magnesium . . O

in . . O
a . . O
trial . . O
of . . O
patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.3 . . O
) . . O
] . . O
, . . O
serum . . B-AdverseReaction
magnesium . . I-AdverseReaction
levels . . I-AdverseReaction
increased . . I-AdverseReaction
by . . O
0.2% . . O
, . . O
9.2% . . O
, . . O
and . . O
14.8% . . O
with . . O
placebo . . O
, . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
four . . O
placebo . . O
controlled . . O
trials . . O
, . . O
the . . O
mean . . O
percent . . O
change . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
phosphate . . I-AdverseReaction
levels . . I-AdverseReaction
were . . O
3.6% . . O
and . . O
5.1% . . O
with . . O
invokana . . O
100 . . O
mg . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
, . . O
compared . . O
to . . O
1.5% . . O
with . . O
placebo . . O
. . . O

the . . O
mean . . O
baseline . . O
ldl . . O
- . . O
c . . O
levels . . O
were . . O
104 . . O
to . . O
110 . . O
mg . . O
/ . . O
dl . . O
across . . O
treatment . . O
groups . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
. . . O

6 . . O
adverse . . O
reactions . . O

* . . O
myelosuppression . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
infections . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
anaphylaxis . . B-AdverseReaction
and . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
other . . O
malignancies . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
extravasation . . B-AdverseReaction
injury . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
* . . O
* . . O
most . . O
common . . O
non . . O
- . . O
hematologic . . O
adverse . . O
reactions . . O
for . . O
cll . . O
( . . O
frequency . . O
> . . O
= . . O
15% . . O
) . . O
are . . O
pyrexia . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
vomiting . . B-AdverseReaction
. . . O

the . . O
population . . O
was . . O
31-84 . . O
years . . O
of . . O
age . . O
, . . O
60% . . O
male . . O
, . . O
and . . O
40% . . O
female . . O
. . . O

adverse . . O
reactions . . O
occurring . . O
less . . O
frequently . . O
but . . O
possibly . . B-Factor
related . . O
to . . O
treanda . . O
treatment . . O
were . . O
hemolysis . . B-AdverseReaction
, . . O
dysgeusia . . B-AdverseReaction
/ . . O
taste . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
atypical . . B-AdverseReaction
pneumonia . . I-AdverseReaction
, . . O
sepsis . . B-AdverseReaction
, . . O
herpes . . B-AdverseReaction
zoster . . I-AdverseReaction
, . . O
erythema . . B-AdverseReaction
, . . O
dermatitis . . B-AdverseReaction
, . . O
and . . O
skin . . B-AdverseReaction
necrosis . . I-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O
* . . O
in . . O
pediatric . . O
patients . . O
age . . O
6 . . O
years . . O
and . . O
older . . O
with . . O
itp . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
10% . . O
and . . O
greater . . O
than . . O
placebo . . O
) . . O
were . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
and . . O
rhinitis . . B-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O
* . . O
in . . O
patients . . O
with . . O
severe . . O
aplastic . . O
anemia . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
20% . . O
) . . O
were . . O
: . . O
nausea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O
excerpt . . O
: . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
glaxosmithkline . . O
at . . O
1-888-825-5249 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

chronic . . O
immune . . O
( . . O
idiopathic . . O
) . . O
thrombocytopenia . . O
: . . O
adults . . O
: . . O
in . . O
clinical . . O
trials . . O
, . . O
hemorrhage . . B-AdverseReaction
was . . O
the . . O
most . . O
common . . O
serious . . O
adverse . . O
reaction . . O
and . . O
most . . O
hemorrhagic . . B-AdverseReaction
reactions . . I-AdverseReaction
followed . . O
discontinuation . . O
of . . O
promacta . . O
. . . O

promacta . . O
was . . O
administered . . O
to . . O
277 . . O
patients . . O
for . . O
at . . O
least . . O
6 . . O
months . . O
and . . O
202 . . O
patients . . O
for . . O
at . . O
least . . O
1 . . O
year . . O
. . . O

table . . O
4 . . O
presents . . O
the . . O
most . . O
common . . O
adverse . . O
drug . . O
reactions . . O
( . . O
experienced . . O
by . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
3% . . O
of . . O
patients . . O
receiving . . O
promacta . . O
) . . O
from . . O
the . . O
three . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
with . . O
a . . O
higher . . O
incidence . . O
in . . O
promacta . . O
versus . . O
placebo . . O
. . . O

table . . O
4 . . O
. . . O

pediatric . . O
patients . . O
: . . O
the . . O
data . . O
described . . O
below . . O
reflect . . O
median . . O
exposure . . O
to . . O
promacta . . O
of . . O
91 . . O
days . . O
for . . O
82 . . O
pediatric . . O
patients . . O
( . . O
aged . . O
6 . . O
to . . O
17 . . O
years . . O
) . . O
with . . O
chronic . . O
itp . . O
, . . O
of . . O
whom . . O
52% . . O
were . . O
female . . O
, . . O
across . . O
the . . O
randomized . . O
phase . . O
of . . O
two . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
and . . O
greater . . O
than . . O
placebo . . O
) . . O
from . . O
two . . O
placebo . . O
- . . O
controlled . . O
trials . . O
in . . O
adults . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
adverse . . O
reaction . . O
promacta . . O
+ . . O
peginterferon . . O
/ . . O
ribavirin . . O
n . . O
= . . O
955 . . O
( . . O
% . . O
) . . O
placebo . . O
+ . . O
peginterferon . . O
/ . . O
ribavirin . . O
n . . O
= . . O
484 . . O
( . . O
% . . O
) . . O
anemia . . B-AdverseReaction
40 . . O
35 . . O
pyrexia . . B-AdverseReaction
30 . . O
24 . . O
fatigue . . B-AdverseReaction
28 . . O
23 . . O
headache . . B-AdverseReaction
21 . . O
20 . . O
nausea . . B-AdverseReaction
19 . . O
14 . . O
diarrhea . . B-AdverseReaction
19 . . O
11 . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
18 . . O
14 . . O
influenza . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
illness . . I-AdverseReaction
18 . . O
16 . . O
asthenia . . B-AdverseReaction
16 . . O
13 . . O
insomnia . . B-AdverseReaction
16 . . O
15 . . O
cough . . B-AdverseReaction
15 . . O
12 . . O
pruritus . . B-AdverseReaction
15 . . O
13 . . O
chills . . B-AdverseReaction
14 . . O
9 . . O
myalgia . . B-AdverseReaction
12 . . O
10 . . O
alopecia . . B-AdverseReaction
10 . . O
6 . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
10 . . O
5 . . O
in . . O
the . . O
two . . O
controlled . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
, . . O
hyperbilirubinemia . . B-AdverseReaction
was . . O
reported . . O
in . . O
8% . . O
of . . O
patients . . O
receiving . . O
promacta . . O
compared . . O
with . . O
3% . . O
for . . O
placebo . . O
. . . O

total . . B-AdverseReaction
bilirubin . . I-AdverseReaction
greater . . I-AdverseReaction
than . . I-AdverseReaction
or . . I-AdverseReaction
equal . . I-AdverseReaction
to . . I-AdverseReaction
1.5 . . I-AdverseReaction
x . . I-AdverseReaction
uln . . I-AdverseReaction
was . . O
reported . . O
in . . O
76% . . O
and . . O
50% . . O
of . . O
patients . . O
receiving . . O
promacta . . O
and . . O
placebo . . O
, . . O
respectively . . O
. . . O

severe . . O
aplastic . . O
anemia . . O
: . . O
in . . O
the . . O
single . . O
- . . O
arm . . O
, . . O
open . . O
- . . O
label . . O
trial . . O
, . . O
43 . . O
patients . . O
with . . O
severe . . O
aplastic . . O
anemia . . O
received . . O
promacta . . O
. . . O

warning . . O
: . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction

the . . O
safety . . O
and . . O
efficacy . . O
of . . O
arcapta . . O
neohaler . . O
in . . O
patients . . O
with . . O
asthma . . O
have . . O
not . . O
been . . O
established . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

( . . O
5.7 . . O
) . . O

farxiga . . O
causes . . O
intravascular . . B-AdverseReaction
volume . . I-AdverseReaction
contraction . . I-AdverseReaction
. . . O

5.2 . . O
impairment . . O
in . . O
renal . . O
function . . O

5.4 . . O
genital . . O
mycotic . . O
infections . . O

5.5 . . O
increases . . O
in . . O
low . . O
- . . O
density . . O
lipoprotein . . O
cholesterol . . O
( . . O
ldl . . O
- . . O
c . . O
) . . O

5.6 . . O
bladder . . O
cancer . . O

across . . O
22 . . O
clinical . . O
studies . . O
, . . O
newly . . O
diagnosed . . O
cases . . O
of . . O
bladder . . B-AdverseReaction
cancer . . I-AdverseReaction
were . . O
reported . . O
in . . O
10 . . O
/ . . O
6045 . . O
patients . . O
( . . O
0.17% . . O
) . . O
treated . . O
with . . O
farxiga . . O
and . . O
1 . . O
/ . . O
3512 . . O
patient . . O
( . . O
0.03% . . O
) . . O
treated . . O
with . . O
placebo . . O
/ . . O
comparator . . O
. . . O

after . . O
excluding . . O
patients . . O
in . . O
whom . . O
exposure . . O
to . . O
study . . O
drug . . O
was . . O
less . . O
than . . O
one . . O
year . . O
at . . O
the . . O
time . . O
of . . O
diagnosis . . O
of . . O
bladder . . B-AdverseReaction
cancer . . I-AdverseReaction
, . . O
there . . O
were . . O
4 . . O
cases . . O
with . . O
farxiga . . O
and . . O
no . . O
cases . . O
with . . O
placebo . . O
/ . . O
comparator . . O
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
advise . . O
patients . . O
taking . . O
ferriprox . . O
to . . O
report . . O
immediately . . O
any . . O
symptoms . . O
indicative . . O
of . . O
infection . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
advise . . O
patients . . O
taking . . O
ferriprox . . O
to . . O
report . . O
immediately . . O
any . . O
symptoms . . O
indicative . . O
of . . O
infection . . O
. . . O

warning . . O
: . . O
anaphylaxis . . B-AdverseReaction

( . . O
4 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O

excerpt . . O
: . . O
warning . . O
: . . O
anaphylaxis . . B-AdverseReaction

has . . O
been . . O
reported . . O
after . . O
administration . . O
of . . O
kalbitor . . O

be . . O
aware . . O
of . . O
the . . O
similarity . . O
of . . O
symptoms . . O
between . . O
hypersensitivity . . O
reactions . . O

see . . O
contraindications . . O

( . . O
6 . . O
) . . O
] . . O
. . . O

6 . . O
adverse . . O
reactions . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
clinical . . O
trials . . O
( . . O
n . . O
= . . O
555 . . O
patients . . O
) . . O
a . . O
includes . . O
the . . O
terms . . O
blood . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
and . . O
hypertension . . B-AdverseReaction
. . . O
b . . O
includes . . O
the . . O
terms . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
haemorrhage . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
irritation . . I-AdverseReaction
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
. . . O
c . . O
includes . . O
the . . O
terms . . O
feeling . . B-AdverseReaction
cold . . I-AdverseReaction
and . . O
chills . . B-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O

cleviprex . . O
clinical . . O
development . . O
included . . O
19 . . O
studies . . O
, . . O
with . . O
99 . . O
healthy . . O
subjects . . O
and . . O
1307 . . O
hypertensive . . O
patients . . O
who . . O
received . . O
at . . O
least . . O
one . . O
dose . . O
of . . O
clevidipine . . O
( . . O
1406 . . O
total . . O
exposures . . O
) . . O
. . . O

the . . O
desired . . O
therapeutic . . O
response . . O
was . . O
achieved . . O
at . . O
doses . . O
of . . O
4-6 . . O
mg . . O
/ . . O
hour . . O
. . . O

perioperative . . O
hypertension . . O

table . . O
2 . . O
. . . O

escape . . O
- . . O
1 . . O
escape . . O
- . . O
2 . . O
clvn . . O
= . . O
53 . . O
( . . O
% . . O
) . . O
pbon . . O
= . . O
51 . . O
( . . O
% . . O
) . . O
clvn . . O
= . . O
61 . . O
( . . O
% . . O
) . . O
pbon . . O
= . . O
49 . . O
( . . O
% . . O
) . . O
any . . O
common . . O
adverse . . O
event . . O
27 . . O
( . . O
51% . . O
) . . O
21 . . O
( . . O
41% . . O
) . . O
32 . . O
( . . O
53% . . O
) . . O
24 . . O
( . . O
49% . . O
) . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
5 . . O
( . . O
9% . . O
) . . O
1 . . O
( . . O
2% . . O
) . . O
- . . O
- . . O
- . . O
- . . O
atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction
- . . O
- . . O
- . . O
- . . O
13 . . O
( . . O
21% . . O
) . . O
6 . . O
( . . O
12% . . O
) . . O
nausea . . B-AdverseReaction
- . . O
- . . O
- . . O
- . . O
13 . . O
( . . O
21% . . O
) . . O
6 . . O
( . . O
12% . . O
) . . O
three . . O
randomized . . O
, . . O
parallel . . O
, . . O
open . . O
- . . O
label . . O
studies . . O
called . . O
eclipse . . O
, . . O
with . . O
longer . . O
exposure . . O
in . . O
cardiac . . O
surgery . . O
patients . . O
define . . O
the . . O
adverse . . O
reactions . . O
for . . O
patients . . O
with . . O
perioperative . . O
hypertension . . O
. . . O

severe . . O
hypertension . . O

adverse . . O
reactions . . O
that . . O
were . . O
reported . . O
in . . O
< . . O
1% . . O
of . . O
patients . . O
with . . O
severe . . O
or . . O
essential . . O
hypertension . . O
included . . O
: . . O
cardiac . . O
: . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
arrestnervous . . O
system . . O
: . . O
syncoperespiratory . . O
: . . O
dyspnea . . B-AdverseReaction

warnings . . O
and . . O
precautions . . O

( . . O
5.3 . . O
) . . O
* . . O
effects . . B-AdverseReaction
on . . I-AdverseReaction
ability . . I-AdverseReaction
to . . I-AdverseReaction
drive . . I-AdverseReaction
and . . O
use . . O
machines . . O
: . . O
advise . . O
patients . . O
to . . O
refrain . . O
from . . O
driving . . O
and . . O
engaging . . O
in . . O
hazardous . . O
occupations . . O
or . . O
activities . . O
such . . O
as . . O
operating . . O
heavy . . O
or . . O
potentially . . O
dangerous . . O
machinery . . O
while . . O
blincyto . . O
is . . O
being . . O
administered . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
preparation . . O
and . . O
administration . . O
errors . . O
: . . O
strictly . . O
follow . . O
instructions . . O
for . . O
preparation . . O
( . . O
including . . O
admixing . . O
) . . O
and . . O
administration . . O
. . . O

( . . O
5.9 . . O
) . . O

life . . B-Severity
- . . I-Severity
threatening . . I-Severity
or . . O
fatal . . B-AdverseReaction
crs . . O
was . . O
infrequently . . O
reported . . O
in . . O
patients . . O
receiving . . O
blincyto . . O
. . . O

in . . O
patients . . O
receiving . . O
blincyto . . O
in . . O
clinical . . O
trials . . O
, . . O
serious . . B-Severity
infections . . B-AdverseReaction
such . . O
as . . O
sepsis . . O
, . . O
pneumonia . . O
, . . O
bacteremia . . O
, . . O
opportunistic . . O
infections . . O
, . . O
and . . O
catheter . . O
- . . O
site . . O
infections . . O
were . . O
observed . . O
in . . O
approximately . . O
25% . . O
of . . O
patients . . O
, . . O
some . . O
of . . O
which . . O
were . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
or . . O
fatal . . B-AdverseReaction
. . . O

monitor . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
infection . . O
and . . O
treat . . O
appropriately . . O
. . . O

5.5 . . O
neutropenia . . O
and . . O
febrile . . O
neutropenia . . O

interrupt . . O
blincyto . . O
if . . O
the . . O
transaminases . . O
rise . . O
to . . O
greater . . O
than . . O
5 . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
or . . O
if . . O
bilirubin . . O
rises . . O
to . . O
more . . O
than . . O
3 . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
. . . O

cranial . . O
magnetic . . O
resonance . . O
imaging . . O
( . . O
mri . . O
) . . O
changes . . O
showing . . O
leukoencephalopathy . . B-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
patients . . O
receiving . . O
blincyto . . O
, . . O
especially . . O
in . . O
patients . . O
with . . O
prior . . O
treatment . . O
with . . O
cranial . . O
irradiation . . O
and . . O
antileukemic . . O
chemotherapy . . O
( . . O
including . . O
systemic . . O
high . . O
- . . O
dose . . O
methotrexate . . O
or . . O
intrathecal . . O
cytarabine . . O
) . . O
. . . O

the . . O
clinical . . O
significance . . O
of . . O
these . . O
imaging . . O
changes . . O
is . . O
unknown . . O
. . . O

preparation . . O
and . . O
administration . . O
errors . . O
have . . O
occurred . . O
with . . O
blincyto . . O
treatment . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

oral . . O
contraceptives . . O
containing . . O
lower . . O
doses . . O
of . . O
norethindrone . . O
and . . O
other . . O
forms . . O
of . . O
hormonal . . O
contraception . . O
have . . O
not . . O
been . . O
studied . . O
or . . O
are . . O
contraindicated . . O
. . . O

in . . O
clinical . . O
trials . . O
with . . O
victrelis . . O
, . . O
the . . O
proportion . . O
of . . O
subjects . . O
who . . O
experienced . . O
hemoglobin . . B-AdverseReaction
values . . I-AdverseReaction
less . . I-AdverseReaction
than . . I-AdverseReaction
10 . . I-AdverseReaction
g . . I-AdverseReaction
per . . I-AdverseReaction
dl . . I-AdverseReaction
and . . O
less . . O
than . . O
8.5 . . O
g . . O
per . . O
dl . . O
was . . O
higher . . O
in . . O
subjects . . O
treated . . O
with . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
( . . O
r . . O
) . . O
/ . . O
rebetol . . O
( . . O
r . . O
) . . O
than . . O
in . . O
those . . O
treated . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
( . . O
see . . O
table . . O
4 . . O
) . . O
. . . O

certain . . O
adverse . . O
reactions . . O
consistent . . O
with . . O
symptoms . . O
of . . O
anemia . . B-AdverseReaction
, . . O
such . . O
as . . O
dyspnea . . B-AdverseReaction
, . . O
exertional . . B-AdverseReaction
dyspnea . . I-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
and . . O
syncope . . B-AdverseReaction
were . . O
reported . . O
more . . O
frequently . . O
in . . O
subjects . . O
who . . O
received . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
than . . O
in . . O
those . . O
treated . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

complete . . O
blood . . O
counts . . O
( . . O
with . . O
white . . O
blood . . O
cell . . O
differential . . O
counts . . O
) . . O
should . . O
be . . O
obtained . . O
at . . O
pretreatment . . O
, . . O
and . . O
at . . O
treatment . . O
weeks . . O
2 . . O
, . . O
4 . . O
, . . O
8 . . O
, . . O
and . . O
12 . . O
, . . O
and . . O
should . . O
be . . O
monitored . . O
closely . . O
at . . O
other . . O
time . . O
points . . O
, . . O
as . . O
clinically . . O
appropriate . . O
. . . O

( . . O
5.3 . . O
) . . O
5.1 . . O
fetal . . O
toxicity . . O

resulting . . O
oligohydramnios . . B-AdverseReaction
can . . B-Factor
be . . O
associated . . O
with . . O
fetal . . B-AdverseReaction
lung . . I-AdverseReaction
hypoplasia . . I-AdverseReaction
and . . O
skeletal . . O
deformations . . O
. . . O

5.3 . . O
impaired . . O
renal . . O
function . . O

as . . O
a . . O
consequence . . O
of . . O
inhibiting . . O
the . . O
renin . . O
- . . O
angiotensin . . O
system . . O
, . . O
changes . . B-AdverseReaction
in . . I-AdverseReaction
renal . . I-AdverseReaction
function . . I-AdverseReaction
may . . B-Factor
be . . O
anticipated . . O
in . . O
susceptible . . O
individuals . . O
treated . . O
with . . O
edarbi . . O
. . . O

there . . O
has . . O
been . . O
no . . O
long . . O
- . . O
term . . O
use . . O
of . . O
edarbi . . O
in . . O
patients . . O
with . . O
unilateral . . O
or . . O
bilateral . . O
renal . . O
artery . . O
stenosis . . O
, . . O
but . . O
similar . . O
results . . O
may . . O
be . . O
expected . . O
. . . O

* . . O
immediate . . O
medical . . O
attention . . O
may . . O
be . . O
required . . O
in . . O
cases . . O
of . . O
respiratory . . O
, . . O
speech . . O
or . . O
swallowing . . O
difficulties . . O
( . . O
5.1 . . O
, . . O
5.4 . . O
) . . O
. . . O

* . . O
use . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
compromised . . O
respiratory . . O
function . . O
or . . O
dysphagia . . O
( . . O
5.4 . . O
) . . O
. . . O

the . . O
symptoms . . O
are . . O
consistent . . O
with . . O
the . . O
mechanism . . O
of . . O
action . . O
of . . O
botulinum . . O
toxin . . O
and . . O
may . . O
include . . O
asthenia . . B-AdverseReaction
, . . O
generalized . . B-AdverseReaction
muscle . . I-AdverseReaction
weakness . . I-AdverseReaction
, . . O
diplopia . . B-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
ptosis . . B-AdverseReaction
, . . O
dysphagia . . B-AdverseReaction
, . . O
dysphonia . . B-AdverseReaction
, . . O
dysarthria . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
incontinence . . I-AdverseReaction
, . . O
and . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
. . . O

5.3 . . O
hypersensitivity . . O
reactions . . O

if . . O
serious . . O
and . . O
/ . . O
or . . O
immediate . . O
hypersensitivity . . O
reactions . . O
occur . . O
further . . O
injection . . O
of . . O
xeomin . . O
should . . O
be . . O
discontinued . . O
and . . O
appropriate . . O
medical . . O
therapy . . O
immediately . . O
instituted . . O
. . . O

when . . O
distant . . O
effects . . O
occur . . O
, . . O
additional . . O
respiratory . . O
muscles . . O
may . . O
be . . O
involved . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

this . . O
may . . B-Factor
result . . O
in . . O
critical . . B-Severity
loss . . B-AdverseReaction
of . . I-AdverseReaction
breathing . . I-AdverseReaction
capacity . . I-AdverseReaction
in . . O
patients . . O
with . . O
respiratory . . O
disorders . . O
who . . O
may . . O
have . . O
become . . O
dependent . . O
upon . . O
these . . O
accessory . . O
muscles . . O
. . . O

to . . O
prevent . . O
ectropion . . O
, . . O
botulinum . . O
toxin . . O
products . . O
should . . O
not . . O
be . . O
injected . . O
into . . O
the . . O
medial . . O
lower . . O
eyelid . . O
area . . O
. . . O

5.8 . . O
human . . O
albumin . . O
and . . O
transmission . . O
of . . O
viral . . O
diseases . . O

a . . O
theoretical . . O
risk . . B-Factor
for . . O
transmission . . O
of . . O
creutzfeldt . . B-AdverseReaction
- . . I-AdverseReaction
jakob . . I-AdverseReaction
disease . . I-AdverseReaction
( . . O
cjd . . O
) . . O
is . . O
also . . O
considered . . O
extremely . . O
remote . . O
. . . O

adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
in . . O
all . . O
controlled . . O
clinical . . O
studies . . O

excerpt . . O
: . . O
* . . O
do . . O
not . . O
use . . O
near . . O
eyes . . O
or . . O
mucous . . O
membranes . . O
. . . O

do . . O
not . . O
apply . . O
qutenza . . O
to . . O
the . . O
face . . O
or . . O
scalp . . O
to . . O
avoid . . O
risk . . O
of . . O
exposure . . O
to . . O
the . . O
eyes . . O
or . . O
mucous . . O
membranes . . O
. . . O

if . . O
irritation . . O
of . . O
eyes . . O
or . . O
airways . . O
occurs . . O
, . . O
remove . . O
the . . O
affected . . O
individual . . O
from . . O
the . . O
vicinity . . O
of . . O
qutenza . . O
. . . O

consider . . O
these . . O
factors . . O
prior . . O
to . . O
initiating . . O
qutenza . . O
treatment . . O
. . . O

warning . . O
: . . O
fetal . . B-AdverseReaction
toxicity . . I-AdverseReaction

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

northera . . O
therapy . . O
may . . B-Factor
cause . . O
or . . O
exacerbate . . O
supine . . B-AdverseReaction
hypertension . . I-AdverseReaction
in . . O
patients . . O
with . . O
noh . . O
. . . O

if . . O
supine . . O
hypertension . . O
is . . O
not . . O
well . . O
- . . O
managed . . O
, . . O
northera . . O
may . . O
increase . . O
the . . O
risk . . O
of . . O
cardiovascular . . O
events . . O
. . . O

northera . . O
may . . B-Factor
exacerbate . . O
existing . . O
ischemic . . O
heart . . O
disease . . O
, . . O
arrhythmias . . O
, . . O
and . . O
congestive . . O
heart . . O
failure . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
in . . O
at . . O
least . . O
2% . . O
and . . O
at . . O
a . . O
rate . . O
greater . . O
than . . O
placebo . . O
of . . O
the . . O
pristiq . . O
treated . . O
patients . . O
in . . O
the . . O
short . . O
- . . O
term . . O
studies . . O
, . . O
up . . O
to . . O
8 . . O
weeks . . O
, . . O
were . . O
: . . O
nausea . . B-AdverseReaction
( . . O
4% . . O
) . . O
; . . O
dizziness . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
and . . O
vomiting . . B-AdverseReaction
( . . O
2% . . O
each . . O
) . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
- . . O
asthenia . . B-AdverseReaction
. . . O

table . . O
4 . . O
: . . O
incidence . . O
( . . O
% . . O
) . . O
of . . O
patients . . O
with . . O
lipid . . B-AdverseReaction
abnormalities . . I-AdverseReaction
of . . O
potential . . O
clinical . . O
significance . . O
* . . O
pristiq . . O
placebo . . O
50 . . O
mg . . O
100 . . O
mg . . O
200 . . O
mg . . O
400 . . O
mg . . O
total . . O
cholesterol . . O
* . . O
( . . O
increase . . O
of . . O
> . . O
= . . O
50 . . O
mg . . O
/ . . O
dl . . O
and . . O
an . . O
absolute . . O
value . . O
of . . O
> . . O
= . . O
261 . . O
mg . . O
/ . . O
dl . . O
) . . O
2 . . O
3 . . O
4 . . O
4 . . O
10 . . O
ldl . . O
cholesterol . . O
* . . O
( . . O
increase . . O
> . . O
= . . O
50 . . O
mg . . O
/ . . O
dl . . O
and . . O
an . . O
absolute . . O
value . . O
of . . O
> . . O
= . . O
190 . . O
mg . . O
/ . . O
dl . . O
) . . O
0 . . O
1 . . O
0 . . O
1 . . O
2 . . O
triglycerides . . O
, . . O
fasting . . O
* . . O
( . . O
fasting . . O
: . . O
> . . O
= . . O
327 . . O
mg . . O
/ . . O
dl . . O
) . . O
3 . . O
2 . . O
1 . . O
4 . . O
6 . . O
proteinuria . . O

proteinuria . . B-AdverseReaction
, . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
trace . . O
, . . O
was . . O
observed . . O
in . . O
the . . O
pre . . O
- . . O
marketing . . O
fixed . . O
- . . O
dose . . O
controlled . . O
studies . . O
( . . O
see . . O
table . . O
5 . . O
) . . O
. . . O

this . . O
proteinuria . . B-AdverseReaction
was . . O
not . . B-Negation
associated . . O
with . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
bun . . I-AdverseReaction
or . . O
creatinine . . O
and . . O
was . . O
generally . . O
transient . . B-Severity
. . . O

table . . O
6 . . O
: . . O
mean . . O
changes . . O
in . . O
vital . . O
signs . . O
at . . O
final . . O
on . . O
therapy . . O
for . . O
all . . O
short . . O
- . . O
term . . O
, . . O
fixed . . O
- . . O
dose . . O
controlled . . O
studies . . O
pristiq . . O
placebo . . O
50 . . O
mg . . O
100 . . O
mg . . O
200 . . O
mg . . O
400 . . O
mg . . O
blood . . O
pressure . . O
supine . . O
systolic . . O
bp . . O
( . . O
mm . . O
hg . . O
) . . O
- . . O
1.4 . . O
1.2 . . O
2.0 . . O
2.5 . . O
2.1 . . O
supine . . O
diastolic . . O
bp . . O
( . . O
mm . . O
hg . . O
) . . O
- . . O
0.6 . . O
0.7 . . O
0.8 . . O
1.8 . . O
2.3 . . O
pulse . . O
rate . . O
supine . . O
pulse . . O
( . . O
bpm . . O
) . . O
- . . O
0.3 . . O
1.3 . . O
1.3 . . O
0.9 . . O
4.1 . . O
weight . . O
( . . O
kg . . O
) . . O
0.0 . . O
- . . O
0.4 . . O
- . . O
0.6 . . O
- . . O
0.9 . . O
- . . O
1.1 . . O
treatment . . O
with . . O
pristiq . . O
at . . O
all . . O
doses . . O
from . . O
50 . . O
mg . . O
per . . O
day . . O
to . . O
400 . . O
mg . . O
per . . O
day . . O
in . . O
controlled . . O
studies . . O
was . . O
associated . . O
with . . O
sustained . . B-Severity
hypertension . . B-AdverseReaction
, . . O
defined . . O
as . . O
treatment . . O
- . . O
emergent . . O
supine . . O
diastolic . . O
blood . . O
pressure . . O
( . . O
sdbp . . O
) . . O
> . . O
= . . O
90 . . O
mm . . O
hg . . O
and . . O
> . . O
= . . O
10 . . O
mm . . O
hg . . O
above . . O
baseline . . O
for . . O
3 . . O
consecutive . . O
on . . O
- . . O
therapy . . O
visits . . O
( . . O
see . . O
table . . O
7 . . O
) . . O
. . . O

patients . . O
receiving . . O
prolia . . O
should . . O
not . . O
receive . . O
xgeva . . O
. . . O

5.3 . . O
hypocalcemia . . O
and . . O
mineral . . O
metabolism . . O

these . . O
patients . . O
may . . B-Factor
also . . O
develop . . O
marked . . B-Severity
elevations . . B-AdverseReaction
of . . I-AdverseReaction
serum . . I-AdverseReaction
parathyroid . . I-AdverseReaction
hormone . . I-AdverseReaction
( . . O
pth . . O
) . . O
. . . O

instruct . . O
all . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O
, . . O
including . . O
those . . O
receiving . . O
dialysis . . O
, . . O
about . . O
the . . O
symptoms . . O
of . . O
hypocalcemia . . O
and . . O
the . . O
importance . . O
of . . O
maintaining . . O
calcium . . O
levels . . O
with . . O
adequate . . O
calcium . . O
and . . O
vitamin . . O
d . . O
supplementation . . O
. . . O

a . . O
dental . . O
examination . . O
with . . O
appropriate . . O
preventive . . O
dentistry . . O
is . . O
recommended . . O
prior . . O
to . . O
treatment . . O
with . . O
prolia . . O
in . . O
patients . . O
with . . O
risk . . O
factors . . O
for . . O
onj . . O
such . . O
as . . O
invasive . . O
dental . . O
procedures . . O
( . . O
e . . O
. . . O
g . . O
. . . O
tooth . . O
extraction . . O
, . . O
dental . . O
implants . . O
, . . O
oral . . O
surgery . . O
) . . O
, . . O
diagnosis . . O
of . . O
cancer . . O
, . . O
concomitant . . O
therapies . . O
( . . O
e . . O
. . . O
g . . O
. . . O
chemotherapy . . O
, . . O
corticosteroids . . O
, . . O
angiogenesis . . O
inhibitors . . O
) . . O
, . . O
poor . . O
oral . . O
hygiene . . O
, . . O
and . . O
co . . O
- . . O
morbid . . O
disorders . . O
( . . O
e . . O
. . . O
g . . O
. . . O
periodontal . . O
and . . O
/ . . O
or . . O
other . . O
pre . . O
- . . O
existing . . O
dental . . O
disease . . O
, . . O
anemia . . O
, . . O
coagulopathy . . O
, . . O
infection . . O
, . . O
ill . . O
- . . O
fitting . . O
dentures . . O
) . . O
. . . O

5.5 . . O
atypical . . O
subtrochanteric . . O
and . . O
diaphyseal . . O
femoral . . O
fractures . . O

atypical . . O
low . . O
- . . O
energy . . O
or . . O
low . . O
trauma . . O
fractures . . O
of . . O
the . . O
shaft . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
prolia . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

causality . . O
has . . O
not . . O
been . . O
established . . O
as . . O
these . . O
fractures . . O
also . . O
occur . . O
in . . O
osteoporotic . . O
patients . . O
who . . O
have . . O
not . . O
been . . O
treated . . O
with . . O
anti . . O
- . . O
resorptive . . O
agents . . O
. . . O

5.6 . . O
serious . . O
infections . . O

endocarditis . . B-AdverseReaction
was . . O
also . . O
reported . . O
more . . O
frequently . . O
in . . O
prolia . . O
- . . O
treated . . O
patients . . O
. . . O

the . . O
incidence . . O
of . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
was . . O
similar . . O
between . . O
placebo . . O
and . . O
prolia . . O
groups . . O
, . . O
and . . O
the . . O
overall . . O
incidence . . O
of . . O
infections . . B-AdverseReaction
was . . O
similar . . O
between . . O
the . . O
treatment . . O
groups . . O
. . . O

5.7 . . O
dermatologic . . O
adverse . . O
reactions . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
clinical . . O
trials . . O
of . . O
dalvance . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
in . . O
patients . . O
treated . . O
with . . O
dalvance . . O
were . . O
nausea . . B-AdverseReaction
( . . O
5.5% . . O
) . . O
, . . O
headache . . B-AdverseReaction
( . . O
4.7% . . O
) . . O
, . . O
and . . O
diarrhea . . B-AdverseReaction
( . . O
4.4% . . O
) . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
durata . . O
therapeutics . . O
, . . O
inc . . O
. . . O
at . . O
1-855-387-2825 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

table . . O
1 . . O
lists . . O
selected . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
more . . O
than . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
dalvance . . O
in . . O
clinical . . O
trials . . O
. . . O

table1 . . O
. . . O

hepatobiliary . . O
disorders . . O
: . . O
hepatotoxicity . . B-AdverseReaction

immune . . O
system . . O
disorders . . O
: . . O
anaphylactoid . . B-AdverseReaction
reaction . . I-AdverseReaction

in . . O
addition . . O
, . . O
one . . O
dalvance . . O
- . . O
treated . . O
subject . . O
in . . O
a . . O
phase . . O
1 . . O
trial . . O
had . . O
post . . O
- . . O
baseline . . O
alt . . B-AdverseReaction
elevations . . I-AdverseReaction
greater . . O
than . . O
20 . . B-Severity
times . . I-Severity
uln . . I-Severity
. . . O

5.1 . . O
anaphylaxis . . O
and . . O
angioedema . . O

5.2 . . O
progressive . . O
multifocal . . O
leukoencephalopathy . . O

5.3 . . O
lymphopenia . . O

tecfidera . . O
may . . B-Factor
decrease . . B-AdverseReaction
lymphocyte . . I-AdverseReaction
counts . . I-AdverseReaction
. . . O

the . . O
incidence . . O
of . . O
infections . . B-AdverseReaction
( . . O
60% . . O
vs . . O
58% . . O
) . . O
and . . O
serious . . B-Severity
infections . . B-AdverseReaction
( . . O
2% . . O
vs . . O
2% . . O
) . . O
was . . O
similar . . O
in . . O
patients . . O
treated . . O
with . . O
tecfidera . . O
or . . O
placebo . . O
, . . O
respectively . . O
. . . O

a . . O
cbc . . O
including . . O
lymphocyte . . O
count . . O
should . . O
also . . O
be . . O
obtained . . O
after . . O
6 . . O
months . . O
of . . O
treatment . . O
, . . O
every . . O
6 . . O
to . . O
12 . . O
months . . O
thereafter . . O
, . . O
and . . O
as . . O
clinically . . O
indicated . . O
. . . O

administration . . O
of . . O
tecfidera . . O
with . . O
food . . O
may . . O
reduce . . O
the . . O
incidence . . O
of . . O
flushing . . B-AdverseReaction
. . . O

5.1 . . O
hypersensitivity . . O
reactions . . O
, . . O
including . . O
anaphylaxis . . O

in . . O
255 . . O
hae . . O
patients . . O
treated . . O
with . . O
intravenous . . O
or . . O
subcutaneous . . O
kalbitor . . O
in . . O
clinical . . O
studies . . O
, . . O
10 . . O
patients . . O
( . . O
4% . . O
) . . O
experienced . . O
anaphylaxis . . B-AdverseReaction
. . . O

for . . O
the . . O
subgroup . . O
of . . O
187 . . O
patients . . O
treated . . O
with . . O
subcutaneous . . O
kalbitor . . O
, . . O
5 . . O
patients . . O
( . . O
3% . . O
) . . O
experienced . . O
anaphylaxis . . B-AdverseReaction
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
. . . O
] . . O

* . . O
candida . . B-AdverseReaction
albicans . . I-AdverseReaction
infection . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
increased . . O
risk . . B-Factor
of . . O
pneumonia . . B-AdverseReaction
in . . O
copd . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
immunosuppression . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
hypercorticism . . B-AdverseReaction
and . . O
adrenal . . B-AdverseReaction
suppression . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
* . . O
reduction . . B-AdverseReaction
in . . I-AdverseReaction
bone . . I-AdverseReaction
mineral . . I-AdverseReaction
density . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.13 . . O
) . . O
] . . O
because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

they . . O
had . . O
a . . O
mean . . O
age . . O
of . . O
62 . . O
years . . O
and . . O
an . . O
average . . O
smoking . . O
history . . O
of . . O
44 . . O
pack . . O
- . . O
years . . O
, . . O
with . . O
54% . . O
identified . . O
as . . O
current . . O
smokers . . O
. . . O

they . . O
had . . O
a . . O
mean . . O
age . . O
of . . O
64 . . O
years . . O
and . . O
an . . O
average . . O
smoking . . O
history . . O
of . . O
46 . . O
pack . . O
- . . O
years . . O
, . . O
with . . O
44% . . O
identified . . O
as . . O
current . . O
smokers . . O
. . . O

subjects . . O
received . . O
1 . . O
inhalation . . O
once . . O
daily . . O
of . . O
the . . O
following . . O
: . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
, . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
, . . O
fluticasone . . O
furoate . . O
/ . . O
vilanterol . . O
50 . . O
mcg . . O
/ . . O
25 . . O
mcg . . O
, . . O
or . . O
vilanterol . . O
25 . . O
mcg . . O
. . . O

while . . O
subjects . . O
aged . . O
12 . . O
to . . O
17 . . O
years . . O
were . . O
included . . O
in . . O
these . . O
trials . . O
, . . O
breo . . O
ellipta . . O
is . . O
not . . O
approved . . O
for . . O
use . . O
in . . O
this . . O
age . . O
- . . O
group . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.4 . . O
) . . O
] . . O
. . . O

adverse . . O
reaction . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
( . . O
n . . O
= . . O
346 . . O
) . . O
% . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
( . . O
n . . O
= . . O
346 . . O
) . . O
% . . O
fluticasone . . O
furoate . . O
100 . . O
mcg . . O
( . . O
n . . O
= . . O
347 . . O
) . . O
% . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
8 . . O
8 . . O
9 . . O
infections . . O
and . . O
infestations . . O
nasopharyngitis . . B-AdverseReaction
7 . . O
6 . . O
7 . . O
influenza . . B-AdverseReaction
3 . . O
3 . . O
1 . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
2 . . O
2 . . O
3 . . O
sinusitis . . B-AdverseReaction
2 . . O
1 . . O
< . . O
1 . . O
bronchitis . . B-AdverseReaction
2 . . O
< . . O
1 . . O
2 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
2 . . O
2 . . O
1 . . O
cough . . B-AdverseReaction
1 . . O
2 . . O
1 . . O
24 . . O
- . . O
week . . O
trial . . O

12 . . O
- . . O
month . . O
trial . . O

long . . O
- . . O
term . . O
safety . . O
data . . O
is . . O
based . . O
on . . O
a . . O
12 . . O
- . . O
month . . O
trial . . O
that . . O
evaluated . . O
the . . O
safety . . O
of . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
once . . O
daily . . O
( . . O
n . . O
= . . O
201 . . O
) . . O
, . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
once . . O
daily . . O
( . . O
n . . O
= . . O
202 . . O
) . . O
, . . O
and . . O
fluticasone . . O
propionate . . O
500 . . O
mcg . . O
twice . . O
daily . . O
( . . O
n . . O
= . . O
100 . . O
) . . O
in . . O
adolescent . . O
and . . O
adult . . O
subjects . . O
with . . O
asthma . . O
( . . O
trial . . O
4 . . O
) . . O
. . . O

exacerbation . . O
trial . . O

in . . O
a . . O
24 . . O
- . . O
to . . O
76 . . O
- . . O
week . . O
trial . . O
, . . O
subjects . . O
received . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
( . . O
n . . O
= . . O
1,009 . . O
) . . O
or . . O
fluticasone . . O
furoate . . O
100 . . O
mcg . . O
( . . O
n . . O
= . . O
1,010 . . O
) . . O
( . . O
trial . . O
5 . . O
) . . O
. . . O

among . . O
subjects . . O
aged . . O
12 . . O
to . . O
17 . . O
years . . O
, . . O
asthma . . O
- . . O
related . . O
hospitalizations . . O
occurred . . O
in . . O
4 . . O
subjects . . O
( . . O
2.6% . . O
) . . O
treated . . O
with . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
( . . O
n . . O
= . . O
151 . . O
) . . O
compared . . O
with . . O
0 . . O
subjects . . O
treated . . O
with . . O
fluticasone . . O
furoate . . O
100 . . O
mcg . . O
( . . O
n . . O
= . . O
130 . . O
) . . O
. . . O

tremor . . B-AdverseReaction
. . . O

do . . O
not . . O
use . . O
nulojix . . O
in . . O
transplant . . O
recipients . . O
who . . O
are . . O
ebv . . O
seronegative . . O
or . . O
with . . O
unknown . . O
ebv . . O
serostatus . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

( . . O
5.1 . . O
, . . O
5.3 . . O
, . . O
5.4 . . O
, . . O
5.5 . . O
) . . O
* . . O
use . . O
in . . O
liver . . O
transplant . . O
patients . . O
is . . O
not . . O
recommended . . O
due . . O
to . . O
an . . O
increased . . O
risk . . O
of . . O
graft . . O
loss . . O
and . . O
death . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
neuroleptic . . B-AdverseReaction
malignant . . I-AdverseReaction
syndrome . . I-AdverseReaction
: . . O
manage . . O
with . . O
immediate . . O
discontinuation . . O
and . . O
close . . O
monitoring . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
and . . O
angioedema . . B-AdverseReaction
, . . O
have . . O
been . . O
observed . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
, . . O
syncope . . B-AdverseReaction
, . . O
and . . O
other . . O
hemodynamic . . B-AdverseReaction
effects . . I-AdverseReaction
: . . O
dizziness . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
or . . O
bradycardia . . B-AdverseReaction
, . . O
and . . O
syncope . . B-AdverseReaction
may . . B-Factor
occur . . O
, . . O
especially . . O
early . . O
in . . O
treatment . . O
. . . O

( . . O
5.7 . . O
) . . O
* . . O
leukopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
and . . O
agranulocytosis . . B-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
antipsychotics . . B-DrugClass
. . . O

closely . . O
supervise . . O
high . . O
- . . O
risk . . O
patients . . O
. . . O

analyses . . O
of . . O
17 . . O
placebo . . O
- . . O
controlled . . O
trials . . O
( . . O
modal . . O
duration . . O
of . . O
10 . . O
weeks . . O
) . . O
, . . O
largely . . O
in . . O
patients . . O
taking . . O
atypical . . B-DrugClass
antipsychotic . . I-DrugClass
drugs . . I-DrugClass
, . . O
revealed . . O
a . . O
risk . . O
of . . O
death . . B-AdverseReaction
in . . O
the . . O
drug . . O
- . . O
treated . . O
patients . . O
of . . O
between . . O
1.6 . . O
to . . O
1.7 . . O
times . . O
that . . O
seen . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

over . . O
the . . O
course . . O
of . . O
a . . O
typical . . O
10 . . O
- . . O
week . . O
controlled . . O
trial . . O
, . . O
the . . O
rate . . O
of . . O
death . . B-AdverseReaction
in . . O
drug . . O
- . . O
treated . . O
patients . . O
was . . O
about . . O
4.5% . . O
, . . O
compared . . O
to . . O
a . . O
rate . . O
of . . O
about . . O
2.6% . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
with . . O
risperidone . . B-DrugClass
, . . O
aripiprazole . . B-DrugClass
, . . O
and . . O
olanzapine . . B-DrugClass
in . . O
elderly . . O
subjects . . O
with . . O
dementia . . O
, . . O
there . . O
was . . O
a . . O
higher . . O
incidence . . O
of . . O
cerebrovascular . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
cerebrovascular . . B-AdverseReaction
accidents . . I-AdverseReaction
and . . O
transient . . B-AdverseReaction
ischemic . . I-AdverseReaction
attacks . . I-AdverseReaction
) . . O
including . . O
fatalities . . B-AdverseReaction
compared . . O
to . . O
placebo . . O
- . . O
treated . . O
subjects . . O
. . . O

additional . . O
signs . . O
may . . B-Factor
include . . O
elevated . . B-AdverseReaction
creatine . . I-AdverseReaction
phosphokinase . . I-AdverseReaction
, . . O
myoglobinuria . . B-AdverseReaction
( . . O
rhabdomyolysis . . B-AdverseReaction
) . . O
, . . O
and . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
. . . O

the . . O
risk . . O
of . . O
developing . . O
td . . O
and . . O
the . . O
likelihood . . O
that . . O
it . . O
will . . O
become . . O
irreversible . . B-Severity
are . . O
believed . . O
to . . O
increase . . O
as . . O
the . . O
duration . . O
of . . O
treatment . . O
and . . O
the . . O
total . . O
cumulative . . O
dose . . O
of . . O
antipsychotic . . B-DrugClass
drugs . . I-DrugClass
administered . . O
to . . O
the . . O
patient . . O
increase . . O
. . . O

if . . O
signs . . O
and . . O
symptoms . . O
of . . O
td . . O
appear . . O
in . . O
a . . O
patient . . O
on . . O
saphris . . O
, . . O
drug . . O
discontinuation . . O
should . . O
be . . O
considered . . O
. . . O

however . . O
, . . O
some . . O
patients . . O
may . . O
require . . O
treatment . . O
with . . O
saphris . . O
despite . . O
the . . O
presence . . O
of . . O
the . . O
syndrome . . O
. . . O

patients . . O
with . . O
risk . . O
factors . . O
for . . O
diabetes . . O
mellitus . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
obesity . . O
, . . O
family . . O
history . . O
of . . O
diabetes . . O
) . . O
who . . O
are . . O
starting . . O
treatment . . O
with . . O
atypical . . O
antipsychotics . . O
should . . O
undergo . . O
fasting . . O
blood . . O
glucose . . O
testing . . O
at . . O
the . . O
beginning . . O
of . . O
treatment . . O
and . . O
periodically . . O
during . . O
treatment . . O
. . . O

any . . O
patient . . O
treated . . O
with . . O
atypical . . O
antipsychotics . . O
should . . O
be . . O
monitored . . O
for . . O
symptoms . . O
of . . O
hyperglycemia . . O
including . . O
polydipsia . . O
, . . O
polyuria . . O
, . . O
polyphagia . . O
, . . O
and . . O
weakness . . O
. . . O

table . . O
1 . . O
: . . O
changes . . O
in . . O
fasting . . O
glucose . . O
in . . O
adult . . O
patients . . O
n . . O
* . . O
= . . O
number . . O
of . . O
patients . . O
who . . O
had . . O
assessments . . O
at . . O
both . . O
baseline . . O
and . . O
endpoint . . O
. . . O

pediatric . . O
patients . . O
: . . O
data . . O
from . . O
the . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
trial . . O
in . . O
pediatric . . O
patients . . O
with . . O
bipolar . . O
i . . O
disorder . . O
are . . O
shown . . O
in . . O
table . . O
2 . . O
. . . O

table . . O
2 . . O
: . . O
changes . . O
in . . O
fasting . . O
glucose . . O
in . . O
pediatric . . O
subjects . . O
bipolar . . O
i . . O
disorder . . O
( . . O
3 . . O
- . . O
weeks . . O
) . . O
placebo . . O
saphris2.5 . . O
mgtwice . . O
daily . . O
saphris5 . . O
mgtwice . . O
daily . . O
saphris10 . . O
mgtwice . . O
daily . . O
mean . . O
change . . O
from . . O
baseline . . O
in . . O
fasting . . O
glucose . . O
at . . O
endpoint . . O
change . . O
from . . O
baseline . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
( . . O
n . . O
* . . O
) . . O
- . . O
2.24(56 . . O
) . . O
1.43(51 . . O
) . . O
- . . O
0.45(57 . . O
) . . O
0.34(52 . . O
) . . O
proportion . . O
of . . O
subjects . . O
with . . O
shifts . . O
from . . O
baseline . . O
to . . O
endpoint . . O
normal . . O
to . . O
high . . O
> . . O
45 . . O
& . . O
< . . O
100 . . O
to . . O
> . . O
= . . O
126 . . O
mg . . O
/ . . O
dl . . O
0% . . O
0% . . O
1.8% . . O
0% . . O
( . . O
n . . O
/ . . O
n . . O
* . . O
) . . O
( . . O
0 . . O
/ . . O
56 . . O
) . . O
( . . O
0 . . O
/ . . O
51 . . O
) . . O
( . . O
1 . . O
/ . . O
57 . . O
) . . O
( . . O
0 . . O
/ . . O
52 . . O
) . . O
dyslipidemia . . B-AdverseReaction

undesirable . . B-AdverseReaction
alterations . . I-AdverseReaction
in . . I-AdverseReaction
lipids . . I-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
atypical . . B-DrugClass
antipsychotics . . I-DrugClass
. . . O

table . . O
4 . . O
: . . O
changes . . O
in . . O
fasting . . O
lipids . . O
in . . O
pediatric . . O
subjects . . O
n . . O
* . . O
= . . O
number . . O
of . . O
patients . . O
who . . O
had . . O
assessments . . O
at . . O
both . . O
baseline . . O
and . . O
endpoint . . O
bipolar . . O
i . . O
disorder . . O
( . . O
3 . . O
- . . O
weeks . . O
) . . O
placebo . . O
saphris2.5 . . O
mgtwice . . O
daily . . O
saphris5 . . O
mgtwice . . O
daily . . O
saphris10 . . O
mgtwice . . O
daily . . O
mean . . O
change . . O
from . . O
baseline . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
total . . O
fasting . . O
cholesterol . . O
( . . O
n . . O
* . . O
) . . O
- . . O
2.3(57 . . O
) . . O
3.7(50 . . O
) . . O
7.2(57 . . O
) . . O
9.3(52 . . O
) . . O
fasting . . O
ldl . . O
( . . O
n . . O
* . . O
) . . O
- . . O
2.5(57 . . O
) . . O
- . . O
0.2(50 . . O
) . . O
3.0(57 . . O
) . . O
4.9(51 . . O
) . . O
fasting . . O
hdl . . O
( . . O
n . . O
* . . O
) . . O
1.6(57 . . O
) . . O
2.3(50 . . O
) . . O
1.5(57 . . O
) . . O
1.7(52 . . O
) . . O
fasting . . O
triglycerides . . O
( . . O
n . . O
* . . O
) . . O
- . . O
6.6(57 . . O
) . . O
8.7(50 . . O
) . . O
13.4(57 . . O
) . . O
14.7(52 . . O
) . . O
proportion . . O
of . . O
subjects . . O
with . . O
shifts . . O
from . . O
baseline . . O
to . . O
endpoint . . O
total . . O
fasting . . O
cholesterolnormal . . O
to . . O
high . . O
< . . O
170 . . O
to . . O
> . . O
= . . O
200 . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
( . . O
n . . O
/ . . O
n . . O
* . . O
) . . O
1.8% . . O
( . . O
1 . . O
/ . . O
57 . . O
) . . O
0% . . O
( . . O
0 . . O
/ . . O
50 . . O
) . . O
1.8% . . O
( . . O
1 . . O
/ . . O
57 . . O
) . . O
0% . . O
( . . O
0 . . O
/ . . O
52 . . O
) . . O
fasting . . O
ldlnormal . . O
to . . O
high . . O
< . . O
110 . . O
to . . O
> . . O
= . . O
130 . . O
( . . O
n . . O
/ . . O
n . . O
* . . O
) . . O
1.8% . . O
( . . O
1 . . O
/ . . O
57 . . O
) . . O
2.0% . . O
( . . O
1 . . O
/ . . O
50 . . O
) . . O
1.8% . . O
( . . O
1 . . O
/ . . O
57 . . O
) . . O
0% . . O
( . . O
0 . . O
/ . . O
51 . . O
) . . O
fasting . . O
hdlnormal . . O
to . . O
low . . O
> . . O
= . . O
40 . . O
to . . O
< . . O
40 . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
( . . O
n . . O
/ . . O
n . . O
* . . O
) . . O
3.5% . . O
( . . O
2 . . O
/ . . O
57 . . O
) . . O
6.0% . . O
( . . O
3 . . O
/ . . O
50 . . O
) . . O
3.5% . . O
( . . O
2 . . O
/ . . O
57 . . O
) . . O
9.6% . . O
( . . O
5 . . O
/ . . O
52 . . O
) . . O
fasting . . O
triglyceridesnormal . . O
to . . O
high . . O
< . . O
150 . . O
to . . O
> . . O
= . . O
200 . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
( . . O
n . . O
/ . . O
n . . O
* . . O
) . . O
0% . . O
( . . O
0 . . O
/ . . O
57 . . O
) . . O
4.0% . . O
( . . O
2 . . O
/ . . O
50 . . O
) . . O
3.5% . . O
( . . O
2 . . O
/ . . O
57 . . O
) . . O
1.9% . . O
( . . O
1 . . O
/ . . O
52 . . O
) . . O
weight . . O
gain . . O

patients . . O
receiving . . O
saphris . . O
should . . O
receive . . O
regular . . O
monitoring . . O
of . . O
weight . . O
[ . . O
see . . O
patient . . O
counseling . . O
information . . O
( . . O
17 . . O
) . . O
] . . O
. . . O

s . . O
includes . . O
subjects . . O
treated . . O
with . . O
flexible . . O
dose . . O
of . . O
saphris . . O
5 . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
( . . O
n . . O
= . . O
90 . . O
) . . O
. . . O

table . . O
6 . . O
: . . O
weight . . O
change . . O
results . . O
categorized . . O
by . . O
bmi . . O
at . . O
baseline . . O
: . . O
comparator . . O
- . . O
controlled . . O
52 . . O
- . . O
week . . O
study . . O
in . . O
adults . . O
with . . O
schizophrenia . . O
bmi . . O
< . . O
23 . . O
saphris . . O
n . . O
= . . O
295 . . O
bmi . . O
23 . . O
- . . O
< . . O
= . . O
27 . . O
saphris . . O
n . . O
= . . O
290 . . O
bmi . . O
> . . O
27 . . O
saphris . . O
n . . O
= . . O
302 . . O
mean . . O
change . . O
from . . O
baseline . . O
( . . O
kg . . O
) . . O
1.7 . . O
1 . . O
0 . . O
% . . O
with . . O
> . . O
= . . O
7% . . B-Severity
increase . . B-AdverseReaction
in . . I-AdverseReaction
body . . I-AdverseReaction
weight . . I-AdverseReaction
22% . . O
13% . . O
9% . . O
pediatric . . O
patients . . O
: . . O
data . . O
on . . O
mean . . O
changes . . B-AdverseReaction
in . . I-AdverseReaction
body . . I-AdverseReaction
weight . . I-AdverseReaction
and . . O
the . . O
proportion . . O
of . . O
pediatric . . O
patients . . O
meeting . . O
a . . O
weight . . B-AdverseReaction
gain . . I-AdverseReaction
criterion . . O
of . . O
> . . O
= . . O
7% . . B-Severity
of . . O
body . . O
weight . . O
from . . O
the . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
bipolar . . O
mania . . O
trial . . O
are . . O
presented . . O
in . . O
table . . O
7 . . O
. . . O

when . . O
treating . . O
pediatric . . O
patients . . O
, . . O
weight . . O
gain . . O
should . . O
be . . O
monitored . . O
and . . O
assessed . . O
against . . O
that . . O
expected . . O
for . . O
normal . . O
growth . . O
. . . O

these . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
included . . O
: . . O
anaphylaxis . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
swollen . . B-AdverseReaction
tongue . . I-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
wheezing . . B-AdverseReaction
and . . O
rash . . B-AdverseReaction
. . . O

saphris . . O
may . . B-Factor
induce . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
and . . O
syncope . . B-AdverseReaction
in . . O
some . . O
patients . . O
, . . O
especially . . O
early . . O
in . . O
treatment . . O
, . . O
because . . O
of . . O
its . . O
alpha1 . . O
- . . O
adrenergic . . O
antagonist . . O
activity . . O
. . . O

in . . O
short . . O
- . . O
term . . O
bipolar . . O
mania . . O
adult . . O
trials . . O
, . . O
syncope . . B-AdverseReaction
was . . O
reported . . O
in . . O
0.3% . . O
( . . O
1 . . O
/ . . O
379 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
therapeutic . . O
doses . . O
( . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
) . . O
of . . O
saphris . . O
, . . O
compared . . O
to . . O
0% . . O
( . . O
0 . . O
/ . . O
203 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
. . . O

saphris . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
( . . O
1 . . O
) . . O
patients . . O
with . . O
known . . O
cardiovascular . . O
disease . . O
( . . O
history . . O
of . . O
myocardial . . O
infarction . . O
or . . O
ischemic . . O
heart . . O
disease . . O
, . . O
heart . . O
failure . . O
or . . O
conduction . . O
abnormalities . . O
) . . O
, . . O
cerebrovascular . . O
disease . . O
, . . O
or . . O
conditions . . O
which . . O
would . . O
predispose . . O
patients . . O
to . . O
hypotension . . O
( . . O
dehydration . . O
, . . O
hypovolemia . . O
, . . O
and . . O
treatment . . O
with . . O
antihypertensive . . O
medications . . O
) . . O
; . . O
and . . O
( . . O
2 . . O
) . . O
in . . O
the . . O
elderly . . O
. . . O

in . . O
such . . O
patients . . O
, . . O
consider . . O
discontinuation . . O
of . . O
saphris . . O
at . . O
the . . O
first . . O
sign . . O
of . . O
a . . O
clinically . . O
significant . . O
decline . . O
in . . O
wbc . . O
in . . O
the . . O
absence . . O
of . . O
other . . O
causative . . O
factors . . O
. . . O

electrocardiogram . . O
( . . O
ecg . . O
) . . O
measurements . . O
were . . O
taken . . O
at . . O
various . . O
time . . O
points . . O
during . . O
the . . O
saphris . . O
clinical . . O
trial . . O
program . . O
( . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
doses . . O
) . . O
. . . O

the . . O
use . . O
of . . O
saphris . . O
should . . O
be . . O
avoided . . O
in . . O
combination . . O
with . . O
other . . O
drugs . . O
known . . O
to . . O
prolong . . O
qtc . . O
including . . O
class . . O
1a . . O
antiarrhythmics . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
quinidine . . O
, . . O
procainamide . . O
) . . O
or . . O
class . . O
3 . . O
antiarrhythmics . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
amiodarone . . O
, . . O
sotalol . . O
) . . O
, . . O
antipsychotic . . O
medications . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
ziprasidone . . O
, . . O
chlorpromazine . . O
, . . O
thioridazine . . O
) . . O
, . . O
and . . O
antibiotics . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
gatifloxacin . . O
, . . O
moxifloxacin . . O
) . . O
. . . O

saphris . . O
should . . O
also . . O
be . . O
avoided . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
cardiac . . O
arrhythmias . . O
and . . O
in . . O
other . . O
circumstances . . O
that . . O
may . . O
increase . . O
the . . O
risk . . O
of . . O
the . . O
occurrence . . O
of . . O
torsade . . O
de . . O
pointes . . O
and . . O
/ . . O
or . . O
sudden . . O
death . . O
in . . O
association . . O
with . . O
the . . O
use . . O
of . . O
drugs . . O
that . . O
prolong . . O
the . . O
qtc . . O
interval . . O
, . . O
including . . O
bradycardia . . O
; . . O
hypokalemia . . O
or . . O
hypomagnesemia . . O
; . . O
and . . O
presence . . O
of . . O
congenital . . O
prolongation . . O
of . . O
the . . O
qt . . O
interval . . O
. . . O

like . . O
other . . O
drugs . . O
that . . O
antagonize . . O
dopamine . . O
d2receptors . . O
, . . O
saphris . . O
can . . B-Factor
elevate . . B-AdverseReaction
prolactin . . I-AdverseReaction
levels . . I-AdverseReaction
, . . O
and . . O
the . . O
elevation . . O
can . . O
persist . . O
during . . O
chronic . . O
administration . . O
. . . O

this . . O
, . . O
in . . O
turn . . O
, . . O
may . . B-Factor
inhibit . . B-AdverseReaction
reproductive . . I-AdverseReaction
function . . I-AdverseReaction
by . . O
impairing . . B-AdverseReaction
gonadal . . I-AdverseReaction
steroidogenesis . . I-AdverseReaction
in . . O
both . . O
female . . O
and . . O
male . . O
patients . . O
. . . O

it . . O
was . . O
usually . . O
transient . . O
with . . O
the . . O
highest . . O
incidence . . O
reported . . O
during . . O
the . . O
first . . O
week . . O
of . . O
treatment . . O
. . . O

somnolence . . B-AdverseReaction
( . . O
including . . O
sedation . . B-AdverseReaction
) . . O
led . . O
to . . O
discontinuation . . O
in . . O
0.6% . . O
( . . O
12 . . O
/ . . O
1953 . . O
) . . O
of . . O
patients . . O
in . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

in . . O
the . . O
short . . O
- . . O
term . . O
placebo . . O
- . . O
controlled . . O
trials . . O
for . . O
both . . O
schizophrenia . . O
and . . O
acute . . O
bipolar . . O
disorder . . O
, . . O
the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
suggestive . . O
of . . O
body . . B-AdverseReaction
temperature . . I-AdverseReaction
increases . . I-AdverseReaction
was . . O
low . . O
( . . O
< . . O
= . . O
1% . . O
) . . O
and . . O
comparable . . O
to . . O
placebo . . O
( . . O
0% . . O
) . . O
. . . O

appropriate . . O
care . . O
is . . O
advised . . O
when . . O
prescribing . . O
saphris . . O
for . . O
patients . . O
who . . O
will . . O
be . . O
experiencing . . O
conditions . . O
that . . O
may . . O
contribute . . O
to . . O
an . . O
elevation . . O
in . . O
core . . O
body . . O
temperature . . O
, . . O
e . . O
. . . O
g . . O
. . . O
, . . O
exercising . . O
strenuously . . O
, . . O
exposure . . O
to . . O
extreme . . O
heat . . O
, . . O
receiving . . O
concomitant . . O
medication . . O
with . . O
anticholinergic . . O
activity . . O
, . . O
or . . O
being . . O
subject . . O
to . . O
dehydration . . O
. . . O

during . . O
adult . . O
pre . . O
- . . O
marketing . . O
clinical . . O
trials . . O
with . . O
saphris . . O
, . . O
including . . O
long . . O
- . . O
term . . O
trials . . O
without . . O
comparison . . O
to . . O
placebo . . O
, . . O
dysphagia . . B-AdverseReaction
was . . O
reported . . O
in . . O
0.1% . . O
( . . O
2 . . O
/ . . O
1953 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
. . . O

saphris . . O
has . . O
not . . O
been . . O
evaluated . . O
in . . O
patients . . O
with . . O
a . . O
recent . . O
history . . O
of . . O
myocardial . . O
infarction . . O
or . . O
unstable . . O
heart . . O
disease . . O
. . . O

because . . O
of . . O
the . . O
risk . . O
of . . O
orthostatic . . O
hypotension . . O
with . . O
saphris . . O
, . . O
caution . . O
should . . O
be . . O
observed . . O
in . . O
cardiac . . O
patients . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

premature . . O
discontinuation . . O
of . . O
any . . O
oral . . O
anticoagulant . . O
, . . O
including . . O
eliquis . . O
, . . O
in . . O
the . . O
absence . . O
of . . O
adequate . . O
alternative . . O
anticoagulation . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
. . . O

these . . O
include . . O
aspirin . . O
and . . O
other . . O
antiplatelet . . O
agents . . O
, . . O
other . . O
anticoagulants . . O
, . . O
heparin . . O
, . . O
thrombolytic . . O
agents . . O
, . . O
selective . . O
serotonin . . O
reuptake . . O
inhibitors . . O
, . . O
serotonin . . O
norepinephrine . . O
reuptake . . O
inhibitors . . O
, . . O
and . . O
nonsteroidal . . O
anti . . O
- . . O
inflammatory . . O
drugs . . O
( . . O
nsaids . . O
) . . O
[ . . O
seedrug . . O
interactions . . O
( . . O
7.3 . . O
) . . O
] . . O
. . . O

discontinue . . O
eliquis . . O
in . . O
patients . . O
with . . O
active . . O
pathological . . O
hemorrhage . . O
. . . O

a . . O
specific . . O
antidote . . O
for . . O
eliquis . . O
is . . O
not . . O
available . . O
. . . O

protamine . . O
sulfate . . O
and . . O
vitamin . . O
k . . O
are . . O
not . . O
expected . . O
to . . O
affect . . O
the . . O
anticoagulant . . O
activity . . O
of . . O
apixaban . . O
. . . O

use . . O
of . . O
procoagulant . . O
reversal . . O
agents . . O
such . . O
as . . O
prothrombin . . O
complex . . O
concentrate . . O
, . . O
activated . . O
prothrombin . . O
complex . . O
concentrate . . O
, . . O
or . . O
recombinant . . O
factor . . O
viia . . O
may . . O
be . . O
considered . . O
but . . O
has . . O
not . . O
been . . O
evaluated . . O
in . . O
clinical . . O
studies . . O
. . . O

the . . O
risk . . O
of . . O
these . . O
events . . O
may . . O
be . . O
increased . . O
by . . O
the . . O
postoperative . . O
use . . O
of . . O
indwelling . . O
epidural . . O
catheters . . O
or . . O
the . . O
concomitant . . O
use . . O
of . . O
medicinal . . O
products . . O
affecting . . O
hemostasis . . O
. . . O

monitor . . O
patients . . O
frequently . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
neurological . . O
impairment . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
numbness . . O
or . . O
weakness . . O
of . . O
the . . O
legs . . O
, . . O
bowel . . O
, . . O
or . . O
bladder . . O
dysfunction . . O
) . . O
. . . O

5.4 . . O
patients . . O
with . . O
prosthetic . . O
heart . . O
valves . . O

5.5 . . O
acute . . O
pe . . O
in . . O
hemodynamically . . O
unstable . . O
patients . . O
or . . O
patients . . O
who . . O
require . . O
thrombolysis . . O
or . . O
pulmonary . . O
embolectomy . . O

the . . O
most . . O
serious . . O
adverse . . O
reactions . . O
reported . . O
with . . O
alglucosidase . . O
alfa . . O
treatment . . O
included . . O
anaphylaxis . . B-AdverseReaction
and . . O
acute . . B-AdverseReaction
cardiorespiratory . . I-AdverseReaction
failure . . I-AdverseReaction
. . . O

adverse . . O
reactions . . O
observed . . O
in . . O
these . . O
patients . . O
were . . O
similar . . O
to . . O
infantile . . O
- . . O
onset . . O
pompe . . O
disease . . O
patients . . O
who . . O
received . . O
alglucosidase . . O
alfa . . O
in . . O
other . . O
clinical . . O
trials . . O
. . . O

patients . . O
were . . O
aged . . O
1 . . O
to . . O
18 . . O
years . . O
with . . O
a . . O
median . . O
duration . . O
of . . O
treatment . . O
of . . O
437 . . O
days . . O
( . . O
range . . O
13 . . O
to . . O
466 . . O
days . . O
) . . O
. . . O

serious . . O
adverse . . O
reactions . . O
reported . . O
with . . O
alglucosidase . . O
alfa . . O
included . . O
anaphylaxis . . B-AdverseReaction
, . . O
which . . O
presented . . O
as . . O
angioedema . . B-AdverseReaction
, . . O
throat . . B-AdverseReaction
tightness . . I-AdverseReaction
and . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
/ . . O
discomfort . . O
. . . O

additional . . O
delayed . . O
- . . O
onset . . O
reactions . . O
occurring . . O
in . . O
alglucosidase . . O
alfa . . O
- . . O
treated . . O
patients . . O
included . . O
fatigue . . B-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
, . . O
and . . O
nausea . . B-AdverseReaction
. . . O

6.2 . . O
immunogenicity . . O

some . . O
patients . . O
who . . O
tested . . O
positive . . O
for . . O
alglucosidase . . O
alfa . . O
- . . O
specific . . O
ige . . O
antibodies . . O
and . . O
experienced . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
were . . O
able . . O
to . . O
be . . O
rechallenged . . O
with . . O
alglucosidase . . O
alfa . . O
using . . O
a . . O
slower . . O
infusion . . O
rate . . O
at . . O
lower . . O
starting . . O
doses . . O
and . . O
have . . O
continued . . O
to . . O
receive . . O
treatment . . O
under . . O
close . . O
clinical . . O
supervision . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

since . . O
patients . . O
who . . O
develop . . O
ige . . O
antibodies . . O
to . . O
alglucosidase . . O
alfa . . O
appear . . O
to . . O
be . . O
at . . O
a . . O
higher . . O
risk . . O
for . . O
developing . . O
anaphylaxis . . O
and . . O
hypersensitivity . . O
reactions . . O
, . . O
these . . O
patients . . O
should . . O
be . . O
monitored . . O
more . . O
closely . . O
during . . O
administration . . O
of . . O
alglucosidase . . O
alfa . . O
. . . O

in . . O
postmarketing . . O
experience . . O
with . . O
alglucosidase . . O
alfa . . O
, . . O
serious . . O
adverse . . O
reactions . . O
have . . O
been . . O
reported . . O
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
[ . . O
seeboxed . . O
warningandwarnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

recurrent . . O
reactions . . O
consisting . . O
of . . O
flu . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
illness . . I-AdverseReaction
or . . O
a . . O
combination . . O
of . . O
events . . O
such . . O
as . . O
pyrexia . . B-AdverseReaction
, . . O
chills . . B-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
pain . . B-AdverseReaction
, . . O
or . . O
fatigue . . B-AdverseReaction
occurring . . O
after . . O
completion . . O
of . . O
infusions . . O
and . . O
lasting . . O
usually . . O
for . . O
1 . . O
- . . O
3 . . O
days . . O
have . . O
been . . O
observed . . O
in . . O
some . . O
patients . . O
treated . . O
with . . O
alglucosidase . . O
alfa . . O
. . . O

in . . O
addition . . O
to . . O
the . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
reported . . O
in . . O
clinical . . O
trials . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
, . . O
the . . O
following . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
at . . O
least . . O
2 . . O
patients . . O
and . . O
included . . O
: . . O
anaphylactic . . B-AdverseReaction
shock . . I-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
arrest . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
arrest . . I-AdverseReaction
, . . O
hypoxia . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
wheezing . . B-AdverseReaction
, . . O
convulsions . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
coldness . . I-AdverseReaction
, . . O
restlessness . . B-AdverseReaction
, . . O
nervousness . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
stridor . . B-AdverseReaction
, . . O
pharyngeal . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
apnea . . B-AdverseReaction
, . . O
muscle . . B-AdverseReaction
spasm . . I-AdverseReaction
, . . O
and . . O
conjunctivitis . . B-AdverseReaction
. . . O

( . . O
5.1 . . O
) . . O
* . . O
infections . . B-AdverseReaction
: . . O
monitor . . O
for . . O
fever . . O
and . . O
other . . O
signs . . O
of . . O
infection . . O
and . . O
treat . . O
promptly . . O
. . . O

women . . O
should . . O
be . . O
advised . . O
to . . O
avoid . . O
becoming . . O
pregnant . . O
when . . O
receiving . . O
treanda . . O
. . . O

( . . O
5.8 . . O
, . . O
8.1 . . O
) . . O

three . . O
patients . . O
( . . O
2% . . O
) . . O
died . . B-AdverseReaction
from . . O
myelosuppression . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
; . . O
one . . O
each . . O
from . . O
neutropenic . . B-AdverseReaction
sepsis . . I-AdverseReaction
, . . O
diffuse . . B-AdverseReaction
alveolar . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
with . . O
grade . . B-Severity
3 . . O
thrombocytopenia . . B-AdverseReaction
, . . O
and . . O
pneumonia . . B-AdverseReaction
from . . O
an . . O
opportunistic . . B-AdverseReaction
infection . . I-AdverseReaction
( . . O
cmv . . O
) . . O
. . . O

5.3 . . O
anaphylaxis . . O
and . . O
infusion . . O
reactions . . O

monitor . . O
clinically . . O
and . . O
discontinue . . O
drug . . O
for . . O
severe . . O
reactions . . O
. . . O

patients . . O
who . . O
experience . . O
grade . . O
3 . . O
or . . O
worse . . O
allergic . . O
- . . O
type . . O
reactions . . O
should . . O
not . . O
be . . O
rechallenged . . O
. . . O

however . . O
, . . O
there . . O
may . . O
be . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
severe . . B-Severity
skin . . B-AdverseReaction
toxicity . . I-AdverseReaction
when . . O
treanda . . O
and . . O
allopurinol . . O
are . . O
administered . . O
concomitantly . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

5.5 . . O
skin . . O
reactions . . O

in . . O
a . . O
study . . O
of . . O
treanda . . O
( . . O
90 . . O
mg . . O
/ . . O
m . . O
2 . . O
) . . O
in . . O
combination . . O
with . . O
rituximab . . O
, . . O
one . . O
case . . O
of . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
( . . O
ten . . B-AdverseReaction
) . . O
occurred . . O
. . . O

ten . . O
has . . O
been . . O
reported . . O
for . . O
rituximab . . O
( . . O
see . . O
rituximab . . O
package . . O
insert . . O
) . . O
. . . O

where . . O
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
occur . . O
, . . O
they . . O
may . . O
be . . O
progressive . . O
and . . O
increase . . O
in . . O
severity . . O
with . . O
further . . O
treatment . . O
. . . O

5.7 . . O
extravasation . . O
injury . . O

[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O

6 . . O
adverse . . O
reactions . . O

the . . O
following . . O
important . . O
adverse . . O
reactions . . O
are . . O
described . . O
below . . O
and . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

in . . O
4 . . O
studies . . O
farxiga . . O
was . . O
used . . O
as . . O
monotherapy . . O
, . . O
and . . O
in . . O
8 . . O
studies . . O
farxiga . . O
was . . O
used . . O
as . . O
add . . O
- . . O
on . . O
to . . O
background . . O
antidiabetic . . O
therapy . . O
or . . O
as . . O
combination . . O
therapy . . O
with . . O
metformin . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

the . . O
mean . . O
age . . O
of . . O
the . . O
population . . O
was . . O
55 . . O
years . . O
and . . O
2% . . O
were . . O
older . . O
than . . O
75 . . O
years . . O
of . . O
age . . O
. . . O

table . . O
1 . . O
shows . . O
common . . O
adverse . . O
reactions . . O
associated . . O
with . . O
the . . O
use . . O
of . . O
farxiga . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
in . . O
placebo . . O
- . . O
controlled . . O
studies . . O
reported . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
farxiga . . O
adverse . . O
reaction . . O
% . . O
of . . O
patients . . O
pool . . O
of . . O
12 . . O
placebo . . O
- . . O
controlled . . O
studies . . O
placebo . . O
n . . O
= . . O
1393 . . O
farxiga . . O
5 . . O
mg . . O
n . . O
= . . O
1145 . . O
farxiga . . O
10 . . O
mg . . O
n . . O
= . . O
1193 . . O
female . . O
genital . . O
mycotic . . O
infectionsgenital . . O
mycotic . . O
infections . . O
include . . O
the . . O
following . . O
adverse . . O
reactions . . O
, . . O
listed . . O
in . . O
order . . O
of . . O
frequency . . O
reported . . O
for . . O
females . . O
: . . O
vulvovaginal . . B-AdverseReaction
mycotic . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
vaginal . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
vulvovaginal . . B-AdverseReaction
candidiasis . . I-AdverseReaction
, . . O
vulvovaginitis . . B-AdverseReaction
, . . O
genital . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
genital . . B-AdverseReaction
candidiasis . . I-AdverseReaction
, . . O
fungal . . B-AdverseReaction
genital . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
vulvitis . . B-AdverseReaction
, . . O
genitourinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
vulval . . B-AdverseReaction
abscess . . I-AdverseReaction
, . . O
and . . O
vaginitis . . B-AdverseReaction
bacterial . . I-AdverseReaction
. . . O

( . . O
n . . O
for . . O
females . . O
: . . O
placebo . . O
= . . O
677 . . O
, . . O
farxiga . . O
5 . . O
mg . . O
= . . O
581 . . O
, . . O
farxiga . . O
10 . . O
mg . . O
= . . O
598 . . O
) . . O
. . . O

1.7 . . O
2.9 . . O
3.8 . . O
male . . O
genital . . O
mycotic . . O
infectionsgenital . . O
mycotic . . O
infections . . O
include . . O
the . . O
following . . O
adverse . . O
reactions . . O
, . . O
listed . . O
in . . O
order . . O
of . . O
frequency . . O
reported . . O
for . . O
males . . O
: . . O
balanitis . . B-AdverseReaction
, . . O
fungal . . B-AdverseReaction
genital . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
balanitis . . B-AdverseReaction
candida . . I-AdverseReaction
, . . O
genital . . B-AdverseReaction
candidiasis . . I-AdverseReaction
, . . O
genital . . B-AdverseReaction
infection . . I-AdverseReaction
male . . I-AdverseReaction
, . . O
penile . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
balanoposthitis . . B-AdverseReaction
, . . O
balanoposthitis . . B-AdverseReaction
infective . . I-AdverseReaction
, . . O
genital . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
posthitis . . B-AdverseReaction
. . . O

0.3 . . O
2.8 . . O
2.7 . . O
nausea . . B-AdverseReaction
2.4 . . O
2.8 . . O
2.5 . . O
influenza . . B-AdverseReaction
2.3 . . O
2.7 . . O
2.3 . . O
dyslipidemia . . B-AdverseReaction
1.5 . . O
2.1 . . O
2.5 . . O
constipation . . B-AdverseReaction
1.5 . . O
2.2 . . O
1.9 . . O
discomfort . . B-AdverseReaction
with . . I-AdverseReaction
urination . . I-AdverseReaction
0.7 . . O
1.6 . . O
2.1 . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
1.4 . . O
2.0 . . O
1.7 . . O
pool . . O
of . . O
13 . . O
placebo . . O
- . . O
controlled . . O
studies . . O
for . . O
farxiga . . O
10 . . O
mg . . O
the . . O
safety . . O
and . . O
tolerability . . O
of . . O
farxiga . . O
10 . . O
mg . . O
was . . O
also . . O
evaluated . . O
in . . O
a . . O
larger . . O
placebo . . O
- . . O
controlled . . O
study . . O
pool . . O
. . . O

at . . O
baseline . . O
, . . O
the . . O
population . . O
had . . O
diabetes . . O
for . . O
an . . O
average . . O
of . . O
9 . . O
years . . O
, . . O
had . . O
a . . O
mean . . O
hba1c . . O
of . . O
8.2% . . O
, . . O
and . . O
30% . . O
had . . O
established . . O
microvascular . . O
disease . . O
. . . O

volume . . O
depletion . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
of . . O
volume . . O
depletionvolume . . O
depletion . . O
includes . . O
reports . . O
of . . O
dehydration . . B-AdverseReaction
, . . O
hypovolemia . . B-AdverseReaction
, . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
, . . O
or . . O
hypotension . . B-AdverseReaction
. . . O
in . . O
clinical . . O
studies . . O
with . . O
farxiga . . O
pool . . O
of . . O
12 . . O
placebo . . O
- . . O
controlled . . O
studies . . O
pool . . O
of . . O
13 . . O
placebo . . O
- . . O
controlled . . O
studies . . O
placebo . . O
farxiga . . O
5 . . O
mg . . O
farxiga . . O
10 . . O
mg . . O
placebo . . O
farxiga . . O
10 . . O
mg . . O
overall . . O
population . . O
n . . O
( . . O
% . . O
) . . O
n . . O
= . . O
1393 . . O
5 . . O
( . . O
0.4% . . O
) . . O
n . . O
= . . O
1145 . . O
7 . . O
( . . O
0.6% . . O
) . . O
n . . O
= . . O
1193 . . O
9 . . O
( . . O
0.8% . . O
) . . O
n . . O
= . . O
2295 . . O
17 . . O
( . . O
0.7% . . O
) . . O
n . . O
= . . O
2360 . . O
27 . . O
( . . O
1.1% . . O
) . . O
patient . . O
subgroup . . O
n . . O
( . . O
% . . O
) . . O
patients . . O
on . . O
loop . . O
diuretics . . O
n . . O
= . . O
551 . . O
( . . O
1.8% . . O
) . . O
n . . O
= . . O
400 . . O
n . . O
= . . O
313 . . O
( . . O
9.7% . . O
) . . O
n . . O
= . . O
2674 . . O
( . . O
1.5% . . O
) . . O
n . . O
= . . O
2366 . . O
( . . O
2.5% . . O
) . . O
patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
with . . O
egfr . . O
> . . O
= . . O
30 . . O
and . . O
< . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m2 . . O
n . . O
= . . O
1072 . . O
( . . O
1.9% . . O
) . . O
n . . O
= . . O
1071 . . O
( . . O
0.9% . . O
) . . O
n . . O
= . . O
891 . . O
( . . O
1.1% . . O
) . . O
n . . O
= . . O
2684 . . O
( . . O
1.5% . . O
) . . O
n . . O
= . . O
2655 . . O
( . . O
1.9% . . O
) . . O
patients . . O
> . . O
= . . O
65 . . O
years . . O
of . . O
age . . O
n . . O
= . . O
2761 . . O
( . . O
0.4% . . O
) . . O
n . . O
= . . O
2161 . . O
( . . O
0.5% . . O
) . . O
n . . O
= . . O
2043 . . O
( . . O
1.5% . . O
) . . O
n . . O
= . . O
7116 . . O
( . . O
0.8% . . O
) . . O
n . . O
= . . O
66511 . . O
( . . O
1.7% . . O
) . . O
impairment . . O
of . . O
renal . . O
function . . O
use . . O
of . . O
farxiga . . O
was . . O
associated . . O
with . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
and . . O
decreases . . B-AdverseReaction
in . . I-AdverseReaction
egfr . . I-AdverseReaction
( . . O
see . . O
table . . O
3 . . O
) . . O
. . . O

in . . O
this . . O
study . . O
13 . . O
patients . . O
experienced . . O
bone . . B-AdverseReaction
fractures . . I-AdverseReaction
for . . O
treatment . . O
durations . . O
up . . O
to . . O
104 . . O
weeks . . O
. . . O

hypersensitivity . . O
reactions . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
angioedema . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
) . . O
were . . O
reported . . O
with . . O
farxiga . . O
treatment . . O
. . . O

increase . . O
in . . O
low . . O
- . . O
density . . O
lipoprotein . . O
cholesterol . . O

( . . O
5.2 . . O
) . . O
* . . O
there . . O
is . . O
a . . O
potential . . O
risk . . O
of . . O
arterial . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
following . . O
intravitreal . . O
use . . O
of . . O
vegf . . B-DrugClass
inhibitors . . I-DrugClass
. . . O

5.2 . . O
increase . . O
in . . O
intraocular . . O
pressure . . O

acute . . B-AdverseReaction
increases . . I-AdverseReaction
in . . I-AdverseReaction
intraocular . . I-AdverseReaction
pressure . . I-AdverseReaction
have . . O
been . . O
seen . . O
within . . O
60 . . O
minutes . . O
of . . O
intravitreal . . O
injection . . O
, . . O
including . . O
with . . O
eylea . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

sustained . . B-AdverseReaction
increases . . I-AdverseReaction
in . . I-AdverseReaction
intraocular . . I-AdverseReaction
pressure . . I-AdverseReaction
have . . O
also . . O
been . . O
reported . . O
after . . O
repeated . . O
intravitreal . . O
dosing . . O
with . . O
vascular . . O
endothelial . . O
growth . . O
factor . . O
( . . O
vegf . . O
) . . O
inhibitors . . O
. . . O

intraocular . . O
pressure . . O
and . . O
the . . O
perfusion . . O
of . . O
the . . O
optic . . O
nerve . . O
head . . O
should . . O
be . . O
monitored . . O
and . . O
managed . . O
appropriately . . O
[ . . O
seedosage . . O
and . . O
administration . . O
( . . O
2.7 . . O
) . . O
] . . O
. . . O

there . . O
is . . O
a . . O
potential . . O
risk . . B-Factor
of . . O
arterial . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
ates . . B-AdverseReaction
) . . O
following . . O
intravitreal . . O
use . . O
of . . O
vegf . . O
inhibitors . . O
, . . O
including . . O
eylea . . O
. . . O

the . . O
incidence . . O
of . . O
reported . . O
thromboembolic . . B-AdverseReaction
events . . I-AdverseReaction
in . . O
wet . . O
amd . . O
studies . . O
during . . O
the . . O
first . . O
year . . O
was . . O
1.8% . . O
( . . O
32 . . O
out . . O
of . . O
1824 . . O
) . . O
in . . O
the . . O
combined . . O
group . . O
of . . O
patients . . O
treated . . O
with . . O
eylea . . O
. . . O

of . . O
thrombotic . . O
events . . O
, . . O
( . . O
b . . O
) . . O
spinal . . O
/ . . O
epidural . . B-AdverseReaction
hematoma . . I-AdverseReaction

( . . O
a . . O
) . . O
premature . . O
discontinuation . . O

discontinuation . . O
of . . O
any . . O
oral . . O
anticoagulant . . O
, . . O
including . . O
pradaxa . . O
, . . O
increases . . O

if . . O
anticoagulation . . O
with . . O
pradaxa . . O
is . . O

discontinued . . O
for . . O
a . . O
reason . . O
other . . O
than . . O
pathological . . O
bleeding . . O
or . . O
completion . . O

hematomaepidural . . O
or . . O
spinal . . B-AdverseReaction
hematomas . . I-AdverseReaction
may . . B-Factor
occur . . O
in . . O
patients . . O

procedures . . O
. . . O

or . . O
spinal . . O
hematomas . . O
in . . O
these . . O
patients . . O
include . . O
: . . O

use . . O
of . . O
indwelling . . O
epidural . . O
catheters . . O
concomitant . . O
use . . O
of . . O
other . . O
drugs . . O
that . . O
affect . . O
hemostasis . . O
, . . O
such . . O
as . . O

of . . O
pradaxa . . O
and . . O
neuraxial . . O
procedures . . O
is . . O
not . . O
known . . O
[ . . O
see . . O
warnings . . O

pradaxa . . O
, . . O
increases . . O
the . . O
risk . . O
of . . O
thrombotic . . O
events . . O
. . . O

risk . . O
, . . O
consider . . O
coverage . . O
with . . O
another . . O
anticoagulant . . O
if . . O
pradaxa . . O
is . . O
discontinued . . O

need . . O
to . . O
be . . O
anticoagulated . . O
( . . O
5.3 . . O
) . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

( . . O
5.3 . . O
) . . O
* . . O
candida . . B-AdverseReaction
albicans . . I-AdverseReaction
infection . . I-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
mouth . . I-AdverseReaction
and . . O
pharynx . . O
may . . B-Factor
occur . . O
. . . O

use . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
these . . O
infections . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
risk . . B-Factor
of . . O
impaired . . B-AdverseReaction
adrenal . . I-AdverseReaction
function . . I-AdverseReaction
when . . O
transferring . . O
from . . O
systemic . . O
corticosteroids . . O
. . . O

if . . O
such . . O
changes . . O
occur . . O
, . . O
discontinue . . O
breo . . O
ellipta . . O
slowly . . O
. . . O

( . . O
5.14 . . O
) . . O
* . . O
use . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
convulsive . . O
disorders . . O
, . . O
thyrotoxicosis . . O
, . . O
diabetes . . O
mellitus . . O
, . . O
and . . O
ketoacidosis . . O
. . . O

laba . . B-DrugClass
, . . O
such . . O
as . . O
vilanterol . . O
, . . O
one . . O
of . . O
the . . O
active . . O
ingredients . . O
in . . O
breo . . O
ellipta . . O
, . . O
increase . . O
the . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
. . . O

currently . . O
available . . O
data . . O
are . . O
inadequate . . O
to . . O
determine . . O
whether . . O
concurrent . . O
use . . O
of . . O
inhaled . . O
corticosteroids . . O
or . . O
other . . O
long . . O
- . . O
term . . O
asthma . . O
control . . O
drugs . . O
mitigates . . O
the . . O
increased . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
from . . O
laba . . B-DrugClass
. . . O

therefore . . O
, . . O
when . . O
treating . . O
patients . . O
with . . O
asthma . . O
, . . O
physicians . . O
should . . O
only . . O
prescribe . . O
breo . . O
ellipta . . O
for . . O
patients . . O
not . . O
adequately . . O
controlled . . O
on . . O
a . . O
long . . O
- . . O
term . . O
asthma . . O
control . . O
medication . . O
, . . O
such . . O
as . . O
an . . O
inhaled . . O
corticosteroid . . O
, . . O
or . . O
whose . . O
disease . . O
severity . . O
clearly . . O
warrants . . O
initiation . . O
of . . O
treatment . . O
with . . O
both . . O
an . . O
inhaled . . O
corticosteroid . . O
and . . O
a . . O
laba . . O
. . . O

once . . O
asthma . . O
control . . O
is . . O
achieved . . O
and . . O
maintained . . O
, . . O
assess . . O
the . . O
patient . . O
at . . O
regular . . O
intervals . . O
and . . O
step . . O
down . . O
therapy . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
discontinue . . O
breo . . O
ellipta . . O
) . . O
if . . O
possible . . O
without . . O
loss . . O
of . . O
asthma . . O
control . . O
and . . O
maintain . . O
the . . O
patient . . O
on . . O
a . . O
long . . O
- . . O
term . . O
asthma . . O
control . . O
medication . . O
, . . O
such . . O
as . . O
an . . O
inhaled . . O
corticosteroid . . O
. . . O

a . . O
28 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
us . . O
trial . . O
that . . O
compared . . O
the . . O
safety . . O
of . . O
another . . O
laba . . B-DrugClass
( . . O
salmeterol . . O
) . . O
with . . O
placebo . . O
, . . O
each . . O
added . . O
to . . O
usual . . O
asthma . . O
therapy . . O
, . . O
showed . . O
an . . O
increase . . O
in . . O
asthma . . O
- . . O
related . . O
deaths . . B-AdverseReaction
in . . O
subjects . . O
receiving . . O
salmeterol . . O
( . . O
13 . . O
/ . . O
13,176 . . O
in . . O
subjects . . O
treated . . O
with . . O
salmeterol . . O
vs . . O
. . . O
3 . . O
/ . . O
13,179 . . O
in . . O
subjects . . O
treated . . O
with . . O
placebo . . O
; . . O
relative . . O
risk . . O
: . . O
4.37 . . O
[ . . O
95% . . O
ci . . O
: . . O
1.25 . . O
, . . O
15.34 . . O
] . . O
) . . O
. . . O

breo . . O
ellipta . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
subjects . . O
with . . O
acutely . . O
deteriorating . . O
copd . . O
or . . O
asthma . . O
. . . O

the . . O
initiation . . O
of . . O
breo . . O
ellipta . . O
in . . O
this . . O
setting . . O
is . . O
not . . O
appropriate . . O
. . . O

in . . O
this . . O
setting . . O
a . . O
reevaluation . . O
of . . O
the . . O
patient . . O
and . . O
the . . O
copd . . O
treatment . . O
regimen . . O
should . . O
be . . O
undertaken . . O
at . . O
once . . O
. . . O

for . . O
copd . . O
, . . O
increasing . . O
the . . O
daily . . O
dose . . O
of . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
is . . O
not . . O
appropriate . . O
in . . O
this . . O
situation . . O
. . . O

increasing . . O
use . . O
of . . O
inhaled . . O
, . . O
short . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonists . . O
is . . O
a . . O
marker . . O
of . . O
deteriorating . . O
asthma . . O
. . . O

when . . O
beginning . . O
treatment . . O
with . . O
breo . . O
ellipta . . O
, . . O
patients . . O
who . . O
have . . O
been . . O
taking . . O
oral . . O
or . . O
inhaled . . O
, . . O
short . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonists . . O
on . . O
a . . O
regular . . O
basis . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
4 . . O
times . . O
a . . O
day . . O
) . . O
should . . O
be . . O
instructed . . O
to . . O
discontinue . . O
the . . O
regular . . O
use . . O
of . . O
these . . O
drugs . . O
and . . O
to . . O
use . . O
them . . O
only . . O
for . . O
symptomatic . . O
relief . . O
of . . O
acute . . O
respiratory . . O
symptoms . . O
. . . O

breo . . O
ellipta . . O
should . . O
not . . O
be . . O
used . . O
more . . O
often . . O
than . . O
recommended . . O
, . . O
at . . O
higher . . O
doses . . O
than . . O
recommended . . O
, . . O
or . . O
in . . O
conjunction . . O
with . . O
other . . O
medicines . . O
containing . . O
laba . . O
, . . O
as . . O
an . . O
overdose . . O
may . . O
result . . O
. . . O

advise . . O
the . . O
patient . . O
to . . O
rinse . . O
his . . O
/ . . O
her . . O
mouth . . O
with . . O
water . . O
without . . O
swallowing . . O
following . . O
inhalation . . O
to . . O
help . . O
reduce . . O
the . . O
risk . . O
of . . O
oropharyngeal . . O
candidiasis . . O
. . . O

in . . O
some . . O
incidences . . O
these . . O
pneumonia . . B-AdverseReaction
events . . O
were . . O
fatal . . B-AdverseReaction
. . . O

during . . O
this . . O
period . . O
of . . O
hpa . . O
suppression . . O
, . . O
patients . . O
may . . O
exhibit . . O
signs . . O
and . . O
symptoms . . O
of . . O
adrenal . . O
insufficiency . . O
when . . O
exposed . . O
to . . O
trauma . . O
, . . O
surgery . . O
, . . O
or . . O
infection . . O
( . . O
particularly . . O
gastroenteritis . . O
) . . O
or . . O
other . . O
conditions . . O
associated . . O
with . . O
severe . . O
electrolyte . . O
loss . . O
. . . O

transfer . . O
of . . O
patients . . O
from . . O
systemic . . O
corticosteroid . . O
therapy . . O
to . . O
breo . . O
ellipta . . O
may . . O
unmask . . O
allergic . . O
conditions . . O
previously . . O
suppressed . . O
by . . O
the . . O
systemic . . O
corticosteroid . . O
therapy . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
rhinitis . . O
, . . O
conjunctivitis . . O
, . . O
eczema . . O
, . . O
arthritis . . O
, . . O
eosinophilic . . O
conditions . . O
) . . O
. . . O

however . . O
, . . O
exceeding . . O
the . . O
recommended . . O
dosage . . O
or . . O
coadministration . . O
with . . O
a . . O
strong . . O
cytochrome . . O
p450 . . O
3a4 . . O
( . . O
cyp3a4 . . O
) . . O
inhibitor . . O
may . . B-Factor
result . . O
in . . O
hpa . . B-AdverseReaction
dysfunction . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
, . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

particular . . O
care . . O
should . . O
be . . O
taken . . O
in . . O
observing . . O
patients . . O
postoperatively . . O
or . . O
during . . O
periods . . O
of . . O
stress . . O
for . . O
evidence . . O
of . . O
inadequate . . O
adrenal . . O
response . . O
. . . O

as . . O
with . . O
other . . O
inhaled . . O
medicines . . O
, . . O
breo . . O
ellipta . . O
can . . B-Factor
produce . . O
paradoxical . . O
bronchospasm . . O
, . . O
which . . O
may . . B-Factor
be . . O
life . . B-Severity
threatening . . I-Severity
. . . O

if . . O
paradoxical . . O
bronchospasm . . O
occurs . . O
following . . O
dosing . . O
with . . O
breo . . O
ellipta . . O
, . . O
it . . O
should . . O
be . . O
treated . . O
immediately . . O
with . . O
an . . O
inhaled . . O
, . . O
short . . O
- . . O
acting . . O
bronchodilator . . O
; . . O
breo . . O
ellipta . . O
should . . O
be . . O
discontinued . . O
immediately . . O
; . . O
and . . O
alternative . . O
therapy . . O
should . . O
be . . O
instituted . . O
. . . O

discontinue . . O
breo . . O
ellipta . . O
if . . O
such . . O
reactions . . O
occur . . O
. . . O

in . . O
healthy . . O
subjects . . O
, . . O
large . . O
doses . . O
of . . O
inhaled . . O
fluticasone . . O
furoate . . O
/ . . O
vilanterol . . O
( . . O
4 . . O
times . . O
the . . O
recommended . . O
dose . . O
of . . O
vilanterol . . O
, . . O
representing . . O
a . . O
12 . . O
- . . O
or . . O
10 . . O
- . . O
fold . . O
higher . . O
systemic . . O
exposure . . O
than . . O
seen . . O
in . . O
subjects . . O
with . . O
copd . . O
or . . O
asthma . . O
, . . O
respectively . . O
) . . O
have . . O
been . . O
associated . . O
with . . O
clinically . . B-Severity
significant . . I-Severity
prolongation . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
qtc . . I-AdverseReaction
interval . . I-AdverseReaction
, . . O
which . . O
has . . O
the . . O
potential . . B-Factor
for . . O
producing . . O
ventricular . . B-AdverseReaction
arrhythmias . . I-AdverseReaction
. . . O

therefore . . O
, . . O
breo . . O
ellipta . . O
, . . O
like . . O
other . . O
sympathomimetic . . O
amines . . O
, . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
cardiovascular . . O
disorders . . O
, . . O
especially . . O
coronary . . O
insufficiency . . O
, . . O
cardiac . . O
arrhythmias . . O
, . . O
and . . O
hypertension . . O
. . . O

breo . . O
ellipta . . O
, . . O
like . . O
all . . O
medicines . . O
containing . . O
sympathomimetic . . O
amines . . O
, . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
convulsive . . O
disorders . . O
or . . O
thyrotoxicosis . . O
and . . O
in . . O
those . . O
who . . O
are . . O
unusually . . O
responsive . . O
to . . O
sympathomimetic . . O
amines . . O
. . . O

[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.4 . . O
) . . O
. . . O
] . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
risk . . B-Factor
of . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction

it . . O
is . . O
unknown . . B-Factor
whether . . O
trulicity . . O
causes . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
, . . O
including . . O
medullary . . B-AdverseReaction
thyroid . . I-AdverseReaction
carcinoma . . I-AdverseReaction
( . . O
mtc . . B-AdverseReaction
) . . O
, . . O
in . . O
humans . . O
as . . O
the . . O
human . . O
relevance . . O
of . . O
dulaglutide . . O
- . . O
induced . . O
rodent . . B-Animal
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
has . . O
not . . O
been . . O
determined . . O
( . . O
5.1 . . O
, . . O
13.1 . . O
) . . O
. . . O

counsel . . O
patients . . O
regarding . . O
the . . O
potential . . O
risk . . O
of . . O
mtc . . O
and . . O
symptoms . . O
of . . O
thyroid . . O
tumors . . O
( . . O
4.1 . . O
, . . O
5.1 . . O
) . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reaction . . O
( . . O
incidence . . O
> . . O
= . . O
1.5% . . O
) . . O
occurring . . O
with . . O
a . . O
higher . . O
frequency . . O
than . . O
placebo . . O
among . . O
entereg . . O
- . . O
treated . . O
patients . . O
undergoing . . O
surgeries . . O
that . . O
included . . O
a . . O
bowel . . O
resection . . O
was . . O
dyspepsia . . B-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
merck . . O
sharp . . O
& . . O
dohme . . O
corp . . O
. . . O
, . . O
a . . O
subsidiary . . O
of . . O
merck . . O
& . . O
co . . O
. . . O
, . . O
inc . . O
. . . O
, . . O
at . . O
1-877-888-4231 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
compared . . O
directly . . O
with . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

the . . O
adverse . . O
event . . O
information . . O
from . . O
clinical . . O
trials . . O
does . . O
, . . O
however . . O
, . . O
provide . . O
a . . O
basis . . O
for . . O
identifying . . O
the . . O
adverse . . O
events . . O
that . . O
appear . . O
to . . O
be . . O
related . . O
to . . O
drug . . O
use . . O
and . . O
for . . O
approximating . . O
rates . . O
. . . O

6 . . O
adverse . . O
reactions . . O

excerpt . . O
: . . O
* . . O
hypertension . . B-AdverseReaction
including . . O
hypertensive . . B-AdverseReaction
crisis . . I-AdverseReaction
has . . O
been . . O
observed . . O
. . . O

for . . O
persistent . . O
hypertension . . O
despite . . O
use . . O
of . . O
anti . . O
- . . O
hypertensive . . O
medications . . O
, . . O
reduce . . O
the . . O
inlyta . . O
dose . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
gastrointestinal . . B-AdverseReaction
perforation . . I-AdverseReaction
and . . O
fistula . . O
, . . O
including . . O
death . . B-AdverseReaction
, . . O
have . . O
occurred . . O
. . . O

( . . O
5.8 . . O
) . . O
* . . O
reversible . . B-AdverseReaction
posterior . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
rpls . . B-AdverseReaction
) . . O
has . . O
been . . O
observed . . O
. . . O

( . . O
5.10 . . O
) . . O
* . . O
liver . . B-AdverseReaction
enzyme . . I-AdverseReaction
elevation . . I-AdverseReaction
has . . O
been . . O
observed . . O
during . . O
treatment . . O
with . . O
inlyta . . O
. . . O

( . . O
2.2,5.12 . . O
) . . O
* . . O
inlyta . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
based . . O
on . . O
its . . O
mechanism . . O
of . . O
action . . O
. . . O

hypertensive . . B-AdverseReaction
crisis . . I-AdverseReaction
was . . O
reported . . O
in . . O
2 . . O
/ . . O
359 . . O
patients . . O
( . . O
< . . O
1% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
none . . O
of . . O
the . . O
patients . . O
receiving . . O
sorafenib . . O
. . . O

discontinue . . O
inlyta . . O
if . . O
hypertension . . O
is . . O
severe . . O
and . . O
persistent . . O
despite . . O
anti . . O
- . . O
hypertensive . . O
therapy . . O
and . . O
dose . . O
reduction . . O
of . . O
inlyta . . O
, . . O
and . . O
discontinuation . . O
should . . O
be . . O
considered . . O
if . . O
there . . O
is . . O
evidence . . O
of . . O
hypertensive . . O
crisis . . O
. . . O

in . . O
clinical . . O
trials . . O
with . . O
inlyta . . O
, . . O
arterial . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
including . . O
transient . . B-AdverseReaction
ischemic . . I-AdverseReaction
attack . . I-AdverseReaction
, . . O
cerebrovascular . . B-AdverseReaction
accident . . I-AdverseReaction
, . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
, . . O
and . . O
retinal . . B-AdverseReaction
artery . . I-AdverseReaction
occlusion . . I-AdverseReaction
) . . O
were . . O
reported . . O
in . . O
17 . . O
/ . . O
715 . . O
patients . . O
( . . O
2% . . O
) . . O
, . . O
with . . O
two . . O
deaths . . B-AdverseReaction
secondary . . O
to . . O
cerebrovascular . . B-AdverseReaction
accident . . I-AdverseReaction
. . . O

in . . O
clinical . . O
trials . . O
, . . O
venous . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
have . . O
been . . O
reported . . O
, . . O
including . . O
deaths . . B-AdverseReaction
. . . O

5.4 . . O
hemorrhage . . O

if . . O
any . . O
bleeding . . O
requires . . O
medical . . O
intervention . . O
, . . O
temporarily . . O
interrupt . . O
the . . O
inlyta . . O
dose . . O
. . . O

monitor . . O
for . . O
signs . . O
or . . O
symptoms . . O
of . . O
cardiac . . O
failure . . O
throughout . . O
treatment . . O
with . . O
inlyta . . O
. . . O

monitor . . O
for . . O
symptoms . . O
of . . O
gastrointestinal . . O
perforation . . O
or . . O
fistula . . O
periodically . . O
throughout . . O
treatment . . O
with . . O
inlyta . . O
. . . O

5.7 . . O
thyroid . . O
dysfunction . . O

hyperthyroidism . . B-AdverseReaction
was . . O
reported . . O
in . . O
4 . . O
/ . . O
359 . . O
patients . . O
( . . O
1% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
4 . . O
/ . . O
355 . . O
patients . . O
( . . O
1% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

monitor . . O
thyroid . . O
function . . O
before . . O
initiation . . O
of . . O
, . . O
and . . O
periodically . . O
throughout . . O
, . . O
treatment . . O
with . . O
inlyta . . O
. . . O

5.8 . . O
wound . . O
healing . . O
complications . . O

stop . . O
treatment . . O
with . . O
inlyta . . O
at . . O
least . . O
24 . . O
hours . . O
prior . . O
to . . O
scheduled . . O
surgery . . O
. . . O

in . . O
a . . O
controlled . . O
clinical . . O
study . . O
with . . O
inlyta . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
rcc . . O
, . . O
proteinuria . . B-AdverseReaction
was . . O
reported . . O
in . . O
39 . . O
/ . . O
359 . . O
patients . . O
( . . O
11% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
26 . . O
/ . . O
355 . . O
patients . . O
( . . O
7% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

5.11 . . O
elevation . . O
of . . O
liver . . O
enzymes . . O

inlyta . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
severe . . O
hepatic . . O
impairment . . O
( . . O
child . . O
- . . O
pugh . . O
class . . O
c . . O
) . . O
[ . . O
seedosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
, . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
, . . O
andclinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

inlyta . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
based . . O
on . . O
its . . O
mechanism . . O
of . . O
action . . O
. . . O

there . . O
are . . O
no . . O
adequate . . O
and . . O
well . . O
- . . O
controlled . . O
studies . . O
in . . O
pregnant . . O
women . . O
using . . O
inlyta . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

* . . O
receiving . . O
medications . . O
that . . O
are . . O
metabolized . . O
by . . O
the . . O
cytochrome . . O
enzyme . . O
cyp2d6 . . O
which . . O
also . . O
have . . O
cardiac . . O
effects . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
flecainide . . O
, . . O
imipramine . . O
, . . O
amitriptyline . . O
, . . O
clomipramine . . O
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
, . . O
drug . . O
interactions . . O
( . . O
7.6 . . O
) . . O
, . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

administration . . O
of . . O
coartem . . O
tablets . . O
with . . O
drugs . . O
that . . O
are . . O
metabolized . . O
by . . O
cyp2d6 . . O
may . . O
significantly . . O
increase . . O
plasma . . O
concentrations . . O
of . . O
the . . O
coadministered . . O
drug . . O
and . . O
increase . . O
the . . O
risk . . O
of . . O
adverse . . O
effects . . O
. . . O

in . . O
the . . O
event . . O
of . . O
recrudescent . . O
p . . O
. . . O
falciparum . . O
infection . . O
after . . O
treatment . . O
with . . O
coartem . . O
tablets . . O
, . . O
patients . . O
should . . O
be . . O
treated . . O
with . . O
a . . O
different . . O
antimalarial . . O
drug . . O
. . . O

coartem . . O
tablets . . O
have . . O
been . . O
shown . . O
in . . O
limited . . O
data . . O
( . . O
43 . . O
patients . . O
) . . O
to . . O
be . . O
effective . . O
in . . O
treating . . O
the . . O
erythrocytic . . O
stage . . O
of . . O
p . . O
. . . O
vivax . . O
infection . . O
. . . O

when . . O
medically . . O
feasible . . O
, . . O
stop . . O
these . . O
drugs . . O
before . . O
adreview . . O
administration . . O
and . . O
monitor . . O
patients . . O
for . . O
withdrawal . . O
signs . . O
and . . O
symptoms . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O
may . . O
have . . O
increased . . O
radiation . . O
exposure . . O
and . . O
decreased . . O
quality . . O
of . . O
adreview . . O
images . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
failure . . O
to . . O
block . . O
thyroid . . O
iodine . . O
uptake . . O
may . . O
result . . O
in . . O
iodine . . O
123 . . O
accumulation . . O
in . . O
the . . O
thyroid . . O
. . . O

5.1 . . O
hypersensitivity . . O
reactions . . O

many . . O
medications . . O
have . . O
the . . O
potential . . O
to . . O
interfere . . O
with . . O
adreview . . O
imaging . . O
and . . O
review . . O
of . . O
the . . O
patient's . . O
medications . . O
is . . O
required . . O
prior . . O
to . . O
adreview . . O
dosing . . O
due . . O
to . . O
the . . O
risk . . O
for . . O
unreliable . . O
imaging . . O
results . . O
. . . O

pheochromocytoma . . O
and . . O
neuroblastoma . . O

adreview . . O
contains . . O
benzyl . . O
alcohol . . O
at . . O
a . . O
concentration . . O
of . . O
10.3 . . O
mg . . O
/ . . O
ml . . O
. . . O
benzyl . . O
alcohol . . O
has . . O
been . . O
associated . . O
with . . O
a . . O
fatal . . B-AdverseReaction
" . . O
gasping . . B-AdverseReaction
syndrome . . I-AdverseReaction
" . . O
in . . O
premature . . O
infants . . O
and . . O
infants . . O
of . . O
low . . O
birth . . O
weight . . O
. . . O

there . . O
have . . O
been . . O
rare . . O
reports . . O
of . . O
deaths . . O
, . . O
primarily . . O
in . . O
preterm . . O
infants . . O
, . . O
associated . . O
with . . O
exposure . . O
to . . O
excessive . . O
amounts . . O
of . . O
benzyl . . O
alcohol . . O
[ . . O
see . . O
description . . O
( . . O
11 . . O
) . . O
] . . O
. . . O

5.4 . . O
increased . . O
radiation . . O
exposure . . O
in . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O

5.7 . . O
hypertension . . O

assess . . O
the . . O
patient's . . O
pulse . . O
and . . O
blood . . O
pressure . . O
before . . O
and . . O
intermittently . . O
for . . O
30 . . O
minutes . . O
after . . O
adreview . . O
administration . . O
. . . O

adreview . . O
may . . B-Factor
increase . . O
release . . O
of . . O
norepinephrine . . O
from . . O
chromaffin . . O
granules . . O
and . . O
produce . . O
a . . O
transient . . B-AdverseReaction
episode . . I-AdverseReaction
of . . I-AdverseReaction
hypertension . . I-AdverseReaction
, . . O
although . . O
this . . O
was . . O
not . . O
observed . . O
in . . O
the . . O
clinical . . O
studies . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
patients . . O
with . . O
abnormal . . O
coagulation . . O
: . . O
use . . O
with . . O
caution . . O
, . . O
including . . O
in . . O
patients . . O
who . . O
have . . O
received . . O
anticoagulant . . O
medications . . O
other . . O
than . . O
low . . O
- . . O
dose . . O
aspirin . . O
within . . O
7 . . O
days . . O
of . . O
the . . O
injection . . O
. . . O

in . . O
the . . O
controlled . . O
and . . O
uncontrolled . . O
portions . . O
of . . O
clinical . . O
trials . . O
in . . O
dupuytren's . . O
contracture . . O
, . . O
flexor . . B-AdverseReaction
tendon . . I-AdverseReaction
ruptures . . I-AdverseReaction
occurred . . O
after . . O
xiaflex . . O
injection . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

in . . O
other . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
( . . O
9 . . O
of . . O
1044 . . O
; . . O
0.9% . . O
) . . O
, . . O
a . . O
combination . . O
of . . O
penile . . B-AdverseReaction
ecchymoses . . I-AdverseReaction
or . . O
hematoma . . O
, . . O
sudden . . O
penile . . B-AdverseReaction
detumescence . . I-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
a . . O
penile . . B-AdverseReaction
" . . I-AdverseReaction
popping . . I-AdverseReaction
" . . I-AdverseReaction
sound . . I-AdverseReaction
or . . O
sensation . . O
was . . O
reported . . O
, . . O
and . . O
in . . O
these . . O
cases . . O
, . . O
a . . O
diagnosis . . O
of . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
can . . B-Factor
not . . I-Factor
be . . I-Factor
excluded . . I-Factor
. . . O

signs . . O
or . . O
symptoms . . O
that . . O
may . . O
reflect . . O
serious . . O
injury . . O
to . . O
the . . O
penis . . O
should . . O
be . . O
promptly . . O
evaluated . . O
in . . O
order . . O
to . . O
assess . . O
for . . O
corporal . . O
rupture . . O
or . . O
severe . . O
penile . . O
hematoma . . O
, . . O
which . . O
may . . O
require . . O
surgical . . O
intervention . . O
. . . O

further . . O
information . . O
is . . O
available . . O
at . . O
www . . O
. . . O
xiaflexrems . . O
. . . O
com . . O
or . . O
1-877-313-1235 . . O
. . . O

evaluation . . O
of . . O
erectile . . O
dysfunction . . O
( . . O
ed . . O
) . . O
should . . O
include . . O
an . . O
appropriate . . O
medical . . O
assessment . . O
to . . O
identify . . O
potential . . O
underlying . . O
causes . . O
, . . O
as . . O
well . . O
as . . O
treatment . . O
options . . O
. . . O

excerpt . . O
: . . O
* . . O
patients . . O
should . . O
not . . O
use . . O
stendra . . O
if . . O
sexual . . O
activity . . O
is . . O
inadvisable . . O
due . . O
to . . O
cardiovascular . . O
status . . O
or . . O
any . . O
other . . O
reason . . O
( . . O
5.1 . . O
) . . O
* . . O
use . . O
of . . O
stendra . . O
with . . O
alpha . . O
- . . O
blockers . . O
, . . O
other . . O
antihypertensives . . O
, . . O
or . . O
substantial . . O
amounts . . O
of . . O
alcohol . . O
( . . O
greater . . O
than . . O
3 . . O
units . . O
) . . O
may . . O
lead . . O
to . . O
hypotension . . B-AdverseReaction
( . . O
2.3,5.6,5.7 . . O
) . . O
* . . O
patients . . O
should . . O
seek . . O
emergency . . O
treatment . . O
if . . O
an . . O
erection . . O
lasts . . O
greater . . O
than . . O
4 . . O
hours . . O
( . . O
5.3 . . O
) . . O
* . . O
patients . . O
should . . O
stop . . O
stendra . . O
and . . O
seek . . O
medical . . O
care . . O
if . . O
a . . O
sudden . . O
loss . . O
of . . O
vision . . O
occurs . . O
in . . O
one . . O
or . . O
both . . O
eyes . . O
, . . O
which . . O
could . . O
be . . O
a . . O
sign . . O
of . . O
non . . O
arteritic . . O
ischemic . . O
optic . . O
neuropathy . . O
( . . O
naion . . O
) . . O
. . . O

therefore . . O
, . . O
treatments . . O
for . . O
ed . . O
, . . O
including . . O
stendra . . O
, . . O
should . . O
not . . O
be . . O
used . . O
in . . O
men . . O
for . . O
whom . . O
sexual . . O
activity . . O
is . . O
inadvisable . . O
because . . O
of . . O
their . . O
underlying . . O
cardiovascular . . O
status . . O
. . . O

stendra . . O
metabolism . . O
is . . O
principally . . O
mediated . . O
by . . O
the . . O
cyp450 . . O
isoform . . O
3a4 . . O
( . . O
cyp3a4 . . O
) . . O
. . . O

5.3 . . O
prolonged . . O
erection . . O

stendra . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
anatomical . . O
deformation . . O
of . . O
the . . O
penis . . O
( . . O
such . . O
as . . O
angulation . . O
, . . O
cavernosal . . O
fibrosis . . O
, . . O
or . . O
peyronie's . . O
disease . . O
) . . O
, . . O
or . . O
in . . O
patients . . O
who . . O
have . . O
conditions . . O
which . . O
may . . O
predispose . . O
them . . O
to . . O
priapism . . O
( . . O
such . . O
as . . O
sickle . . O
cell . . O
anemia . . O
, . . O
multiple . . O
myeloma . . O
, . . O
or . . O
leukemia . . O
) . . O
. . . O

physicians . . O
should . . O
advise . . O
patients . . O
to . . O
stop . . O
use . . O
of . . O
all . . O
pde5 . . O
inhibitors . . O
, . . O
including . . O
stendra . . O
, . . O
and . . O
seek . . O
medical . . O
attention . . O
in . . O
the . . O
event . . O
of . . O
a . . O
sudden . . O
loss . . O
of . . O
vision . . O
in . . O
one . . O
or . . O
both . . O
eyes . . O
. . . O

based . . O
on . . O
published . . O
literature . . O
, . . O
the . . O
annual . . O
incidence . . O
of . . O
naion . . O
is . . O
2.5-11.8 . . O
cases . . O
per . . O
100,000 . . O
in . . O
males . . O
aged . . O
> . . O
= . . O
50 . . O
. . . O

an . . O
observational . . O
study . . O
evaluated . . O
whether . . O
recent . . O
use . . O
of . . O
pde5 . . B-DrugClass
inhibitors . . I-DrugClass
, . . O
as . . O
a . . O
class . . O
, . . O
was . . O
associated . . O
with . . O
acute . . O
onset . . O
of . . O
naion . . B-AdverseReaction
. . . O

from . . O
this . . O
information . . O
, . . O
it . . O
is . . O
not . . O
possible . . O
to . . O
determine . . O
whether . . O
these . . O
events . . O
are . . O
related . . O
directly . . O
to . . O
the . . O
use . . O
of . . O
pde5 . . O
inhibitors . . O
or . . O
to . . O
other . . O
factors . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

use . . O
of . . O
pde5 . . B-DrugClass
inhibitors . . I-DrugClass
has . . O
been . . O
associated . . O
with . . O
sudden . . O
decrease . . O
or . . O
loss . . B-AdverseReaction
of . . I-AdverseReaction
hearing . . I-AdverseReaction
, . . O
which . . O
may . . O
be . . O
accompanied . . O
by . . O
tinnitus . . B-AdverseReaction
or . . O
dizziness . . B-AdverseReaction
. . . O

it . . O
is . . O
not . . O
possible . . O
to . . O
determine . . O
whether . . O
these . . O
events . . O
are . . O
related . . O
directly . . O
to . . O
the . . O
use . . O
of . . O
pde5 . . O
inhibitors . . O
or . . O
to . . O
other . . O
factors . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

physicians . . O
should . . O
discuss . . O
with . . O
patients . . O
the . . O
potential . . O
for . . O
stendra . . O
to . . O
augment . . O
the . . O
blood . . O
pressure . . O
- . . O
lowering . . O
effect . . O
of . . O
alpha . . O
- . . O
blockers . . O
and . . O
other . . O
antihypertensive . . O
medications . . O
[ . . O
seedrug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
andclinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

caution . . O
is . . O
advised . . O
when . . O
pde5 . . O
inhibitors . . O
are . . O
co . . O
- . . O
administered . . O
with . . O
alpha . . O
- . . O
blockers . . O
. . . O

consideration . . O
should . . O
be . . O
given . . O
to . . O
the . . O
following . . O
: . . O

* . . O
patients . . O
should . . O
be . . O
stable . . O
on . . O
alpha . . O
- . . O
blocker . . O
therapy . . O
prior . . O
to . . O
initiating . . O
treatment . . O
with . . O
a . . O
pde5 . . O
inhibitor . . O
. . . O

5.7 . . O
alcohol . . O

therefore . . O
, . . O
physicians . . O
should . . O
inform . . O
patients . . O
that . . O
substantial . . O
consumption . . O
of . . O
alcohol . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
greater . . O
than . . O
3 . . O
units . . O
) . . O
in . . O
combination . . O
with . . O
stendra . . O
may . . O
increase . . O
the . . O
potential . . O
for . . O
orthostatic . . O
signs . . O
and . . O
symptoms . . O
, . . O
including . . O
increase . . O
in . . O
heart . . O
rate . . O
, . . O
decrease . . O
in . . O
standing . . O
blood . . O
pressure . . O
, . . O
dizziness . . O
, . . O
and . . O
headache . . O
[ . . O
seedrug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
andclinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

the . . O
safety . . O
and . . O
efficacy . . O
of . . O
combinations . . O
of . . O
stendra . . O
with . . O
other . . O
treatments . . O
for . . O
ed . . O
has . . O
not . . O
been . . O
studied . . O
. . . O

5.10 . . O
counseling . . O
patients . . O
about . . O
sexually . . O
transmitted . . O
diseases . . O

monitor . . O
supine . . O
blood . . O
pressure . . O
prior . . O
to . . O
and . . O
during . . O
treatment . . O
and . . O
more . . O
frequently . . O
when . . O
increasing . . O
doses . . O
. . . O

excerpt . . O
: . . O
* . . O
driving . . B-AdverseReaction
impairment . . I-AdverseReaction
: . . O
warn . . O
patients . . O
not . . O
to . . O
drive . . O
until . . O
they . . O
have . . O
gained . . O
sufficient . . O
experience . . O
with . . O
horizant . . O
to . . O
assess . . O
whether . . O
it . . O
will . . O
impair . . O
their . . O
ability . . O
to . . O
drive . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
horizant . . O
is . . O
not . . O
interchangeable . . O
with . . O
other . . O
gabapentin . . O
products . . O
. . . O

aeds . . B-DrugClass
increase . . O
the . . O
risk . . O
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behaviors . . O
. . . O

monitor . . O
for . . O
suicidal . . O
thoughts . . O
or . . O
behaviors . . O
. . . O

dizziness . . B-AdverseReaction
led . . O
to . . O
withdrawal . . O
in . . O
1% . . O
of . . O
patients . . O
receiving . . O
600 . . O
mg . . O
of . . O
horizant . . O
per . . O
day . . O
. . . O

during . . O
the . . O
12 . . O
- . . O
week . . O
, . . O
controlled . . O
study . . O
in . . O
patients . . O
with . . O
phn . . O
, . . O
somnolence . . B-AdverseReaction
was . . O
reported . . O
in . . O
10% . . O
of . . O
patients . . O
treated . . O
with . . O
1,200 . . O
mg . . O
of . . O
horizant . . O
per . . O
day . . O
compared . . O
with . . O
8% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

dizziness . . B-AdverseReaction
was . . O
reported . . O
in . . O
17% . . O
of . . O
patients . . O
receiving . . O
1,200 . . O
mg . . O
of . . O
horizant . . O
per . . O
day . . O
compared . . O
with . . O
15% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

in . . O
those . . O
patients . . O
treated . . O
with . . O
1,200 . . O
mg . . O
of . . O
horizant . . O
per . . O
day . . O
who . . O
reported . . O
dizziness . . B-AdverseReaction
, . . O
symptoms . . O
persisted . . O
during . . O
treatment . . O
in . . O
about . . O
6% . . O
. . . O

horizant . . O
( . . O
gabapentin . . O
enacarbil . . O
) . . O
is . . O
a . . O
prodrug . . O
of . . O
gabapentin . . O
, . . O
an . . O
antiepileptic . . O
drug . . O
( . . O
aed . . O
) . . O
. . . O

patients . . O
treated . . O
with . . O
any . . O
aed . . O
for . . O
any . . O
indication . . O
should . . O
be . . O
monitored . . O
for . . O
the . . O
emergence . . O
or . . O
worsening . . O
of . . O
depression . . O
, . . O
suicidal . . O
thoughts . . O
or . . O
behavior . . O
, . . O
and . . O
/ . . O
or . . O
any . . O
unusual . . O
changes . . O
in . . O
mood . . O
or . . O
behavior . . O
. . . O

the . . O
finding . . O
of . . O
increased . . O
risk . . O
with . . O
aeds . . O
of . . O
varying . . O
mechanisms . . O
of . . O
action . . O
and . . O
across . . O
a . . O
range . . O
of . . O
indications . . O
suggests . . O
that . . O
the . . O
risk . . O
applies . . O
to . . O
all . . O
aeds . . O
used . . O
for . . O
any . . O
indication . . O
. . . O

the . . O
risk . . O
did . . O
not . . O
vary . . O
substantially . . O
by . . O
age . . O
( . . O
5 . . O
to . . O
100 . . O
years . . O
) . . O
in . . O
the . . O
clinical . . O
trials . . O
analyzed . . O
. . . O

should . . O
suicidal . . O
thoughts . . O
and . . O
behavior . . O
emerge . . O
during . . O
treatment . . O
, . . O
the . . O
prescriber . . O
needs . . O
to . . O
consider . . O
whether . . O
the . . O
emergence . . O
of . . O
these . . O
symptoms . . O
in . . O
any . . O
given . . O
patient . . O
may . . O
be . . O
related . . O
to . . O
the . . O
illness . . O
being . . O
treated . . O
. . . O

5.5 . . O
drug . . O
reaction . . O
with . . O
eosinophilia . . O
and . . O
systemic . . O
symptoms . . O
( . . O
dress . . O
) . . O
/ . . O
multiorgan . . O
hypersensitivity . . O

dress . . B-AdverseReaction
typically . . O
, . . O
although . . O
not . . O
exclusively . . O
, . . O
presents . . O
with . . O
fever . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
lymphadenopathy . . B-AdverseReaction
, . . O
in . . O
association . . O
with . . O
other . . O
organ . . O
system . . O
involvement . . O
, . . O
such . . O
as . . O
hepatitis . . B-AdverseReaction
, . . O
nephritis . . B-AdverseReaction
, . . O
hematological . . B-AdverseReaction
abnormalities . . I-AdverseReaction
, . . O
myocarditis . . B-AdverseReaction
, . . O
or . . O
myositis . . B-AdverseReaction
sometimes . . O
resembling . . O
an . . O
acute . . O
viral . . O
infection . . O
. . . O

eosinophilia . . B-AdverseReaction
is . . O
often . . O
present . . O
. . . O

horizant . . O
should . . O
be . . O
discontinued . . O
if . . O
an . . O
alternative . . O
etiology . . O
for . . O
the . . O
signs . . O
or . . O
symptoms . . O
cannot . . O
be . . O
established . . O
. . . O

5.7 . . O
tumorigenic . . O
potential . . O

* . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
was . . O
seen . . O
in . . O
the . . O
sirturo . . O
treatment . . O
group . . O
( . . O
9 . . O
/ . . O
79 . . O
, . . O
11.4% . . O
) . . O
compared . . O
to . . O
the . . O
placebo . . O
treatment . . O
group . . O
( . . O
2 . . O
/ . . O
81 . . O
, . . O
2.5% . . O
) . . O
in . . O
one . . O
placebo . . O
- . . O
controlled . . O
trial . . O
. . . O

( . . O
5.1 . . O
) . . O
qt . . O
prolongation . . O

increased . . O
mortality . . O

* . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
was . . O
seen . . O
in . . O
the . . O
sirturo . . O
treatment . . O
group . . O
( . . O
9 . . O
/ . . O
79 . . O
, . . O
11.4% . . O
) . . O
compared . . O
to . . O
the . . O
placebo . . O
treatment . . O
group . . O
( . . O
2 . . O
/ . . O
81 . . O
, . . O
2.5% . . O
) . . O
in . . O
one . . O
placebo . . O
- . . O
controlled . . O
trial . . O
. . . O

monitor . . O
ecgs . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
the . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
other . . O
clinical . . O
trials . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

the . . O
most . . O
common . . O
serious . . O
adverse . . O
reactions . . O
reported . . O
in . . O
patients . . O
receiving . . O
halaven . . O
were . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
( . . O
4% . . O
) . . O
and . . O
neutropenia . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reaction . . O
resulting . . O
in . . O
discontinuation . . O
of . . O
halaven . . O
was . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
5% . . O
) . . O
. . . O

dose . . O
reduction . . O
due . . O
to . . O
neutropenia . . B-AdverseReaction
was . . O
required . . O
in . . O
12% . . O
( . . O
62 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
and . . O
discontinuation . . O
was . . O
required . . O
in . . O
< . . O
1% . . O
of . . O
patients . . O
. . . O

four . . O
percent . . O
( . . O
20 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
experienced . . O
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
of . . O
any . . O
grade . . O
and . . O
2% . . O
( . . O
8 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
developed . . O
grade . . B-Severity
3 . . I-Severity
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
. . . O

liver . . O
function . . O
test . . O
abnormalities . . O
: . . O
among . . O
patients . . O
with . . O
grade . . O
0 . . O
or . . O
1 . . O
alt . . O
levels . . O
at . . O
baseline . . O
, . . O
18% . . O
of . . O
halaven . . O
- . . O
treated . . O
patients . . O
experienced . . O
grade . . B-Severity
2 . . I-Severity
or . . O
greater . . O
alt . . B-AdverseReaction
elevation . . I-AdverseReaction
. . . O

* . . O
anaphylaxis . . B-AdverseReaction
and . . O
angioedema . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

* . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
biogen . . O
at . . O
1-800-456-2255 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

adverse . . O
reactions . . O
in . . O
placebo . . O
- . . O
controlled . . O
trials . . O

the . . O
incidence . . O
of . . O
gi . . B-AdverseReaction
events . . I-AdverseReaction
was . . O
higher . . O
early . . O
in . . O
the . . O
course . . O
of . . O
treatment . . O
( . . O
primarily . . O
in . . O
month . . O
1 . . O
) . . O
and . . O
usually . . O
decreased . . O
over . . O
time . . O
in . . O
patients . . O
treated . . O
with . . O
tecfidera . . O
compared . . O
with . . O
placebo . . O
. . . O

there . . O
were . . O
no . . B-Negation
elevations . . B-AdverseReaction
in . . I-AdverseReaction
transaminases . . I-AdverseReaction
> . . O
= . . O
3 . . B-Severity
times . . I-Severity
the . . I-Severity
uln . . I-Severity
with . . O
concomitant . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
total . . I-AdverseReaction
bilirubin . . I-AdverseReaction
> . . O
2 . . B-Severity
times . . I-Severity
the . . I-Severity
uln . . I-Severity
. . . O

in . . O
placebo . . O
- . . O
controlled . . O
and . . O
uncontrolled . . O
clinical . . O
studies . . O
, . . O
a . . O
total . . O
of . . O
2513 . . O
patients . . O
have . . O
received . . O
tecfidera . . O
and . . O
been . . O
followed . . O
for . . O
periods . . O
up . . O
to . . O
4 . . O
years . . O
with . . O
an . . O
overall . . O
exposure . . O
of . . O
4603 . . O
person . . O
- . . O
years . . O
. . . O

the . . O
adverse . . O
reaction . . O
profile . . O
of . . O
tecfidera . . O
in . . O
the . . O
uncontrolled . . O
clinical . . O
studies . . O
was . . O
consistent . . O
with . . O
the . . O
experience . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
. . . O

yervoy . . O
can . . B-Factor
result . . O
in . . O
severe . . B-Severity
and . . O
fatal . . B-AdverseReaction
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
due . . O
to . . O
t . . O
- . . O
cell . . O
activation . . O
and . . O
proliferation . . O
. . . O

excerpt . . O
: . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
: . . O
permanently . . O
discontinue . . O
for . . O
severe . . O
reactions . . O
. . . O

* . . O
? . . O

immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
hepatitis . . I-AdverseReaction
: . . O
evaluate . . O
liver . . O
function . . O
tests . . O
before . . O
each . . O
dose . . O
of . . O
yervoy . . O
. . . O

among . . O
the . . O
28 . . O
patients . . O
with . . O
grade . . B-Severity
2 . . I-Severity
enterocolitis . . B-AdverseReaction
, . . O
79% . . O
experienced . . O
complete . . O
resolution . . O
, . . O
11% . . O
improved . . O
, . . O
and . . O
11% . . O
did . . O
not . . O
improve . . O
. . . O

the . . O
underlying . . O
pathology . . O
was . . O
not . . O
ascertained . . O
in . . O
all . . O
patients . . O
but . . O
in . . O
some . . O
instances . . O
included . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
hepatitis . . I-AdverseReaction
. . . O

in . . O
patients . . O
with . . O
hepatotoxicity . . O
, . . O
rule . . O
out . . O
infectious . . O
or . . O
malignant . . O
causes . . O
and . . O
increase . . O
frequency . . O
of . . O
liver . . O
function . . O
test . . O
monitoring . . O
until . . O
resolution . . O
. . . O

when . . O
liver . . O
function . . O
tests . . O
show . . O
sustained . . O
improvement . . O
or . . O
return . . O
to . . O
baseline . . O
, . . O
initiate . . O
corticosteroid . . O
tapering . . O
and . . O
continue . . O
to . . O
taper . . O
over . . O
1 . . O
month . . O
. . . O

monitor . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
dermatitis . . O
such . . O
as . . O
rash . . O
and . . O
pruritus . . O
. . . O

[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
. . . O
] . . O

across . . O
the . . O
clinical . . O
development . . O
program . . O
of . . O
yervoy . . O
, . . O
myasthenia . . B-AdverseReaction
gravis . . I-AdverseReaction
and . . O
additional . . O
cases . . O
of . . O
guillain . . B-AdverseReaction
- . . I-AdverseReaction
barre . . I-AdverseReaction
syndrome . . I-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

of . . O
the . . O
21 . . O
patients . . O
with . . O
moderate . . B-Severity
to . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
endocrinopathy . . B-AdverseReaction
, . . O
17 . . O
patients . . O
required . . O
long . . O
- . . O
term . . O
hormone . . O
replacement . . O
therapy . . O
including . . O
, . . O
most . . O
commonly . . O
, . . O
adrenal . . O
hormones . . O
( . . O
n . . O
= . . O
10 . . O
) . . O
and . . O
thyroid . . O
hormones . . O
( . . O
n . . O
= . . O
13 . . O
) . . O
. . . O

monitor . . O
patients . . O
for . . O
clinical . . O
signs . . O
and . . O
symptoms . . O
of . . O
hypophysitis . . O
, . . O
adrenal . . O
insufficiency . . O
( . . O
including . . O
adrenal . . O
crisis . . O
) . . O
, . . O
and . . O
hyper . . O
- . . O
or . . O
hypothyroidism . . O
. . . O

the . . O
following . . O
clinically . . O
significant . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
seen . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
yervoy . . O
- . . O
treated . . O
patients . . O
in . . O
study . . O
1 . . O
: . . O
nephritis . . B-AdverseReaction
, . . O
pneumonitis . . B-AdverseReaction
, . . O
meningitis . . B-AdverseReaction
, . . O
pericarditis . . B-AdverseReaction
, . . O
uveitis . . B-AdverseReaction
, . . O
iritis . . B-AdverseReaction
, . . O
and . . O
hemolytic . . B-AdverseReaction
anemia . . I-AdverseReaction
. . . O

across . . O
the . . O
clinical . . O
development . . O
program . . O
for . . O
yervoy . . O
, . . O
the . . O
following . . O
likely . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
also . . O
reported . . O
with . . O
less . . O
than . . O
1% . . O
incidence . . O
: . . O
myocarditis . . B-AdverseReaction
, . . O
angiopathy . . B-AdverseReaction
, . . O
temporal . . B-AdverseReaction
arteritis . . I-AdverseReaction
, . . O
vasculitis . . B-AdverseReaction
, . . O
polymyalgia . . B-AdverseReaction
rheumatica . . I-AdverseReaction
, . . O
conjunctivitis . . B-AdverseReaction
, . . O
blepharitis . . B-AdverseReaction
, . . O
episcleritis . . B-AdverseReaction
, . . O
scleritis . . B-AdverseReaction
, . . O
leukocytoclastic . . B-AdverseReaction
vasculitis . . I-AdverseReaction
, . . O
erythema . . B-AdverseReaction
multiforme . . I-AdverseReaction
, . . O
psoriasis . . B-AdverseReaction
, . . O
pancreatitis . . B-AdverseReaction
, . . O
arthritis . . B-AdverseReaction
, . . O
autoimmune . . B-AdverseReaction
thyroiditis . . I-AdverseReaction
, . . O
sarcoidosis . . B-AdverseReaction
, . . O
neurosensory . . B-AdverseReaction
hypoacusis . . I-AdverseReaction
, . . O
autoimmune . . B-AdverseReaction
central . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
encephalitis . . B-AdverseReaction
) . . O
, . . O
myositis . . B-AdverseReaction
, . . O
polymyositis . . B-AdverseReaction
, . . O
and . . O
ocular . . B-AdverseReaction
myositis . . I-AdverseReaction
. . . O

permanently . . O
discontinue . . O
yervoy . . O
for . . O
immune . . O
- . . O
mediated . . O
ocular . . O
disease . . O
that . . O
is . . O
unresponsive . . O
to . . O
local . . O
immunosuppressive . . O
therapy . . O
. . . O

* . . O
neurological . . O
toxicities . . O
, . . O
which . . O
may . . B-Factor
be . . O
severe . . B-Severity
, . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
, . . O
or . . O
fatal . . B-AdverseReaction
, . . O
occurred . . O
in . . O
patients . . O
receiving . . O
blincyto . . O
. . . O

interrupt . . O
or . . O
discontinue . . O
blincyto . . O
as . . O
recommended . . O
. . . O

interrupt . . O
or . . O
discontinue . . O
blincyto . . O
as . . O
recommended . . O
. . . O

( . . O
2.3 . . O
) . . O
, . . O
( . . O
5.2 . . O
) . . O

* . . O
cytopenias . . B-AdverseReaction
: . . O
check . . O
complete . . O
blood . . O
counts . . O
monthly . . O
( . . O
5.3 . . O
) . . O
. . . O

grade . . B-Severity
3 . . I-Severity
or . . O
higher . . O
bleeding . . B-AdverseReaction
events . . I-AdverseReaction
( . . O
subdural . . B-AdverseReaction
hematoma . . I-AdverseReaction
, . . O
gastrointestinal . . B-AdverseReaction
bleeding . . I-AdverseReaction
, . . O
hematuria . . B-AdverseReaction
and . . O
post . . B-AdverseReaction
procedural . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
) . . O
have . . O
occurred . . O
in . . O
up . . O
to . . O
6% . . O
of . . O
patients . . O
. . . O

bleeding . . B-AdverseReaction
events . . O
of . . O
any . . O
grade . . O
, . . O
including . . O
bruising . . B-AdverseReaction
and . . O
petechiae . . B-AdverseReaction
, . . O
occurred . . O
in . . O
approximately . . O
half . . O
of . . O
patients . . O
treated . . O
with . . O
imbruvica . . O
. . . O

[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

5.3 . . O
cytopenias . . O

periodically . . O
monitor . . O
patients . . O
clinically . . O
for . . O
atrial . . O
fibrillation . . O
. . . O

5.6 . . O
tumor . . O
lysis . . O
syndrome . . O

monitor . . O
patients . . O
closely . . O
and . . O
take . . O
appropriate . . O
precautions . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
tumor . . O
lysis . . O
syndrome . . O
( . . O
e . . O
. . . O
g . . O
. . . O
high . . O
tumor . . O
burden . . O
) . . O
. . . O

advise . . O
women . . O
to . . O
avoid . . O
becoming . . O
pregnant . . O
while . . O
taking . . O
imbruvica . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
shire . . O
human . . O
genetic . . O
therapies . . O
at . . O
the . . O
onepath . . O
( . . O
r . . O
) . . O
phone . . O
# . . O
1-866-888-0660 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

a . . O
total . . O
of . . O
225 . . O
patients . . O
were . . O
treated . . O
with . . O
1,076 . . O
doses . . O
of . . O
30 . . O
mg . . O
firazyr . . O
for . . O
987 . . O
attacks . . O
of . . O
acute . . O
hae . . O
. . . O

other . . O
adverse . . O
reactions . . O
reported . . O
included . . O
rash . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
in . . O
patients . . O
exposed . . O
to . . O
firazyr . . O
. . . O

the . . O
safety . . O
of . . O
self . . O
- . . O
administration . . O
was . . O
evaluated . . O
in . . O
a . . O
separate . . O
, . . O
open . . O
- . . O
label . . O
trial . . O
in . . O
56 . . O
patients . . O
with . . O
hae . . O
. . . O

6.3 . . O
postmarketing . . O
experience . . O

because . . O
these . . O
events . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

excerpt . . O
: . . O
* . . O
suicidal . . B-AdverseReaction
behavior . . I-AdverseReaction
and . . O
ideation . . O
: . . O
monitor . . O
for . . O
suicidal . . O
thoughts . . O
or . . O
behavior . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
neurological . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
: . . O
monitor . . O
for . . O
dizziness . . O
, . . O
disturbance . . O
in . . O
gait . . O
and . . O
coordination . . O
, . . O
somnolence . . O
, . . O
fatigue . . O
, . . O
cognitive . . O
dysfunction . . O
, . . O
and . . O
visual . . O
changes . . O
. . . O

patients . . O
treated . . O
with . . O
any . . O
aed . . O
for . . O
any . . O
indication . . O
should . . O
be . . O
monitored . . O
for . . O
the . . O
emergence . . O
or . . O
worsening . . O
of . . O
depression . . O
, . . O
suicidal . . O
thoughts . . O
or . . O
behavior . . O
, . . O
and . . O
/ . . O
or . . O
any . . O
unusual . . O
changes . . O
in . . O
mood . . O
or . . O
behavior . . O
. . . O

pooled . . O
analyses . . O
of . . O
199 . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
( . . O
mono . . O
- . . O
and . . O
adjunctive . . O
therapy . . O
) . . O
of . . O
11 . . O
different . . O
aeds . . O
showed . . O
that . . O
patients . . O
randomized . . O
to . . O
one . . O
of . . O
the . . O
aeds . . O
had . . O
approximately . . O
twice . . O
the . . O
risk . . O
( . . O
adjusted . . O
relative . . O
risk . . O
1.8 . . O
, . . O
95% . . O
confidence . . O
interval . . O
[ . . O
ci . . O
] . . O
: . . O
1.2 . . O
, . . O
2.7 . . O
) . . O
of . . O
suicidal . . B-AdverseReaction
thinking . . I-AdverseReaction
or . . O
behavior . . O
compared . . O
to . . O
patients . . O
randomized . . O
to . . O
placebo . . O
. . . O

there . . O
were . . O
four . . O
suicides . . B-AdverseReaction
in . . O
drug . . O
- . . O
treated . . O
patients . . O
in . . O
the . . O
trials . . O
and . . O
none . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
but . . O
the . . O
number . . B-Factor
of . . I-Factor
events . . I-Factor
is . . I-Factor
too . . I-Factor
small . . I-Factor
to . . I-Factor
allow . . I-Factor
any . . I-Factor
conclusion . . I-Factor
about . . O
drug . . O
effect . . O
on . . O
suicide . . B-AdverseReaction
. . . O

because . . O
most . . O
trials . . O
included . . O
in . . O
the . . O
analysis . . O
did . . O
not . . O
extend . . O
beyond . . O
24 . . O
weeks . . O
, . . O
the . . O
risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
beyond . . O
24 . . O
weeks . . O
could . . O
not . . O
be . . O
assessed . . O
. . . O

the . . O
finding . . O
of . . O
increased . . O
risk . . O
with . . O
aeds . . O
of . . O
varying . . O
mechanisms . . O
of . . O
action . . O
and . . O
across . . O
a . . O
range . . O
of . . O
indications . . O
suggests . . O
that . . O
the . . O
risk . . O
applies . . O
to . . O
all . . O
aeds . . O
used . . O
for . . O
any . . O
indication . . O
. . . O

epilepsy . . O
and . . O
many . . O
other . . O
illnesses . . B-Negation
for . . I-Negation
which . . I-Negation
aeds . . I-Negation
are . . I-Negation
prescribed . . I-Negation
are . . O
themselves . . O
associated . . O
with . . O
morbidity . . B-AdverseReaction
and . . O
mortality . . B-AdverseReaction
and . . O
an . . O
increased . . O
risk . . O
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
and . . O
behavior . . O
. . . O

behaviors . . O
of . . O
concern . . O
should . . O
be . . O
reported . . O
immediately . . O
to . . O
healthcare . . O
providers . . O
. . . O

drug . . B-AdverseReaction
reaction . . I-AdverseReaction
with . . I-AdverseReaction
eosinophilia . . I-AdverseReaction
and . . I-AdverseReaction
systemic . . I-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
dress . . B-AdverseReaction
) . . O
, . . O
also . . O
known . . O
as . . O
multiorgan . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
, . . O
has . . O
been . . O
reported . . O
in . . O
patients . . O
taking . . O
aptiom . . O
. . . O

eosinophilia . . B-AdverseReaction
is . . O
often . . O
present . . O
. . . O

5.4 . . O
anaphylactic . . O
reactions . . O
and . . O
angioedema . . O

anaphylaxis . . B-AdverseReaction
and . . O
angioedema . . B-AdverseReaction
associated . . O
with . . O
laryngeal . . B-AdverseReaction
edema . . I-AdverseReaction
can . . B-Factor
be . . O
fatal . . B-AdverseReaction
. . . O

patients . . O
with . . O
a . . O
prior . . O
anaphylactic . . O
- . . O
type . . O
reaction . . O
with . . O
either . . O
oxcarbazepine . . O
or . . O
aptiom . . O
should . . O
not . . O
be . . O
treated . . O
with . . O
aptiom . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

a . . O
higher . . O
percentage . . O
of . . O
aptiom . . O
- . . O
treated . . O
patients . . O
( . . O
5.1% . . O
) . . O
than . . O
placebo . . O
- . . O
treated . . O
patients . . O
( . . O
0.7% . . O
) . . O
experienced . . O
decreases . . B-AdverseReaction
in . . I-AdverseReaction
sodium . . I-AdverseReaction
values . . I-AdverseReaction
of . . O
more . . O
than . . O
10 . . B-Severity
meq . . I-Severity
/ . . I-Severity
l . . I-Severity
. . . O
these . . O
effects . . O
were . . O
dose . . O
- . . O
related . . O
and . . O
generally . . O
appeared . . O
within . . O
the . . O
first . . O
8 . . O
weeks . . O
of . . O
treatment . . O
( . . O
as . . O
early . . O
as . . O
after . . O
3 . . O
days . . O
) . . O
. . . O

events . . O
related . . O
to . . O
dizziness . . B-AdverseReaction
and . . O
disturbance . . B-AdverseReaction
in . . I-AdverseReaction
gait . . I-AdverseReaction
and . . O
coordination . . O
were . . O
more . . O
often . . O
serious . . O
in . . O
aptiom . . O
- . . O
treated . . O
patients . . O
than . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
( . . O
2% . . O
vs . . O
. . . O
0% . . O
) . . O
, . . O
and . . O
more . . O
often . . O
led . . O
to . . O
study . . O
withdrawal . . O
in . . O
aptiom . . O
- . . O
treated . . O
patients . . O
than . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
( . . O
9% . . O
vs . . O
. . . O
0.7% . . O
) . . O
. . . O

therefore . . O
, . . O
consider . . O
dosage . . O
modifications . . O
of . . O
both . . O
aptiom . . O
and . . O
carbamazepine . . O
if . . O
these . . O
drugs . . O
are . . O
used . . O
concomitantly . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

somnolence . . B-AdverseReaction
and . . O
fatigue . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
events . . I-AdverseReaction
were . . O
serious . . O
in . . O
0.3% . . O
of . . O
aptiom . . O
- . . O
treated . . O
patients . . O
( . . O
and . . O
0 . . O
placebo . . O
patients . . O
) . . O
and . . O
led . . O
to . . O
discontinuation . . O
in . . O
3% . . O
of . . O
aptiom . . O
- . . O
treated . . O
patients . . O
( . . O
and . . O
0.7% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
) . . O
. . . O

cognitive . . O
dysfunction . . O

visual . . O
changes . . O

in . . O
the . . O
controlled . . O
adjunctive . . O
epilepsy . . O
trials . . O
, . . O
these . . O
events . . O
were . . O
reported . . O
in . . O
16% . . O
of . . O
patients . . O
randomized . . O
to . . O
receive . . O
aptiom . . O
compared . . O
to . . O
6% . . O
of . . O
placebo . . O
patients . . O
. . . O

there . . O
was . . O
an . . O
increased . . O
risk . . O
of . . O
these . . O
adverse . . O
reactions . . O
during . . O
the . . O
titration . . O
period . . O
( . . O
compared . . O
to . . O
the . . O
maintenance . . O
period . . O
) . . O
and . . O
also . . O
in . . O
patients . . O
60 . . O
years . . O
of . . O
age . . O
and . . O
older . . O
( . . O
compared . . O
to . . O
younger . . O
adults . . O
) . . O
. . . O

as . . O
with . . O
all . . O
antiepileptic . . O
drugs . . O
, . . O
aptiom . . O
should . . O
be . . O
withdrawn . . O
gradually . . O
because . . O
of . . O
the . . O
risk . . O
of . . O
increased . . O
seizure . . O
frequency . . O
and . . O
status . . O
epilepticus . . O
. . . O

baseline . . O
evaluations . . O
of . . O
liver . . O
laboratory . . O
tests . . O
are . . O
recommended . . O
. . . O

these . . O
changes . . O
were . . O
not . . B-Negation
associated . . O
with . . O
other . . O
abnormal . . B-AdverseReaction
thyroid . . I-AdverseReaction
function . . I-AdverseReaction
tests . . O
suggesting . . O
hypothyroidism . . B-AdverseReaction
. . . O

* . . O
myelosuppression . . B-AdverseReaction
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.4 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

serious . . O
adverse . . O
reactions . . O
reported . . O
include . . O
anaphylactic . . B-AdverseReaction
shock . . I-AdverseReaction
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
, . . O
myelosuppression . . B-AdverseReaction
, . . O
gastrointestinal . . B-AdverseReaction
toxicity . . I-AdverseReaction
( . . O
diarrhea . . B-AdverseReaction
) . . O
, . . O
fluid . . B-AdverseReaction
retention . . I-AdverseReaction
, . . O
hepatotoxicity . . B-AdverseReaction
and . . O
rash . . B-AdverseReaction
. . . O

* . . O
287 . . O
patients . . O
with . . O
cp . . O
cml . . O
previously . . O
treated . . O
with . . O
imatinib . . O
only . . O
who . . O
had . . O
a . . O
median . . O
duration . . O
of . . O
bosulif . . O
treatment . . O
of . . O
24 . . O
months . . O
, . . O
and . . O
a . . O
median . . O
dose . . O
intensity . . O
of . . O
484 . . O
mg . . O
/ . . O
day . . O
. . . O

these . . O
adverse . . O
reactions . . O
are . . O
presented . . O
by . . O
system . . O
organ . . O
class . . O
and . . O
are . . O
ranked . . O
by . . O
frequency . . O
. . . O

these . . O
adverse . . O
reactions . . O
are . . O
included . . O
based . . O
on . . O
clinical . . O
relevance . . O
and . . O
ranked . . O
in . . O
order . . O
of . . O
decreasing . . O
seriousness . . O
within . . O
each . . O
category . . O
. . . O

ear . . O
and . . O
labyrinth . . O
disorders . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
tinnitus . . B-AdverseReaction

( . . O
5.6 . . O
) . . O

cleviprex . . O
may . . B-Factor
produce . . O
systemic . . B-AdverseReaction
hypotension . . I-AdverseReaction
and . . O
reflex . . B-AdverseReaction
tachycardia . . I-AdverseReaction
. . . O

5.3 . . O
lipid . . O
intake . . O

cleviprex . . O
contains . . O
approximately . . O
0.2 . . O
g . . O
of . . O
lipid . . O
per . . O
ml . . O
( . . O
2.0 . . O
kcal . . O
) . . O
. . . O

lipid . . O
intake . . O
restrictions . . O
may . . O
be . . O
necessary . . O
for . . O
patients . . O
with . . O
significant . . O
disorders . . O
of . . O
lipid . . O
metabolism . . O
. . . O

reduction . . O
in . . O
heart . . O
rate . . O

heart . . B-AdverseReaction
rates . . I-AdverseReaction
below . . I-AdverseReaction
40 . . I-AdverseReaction
beats . . I-AdverseReaction
per . . I-AdverseReaction
minute . . I-AdverseReaction
were . . O
rarely . . O
observed . . O
. . . O

patients . . O
who . . O
experienced . . O
bradycardia . . B-AdverseReaction
were . . O
generally . . O
asymptomatic . . O
, . . O
but . . O
some . . O
patients . . O
experienced . . O
hypotension . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
palpitations . . B-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
that . . O
usually . . O
resolved . . O
within . . O
the . . O
first . . O
24 . . O
hours . . O
on . . O
treatment . . O
. . . O

following . . O
the . . O
second . . O
dose . . O
, . . O
a . . O
further . . O
decrease . . B-AdverseReaction
in . . I-AdverseReaction
heart . . I-AdverseReaction
rate . . I-AdverseReaction
may . . O
occur . . O
when . . O
compared . . O
to . . O
the . . O
heart . . O
rate . . O
prior . . O
to . . O
the . . O
second . . O
dose . . O
, . . O
but . . O
this . . O
change . . O
is . . O
of . . O
a . . O
smaller . . O
magnitude . . O
than . . O
that . . O
observed . . O
following . . O
the . . O
first . . O
dose . . O
. . . O

consider . . O
suspending . . O
treatment . . O
with . . O
gilenya . . O
if . . O
a . . O
patient . . O
develops . . O
a . . O
serious . . O
infection . . O
, . . O
and . . O
reassess . . O
the . . O
benefits . . O
and . . O
risks . . O
prior . . O
to . . O
reinitiation . . O
of . . O
therapy . . O
. . . O

cryptococcal . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
including . . O
cases . . O
of . . O
cryptococcal . . B-AdverseReaction
meningitis . . I-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
with . . O
gilenya . . O
in . . O
the . . O
postmarketing . . O
setting . . O
. . . O

patients . . O
with . . O
symptoms . . O
and . . O
signs . . O
consistent . . O
with . . O
cryptococcal . . O
meningitis . . O
should . . O
undergo . . O
prompt . . O
diagnostic . . O
evaluation . . O
and . . O
treatment . . O
. . . O

when . . O
switching . . O
to . . O
gilenya . . O
from . . O
immune . . O
- . . O
modulating . . O
or . . O
immunosuppressive . . O
medications . . O
, . . O
consider . . O
the . . O
duration . . O
of . . O
their . . O
effects . . O
and . . O
their . . O
mode . . O
of . . O
action . . O
to . . O
avoid . . O
unintended . . O
additive . . O
immunosuppressive . . O
effects . . O
. . . O

pml . . B-AdverseReaction
is . . O
an . . O
opportunistic . . B-AdverseReaction
viral . . I-AdverseReaction
infection . . I-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
brain . . I-AdverseReaction
caused . . O
by . . O
the . . O
jc . . B-AdverseReaction
virus . . I-AdverseReaction
( . . O
jcv . . B-AdverseReaction
) . . O
that . . O
typically . . B-Factor
only . . O
occurs . . O
in . . O
patients . . O
who . . O
are . . O
immunocompromised . . O
, . . O
and . . O
that . . O
usually . . B-Factor
leads . . O
to . . O
death . . B-AdverseReaction
or . . O
severe . . B-Severity
disability . . B-AdverseReaction
. . . O

5.4 . . O
macular . . O
edema . . O

fingolimod . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
. . . O

symptoms . . O
of . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
included . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
and . . O
decreased . . B-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
. . . O

macular . . B-AdverseReaction
edema . . I-AdverseReaction
has . . O
also . . O
been . . O
reported . . O
in . . O
patients . . O
taking . . O
gilenya . . O
0.5 . . O
mg . . O
in . . O
the . . O
postmarketing . . O
setting . . O
, . . O
usually . . O
within . . O
the . . O
first . . O
6 . . O
months . . O
of . . O
treatment . . O
. . . O

the . . O
risk . . O
of . . O
recurrence . . O
after . . O
rechallenge . . O
has . . O
not . . O
been . . O
evaluated . . O
. . . O

the . . O
incidence . . O
of . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
is . . O
also . . O
increased . . O
in . . O
ms . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
uveitis . . O
. . . O

symptoms . . O
reported . . O
included . . O
sudden . . O
onset . . O
of . . O
severe . . B-Severity
headache . . B-AdverseReaction
, . . O
altered . . B-AdverseReaction
mental . . I-AdverseReaction
status . . I-AdverseReaction
, . . O
visual . . B-AdverseReaction
disturbances . . I-AdverseReaction
, . . O
and . . O
seizure . . B-AdverseReaction
. . . O

if . . O
pres . . O
is . . O
suspected . . O
, . . O
gilenya . . O
should . . O
be . . O
discontinued . . O
. . . O

in . . O
ms . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
dyspnea . . B-AdverseReaction
was . . O
reported . . O
in . . O
9% . . O
of . . O
patients . . O
receiving . . O
gilenya . . O
0.5 . . O
mg . . O
and . . O
7% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

several . . O
patients . . O
discontinued . . O
gilenya . . O
because . . O
of . . O
unexplained . . O
dyspnea . . B-AdverseReaction
during . . O
the . . O
extension . . O
( . . O
uncontrolled . . O
) . . O
studies . . O
. . . O

